

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)

For Current Week and Past Week Comparison

Following ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines (AGES 5 YEARS-11 YEARS)

Compared to ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines (AGES 5 YEARS-11 YEARS)

AGES 5 YEARS-11 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022

Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)

N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00

MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (5 Yrs-11 Yrs)	12/14/2020- 07/22/2022 COVID19 mRNA N=12185	01/01/2009- 07/22/2022 NON-COVID19 N=29047	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020- 07/15/2022 COVID19 mRNA N=12064	01/01/2009- 07/15/2022 NON-COVID19 N=29022	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
PRODUCT PREPARATION ISSUE	1913	45	4582.30	101.34	75.46	136.09	1880	43	4547.39	105.18	77.80	142.19
COVID-19	225	4	518.75	134.09	49.90	360.30	218	4	506.58	131.11	48.78	352.39
INCORRECT DOSE ADMINISTERED	1956	264	3861.33	17.66	15.56	20.05	1926	263	3828.11	17.62	15.51	20.00
PRODUCT ADMINISTRATION ERROR	98	12	184.94	19.47	10.69	35.44	95	12	179.77	19.04	10.45	34.71
UNDERDOSE	414	83	695.43	11.89	9.40	15.04	412	83	698.38	11.94	9.44	15.10
IMMUNISATION	71	13	119.54	13.02	7.21	23.51	71	13	120.83	13.14	7.28	23.72
ILLNESS	33	4	60.43	19.67	6.97	55.50	33	4	61.05	19.85	7.03	56.01
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	1570	498	2245.92	7.52	6.81	8.29	1560	495	2257.58	7.58	6.87	8.37
PRODUCT PREPARATION ERROR	269	83	372.33	7.73	6.05	9.87	259	83	355.24	7.51	5.87	9.60
INCORRECT PRODUCT FORMULATION ADMINISTERED	173	60	222.70	6.87	5.13	9.21	172	60	223.36	6.90	5.14	9.24
PRODUCT USE ISSUE	44	11	64.92	9.54	4.93	18.46	44	11	65.66	9.62	4.97	18.62
INJURY ASSOCIATED WITH DEVICE	19	3	31.45	15.10	4.47	51.01	19	3	31.79	15.24	4.51	51.48
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	260	112	291.47	5.53	4.44	6.90	258	110	295.25	5.64	4.52	7.05
MYOCARDITIS	20	4	30.83	11.92	4.07	34.86	20	4	31.17	12.03	4.11	35.18
APPENDICITIS	18	4	26.43	10.73	3.63	31.69	18	4	26.73	10.83	3.66	31.98
VACCINATION FAILURE	30	12	33.43	5.96	3.05	11.64	27	12	28.02	5.41	2.74	10.68
OVERDOSE	37	17	37.58	5.19	2.92	9.21	37	17	38.10	5.24	2.95	9.29
PRODUCT STORAGE ERROR	1147	866	763.32	3.16	2.90	3.44	1162	863	804.85	3.24	2.97	3.53
POOR QUALITY PRODUCT ADMINISTERED	18	6	21.69	7.15	2.84	18.01	18	6	21.96	7.22	2.87	18.18
ANGINA PECTORIS	12	3	16.00	9.54	2.69	33.78	12	3	16.19	9.62	2.72	34.09
OROPHARYNGEAL DISCOMFORT	12	3	16.00	9.54	2.69	33.78	12	3	16.19	9.62	2.72	34.09
PHARYNGEAL SWELLING	13	4	15.80	7.75	2.53	23.76	13	4	16.00	7.82	2.55	23.97
NEEDLE ISSUE	16	6	17.69	6.36	2.49	16.24	16	6	17.92	6.42	2.51	16.39
PERIORBITAL SWELLING	19	8	19.70	5.66	2.48	12.93	19	8	19.97	5.71	2.50	13.05
EXPIRED PRODUCT ADMINISTERED	639	551	341.94	2.76	2.47	3.09	624	549	329.53	2.73	2.44	3.06
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS	52	36	35.55	3.44	2.25	5.26	52	36	36.15	3.47	2.27	5.31
CHEST PAIN	196	188	84.94	2.49	2.04	3.03	194	188	84.28	2.48	2.03	3.03
VACCINE BREAKTHROUGH INFECTION	12	5	11.85	5.72	2.02	16.24	12	5	12.02	5.77	2.03	16.38
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR	49	38	28.73	3.07	2.01	4.69	49	38	29.26	3.10	2.03	4.74
NO ADVERSE EVENT	2522	2958	822.51	2.03	1.94	2.13	2494	2951	817.08	2.03	1.94	2.14
CONJUNCTIVITIS	33	25	19.57	3.15	1.87	5.29	33	25	19.92	3.18	1.89	5.34
MENSTRUATION IRREGULAR	10	4	9.87	5.96	1.87	19.00	10	4	10.01	6.01	1.89	19.17
SYRINGE ISSUE	41	34	21.57	2.87	1.83	4.53	40	34	20.61	2.83	1.79	4.47
COSTOCHONDRITIS	8	3	7.89	6.36	1.69	23.96	7	3	6.12	5.61	1.45	21.70
KAWASAKI'S DISEASE	8	3	7.89	6.36	1.69	23.96	8	3	7.99	6.42	1.70	24.18
APPENDICECTOMY	13	8	9.07	3.87	1.61	9.34	13	8	9.22	3.91	1.62	9.43
SHOCK	11	7	7.17	3.75	1.45	9.66	11	7	7.29	3.78	1.47	9.75
PAINFUL RESPIRATION	13	10	6.80	3.10	1.36	7.07	13	10	6.93	3.13	1.37	7.13
SLEEP DISORDER	39	45	10.72	2.07	1.35	3.17	38	45	10.03	2.03	1.32	3.13
SWELLING OF EYELID	17	17	5.89	2.38	1.22	4.67	16	17	4.94	2.26	1.14	4.48
PITYRIASIS ROSEA	7	4	4.61	4.17	1.22	14.25	7	4	4.69	4.21	1.23	14.38
AGEUSIA	6	3	4.31	4.77	1.19	19.06	6	3	4.37	4.81	1.20	19.23
VENTRICULAR EXTRASYSTOLES	6	3	4.31	4.77	1.19	19.06	6	3	4.37	4.81	1.20	19.23
OFF LABEL USE	22	26	5.36	2.02	1.14	3.56	22	26	5.52	2.04	1.15	3.59
VACCINATION ERROR	17	20	4.02	2.03	1.06	3.87	16	18	4.32	2.14	1.09	4.19
INTERCHANGE OF VACCINE PRODUCTS	20	20	7.09	2.38	1.28	4.43	16	20	3.26	1.92	1.00	3.71
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	70	1	159.53	166.87	23.18	1201.11	70	1	161.02	168.40	23.40	1212.12
DRUG INEFFECTIVE	26	2	50.93	30.99	7.36	130.55	25	2	49.07	30.07	7.12	126.93
BELL'S PALSY	17	1	33.37	40.53	5.39	304.48	16	1	31.33	38.49	5.11	290.21
LEFT VENTRICULAR DYSFUNCTION	12	1	21.68	28.61	3.72	219.97	12	1	21.90	28.87	3.75	221.99
MITRAL VALVE INCOMPETENCE	9	1	14.77	21.45	2.72	169.32	9	1	14.93	21.65	2.74	170.87
PERICARDITIS	8	1	12.51	19.07	2.39	152.46	8	1	12.64	19.25	2.41	153.86
SINUS TACHYCARDIA	9	2	12.04	10.73	2.32	49.64	9	2	12.18	10.83	2.34	50.10
PERICARDIAL EFFUSION	7	1	10.27	16.69	2.05	135.61	7	1	10.39	16.84	2.07	136.85

MENSTRUAL DISORDER	8	2	9.92	9.54	2.03	44.90	8	2	10.04	9.62	2.04	45.31
TASTE DISORDER	8	2	9.92	9.54	2.03	44.90	8	2	10.04	9.62	2.04	45.31
APHONIA	7	2	7.87	8.34	1.73	40.16	7	2	7.97	8.42	1.75	40.52
PLEURAL EFFUSION	7	2	7.87	8.34	1.73	40.16	7	2	7.97	8.42	1.75	40.52
BEHAVIOUR DISORDER	6	1	8.08	14.30	1.72	118.79	6	1	8.17	14.43	1.74	119.88
BLOOD PRESSURE DIASTOLIC DECREASED	6	1	8.08	14.30	1.72	118.79	6	1	8.17	14.43	1.74	119.88
TRICUSPID VALVE INCOMPETENCE	6	1	8.08	14.30	1.72	118.79	6	1	8.17	14.43	1.74	119.88
HEPATOMEGALY	6	2	5.91	7.15	1.44	35.43	6	2	5.98	7.22	1.46	35.75
VITILIGO	5	1	5.95	11.92	1.39	102.01	5	1	6.03	12.03	1.41	102.94
APHTHOUS ULCER	5	2	4.06	5.96	1.16	30.71	5	2	4.12	6.01	1.17	30.99
PAROSMIA	5	2	4.06	5.96	1.16	30.71	5	2	4.12	6.01	1.17	30.99

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines \(AGES 12 YEARS-17 YEARS\)](#)
Compared to [ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines \(AGES 12 YEARS-17 YEARS\)](#)
AGES 12 YEARS-17 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022
Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (12 Yrs-17 Yrs)	12/14/2020- 07/22/2022 COVID19 mRNA N=31374	01/01/2009- 07/22/2022 NON-COVID19 N=30040	12/14-07/22 Chi-Square	12/14/07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020- 07/15/2022 COVID19 mRNA N=31273	01/01/2009- 07/15/2022 NON-COVID19 N=29994	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
COVID-19	565	3	535.18	180.33	57.99	560.73	557	3	528.30	178.07	57.26	553.75
MYOCARDITIS	738	11	681.14	64.24	35.43	116.48	737	11	681.38	64.26	35.44	116.52
UNDERDOSE	1055	58	864.63	17.42	13.38	22.68	1053	58	864.35	17.41	13.37	22.67
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	8622	578	7868.28	14.28	13.15	15.51	8608	576	7874.81	14.33	13.19	15.57
PERICARDITIS	218	12	174.66	17.39	9.73	31.10	217	12	174.04	17.34	9.70	31.01
HEAVY MENSTRUAL BLEEDING	133	6	109.11	21.22	9.37	48.09	132	6	108.36	21.10	9.31	47.81
BELL'S PALSY	76	3	62.64	24.26	7.65	76.88	76	3	62.76	24.30	7.67	77.01
ILLNESS	81	5	62.31	15.51	6.29	38.27	81	5	62.43	15.54	6.30	38.33
PRODUCT ADMINISTRATION ERROR	91	7	66.87	12.45	5.77	26.85	91	4	74.45	21.82	8.02	59.38
ANTICOAGULANT THERAPY	61	4	45.91	14.60	5.31	40.15	61	4	46.01	14.63	5.32	40.22
PRODUCT PREPARATION ISSUE	511	75	307.36	6.52	5.12	8.31	511	74	310.10	6.62	5.19	8.45
PERICARDIAL EFFUSION	72	7	49.19	9.85	4.53	21.39	72	7	49.30	9.87	4.54	21.43
PLEURITIC PAIN	56	5	38.90	10.72	4.30	26.77	56	5	38.98	10.74	4.30	26.81
AGEUSIA	74	8	48.83	8.86	4.27	18.37	74	8	48.93	8.87	4.28	18.40
ANGINA PECTORIS	50	5	33.36	9.57	3.82	24.01	50	5	33.43	9.59	3.83	24.05
IMMUNISATION	96	14	56.31	6.57	3.75	11.50	96	14	56.44	6.58	3.75	11.52
PAINFUL RESPIRATION	141	26	73.18	5.19	3.42	7.89	140	26	72.50	5.16	3.40	7.85
CHEST PAIN	1824	470	769.39	3.72	3.36	4.11	1822	470	770.06	3.72	3.36	4.11
PHARYNGEAL SWELLING	76	15	37.07	4.85	2.79	8.44	76	14	38.91	5.21	2.94	9.20
PRODUCT STORAGE ERROR	2668	873	884.00	2.93	2.72	3.15	2641	869	871.44	2.91	2.70	3.14
VENTRICULAR EXTRASYSTOLES	40	6	22.29	6.38	2.71	15.05	40	6	22.34	6.39	2.71	15.08
RESPIRATORY RATE INCREASED	198	53	76.83	3.58	2.64	4.84	198	53	77.06	3.58	2.65	4.85
TASTE DISORDER	27	3	16.66	8.62	2.61	28.40	27	3	16.70	8.63	2.62	28.45
TRICUSPID VALVE INCOMPETENCE	29	4	16.44	6.94	2.44	19.74	28	4	15.60	6.71	2.36	19.14
FEAR OF INJECTION	35	6	17.95	5.59	2.35	13.28	35	6	17.99	5.59	2.35	13.30
SINUS ARRHYTHMIA	35	6	17.95	5.59	2.35	13.28	35	6	17.99	5.59	2.35	13.30
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	610	214	175.01	2.73	2.34	3.19	610	212	177.99	2.76	2.36	3.22
RESPIRATORY RATE DECREASED	48	10	22.05	4.60	2.33	9.08	48	10	22.11	4.60	2.33	9.10
PULMONARY EMBOLISM	31	5	16.31	5.94	2.31	15.26	30	5	15.49	5.75	2.23	14.83
ACUTE KIDNEY INJURY	40	8	18.72	4.79	2.24	10.23	40	8	18.77	4.80	2.25	10.24
BLOOD PRESSURE INCREASED	195	63	61.23	2.96	2.23	3.94	194	63	60.72	2.95	2.22	3.92
OFF LABEL USE	92	27	31.77	3.26	2.13	5.01	92	27	31.88	3.27	2.13	5.02
CHEST DISCOMFORT	646	254	155.66	2.44	2.11	2.81	643	254	154.35	2.43	2.10	2.81
PRODUCT TEMPERATURE EXCURSION ISSUE	36	8	15.43	4.31	2.00	9.27	36	8	15.48	4.32	2.01	9.28
INCORRECT DOSE ADMINISTERED	862	386	164.15	2.14	1.90	2.41	853	383	162.26	2.14	1.90	2.41
HEART SOUNDS ABNORMAL	20	3	10.46	6.38	1.90	21.48	19	3	9.62	6.07	1.80	20.52
APPENDICITIS	57	17	18.93	3.21	1.87	5.52	57	17	18.99	3.22	1.87	5.53
INTENSIVE CARE	374	161	75.75	2.22	1.85	2.67	372	161	74.89	2.22	1.84	2.66
THROMBOSIS	33	8	13.04	3.95	1.82	8.55	33	8	13.08	3.96	1.83	8.56
SINUS TACHYCARDIA	67	22	19.92	2.92	1.80	4.72	67	22	19.99	2.92	1.80	4.73
HEART RATE INCREASED	476	220	83.66	2.07	1.77	2.43	475	220	83.51	2.07	1.77	2.43
INTERCHANGE OF VACCINE PRODUCTS	230	100	45.24	2.20	1.74	2.78	229	100	44.86	2.20	1.74	2.78
CARDIAC DISORDER	29	7	11.37	3.97	1.74	9.05	28	7	10.62	3.84	1.68	8.78
VULVOVAGINAL PAIN	18	3	8.74	5.74	1.69	19.50	18	3	8.76	5.75	1.70	19.53
CARDIAC FLUTTER	28	7	10.59	3.83	1.67	8.77	28	7	10.62	3.84	1.68	8.78
VAGINAL ULCERATION	25	6	9.69	3.99	1.64	9.72	25	6	9.72	4.00	1.64	9.74
PERIORBITAL SWELLING	22	5	8.81	4.21	1.60	11.12	22	5	8.83	4.22	1.60	11.14
TACHYPNOEA	74	29	16.97	2.44	1.59	3.75	73	29	16.41	2.41	1.57	3.71
OROPHARYNGEAL DISCOMFORT	38	12	11.45	3.03	1.58	5.80	38	11	12.75	3.31	1.69	6.48
APHTHOUS ULCER	19	4	7.93	4.55	1.55	13.37	19	4	7.95	4.56	1.55	13.39
MENSTRUAL DISORDER	79	34	15.31	2.22	1.49	3.32	79	34	15.38	2.23	1.49	3.33
AXILLARY PAIN	113	53	18.54	2.04	1.47	2.83	113	53	18.64	2.04	1.48	2.83
IMMUNE THROMBOCYTOPENIA	20	5	7.25	3.83	1.44	10.20	20	5	7.27	3.84	1.44	10.22
VACCINATION ERROR	42	16	9.73	2.51	1.41	4.47	42	16	9.77	2.52	1.42	4.48
ELECTROCARDIOGRAM T WAVE INVERSION	15	3	6.26	4.79	1.39	16.53	15	3	6.28	4.80	1.39	16.56
LYMPHOPENIA	15	3	6.26	4.79	1.39	16.53	15	3	6.28	4.80	1.39	16.56
OVERDOSE	40	16	8.49	2.39	1.34	4.27	40	16	8.52	2.40	1.34	4.28
PLEURAL EFFUSION	36	14	7.94	2.46	1.33	4.56	36	14	7.97	2.47	1.33	4.57
PAROSMIA	26	9	6.64	2.77	1.30	5.90	26	9	6.67	2.77	1.30	5.91
SENSITIVE SKIN	14	3	5.46	4.47	1.28	15.55	14	3	5.48	4.48	1.29	15.57
SINUS BRADYCARDIA	32	13	6.45	2.36	1.24	4.49	32	13	6.48	2.36	1.24	4.50
STEROID THERAPY	21	7	5.49	2.87	1.22	6.76	21	7	5.51	2.88	1.22	6.77

NEEDLE ISSUE	19	6	5.26	3.03	1.21	7.59	19	6	5.27	3.04	1.21	7.60
ELECTROCARDIOGRAM AMBULATORY	17	5	5.04	3.26	1.20	8.82	17	5	5.05	3.26	1.20	8.84
MOUTH SWELLING	24	9	5.35	2.55	1.19	5.49	24	9	5.37	2.56	1.19	5.50
SWELLING OF EYELID	36	17	5.36	2.03	1.14	3.61	36	17	5.39	2.03	1.14	3.62
RESPIRATORY SYMPTOM	19	7	4.19	2.60	1.09	6.18	19	6	5.27	3.04	1.21	7.60
ACUTE RESPIRATORY FAILURE	22	9	4.14	2.34	1.08	5.08	22	9	4.16	2.34	1.08	5.09
POOR QUALITY PRODUCT ADMINISTERED	71	4	55.34	17.00	6.21	46.53	71	1	63.38	68.10	9.46	490.08
TROPONIN I INCREASED	146	1	135.26	139.79	19.56	999.00	145	1	134.53	139.07	19.46	993.89
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	130	2	117.04	62.24	15.40	251.48	130	2	117.25	62.34	15.43	251.91
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	61	1	53.69	58.41	8.10	421.29	61	1	53.79	58.51	8.11	422.00
DRUG INEFFECTIVE	57	1	49.86	54.58	7.56	394.11	56	1	49.00	53.71	7.44	387.97
ANOSMIA	63	2	52.89	30.16	7.38	123.25	63	2	52.99	30.21	7.39	123.45
BLOOD PRESSURE SYSTOLIC INCREASED	49	1	42.22	46.92	6.48	339.74	48	1	41.34	46.04	6.35	333.50
VACCINE BREAKTHROUGH INFECTION	43	1	36.49	41.17	5.67	298.96	41	1	34.64	39.32	5.41	285.85
MITRAL VALVE INCOMPETENCE	39	1	32.67	37.34	5.13	271.78	39	1	32.73	37.40	5.14	272.24
TROPONIN I INCREASED	38	1	31.72	36.38	5.00	264.98	38	1	31.78	36.45	5.00	265.43
VENTRICULAR TACHYCARDIA	43	2	33.88	20.59	4.99	84.97	43	2	33.94	20.62	5.00	85.11
EXPOSURE TO SARS-COV-2	39	2	30.10	18.67	4.51	77.31	39	2	30.16	18.70	4.52	77.44
EPINEPHRINE	30	1	24.11	28.72	3.92	210.62	30	1	24.16	28.77	3.92	210.97
COVID-19 IMMUNISATION	26	1	20.32	24.89	3.38	183.44	26	1	20.36	24.94	3.38	183.75
PRODUCT DOSE OMISSION ISSUE	26	2	17.92	12.45	2.95	52.44	26	2	17.96	12.47	2.96	52.53
BLOOD PRESSURE DIASTOLIC INCREASED	21	1	15.61	20.11	2.70	149.47	21	1	15.64	20.14	2.71	149.72
GENITAL ULCERATION	19	1	13.73	18.19	2.44	135.88	19	1	13.76	18.22	2.44	136.11
VULVAL ULCERATION	20	2	12.42	9.57	2.24	40.96	20	2	12.45	9.59	2.24	41.03
BLOOD PRESSURE DIASTOLIC DECREASED	17	1	11.87	16.28	2.17	122.30	17	1	11.89	16.30	2.17	122.51
C-REACTIVE PROTEIN INCREASED	15	2	7.96	7.18	1.64	31.40	15	2	7.98	7.19	1.65	31.45
ELECTROCARDIOGRAM ABNORMAL	15	2	7.96	7.18	1.64	31.40	15	2	7.98	7.19	1.65	31.45
GENERAL PHYSICAL CONDITION ABNORMAL	14	2	7.10	6.70	1.52	29.49	14	2	7.12	6.71	1.53	29.54
PULMONARY VALVE INCOMPETENCE	11	1	6.37	10.53	1.36	81.57	11	1	6.38	10.55	1.36	81.71
SEDATION	11	1	6.37	10.53	1.36	81.57	11	1	6.38	10.55	1.36	81.71
BUNDLE BRANCH BLOCK RIGHT	12	2	5.41	5.74	1.29	25.67	12	2	5.42	5.75	1.29	25.71
APPENDICITIS PERFORATED	9	1	4.60	8.62	1.09	68.01	9	1	4.61	8.63	1.09	68.13
GENITAL PAIN	9	1	4.60	8.62	1.09	68.01	9	1	4.61	8.63	1.09	68.13

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)

For Current Week and Past Week Comparison

Following ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines (AGES 18+ YEARS)

Compared to ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines (AGES 18+ YEARS)

AGES 18+ YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022

Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)

N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00

MedDRA PT's sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (18+)	12/14/2020- 07/22/2022 COVID19 mRNA N=658300	01/01/2009- 07/22/2022 NON-COVID19 N=241884	12/14-07/22 Chi-Square	12/14/07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020- 07/15/2022 COVID19 mRNA N=656312	01/01/2009- 07/15/2022 NON-COVID19 N=241554	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
COVID-19	46542	154	17653.68	111.05	94.81	130.07	45607	155	17301.64	108.29	92.50	126.78
COVID-19 PNEUMONIA	5051	11	1838.99	168.72	93.38	304.85	5002	11	1823.87	167.36	92.63	302.40
EXPOSURE TO SARS-COV-2	2388	4	868.96	219.36	82.26	584.94	2336	4	851.18	214.94	80.60	573.16
PRODUCT TEMPERATURE EXCURSION ISSUE	3021	7	1095.87	158.58	75.53	332.91	3019	7	1096.98	158.73	75.61	333.24
POOR QUALITY PRODUCT ADMINISTERED	3207	8	1162.33	147.30	73.60	294.79	3205	7	1165.91	168.51	80.27	353.76
VACCINE BREAKTHROUGH INFECTION	4749	17	1712.74	102.64	63.76	165.25	4691	17	1694.10	101.56	63.08	163.50
ASYMPTOMATIC COVID-19	1171	3	422.40	143.42	46.19	445.33	1155	3	417.21	141.70	45.63	439.99
HEAVY MENSTRUAL BLEEDING	4300	29	1518.28	54.48	37.82	78.49	4284	29	1514.98	54.37	37.74	78.33
SARS-COV-2 TEST POSITIVE	943	3	338.45	115.50	37.18	358.75	943	3	339.02	115.69	37.25	359.35
LUNG OPACITY	1883	11	666.23	62.90	34.77	113.77	1873	11	663.69	62.67	34.65	113.35
INTERMENSTRUAL BLEEDING	1337	7	474.25	70.18	33.39	147.49	1336	7	474.69	70.24	33.42	147.63
VACCINATION SITE PRURITUS	3989	35	1389.28	41.88	30.03	58.41	3988	35	1391.35	41.94	30.07	58.49
INTERCHANGE OF VACCINE PRODUCTS	8533	100	2931.30	31.35	25.74	38.18	8528	100	2934.69	31.39	25.77	38.22
PRODUCT DOSE OMISSION ISSUE	1711	16	591.38	39.29	24.02	64.28	1710	16	592.04	39.34	24.04	64.35
DRUG INEFFECTIVE	3423	40	1168.58	31.44	23.02	42.94	3272	40	1114.79	30.11	22.04	41.12
SUSPECTED COVID-19	857	7	297.57	44.98	21.38	94.64	822	7	285.20	43.22	20.54	90.94
POSITIVE AIRWAY PRESSURE THERAPY	964	9	332.37	39.36	20.42	75.87	949	9	327.43	38.81	20.13	74.82
PULMONARY THROMBOSIS	642	5	223.09	47.18	19.57	113.73	641	5	223.11	47.18	19.57	113.75
DYSMENORRHOEA	1843	25	619.69	27.09	18.26	40.19	1840	25	619.70	27.09	18.26	40.19
POLYMENORRHOEA	692	7	236.92	36.32	17.25	76.48	691	7	236.97	36.33	17.26	76.49
MENSTRUATION IRREGULAR	3295	59	1079.05	20.52	15.86	26.54	3285	59	1077.35	20.49	15.84	26.51
MENSTRUAL DISORDER	2469	43	810.13	21.10	15.61	28.52	2466	43	810.51	21.11	15.61	28.53
ANOSMIA	3749	72	1217.87	19.13	15.15	24.16	3724	72	1210.90	19.04	15.08	24.03
POSTMENOPAUSAL HAEMORRHAGE	541	6	183.72	33.13	14.82	74.07	539	6	183.31	33.06	14.79	73.92
OLIGOMENORRHOEA	572	7	192.85	30.02	14.25	63.26	570	7	192.46	29.97	14.22	63.15
ILLNESS	4444	95	1424.02	17.19	14.03	21.06	4434	95	1423.01	17.18	14.02	21.05
POST-ACUTE COVID-19 SYNDROME	343	3	117.79	42.01	13.48	130.90	342	3	117.63	41.96	13.47	130.74
ANTICOAGULANT THERAPY	4140	98	1305.61	15.52	12.71	18.96	4107	96	1300.22	15.75	12.86	19.28
THROMBECTOMY	375	5	125.04	27.56	11.40	66.59	372	5	124.17	27.38	11.33	66.17
TASTE DISORDER	2172	60	664.65	13.30	10.29	17.19	2162	60	662.28	13.26	10.26	17.14
MECHANICAL URTICARIA	870	23	267.26	13.90	9.19	21.03	869	23	267.41	13.91	9.19	21.04
MATERNAL EXPOSURE DURING BREAST FEEDING	296	5	96.10	21.75	8.99	52.65	296	5	96.28	21.79	9.00	52.73
IMMUNISATION	2761	99	798.91	10.25	8.39	12.52	2760	99	800.16	10.26	8.40	12.54
AGEUSIA	4602	183	1299.05	9.24	7.97	10.71	4581	182	1296.11	9.26	7.99	10.74
THROMBOSIS	3246	126	920.64	9.47	7.92	11.31	3231	126	917.09	9.44	7.90	11.28
APPENDICITIS	644	19	193.34	12.45	7.89	19.65	642	19	192.99	12.44	7.88	19.63
MENSTRUATION DELAYED	1092	37	319.02	10.84	7.82	15.05	1090	37	318.93	10.84	7.81	15.05
VACCINATION SITE ERYTHEMA	6219	264	1726.07	8.66	7.65	9.79	6218	264	1729.36	8.67	7.66	9.80
BELL'S PALSY	3135	127	878.43	9.07	7.60	10.83	3137	126	882.97	9.16	7.67	10.95
VACCINATION SITE MASS	1183	43	339.83	10.11	7.46	13.70	1183	43	340.52	10.13	7.47	13.73
VACCINATION SITE URTICARIA	325	8	100.25	14.93	7.40	30.10	325	8	100.44	14.95	7.41	30.15
PULMONARY EMBOLISM	3142	136	863.22	8.49	7.15	10.08	3132	135	863.39	8.54	7.19	10.14
EPINEPHRINE	431	13	128.37	12.18	7.02	21.15	431	13	128.63	12.20	7.03	21.19
SYMPTOM RECURRENCE	192	4	60.25	17.64	6.55	47.47	191	4	60.00	17.57	6.53	47.30
PRODUCT USE ISSUE	569	21	162.08	9.96	6.44	15.39	567	21	161.69	9.94	6.43	15.36
THROAT CLEARING	418	14	121.61	10.97	6.44	18.69	416	14	121.13	10.94	6.42	18.63
HYPERVOLAEMIA	282	8	84.61	12.95	6.41	26.15	275	8	82.22	12.65	6.26	25.55
BLOOD PRESSURE DIASTOLIC INCREASED	279	8	83.52	12.81	6.35	25.88	277	8	82.95	12.74	6.31	25.74
LEFT VENTRICULAR FAILURE	253	7	76.15	13.28	6.27	28.14	247	7	74.11	12.99	6.13	27.53
PAROSMIA	1360	63	364.19	7.93	6.16	10.21	1356	63	363.54	7.92	6.15	10.20
BLOOD LOSS ANAEMIA	196	5	59.59	14.40	5.93	34.99	194	5	58.98	14.28	5.88	34.70
CARDIAC FLUTTER	1317	66	343.10	7.33	5.73	9.39	1311	66	341.71	7.31	5.71	9.36
ELECTRIC SHOCK SENSATION	856	40	228.00	7.86	5.73	10.80	854	38	231.64	8.27	5.98	11.45
VITAL SIGNS MEASUREMENT	146	3	45.60	17.88	5.70	56.09	146	3	45.69	17.91	5.71	56.18
OFF LABEL USE	1267	64	329.05	7.27	5.66	329.78	1267	64	329.78	7.29	5.67	9.37
DEATH	10117	625	2450.95	5.95	5.49	6.45	10024	624	2425.29	5.91	5.45	6.41

OROPHARYNGEAL DISCOMFORT	1558	85	393.23	6.73	5.41	8.38	1549	84	392.77	6.79	5.45	8.45
CARDIAC FAILURE ACUTE	351	14	97.43	9.21	5.40	15.72	343	14	94.75	9.02	5.28	15.39
INFUSION	196	6	57.52	12.00	5.33	27.04	196	6	57.64	12.02	5.34	27.09
VACCINATION SITE MOVEMENT IMPAIRMENT	363	15	99.78	8.89	5.31	14.90	363	15	99.99	8.91	5.31	14.93
FACIAL DISCOMFORT	327	13	90.77	9.24	5.31	16.09	327	13	90.96	9.26	5.32	16.11
BLOOD PRESSURE MEASUREMENT	194	6	56.80	11.88	5.27	26.77	194	6	56.91	11.90	5.28	26.82
THERAPEUTIC RESPONSE UNEXPECTED	536	27	138.58	7.29	4.96	10.74	535	27	138.53	7.29	4.95	10.73
SUPERINFECTION	127	3	38.68	15.55	4.95	48.87	124	3	37.66	15.21	4.84	47.81
CHRONIC SPONTANEOUS URTICARIA	162	5	47.25	11.90	4.89	28.99	163	5	47.71	12.00	4.93	29.21
OPHTHALMIC MIGRAINE	124	3	37.59	15.19	4.83	47.73	123	3	37.30	15.09	4.80	47.43
DEEP VEIN THROMBOSIS	2218	143	520.82	5.70	4.81	6.75	2216	143	521.35	5.70	4.82	6.75
ACUTE LEFT VENTRICULAR FAILURE	159	5	46.16	11.68	4.80	28.46	159	5	46.26	11.70	4.81	28.51
GENERAL PHYSICAL CONDITION ABNORMAL	383	19	99.24	7.41	4.67	11.74	379	19	98.03	7.34	4.63	11.64
PREMENSTRUAL SYNDROME	153	5	44.00	11.24	4.61	27.40	152	5	43.72	11.19	4.59	27.27
DEVICE CONNECTION ISSUE	343	17	88.78	7.41	4.56	12.06	343	17	88.98	7.43	4.56	12.08
END STAGE RENAL DISEASE	201	8	55.32	9.23	4.55	18.71	197	8	54.00	9.06	4.47	18.38
SUPPRESSED LACTATION	133	4	38.79	12.22	4.52	33.03	133	4	38.87	12.24	4.53	33.09
ACCIDENTAL OVERDOSE	339	17	87.36	7.33	4.50	11.93	336	16	88.37	7.73	4.68	12.76
STENT PLACEMENT	324	16	83.91	7.44	4.50	12.29	324	16	84.09	7.45	4.51	12.31
ACUTE RESPIRATORY FAILURE	4100	298	907.16	5.06	4.49	5.69	4056	298	894.15	5.01	4.45	5.63
PHARYNGEAL PARAESTHESIA	930	59	219.13	5.79	4.45	7.53	928	59	218.95	5.79	4.45	7.53
VACCINATION SITE PAIN	14514	1147	3097.94	4.65	4.38	4.94	14499	1145	3104.15	4.66	4.39	4.95
CARDIAC DISCOMFORT	357	19	90.01	6.90	4.35	10.95	355	19	89.50	6.88	4.33	10.91
PHARYNGEAL SWELLING	4301	325	930.90	4.86	4.34	5.44	4297	323	935.25	4.90	4.37	5.48
BLOOD PRESSURE SYSTOLIC INCREASED	638	40	150.79	5.86	4.26	8.07	633	40	149.39	5.82	4.23	8.02
VACCINATION SITE RASH	2533	190	549.02	4.90	4.23	5.68	2532	190	550.06	4.90	4.23	5.68
HYPOMENORRHOEA	169	7	45.79	8.87	4.17	18.89	168	7	45.53	8.83	4.15	18.81
APPENDICECTOMY	489	30	116.47	5.99	4.14	8.66	489	30	116.75	6.00	4.15	8.67
HOSPICE CARE	312	17	77.79	6.74	4.14	10.99	310	16	79.11	7.13	4.31	11.79
BLOOD PRESSURE DIASTOLIC DECREASED	164	7	44.00	8.61	4.04	18.34	164	7	44.10	8.62	4.05	18.37
PRODUCT STORAGE ERROR	19859	1735	3993.69	4.21	4.01	4.42	19788	1731	3986.48	4.21	4.01	4.42
BREAST FEEDING	118	4	33.37	10.84	4.00	29.36	118	4	33.44	10.86	4.01	29.41
IMMUNE THROMBOCYTOPENIA	350	21	83.89	6.12	3.94	9.51	350	21	84.09	6.13	3.95	9.53
TROPONIN INCREASED	429	28	99.07	5.63	3.84	8.25	428	28	98.96	5.63	3.84	8.25
GENERAL PHYSICAL HEALTH DETERIORATION	1226	97	256.41	4.64	3.78	5.71	1215	97	253.32	4.61	3.75	5.67
TONGUE DISCOMFORT	601	43	132.71	5.14	3.77	7.00	600	43	132.69	5.14	3.77	7.00
OXYGEN SATURATION DECREASED	3386	294	669.42	4.23	3.76	4.77	3363	294	663.47	4.21	3.74	4.74
HYPOXIA	4239	378	823.44	4.12	3.71	4.58	4198	377	813.48	4.10	3.69	4.55
CHRONIC LEFT VENTRICULAR FAILURE	164	8	42.10	7.53	3.70	15.32	160	8	40.77	7.36	3.62	14.97
BODY TEMPERATURE ABNORMAL	174	9	43.78	7.10	3.64	13.88	174	9	43.88	7.12	3.64	13.91
PULMONARY INFARCTION	134	6	35.21	8.21	3.62	18.59	133	5	36.86	9.79	4.01	23.91
PERCUTANEOUS CORONARY INTERVENTION	93	3	26.35	11.39	3.61	35.96	93	3	26.41	11.41	3.61	36.02
DYSPNOEA AT REST	120	5	32.12	8.82	3.60	21.57	119	5	31.83	8.76	3.58	21.43
PNEUMONIA VIRAL	209	12	50.63	6.40	3.58	11.45	206	12	49.69	6.32	3.53	11.31
TINNITUS	13478	1310	2481.39	3.78	3.57	4.00	13452	1308	2482.89	3.79	3.58	4.01
PULSELESS ELECTRICAL ACTIVITY	395	28	87.30	5.18	3.53	7.60	391	28	86.13	5.14	3.50	7.54
CORONARY ARTERIAL STENT INSERTION	290	19	66.49	5.61	3.53	8.92	288	19	65.96	5.58	3.51	8.87
ACUTE MYOCARDIAL INFARCTION	1482	130	289.69	4.19	3.50	5.01	1476	129	290.04	4.21	3.52	5.04
ISCHAEMIC STROKE	488	37	104.04	4.85	3.47	6.77	486	37	103.62	4.83	3.46	6.75
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	295	20	66.49	5.42	3.45	8.52	294	20	66.31	5.41	3.44	8.51
VENTRICULAR HYPOKINESIA	165	9	40.60	6.74	3.44	13.18	162	9	39.63	6.62	3.39	12.96
HEART RATE	126	6	32.36	7.72	3.40	17.50	126	6	32.43	7.73	3.41	17.53
CEREBROVASCULAR ACCIDENT	3153	305	574.65	3.80	3.38	4.27	3142	305	572.66	3.79	3.37	4.26
RESPIRATORY RATE DECREASED	389	29	83.54	4.93	3.38	7.19	388	29	83.41	4.92	3.38	7.18
ENERGY INCREASED	173	10	41.60	6.36	3.36	12.02	173	10	41.70	6.37	3.37	12.04
TONGUE PRURITUS	492	39	102.10	4.64	3.35	6.42	492	39	102.36	4.64	3.35	6.43
PNEUMONIA BACTERIAL	415	32	87.43	4.77	3.33	6.83	408	32	85.27	4.69	3.27	6.72
AMENORRHOEA	713	61	141.19	4.29	3.31	5.58	709	61	140.23	4.28	3.29	5.56
CORONARY ARTERY OCCLUSION	205	13	47.45	5.79	3.31	10.15	206	13	47.91	5.83	3.33	10.21
BLOOD PRESSURE SYSTOLIC DECREASED	122	6	30.94	7.47	3.29	16.96	121	6	30.65	7.42	3.27	16.85

EXPIRED PRODUCT ADMINISTERED	21179	2276	3610.81	3.42	3.28	3.57	20988	2256	3587.71	3.42	3.28	3.58
LUNG INFILTRATION	1232	114	231.34	3.97	3.28	4.81	1221	114	228.34	3.94	3.25	4.78
MULTIPLE ORGAN DYSFUNCTION SYNDROME	314	23	67.92	5.02	3.28	7.66	311	23	67.06	4.98	3.26	7.60
CARDIAC FAILURE	696	60	137.08	4.26	3.27	5.55	687	59	136.01	4.29	3.29	5.59
AUTOPSY	363	28	76.33	4.76	3.24	7.00	360	28	75.50	4.73	3.22	6.95
IMMUNODEFICIENCY	616	53	121.36	4.27	3.23	5.65	615	53	121.35	4.27	3.23	5.65
BREAST MASS	441	36	89.71	4.50	3.20	6.32	440	36	89.60	4.50	3.20	6.32
DRAINAGE	231	16	51.25	5.30	3.20	8.80	226	16	49.66	5.20	3.13	8.63
HYPERAESTHESIA TEETH	153	9	36.39	6.25	3.19	12.23	153	9	36.47	6.26	3.19	12.25
CARDIO-RESPIRATORY ARREST	773	70	147.08	4.06	3.18	5.18	767	69	147.05	4.09	3.20	5.23
PRODUCT PREPARATION ISSUE	2307	234	403.60	3.62	3.17	4.14	2300	230	408.43	3.68	3.21	4.21
EXTRASYSTOLES	613	54	118.78	4.17	3.16	5.51	609	54	117.77	4.15	3.14	5.48
SITTING DISABILITY	174	11	40.17	5.81	3.16	10.69	174	11	40.27	5.82	3.17	10.71
VACCINATION SITE DISCOMFORT	298	23	62.46	4.76	3.12	7.28	298	23	62.62	4.77	3.12	7.29
CARDIAC ARREST	1776	180	310.50	3.63	3.11	4.23	1754	180	304.26	3.59	3.08	4.18
ACUTE KIDNEY INJURY	2927	316	484.95	3.40	3.03	3.82	2897	316	476.81	3.37	3.00	3.79
LUNG CONSOLIDATION	358	30	71.38	4.38	3.02	6.36	356	30	70.90	4.37	3.01	6.34
CARDIAC ABLATION	177	12	39.48	5.42	3.02	9.72	174	12	38.54	5.34	2.97	9.58
GIANT CELL ARTERITIS	78	3	20.96	9.55	3.02	30.27	78	3	21.01	9.57	3.02	30.32
CHRONIC KIDNEY DISEASE	684	65	125.33	3.87	3.00	4.99	668	65	120.43	3.78	2.93	4.88
CARDIAC ASSISTANCE DEVICE USER	89	4	22.98	8.18	3.00	22.26	89	4	23.03	8.19	3.01	22.30
HAEMORRHAGE URINARY TRACT	133	8	31.17	6.11	2.99	12.47	133	8	31.25	6.12	3.00	12.49
PULMONARY PAIN	504	46	94.98	4.03	2.98	5.44	503	46	94.92	4.02	2.98	5.44
HEART RATE ABNORMAL	495	45	93.55	4.04	2.98	5.48	494	45	93.47	4.04	2.98	5.48
SARS-COV-2 ANTIBODY TEST NEGATIVE	77	3	20.60	9.43	2.98	29.89	76	3	20.29	9.32	2.94	29.56
DEMENTIA	485	44	91.78	4.05	2.97	5.51	481	44	90.70	4.02	2.95	5.48
CEREBRAL INFARCTION	438	39	83.93	4.13	2.97	5.73	436	39	83.49	4.11	2.97	5.71
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	10196	1200	1567.52	3.12	2.94	3.31	10136	1190	1567.28	3.13	2.95	3.33
NEAR DEATH EXPERIENCE	151	10	33.93	5.55	2.93	10.52	151	10	34.01	5.56	2.93	10.54
PERICARDIAL EFFUSION	835	84	146.27	3.65	2.92	4.57	832	84	145.72	3.65	2.91	4.56
VACCINATION SITE HAEMORRHAGE	241	19	49.66	4.66	2.92	7.43	240	19	49.45	4.65	2.91	7.42
PARANASAL SINUS DISCOMFORT	958	99	164.12	3.56	2.89	4.37	948	99	161.38	3.52	2.87	4.33
APPENDICITIS PERFORATED	118	7	27.71	6.19	2.89	13.28	118	7	27.78	6.20	2.89	13.30
ATYPICAL PNEUMONIA	138	9	31.16	5.63	2.87	11.06	136	9	30.54	5.56	2.83	10.92
OXYGEN SATURATION	96	5	23.60	7.05	2.87	17.34	96	5	23.65	7.07	2.88	17.36
HEAD DISCOMFORT	3021	350	467.27	3.17	2.84	3.54	3010	349	466.67	3.17	2.84	3.55
MYOCARDIAL INFARCTION	1609	179	258.29	3.30	2.83	3.85	1601	178	257.95	3.31	2.84	3.86
HOSPITALISATION	155	11	33.60	5.18	2.81	9.54	155	11	33.69	5.19	2.81	9.56
RESPIRATORY RATE INCREASED	1805	205	284.09	3.24	2.80	3.74	1789	205	279.94	3.21	2.78	3.71
IMPAIRED SELF-CARE	114	7	26.32	5.98	2.79	12.84	114	7	26.38	5.99	2.79	12.86
EMBOLIC STROKE	93	5	22.54	6.83	2.78	16.81	93	5	22.59	6.85	2.78	16.83
CARDIOGENIC SHOCK	275	24	53.09	4.21	2.77	6.39	273	24	52.57	4.19	2.76	6.35
BRADYKINESIA	182	14	37.83	4.78	2.77	8.23	182	14	37.93	4.78	2.78	8.24
ANGINA PECTORIS	1095	121	176.54	3.33	2.76	4.01	1092	120	177.54	3.35	2.77	4.04
CLUSTER HEADACHE	133	9	29.43	5.43	2.76	10.67	134	9	29.85	5.48	2.79	10.76
FIBRIN D DIMER INCREASED	161	12	33.98	4.93	2.74	8.86	160	12	33.73	4.91	2.73	8.82
DEMENTIA ALZHEIMER'S TYPE	159	12	33.30	4.87	2.71	8.75	157	12	32.71	4.82	2.68	8.66
MYOCARDITIS	2022	241	302.95	3.08	2.70	3.52	2016	241	302.08	3.08	2.69	3.52
BLOOD GLUCOSE DECREASED	312	29	57.63	3.95	2.70	5.78	312	29	57.79	3.96	2.71	5.79
EJECTION FRACTION DECREASED	240	21	46.13	4.20	2.69	6.56	236	21	44.92	4.14	2.65	6.46
HAEMOGLOBIN DECREASED	109	7	24.58	5.72	2.66	12.29	106	7	23.60	5.57	2.59	11.98
PERIORBITAL SWELLING	708	78	114.12	3.34	2.64	4.21	706	78	113.83	3.33	2.64	4.21
ADNEXA UTERI PAIN	136	10	28.78	5.00	2.63	9.50	136	10	28.85	5.01	2.63	9.51
PALLIATIVE CARE	117	8	25.63	5.37	2.63	11.00	117	8	25.69	5.38	2.63	11.02
JUGULAR VEIN DISTENSION	78	4	19.08	7.17	2.62	19.57	75	4	18.07	6.90	2.52	18.87
VENTRICULAR EXTRASYSTOLES	1062	124	162.01	3.15	2.61	3.79	1055	124	160.35	3.13	2.60	3.77
PULSE ABSENT	749	84	118.71	3.28	2.61	4.10	743	84	117.19	3.26	2.60	4.08
BLOOD DISORDER	77	4	18.73	7.07	2.59	19.33	77	4	18.77	7.08	2.59	19.36
ATRIAL FIBRILLATION	3946	515	535.11	2.82	2.57	3.09	3918	514	529.80	2.81	2.56	3.08
CEREBRAL HAEMORRHAGE	440	47	72.65	3.44	2.55	4.65	438	47	72.23	3.43	2.54	4.63
GASTROINTESTINAL WALL THICKENING	66	3	16.69	8.08	2.54	25.71	66	3	16.72	8.10	2.55	25.75
SINUS RHYTHM	66	3	16.69	8.08	2.54	25.71	66	3	16.72	8.10	2.55	25.75
RESUSCITATION	1218	150	175.58	2.98	2.52	3.53	1200	150	170.66	2.94	2.48	3.49
CARDIAC DISORDER	994	120	146.29	3.04	2.52	3.68	986	120	144.30	3.02	2.50	3.65
BREAST SWELLING	759	89	114.99	3.13	2.52	3.90	757	89	114.74	3.13	2.51	3.90
MENOPAUSE	139	11	28.16	4.64	2.51	8.58	139	10	29.88	5.12	2.69	9.72
CORONARY ARTERY THROMBOSIS	65	3	16.33	7.96	2.50	25.33	66	3	16.72	8.10	2.55	25.75
DYSPNOEA EXERTIONAL	2443	321	327.65	2.80	2.49	3.14	2428	320	325.55	2.79	2.49	3.14
ATRIOVENTRICULAR BLOCK COMPLETE	93	6	20.77	5.70	2.49	13.00	93	6	20.82	5.70	2.50	13.02
LUNG DISORDER	679	80	102.26	3.12	2.47	3.93	675	80	101.35	3.11	2.46	3.92
EUPHORIC MOOD	261	26	45.45	3.69	2.46	5.52	261	26	45.58	3.69	2.47	5.53
PERICARDITIS	1695	221	229.03	2.82	2.45	3.24	1689	221	228.03	2.81	2.45	3.24
BREAST TENDERNESS	537	62	82.41	3.18	2.45	4.14	536	62	82.36	3.18	2.45	4.14

HYPERTENSIVE EMERGENCY	91	6	20.08	5.57	2.44	12.73	90	6	19.79	5.52	2.42	12.62
CARDIOMEGALY	961	120	136.17	2.94	2.43	3.56	949	120	132.97	2.91	2.41	3.52
EAR DISCOMFORT	2687	366	344.52	2.70	2.42	3.01	2677	365	344.04	2.70	2.42	3.01
SENSITIVE SKIN	1306	169	177.82	2.84	2.42	3.33	1303	168	178.81	2.85	2.43	3.35
GENERAL SYMPTOM	159	14	30.10	4.17	2.42	7.21	157	14	29.52	4.13	2.39	7.13
LYMPHADENOPATHY	21974	3245	2588.41	2.49	2.40	2.58	21943	3242	2593.06	2.49	2.40	2.58
BLOOD PRESSURE ABNORMAL	567	68	83.65	3.06	2.38	3.94	566	67	84.95	3.11	2.41	4.00
NORMAL LABOUR	62	3	15.27	7.59	2.38	24.19	62	3	15.31	7.61	2.39	24.23
VACCINATION SITE DISCOLOURATION	334	37	53.07	3.32	2.36	4.66	334	37	53.24	3.32	2.37	4.67
THALAMIC INFARCTION	70	4	16.28	6.43	2.35	17.61	70	4	16.32	6.44	2.35	17.64
PALPITATIONS	14784	2216	1687.13	2.45	2.34	2.56	14750	2215	1685.20	2.45	2.34	2.56
OCULAR DISCOMFORT	919	119	124.74	2.84	2.34	3.43	918	119	124.87	2.84	2.35	3.44
RETINAL VEIN OCCLUSION	96	7	20.12	5.04	2.34	10.85	95	7	19.83	4.99	2.32	10.76
CARDIOVERSION	569	70	81.62	2.99	2.33	3.83	569	70	81.90	2.99	2.33	3.83
PULMONARY MASS	552	68	79.04	2.98	2.32	3.84	549	67	79.70	3.02	2.34	3.89
THROMBOLYSIS	69	4	15.93	6.34	2.31	17.37	69	4	15.97	6.35	2.32	17.40
ARRHYTHMIA	1211	165	154.51	2.70	2.29	3.17	1204	165	153.01	2.69	2.28	3.16
RESPIRATORY SYMPTOM	402	48	59.34	3.08	2.28	4.15	393	48	56.76	3.01	2.23	4.07
EYE HAEMORRHAGE	308	35	47.66	3.23	2.28	4.59	307	35	47.50	3.23	2.28	4.58
LYMPHADENOPATHY MEDIASTINAL NEOPLASM	126	11	23.80	4.21	2.27	7.79	126	11	23.87	4.22	2.28	7.81
	101	8	20.18	4.64	2.26	9.53	101	8	20.23	4.65	2.26	9.54
HEART RATE DECREASED	1571	223	190.01	2.59	2.25	2.98	1564	223	188.70	2.58	2.24	2.97
PULMONARY OEDEMA	869	117	112.33	2.73	2.25	3.31	860	117	110.07	2.71	2.23	3.28
HEART RATE IRREGULAR	2151	313	251.66	2.53	2.24	2.84	2139	313	249.19	2.52	2.23	2.83
URTICARIA CHRONIC	186	19	31.44	3.60	2.24	5.77	184	19	30.89	3.56	2.22	5.72
CARDIAC FAILURE CHRONIC DISCOLOURED VOMIT	58	3	13.86	7.10	2.23	22.67	57	3	13.55	6.99	2.19	22.33
	58	3	13.86	7.10	2.23	22.67	58	3	13.90	7.12	2.23	22.71
PLATELET COUNT DECREASED	293	34	44.34	3.17	2.22	4.52	292	34	44.17	3.16	2.22	4.51
VENTRICULAR FIBRILLATION	264	30	40.73	3.23	2.22	4.72	264	30	40.86	3.24	2.22	4.72
RETINAL ARTERY OCCLUSION	107	9	20.60	4.37	2.21	8.62	107	9	20.66	4.38	2.22	8.64
HYPERTENSIVE URGENCY	122	11	22.48	4.08	2.20	7.55	122	11	22.54	4.08	2.20	7.57
BREAST CYST	74	5	15.94	5.44	2.20	13.45	74	5	15.98	5.45	2.20	13.47
LYMPH NODE PAIN	5305	828	561.04	2.35	2.19	2.53	5297	828	561.14	2.35	2.19	2.53
TONGUE ERYTHEMA	137	13	24.38	3.87	2.19	6.84	137	13	24.45	3.88	2.20	6.85
SLEEP DEFICIT	98	8	19.17	4.50	2.19	9.25	98	8	19.22	4.51	2.19	9.27
UTERINE PAIN	57	3	13.51	6.98	2.19	22.29	57	3	13.55	6.99	2.19	22.33
EPISTAXIS	2027	304	226.74	2.45	2.17	2.76	2023	304	226.51	2.45	2.17	2.76
ACUTE CORONARY SYNDROME	97	8	18.84	4.46	2.17	9.16	95	8	18.22	4.37	2.12	8.99
SWELLING OF EYELID	1122	162	132.22	2.54	2.16	3.00	1120	162	132.15	2.54	2.16	3.00
VAGINAL HAEMORRHAGE	1587	237	178.41	2.46	2.15	2.82	1580	237	177.14	2.45	2.14	2.81
IMPAIRED QUALITY OF LIFE	127	12	22.61	3.89	2.15	7.03	126	12	22.35	3.86	2.14	6.99
MIGRAINE	8296	1346	826.09	2.26	2.14	2.40	8282	1346	825.85	2.26	2.14	2.40
BREAST ENLARGEMENT	72	5	15.25	5.29	2.14	13.10	72	5	15.29	5.30	2.14	13.12
BONE SWELLING	64	4	14.20	5.88	2.14	16.14	64	4	14.23	5.89	2.14	16.17
DIVERTICULITIS	322	40	45.33	2.96	2.13	4.11	320	40	44.87	2.94	2.12	4.09
BREAST DISCOMFORT	118	11	21.17	3.94	2.12	7.31	118	11	21.23	3.95	2.13	7.32
BREAST DISCHARGE	63	4	13.85	5.79	2.11	15.90	63	4	13.88	5.80	2.11	15.93
BLOOD IRON DECREASED	55	3	12.81	6.74	2.11	21.53	55	3	12.85	6.75	2.11	21.57
VENTRICULAR TACHYCARDIA	434	58	56.22	2.75	2.09	3.62	432	58	55.83	2.74	2.08	3.61
DISORGANISED SPEECH	138	14	23.24	3.62	2.09	6.28	137	14	22.99	3.60	2.08	6.24
BLOOD URINE PRESENT	621	88	74.75	2.59	2.07	3.24	619	87	75.64	2.62	2.09	3.28
HYPERTENSIVE HEART DISEASE	247	30	35.47	3.03	2.07	4.42	243	30	34.36	2.98	2.04	4.36
VEIN DISORDER	137	14	22.92	3.60	2.07	6.23	136	14	22.67	3.58	2.06	6.20
PLEURAL EFFUSION	1377	214	145.39	2.36	2.05	2.73	1367	213	144.32	2.36	2.04	2.73
CARDIAC FAILURE CONGESTIVE	1296	200	138.32	2.38	2.05	2.76	1279	200	134.19	2.35	2.03	2.73
PRODUCT ADMINISTRATION ERROR	787	116	89.76	2.49	2.05	3.03	788	116	90.40	2.50	2.06	3.04
CHEST PAIN	21704	3783	1930.38	2.11	2.04	2.18	21658	3779	1931.29	2.11	2.04	2.18
CONDITION AGGRAVATED	18471	3207	1648.04	2.12	2.04	2.20	18394	3203	1639.40	2.11	2.04	2.19
PANIC ATTACK	1249	193	133.00	2.38	2.04	2.77	1245	193	132.43	2.37	2.04	2.76
DIABETIC KETOACIDOSIS	223	27	32.05	3.03	2.04	4.52	221	27	31.55	3.01	2.02	4.49
FEAR OF INJECTION	227	28	31.97	2.98	2.01	4.41	227	28	32.08	2.98	2.02	4.42
VACCINATION SITE INDURATION	1197	189	123.05	2.33	2.00	2.71	1197	188	124.64	2.34	2.01	2.73
SUPRAVENTRICULAR EXTRASYSTOLES	296	39	38.78	2.79	2.00	3.89	291	39	37.44	2.75	1.97	3.84
CROHN'S DISEASE	193	23	28.11	3.08	2.00	4.75	193	23	28.21	3.09	2.00	4.76
INJECTION SITE LYMPHADENOPATHY	125	13	20.51	3.53	2.00	6.25	125	13	20.57	3.54	2.00	6.26
FEAR	912	142	95.72	2.36	1.98	2.82	908	141	96.10	2.37	1.98	2.83
SUPRAVENTRICULAR TACHYCARDIA	558	82	63.70	2.50	1.98	3.15	555	82	63.10	2.49	1.98	3.14
LEFT ATRIAL ENLARGEMENT	96	9	16.98	3.92	1.98	7.76	95	9	16.70	3.88	1.96	7.70
VENTRICULAR HYPERTROPHY	67	5	13.55	4.92	1.98	12.22	65	5	12.91	4.78	1.93	11.88
HOT FLUSH	3463	593	310.53	2.15	1.97	2.34	3459	590	313.89	2.16	1.98	2.35
PHARYNGEAL HYPOAESTHESIA	464	67	54.20	2.54	1.97	3.29	464	67	54.41	2.55	1.97	3.29
HEART VALVE INCOMPETENCE	74	6	14.31	4.53	1.97	10.41	74	6	14.35	4.54	1.98	10.43
SUDDEN CARDIAC DEATH	74	6	14.31	4.53	1.97	10.41	74	6	14.35	4.54	1.98	10.43

PERIPHERAL ISCHAEMIA	59	4	12.48	5.42	1.97	14.92	58	4	12.17	5.34	1.94	14.70
ACUTE RESPIRATORY DISTRESS SYNDROME	455	66	52.79	2.53	1.96	3.28	447	66	50.72	2.49	1.93	3.23
PULMONARY FIBROSIS	228	29	30.99	2.89	1.96	4.25	223	29	29.60	2.83	1.92	4.17
IMPLANTABLE DEFIBRILLATOR INSERTION	88	8	15.86	4.04	1.96	8.33	88	8	15.90	4.05	1.96	8.35
BLOOD GLUCOSE INCREASED	843	132	87.61	2.35	1.95	2.82	843	132	87.97	2.35	1.96	2.82
NIPPLE PAIN	122	13	19.56	3.45	1.95	6.11	121	13	19.30	3.43	1.93	6.07
DIZZINESS EXERTIONAL	51	3	11.42	6.25	1.95	20.01	51	3	11.45	6.26	1.95	20.05
INTERSTITIAL LUNG DISEASE	250	33	32.56	2.78	1.94	4.00	250	33	32.67	2.79	1.94	4.01
SKIN SENSITISATION	174	21	24.92	3.04	1.94	4.79	173	21	24.70	3.03	1.93	4.77
HEPATIC CIRRHOSIS	155	18	23.04	3.16	1.94	5.15	152	18	22.19	3.11	1.91	5.07
HORMONE LEVEL ABNORMAL	101	10	17.13	3.71	1.94	7.11	101	10	17.18	3.72	1.94	7.12
TACHYPNOEA	1544	258	144.16	2.20	1.93	2.51	1527	257	141.33	2.19	1.92	2.50
SINUS PAIN	508	76	56.40	2.46	1.93	3.13	501	76	54.66	2.43	1.91	3.09
ASCITES	205	26	27.88	2.90	1.93	4.36	203	26	27.38	2.87	1.91	4.32
CORONARY ARTERY DISEASE	748	118	76.71	2.33	1.92	2.83	734	116	75.35	2.33	1.91	2.83
DIALYSIS	285	39	35.54	2.69	1.92	3.75	281	39	34.51	2.65	1.90	3.71
ARTERIOSCLEROSIS CORONARY ARTERY	272	37	34.15	2.70	1.92	3.81	271	36	35.20	2.77	1.96	3.92
THROMBOPHLEBITIS SUPERFICIAL	140	16	21.08	3.22	1.92	5.39	140	16	21.15	3.22	1.92	5.40
PERICARDIAL DRAINAGE	100	10	16.80	3.67	1.92	7.04	99	10	16.53	3.64	1.90	6.98
INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION	65	5	12.88	4.78	1.92	11.86	64	5	12.58	4.71	1.90	11.70
LUNG HYPERINFLATION	65	5	12.88	4.78	1.92	11.86	65	5	12.91	4.78	1.93	11.88
PARAESTHESIA ORAL	6340	1146	512.94	2.03	1.91	2.16	6337	1146	514.70	2.04	1.91	2.17
VACCINATION SITE WARMTH	3309	584	279.71	2.08	1.91	2.27	3309	583	282.00	2.09	1.91	2.28
FEEDING DISORDER	1476	248	136.39	2.19	1.91	2.50	1466	248	134.38	2.18	1.90	2.49
VACCINATION SITE REACTION	1279	214	118.98	2.20	1.90	2.54	1276	214	118.72	2.19	1.90	2.54
POLYURIA	330	47	39.09	2.58	1.90	3.50	323	47	37.24	2.53	1.86	3.43
BREAST PAIN	1967	340	172.65	2.13	1.89	2.38	1964	340	172.67	2.13	1.89	2.39
TRANSIENT ISCHAEMIC ATTACK	783	126	77.71	2.28	1.89	2.76	781	126	77.50	2.28	1.89	2.75
SMALL INTESTINAL OBSTRUCTION	164	20	23.17	3.01	1.89	4.79	164	20	23.25	3.02	1.90	4.80
SUDDEN DEATH	164	20	23.17	3.01	1.89	4.79	163	20	22.95	3.00	1.89	4.77
AUTOSCOPY	85	8	14.88	3.90	1.89	8.06	85	8	14.92	3.91	1.89	8.07
HEPATIC LESION	64	5	12.54	4.70	1.89	11.69	64	4	14.23	5.89	2.14	16.17
HILAR LYMPHADENOPATHY	64	5	12.54	4.70	1.89	11.69	64	5	12.58	4.71	1.90	11.70
VACCINATION FAILURE	2370	418	200.18	2.08	1.88	2.31	2274	413	181.69	2.03	1.82	2.25
RENAL IMPAIRMENT	431	65	47.16	2.44	1.88	3.16	428	65	46.51	2.42	1.87	3.15
UNRESPONSIVE TO STIMULI	4478	818	353.29	2.01	1.87	2.17	4464	816	353.41	2.01	1.87	2.17
UTERINE SPASM	130	15	19.32	3.18	1.87	5.43	130	15	19.39	3.19	1.87	5.44
HAEMORRHAGIC STROKE	124	14	18.81	3.25	1.87	5.66	121	14	17.94	3.18	1.83	5.53
SEPTIC SHOCK	636	102	63.34	2.29	1.86	2.82	628	102	61.46	2.27	1.84	2.79
GASTROINTESTINAL HAEMORRHAGE	467	72	49.43	2.38	1.86	3.05	466	72	49.35	2.38	1.86	3.05
TOXIC ENCEPHALOPATHY	117	13	17.98	3.31	1.86	5.87	116	13	17.73	3.28	1.85	5.83
MENTAL FATIGUE	77	7	13.76	4.04	1.86	8.76	77	7	13.80	4.05	1.87	8.78
SINUS OPERATION	251	35	30.43	2.64	1.85	3.75	247	35	29.39	2.60	1.82	3.70
MOUTH SWELLING	935	158	85.20	2.17	1.84	2.57	934	157	86.33	2.19	1.85	2.59
HYPERKALAEMIA	416	64	44.10	2.39	1.84	3.11	412	64	43.18	2.37	1.82	3.08
NASAL DRYNESS	122	14	18.19	3.20	1.84	5.57	121	14	17.94	3.18	1.83	5.53
PNEUMONITIS	272	39	31.79	2.56	1.83	3.58	270	39	31.34	2.55	1.82	3.56
RENAL INFARCT	55	4	11.12	5.05	1.83	13.94	55	4	11.15	5.06	1.83	13.96
ALOPECIA	1432	254	119.20	2.07	1.81	2.37	1425	254	118.00	2.06	1.81	2.36
NEW DAILY PERSISTENT HEADACHE	68	6	12.32	4.16	1.81	9.59	68	6	12.36	4.17	1.81	9.61
BLOOD PRESSURE FLUCTUATION	486	78	48.18	2.29	1.80	2.91	485	78	48.12	2.29	1.80	2.91
SYSTOLIC DYSFUNCTION	61	5	11.54	4.48	1.80	11.16	60	5	11.24	4.42	1.77	11.00
HYPOGEUSIA	155	20	20.46	2.85	1.79	4.54	155	20	20.53	2.85	1.79	4.54
CARDITIS	87	9	14.08	3.55	1.79	7.06	86	9	13.80	3.52	1.77	6.99
OXYGEN SATURATION ABNORMAL	87	9	14.08	3.55	1.79	7.06	84	9	13.17	3.44	1.73	6.83
INSULIN THERAPY	47	3	10.05	5.76	1.79	18.49	46	3	9.73	5.64	1.76	18.14
ATRIAL FLUTTER	371	58	38.25	2.35	1.78	3.10	366	58	37.05	2.32	1.76	3.06
SUBDURAL HAEMATOMA	160	21	20.71	2.80	1.78	4.41	159	21	20.49	2.79	1.77	4.39
MUSCLE DISCOMFORT	194	27	23.41	2.64	1.77	3.95	194	26	24.70	2.75	1.82	4.14
CHEST TUBE INSERTION	164	22	20.66	2.74	1.76	4.27	163	22	20.45	2.73	1.75	4.26
SHOCK HAEMORRHAGIC	53	4	10.45	4.87	1.76	13.45	53	4	10.47	4.88	1.77	13.47
ARTERIOSCLEROSIS	574	97	52.04	2.17	1.75	2.70	563	97	49.42	2.14	1.72	2.65
BRAIN INJURY	192	27	22.84	2.61	1.75	3.91	188	27	21.78	2.56	1.71	3.84
COMA SCALE ABNORMAL	128	16	17.41	2.94	1.75	4.94	127	16	17.17	2.92	1.74	4.91
PSORIATIC ARTHROPATHY	116	14	16.34	3.04	1.75	5.30	116	14	16.40	3.05	1.75	5.31
CARDIAC TAMPONADE	85	9	13.45	3.47	1.75	6.90	84	9	13.17	3.44	1.73	6.83
SEDATION	242	36	26.72	2.47	1.74	3.51	241	36	26.55	2.46	1.74	3.50
BREAST CANCER	59	5	10.88	4.34	1.74	10.80	58	5	10.58	4.27	1.71	10.64
DENTAL DISCOMFORT	59	5	10.88	4.34	1.74	10.80	59	5	10.91	4.34	1.74	10.82
SKIN SWELLING	720	127	60.25	2.08	1.73	2.52	720	127	60.54	2.09	1.73	2.52
USE OF ACCESSORY RESPIRATORY MUSCLES	196	28	22.82	2.57	1.73	3.82	193	28	22.05	2.54	1.71	3.77
ARTERIAL OCCLUSIVE DISEASE	78	8	12.63	3.58	1.73	7.42	77	8	12.35	3.54	1.71	7.34
ATRIAL ENLARGEMENT	52	4	10.11	4.78	1.73	13.21	50	4	9.47	4.60	1.66	12.74

INCORRECT PRODUCT FORMULATION ADMINISTERED	701	124	58.31	2.08	1.72	2.51	698	124	57.83	2.07	1.71	2.51
AORTIC ANEURYSM	132	17	17.35	2.85	1.72	4.73	131	17	17.11	2.84	1.71	4.70
INCREASED APPETITE	90	10	13.64	3.31	1.72	6.36	90	10	13.68	3.31	1.72	6.37
THYROID MASS	154	21	18.95	2.69	1.71	4.25	153	21	18.73	2.68	1.70	4.23
DISCHARGE	113	14	15.44	2.97	1.70	5.17	110	13	15.87	3.11	1.75	5.53
VASCULAR PAIN	107	13	14.90	3.02	1.70	5.38	106	13	14.65	3.00	1.69	5.34
RENAL PAIN	619	110	50.94	2.07	1.69	2.53	618	110	50.93	2.07	1.69	2.53
LIP PRURITUS	374	62	34.88	2.22	1.69	2.90	373	62	34.78	2.21	1.69	2.90
HYPERCAPNIA	235	36	24.78	2.40	1.69	3.41	232	36	24.05	2.37	1.67	3.37
ASTHENOPIA	370	62	33.84	2.19	1.68	2.87	370	62	33.99	2.20	1.68	2.87
COLITIS	335	55	31.72	2.24	1.68	2.98	333	55	31.33	2.23	1.68	2.96
LEFT VENTRICULAR DYSFUNCTION	223	34	23.65	2.41	1.68	3.46	218	34	22.38	2.36	1.64	3.39
CHRONIC RESPIRATORY FAILURE	94	11	13.54	3.14	1.68	5.86	92	11	12.97	3.08	1.65	5.75
NEPHROSCLEROSIS	57	5	10.22	4.19	1.68	10.45	57	5	10.25	4.20	1.68	10.47
ACQUIRED DIAPHRAGMATIC EVENTRATION	63	6	10.69	3.86	1.67	8.91	61	6	10.08	3.74	1.62	8.66
CORONARY ANGIOPLASTY	44	3	9.02	5.39	1.67	17.36	44	3	9.05	5.40	1.68	17.38
IMMUNE-MEDIATED ADVERSE REACTION	44	3	9.02	5.39	1.67	17.36	44	3	9.05	5.40	1.68	17.38
PHYSICAL DECONDITIONING	161	23	18.62	2.57	1.66	3.98	157	23	17.56	2.51	1.62	3.89
METAMORPHOPSIA	144	20	17.24	2.65	1.66	4.22	144	20	17.30	2.65	1.66	4.23
MUSCLE STRENGTH ABNORMAL	116	15	15.08	2.84	1.66	4.87	115	15	14.84	2.82	1.65	4.83
ISCHAEMIC CARDIOMYOPATHY	93	11	13.24	3.11	1.66	5.80	92	11	12.97	3.08	1.65	5.75
CORONARY ARTERY STENOSIS	81	9	12.19	3.31	1.66	6.58	81	9	12.23	3.31	1.66	6.60
THYROIDITIS	81	9	12.19	3.31	1.66	6.58	81	9	12.23	3.31	1.66	6.60
ACUTE PULMONARY OEDEMA	69	7	11.18	3.62	1.66	7.88	69	7	11.22	3.63	1.67	7.89
CHEST INJURY	50	4	9.44	4.59	1.66	12.72	50	4	9.47	4.60	1.66	12.74
ABNORMAL DREAMS	515	92	41.82	2.06	1.65	2.57	515	92	42.02	2.06	1.65	2.57
HAEMORRHAGE INTRACRANIAL	149	21	17.51	2.61	1.65	4.12	145	21	16.43	2.54	1.61	4.02
VACCINATION SITE BRUISING	521	94	41.45	2.04	1.64	2.54	522	94	41.90	2.04	1.64	2.55
METABOLIC ENCEPHALOPATHY	443	78	36.96	2.09	1.64	2.65	438	78	35.88	2.07	1.62	2.63
LYMPHOEDEMA	321	54	29.06	2.18	1.64	2.91	321	53	30.20	2.23	1.67	2.98
HUNGER	202	31	21.14	2.39	1.64	3.49	200	31	20.68	2.37	1.63	3.47
LACUNAR INFARCTION	109	14	14.24	2.86	1.64	4.99	109	14	14.29	2.87	1.64	5.00
AORTIC DILATATION	74	8	11.37	3.40	1.64	7.05	74	8	11.40	3.40	1.64	7.06
POOR PERIPHERAL CIRCULATION	125	17	15.29	2.70	1.63	4.48	124	17	15.06	2.68	1.62	4.46
SUBARACHNOID HAEMORRHAGE	194	30	20.03	2.38	1.62	3.49	193	30	19.84	2.37	1.61	3.48
ANGINA UNSTABLE	61	6	10.05	3.74	1.62	8.64	60	6	9.76	3.68	1.59	8.52
THYROIDITIS SUBACUTE	49	4	9.11	4.50	1.62	12.47	49	4	9.14	4.51	1.63	12.49
COSTOCHONDRITIS	245	40	23.25	2.25	1.61	3.14	243	40	22.83	2.24	1.60	3.12
HYPOTHERMIA	177	27	18.62	2.41	1.61	3.61	177	27	18.69	2.41	1.61	3.62
BASEDOW'S DISEASE	145	21	16.37	2.54	1.61	4.01	145	21	16.43	2.54	1.61	4.02
HYPOSMIA	107	14	13.65	2.81	1.61	4.90	106	14	13.40	2.79	1.60	4.87
VASODILATATION	149	22	16.37	2.49	1.59	3.89	148	22	16.15	2.48	1.58	3.87
HIP FRACTURE	138	20	15.53	2.54	1.59	4.05	138	20	15.59	2.54	1.59	4.06
ANGIOPLASTY	72	8	10.75	3.31	1.59	6.87	72	8	10.78	3.31	1.60	6.88
AUTOIMMUNE HEPATITIS	60	6	9.73	3.67	1.59	8.50	60	6	9.76	3.68	1.59	8.52
CHOLECYSTITIS ACUTE	60	6	9.73	3.67	1.59	8.50	58	6	9.13	3.56	1.54	8.25
SPLENIC INFARCTION	54	5	9.25	3.97	1.59	9.92	53	5	8.95	3.90	1.56	9.76
AORTIC VALVE STENOSIS	42	3	8.35	5.14	1.59	16.60	42	3	8.37	5.15	1.60	16.62
CEREBRAL VENOUS THROMBOSIS	42	3	8.35	5.14	1.59	16.60	42	3	8.37	5.15	1.60	16.62
HYPOSMOLAR STATE	42	3	8.35	5.14	1.59	16.60	42	3	8.37	5.15	1.60	16.62
PARANASAL SINUS INFLAMMATION	42	3	8.35	5.14	1.59	16.60	42	3	8.37	5.15	1.60	16.62
RED BLOOD CELL COUNT DECREASED	42	3	8.35	5.14	1.59	16.60	42	3	8.37	5.15	1.60	16.62
BUNDLE BRANCH BLOCK RIGHT	280	48	24.38	2.14	1.58	2.91	279	48	24.24	2.14	1.57	2.91
AORTIC STENOSIS	132	19	14.97	2.55	1.58	4.13	130	19	14.46	2.52	1.56	4.08
FAILURE TO THRIVE	189	30	18.68	2.31	1.57	3.40	188	30	18.49	2.31	1.57	3.39
HYPOAESTHESIA EYE	163	25	16.94	2.40	1.57	3.65	162	25	16.74	2.38	1.57	3.63
INTRACRANIAL ANEURYSM	82	10	11.19	3.01	1.56	5.81	82	10	11.23	3.02	1.57	5.82
INFLAMMATORY MARKER INCREASED	53	5	8.92	3.89	1.56	9.74	52	5	8.63	3.83	1.53	9.58
PATIENT UNCOOPERATIVE	47	4	8.45	4.32	1.56	11.98	47	4	8.48	4.32	1.56	12.00
PUPIL FIXED	347	63	27.05	2.02	1.55	2.65	347	63	27.18	2.03	1.55	2.65
EAR DISORDER	166	26	16.69	2.35	1.55	3.55	166	26	16.76	2.35	1.55	3.55
BOWEL MOVEMENT IRREGULARITY	234	40	20.39	2.15	1.54	3.01	234	40	20.48	2.15	1.54	3.01
MYOCARDIAL ISCHAEMIA	165	26	16.42	2.33	1.54	3.53	164	26	16.22	2.32	1.53	3.51
C-REACTIVE PROTEIN INCREASED	92	12	11.67	2.82	1.54	5.14	92	12	11.72	2.82	1.55	5.15
IRREGULAR BREATHING	81	10	10.89	2.98	1.54	5.74	81	10	10.93	2.98	1.55	5.75
CORONAVIRUS INFECTION	52	5	8.60	3.82	1.53	9.57	52	5	8.63	3.83	1.53	9.58
INTRAVENTRICULAR HAEMORRHAGE	52	5	8.60	3.82	1.53	9.57	52	5	8.63	3.83	1.53	9.58
ATRIOVENTRICULAR BLOCK	163	26	15.88	2.30	1.52	3.48	163	26	15.95	2.31	1.53	3.49
BLOOD THYROID STIMULATING HORMONE INCREASED	46	4	8.13	4.23	1.52	11.74	46	4	8.15	4.23	1.52	11.76
EPIDIDYMITIS	40	3	7.68	4.90	1.52	15.84	40	3	7.70	4.91	1.52	15.86

GINGIVAL BLEEDING	273	49	21.67	2.05	1.51	2.77	272	49	21.53	2.04	1.51	2.77
HYPERTHYROIDISM	206	35	18.08	2.16	1.51	3.09	205	34	18.90	2.22	1.54	3.19
NONINFECTIVE GINGIVITIS	90	12	11.09	2.76	1.51	5.03	90	12	11.13	2.76	1.51	5.04
COLITIS MICROSCOPIC	74	9	10.05	3.02	1.51	6.03	74	9	10.09	3.03	1.51	6.04
MAST CELL ACTIVATION SYNDROME	74	9	10.05	3.02	1.51	6.03	73	9	9.78	2.99	1.49	5.97
PUPILLARY LIGHT REFLEX TESTS ABNORMAL	63	7	9.30	3.31	1.51	7.22	63	7	9.33	3.31	1.52	7.23
MEDICAL DIET	57	6	8.79	3.49	1.51	8.10	56	6	8.50	3.44	1.48	7.97
HAEMODIALYSIS	190	32	16.90	2.18	1.50	3.17	188	32	16.47	2.16	1.49	3.15
LUNG NEOPLASM MALIGNANT	105	15	11.89	2.57	1.50	4.42	104	15	11.66	2.55	1.49	4.38
HEPATIC PAIN	100	14	11.62	2.62	1.50	4.59	100	14	11.66	2.63	1.50	4.60
EMBOLISM VENOUS	51	5	8.28	3.75	1.50	9.39	49	5	7.68	3.61	1.44	9.05
RED BLOOD CELL SEDIMENTATION RATE INCREASED	51	5	8.28	3.75	1.50	9.39	51	5	8.31	3.75	1.50	9.41
APPETITE DISORDER	125	19	13.02	2.42	1.49	3.92	124	19	12.80	2.40	1.48	3.89
BLOOD GLUCOSE ABNORMAL	94	13	11.06	2.66	1.49	4.75	94	13	11.11	2.66	1.49	4.75
BLADDER PAIN	89	12	10.80	2.73	1.49	4.98	89	12	10.84	2.73	1.49	4.99
EMBOLISM	73	9	9.75	2.98	1.49	5.96	73	9	9.78	2.99	1.49	5.97
HYPERCOAGULATION	73	9	9.75	2.98	1.49	5.96	73	9	9.78	2.99	1.49	5.97
BREATH SOUNDS ABSENT	45	4	7.80	4.13	1.49	11.49	45	4	7.82	4.14	1.49	11.51
ISCHAEMIC CEREBRAL INFARCTION	45	4	7.80	4.13	1.49	11.49	45	4	7.82	4.14	1.49	11.51
MUCOSAL DISORDER	45	4	7.80	4.13	1.49	11.49	45	4	7.82	4.14	1.49	11.51
BILIARY COLIC	56	6	8.47	3.43	1.48	7.96	56	6	8.50	3.44	1.48	7.97
HYPORESPONSIVE TO STIMULI	242	44	18.63	2.02	1.47	2.79	240	44	18.23	2.01	1.46	2.77
COAGULOPATHY	205	36	16.87	2.09	1.47	2.98	202	36	16.20	2.07	1.45	2.94
COLITIS ULCERATIVE	200	35	16.56	2.10	1.47	3.01	200	35	16.63	2.10	1.47	3.01
MELAENA	176	30	15.26	2.16	1.46	3.17	175	30	15.08	2.15	1.46	3.16
NORMOCYTIC ANAEMIA	127	20	12.50	2.33	1.46	3.74	127	19	13.63	2.46	1.52	3.98
CARDIOVASCULAR DISORDER	122	19	12.20	2.36	1.46	3.83	118	19	11.18	2.29	1.41	3.71
FEMUR FRACTURE	82	11	9.96	2.74	1.46	5.14	82	11	10.00	2.74	1.46	5.15
CORONARY ARTERY BYPASS	107	16	11.33	2.46	1.45	4.16	107	16	11.38	2.46	1.46	4.16
THERMAL BURN	107	16	11.33	2.46	1.45	4.16	107	16	11.38	2.46	1.46	4.16
CARDIAC VALVE DISEASE	55	6	8.16	3.37	1.45	7.82	52	6	7.27	3.19	1.37	7.43
TESTICULAR PAIN	206	37	16.18	2.05	1.44	2.90	206	37	16.26	2.05	1.44	2.91
PARKINSON'S DISEASE	135	22	12.56	2.25	1.44	3.54	131	22	11.58	2.19	1.40	3.44
LANGUAGE DISORDER	38	3	7.01	4.65	1.44	15.08	38	3	7.03	4.66	1.44	15.10
ORAL LICHEN PLANUS	38	3	7.01	4.65	1.44	15.08	38	3	7.03	4.66	1.44	15.10
EMPHYSEMA	213	39	16.08	2.01	1.43	2.82	213	39	16.16	2.01	1.43	2.83
EYE CONTUSION	130	21	12.26	2.27	1.43	3.61	130	21	12.32	2.28	1.44	3.61
FEEDING TUBE USER	49	5	7.65	3.60	1.43	9.04	49	5	7.68	3.61	1.44	9.05
VACCINATION SITE DISCHARGE	49	5	7.65	3.60	1.43	9.04	49	5	7.68	3.61	1.44	9.05
DISSOCIATION	138	23	12.35	2.20	1.42	3.43	138	23	12.40	2.21	1.42	3.43
GASTROINTESTINAL INFLAMMATION	90	13	9.93	2.54	1.42	4.55	90	13	9.97	2.55	1.42	4.56
WHITE BLOOD CELL COUNT DECREASED	85	12	9.65	2.60	1.42	4.76	85	12	9.69	2.61	1.42	4.77
ENTERAL NUTRITION	43	4	7.16	3.95	1.42	11.00	42	4	6.86	3.86	1.39	10.78
LEG AMPUTATION	43	4	7.16	3.95	1.42	11.00	43	4	7.18	3.96	1.42	11.02
MENOMETRORRHAGIA	43	4	7.16	3.95	1.42	11.00	43	4	7.18	3.96	1.42	11.02
PERICARDIAL EXCISION	43	4	7.16	3.95	1.42	11.00	43	4	7.18	3.96	1.42	11.02
ISCHAEMIA	99	15	10.22	2.43	1.41	4.17	99	15	10.27	2.43	1.41	4.18
COLECTOMY	69	9	8.57	2.82	1.41	5.64	68	9	8.31	2.78	1.39	5.57
INTESTINAL ISCHAEMIA	64	8	8.32	2.94	1.41	6.13	63	8	8.05	2.90	1.39	6.05
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	59	7	8.08	3.10	1.41	6.78	59	7	8.10	3.10	1.42	6.79
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	59	7	8.08	3.10	1.41	6.78	58	7	7.80	3.05	1.39	6.68
HORDEOLUM	155	27	12.81	2.11	1.40	3.17	154	27	12.62	2.10	1.39	3.16
ACIDOSIS	113	18	10.84	2.31	1.40	3.79	112	18	10.62	2.29	1.39	3.77
PERITONITIS	53	6	7.55	3.25	1.40	7.55	53	6	7.57	3.25	1.40	7.56
FOOD AVERSION	48	5	7.34	3.53	1.40	8.86	47	5	7.05	3.46	1.38	8.70
ESCHERICHIA BACTERAEMIA	37	3	6.68	4.53	1.40	14.70	37	3	6.70	4.54	1.40	14.72
COMMUNICATION DISORDER	177	32	13.63	2.03	1.39	2.96	176	32	13.46	2.02	1.39	2.95
STRESS CARDIOMYOPATHY	88	13	9.37	2.49	1.39	4.45	88	13	9.41	2.49	1.39	4.46
STAPHYLOCOCCAL BACTERAEMIA	83	12	9.09	2.54	1.39	4.66	81	12	8.57	2.48	1.35	4.56
CHRONIC LYMPHOCYTIC LEUKAEMIA	73	10	8.54	2.68	1.39	5.19	73	10	8.57	2.69	1.39	5.20
PNEUMOMEDIASTINUM	58	7	7.78	3.04	1.39	6.67	58	7	7.80	3.05	1.39	6.68
MYOCARDIAL OEDEMA	42	4	6.84	3.86	1.38	10.76	42	4	6.86	3.86	1.39	10.78
RESPIRATORY ACIDOSIS	82	12	8.81	2.51	1.37	4.60	81	12	8.57	2.48	1.35	4.56
VITILIGO	82	12	8.81	2.51	1.37	4.60	80	12	8.30	2.45	1.34	4.50
BREAST INFLAMMATION	52	6	7.24	3.18	1.37	7.41	52	6	7.27	3.19	1.37	7.43
SUFFOCATION FEELING	47	5	7.03	3.45	1.37	8.68	47	5	7.05	3.46	1.38	8.70
PANCREATITIS ACUTE	159	29	11.96	2.01	1.36	2.99	159	29	12.02	2.02	1.36	3.00
ADULT FAILURE TO THRIVE	62	8	7.73	2.85	1.36	5.95	62	8	7.76	2.85	1.37	5.96
BUNDLE BRANCH BLOCK LEFT	158	29	11.72	2.00	1.35	2.97	158	29	11.78	2.01	1.35	2.98
GLOSSITIS	141	25	11.19	2.07	1.35	3.17	141	25	11.25	2.08	1.36	3.18
FAECES SOFT	104	17	9.48	2.25	1.35	3.75	104	17	9.52	2.25	1.35	3.76
CRANIOTOMY	76	11	8.25	2.54	1.35	4.78	74	11	7.73	2.48	1.31	4.66
LAPAROSCOPIC SURGERY	131	23	10.57	2.09	1.34	3.26	130	23	10.37	2.08	1.34	3.24
BRONCHIAL WALL THICKENING	56	7	7.18	2.94	1.34	6.45	56	7	7.21	2.94	1.34	6.46
BRAIN HERNIATION	51	6	6.94	3.12	1.34	7.28	50	6	6.66	3.07	1.32	7.15
JAW DISORDER	116	20	9.63	2.13	1.33	3.43	116	20	9.68	2.13	1.33	3.43

HYDRONEPHROSIS	107	18	9.27	2.18	1.33	3.60	105	18	8.80	2.15	1.30	3.54
SICK RELATIVE	70	10	7.69	2.57	1.33	4.99	68	10	7.17	2.50	1.29	4.86
SKIN TEXTURE ABNORMAL	70	10	7.69	2.57	1.33	4.99	70	10	7.72	2.58	1.33	5.00
ALOPECIA AREATA	120	21	9.69	2.10	1.32	3.34	119	21	9.49	2.09	1.31	3.32
CAROTID ARTERY OCCLUSION	65	9	7.42	2.65	1.32	5.33	65	9	7.44	2.66	1.32	5.34
FEBRILE NEUTROPENIA	60	8	7.15	2.76	1.32	5.76	60	8	7.17	2.76	1.32	5.77
DECREASED NASOLABIAL FOLD	35	3	6.03	4.29	1.32	13.94	35	3	6.05	4.29	1.32	13.96
PANCREATIC CARCINOMA	35	3	6.03	4.29	1.32	13.94	35	3	6.05	4.29	1.32	13.96
CACHEXIA	123	22	9.51	2.05	1.31	3.23	122	22	9.32	2.04	1.30	3.21
VACCINATION SITE VESICLES	92	15	8.35	2.25	1.31	3.89	92	15	8.39	2.26	1.31	3.90
ELECTROCARDIOGRAM T WAVE INVERSION	88	14	8.31	2.31	1.31	4.06	89	14	8.62	2.34	1.33	4.11
ANGIOPATHY	74	11	7.70	2.47	1.31	4.66	72	11	7.19	2.41	1.28	4.54
PLASMA CELL MYELOMA	69	10	7.41	2.54	1.31	4.92	69	10	7.44	2.54	1.31	4.93
BLOOD URINE	45	5	6.41	3.31	1.31	8.33	45	5	6.43	3.31	1.31	8.34
RIGHT VENTRICULAR FAILURE	45	5	6.41	3.31	1.31	8.33	45	5	6.43	3.31	1.31	8.34
CIRCUMORAL SWELLING	40	4	6.20	3.67	1.31	10.27	40	4	6.22	3.68	1.32	10.29
MUCOSAL HYPERTROPHY	40	4	6.20	3.67	1.31	10.27	39	4	5.91	3.59	1.28	10.04
RENAL TRANSPLANT	40	4	6.20	3.67	1.31	10.27	40	4	6.22	3.68	1.32	10.29
TYPE IV HYPERSENSITIVITY REACTION	131	24	9.66	2.01	1.30	3.10	131	24	9.71	2.01	1.30	3.10
IMMUNOSUPPRESSION	105	18	8.76	2.14	1.30	3.53	103	18	8.30	2.11	1.28	3.47
PALATAL SWELLING	82	13	7.75	2.32	1.29	4.16	81	13	7.52	2.29	1.28	4.12
CONTRACEPTION	49	6	6.34	3.00	1.29	7.00	49	6	6.36	3.01	1.29	7.02
SPINAL STENOSIS	99	17	8.20	2.14	1.28	3.58	98	17	7.99	2.12	1.27	3.55
HANGOVER	95	16	8.14	2.18	1.28	3.71	95	16	8.18	2.19	1.29	3.71
SKIN ODOUR ABNORMAL	86	14	7.79	2.26	1.28	3.97	86	14	7.82	2.26	1.29	3.98
GANGRENE	44	5	6.10	3.23	1.28	8.15	43	5	5.82	3.17	1.25	7.99
INTRACRANIAL MASS	44	5	6.10	3.23	1.28	8.15	44	5	6.13	3.24	1.28	8.17
ATTENTION DEFICIT/HYPERACTIVITY DISORDER	39	4	5.89	3.58	1.28	10.02	39	4	5.91	3.59	1.28	10.04
BASAL GANGLIA INFARCTION	39	4	5.89	3.58	1.28	10.02	39	4	5.91	3.59	1.28	10.04
ANTIPHOSPHOLIPID SYNDROME	34	3	5.71	4.16	1.28	13.56	34	3	5.73	4.17	1.28	13.58
COR PULMONALE	34	3	5.71	4.16	1.28	13.56	34	3	5.73	4.17	1.28	13.58
PHANTOM LIMB SYNDROME	34	3	5.71	4.16	1.28	13.56	34	3	5.73	4.17	1.28	13.58
UPPER GASTROINTESTINAL HAEMORRHAGE	81	13	7.49	2.29	1.27	4.11	81	13	7.52	2.29	1.28	4.12
LICHEN PLANUS	115	21	8.47	2.01	1.26	3.20	115	21	8.51	2.02	1.27	3.21
MASTITIS	106	19	8.08	2.05	1.26	3.34	106	19	8.12	2.05	1.26	3.35
DYSPNOEA PAROXYSMAL NOCTURNAL	57	8	6.29	2.62	1.25	5.49	57	8	6.32	2.62	1.25	5.50
PULMONARY HAEMORRHAGE	43	5	5.80	3.16	1.25	7.98	43	5	5.82	3.17	1.25	7.99
VENOUS THROMBOSIS LIMB FIBROSIS	43	5	5.80	3.16	1.25	7.98	43	5	5.82	3.17	1.25	7.99
THIRST DECREASED	38	4	5.58	3.49	1.25	9.78	38	4	5.60	3.50	1.25	9.80
VACCINATION SITE JOINT PAIN	38	4	5.58	3.49	1.25	9.78	38	4	5.60	3.50	1.25	9.80
LOWER RESPIRATORY TRACT CONGESTION	83	14	7.02	2.18	1.24	3.84	79	14	6.05	2.08	1.18	3.67
INNER EAR INFLAMMATION	33	3	5.39	4.04	1.24	13.18	33	3	5.40	4.05	1.24	13.20
CONGESTIVE CARDIOMYOPATHY	91	16	7.14	2.09	1.23	3.56	88	16	6.44	2.02	1.19	3.45
ANTIBIOTIC THERAPY	65	10	6.32	2.39	1.23	4.65	65	10	6.35	2.39	1.23	4.66
CUTANEOUS VASCULITIS	47	6	5.75	2.88	1.23	6.73	47	6	5.78	2.88	1.23	6.74
HIDRADENITIS	42	5	5.50	3.09	1.22	7.80	42	5	5.52	3.09	1.22	7.81
URETERAL STENT INSERTION	42	5	5.50	3.09	1.22	7.80	42	5	5.52	3.09	1.22	7.81
PATIENT ISOLATION	51	7	5.74	2.68	1.21	5.90	51	7	5.76	2.68	1.22	5.91
HEMIPLEGIC MIGRAINE	37	4	5.27	3.40	1.21	9.54	37	4	5.29	3.40	1.21	9.55
NEUTROPHILIA	37	4	5.27	3.40	1.21	9.54	37	4	5.29	3.40	1.21	9.55
RIGHT ATRIAL DILATATION	37	4	5.27	3.40	1.21	9.54	36	4	4.98	3.31	1.18	9.31
STENOSIS	37	4	5.27	3.40	1.21	9.54	37	4	5.29	3.40	1.21	9.55
WRONG TECHNIQUE IN DEVICE USAGE PROCESS	37	4	5.27	3.40	1.21	9.54	37	4	5.29	3.40	1.21	9.55
MENIERE'S DISEASE	85	15	6.58	2.08	1.20	3.60	86	15	6.86	2.11	1.22	3.65
LIVER INJURY	68	11	6.10	2.27	1.20	4.29	67	11	5.86	2.24	1.18	4.24
SLEEP TERROR	46	6	5.47	2.82	1.20	6.60	46	6	5.49	2.82	1.21	6.61
BODY HEIGHT	32	3	5.07	3.92	1.20	12.80	32	3	5.09	3.93	1.20	12.82
OVARIAN CYST RUPTURED	32	3	5.07	3.92	1.20	12.80	32	3	5.09	3.93	1.20	12.82
LIVER FUNCTION TEST INCREASED	84	15	6.34	2.06	1.19	3.56	84	15	6.37	2.06	1.19	3.57
ATRIAL SEPTAL DEFECT	76	13	6.20	2.15	1.19	3.87	76	13	6.23	2.15	1.19	3.87
CAPILLARY NAIL REFILL TEST ABNORMAL	63	10	5.79	2.31	1.19	4.51	62	10	5.56	2.28	1.17	4.45
ISCHAEMIC HEPATITIS	63	10	5.79	2.31	1.19	4.51	62	10	5.56	2.28	1.17	4.45
DYSCHROMATOPSIA	59	9	5.76	2.41	1.19	4.86	59	9	5.78	2.41	1.20	4.87
GALLBLADDER ENLARGEMENT	41	5	5.21	3.01	1.19	7.62	40	5	4.93	2.94	1.16	7.46
INTESTINAL PERFORATION	41	5	5.21	3.01	1.19	7.62	41	5	5.23	3.02	1.19	7.64
ORAL BLOOD BLISTER	45	6	5.18	2.76	1.18	6.46	45	6	5.20	2.76	1.18	6.47
B-CELL LYMPHOMA	36	4	4.97	3.31	1.18	9.29	35	4	4.68	3.22	1.14	9.06

LAZINESS	36	4	4.97	3.31	1.18	9.29	35	4	4.68	3.22	1.14	9.06
INFARCTION	49	7	5.18	2.57	1.17	5.68	49	7	5.20	2.58	1.17	5.69
CLOSTRIDIUM DIFFICILE INFECTION	78	14	5.78	2.05	1.16	3.62	77	14	5.57	2.02	1.15	3.58
COLITIS ISCHAEMIC	70	12	5.64	2.14	1.16	3.95	70	12	5.67	2.15	1.16	3.96
BLADDER DISCOMFORT	40	5	4.91	2.94	1.16	7.45	40	5	4.93	2.94	1.16	7.46
LOWER GASTROINTESTINAL HAEMORRHAGE	31	3	4.75	3.80	1.16	12.42	31	3	4.77	3.80	1.16	12.44
METASTASES TO LIVER	31	3	4.75	3.80	1.16	12.42	31	3	4.77	3.80	1.16	12.44
PRODUCT AVAILABILITY ISSUE	31	3	4.75	3.80	1.16	12.42	31	3	4.77	3.80	1.16	12.44
PULMONARY VASCULAR DISORDER	31	3	4.75	3.80	1.16	12.42	31	3	4.77	3.80	1.16	12.44
AZOTAEMIA	73	13	5.46	2.06	1.14	3.72	73	13	5.49	2.07	1.15	3.73
THROMBOTIC THROMBOCYTOPENIC PURPURA	64	11	5.08	2.14	1.13	4.05	64	11	5.11	2.14	1.13	4.06
BRAIN DEATH	60	10	5.02	2.20	1.13	4.31	60	10	5.04	2.21	1.13	4.31
RED BLOOD CELL ABNORMALITY	39	5	4.62	2.87	1.13	7.27	39	5	4.64	2.87	1.13	7.28
VEIN DISCOLOURATION	39	5	4.62	2.87	1.13	7.27	39	5	4.64	2.87	1.13	7.28
ANTIALLERGIC THERAPY	47	7	4.63	2.47	1.12	5.46	47	7	4.65	2.47	1.12	5.47
ELECTROCARDIOGRAM AMBULATORY	47	7	4.63	2.47	1.12	5.46	46	7	4.38	2.42	1.09	5.36
OESOPHAGEAL DISORDER	47	7	4.63	2.47	1.12	5.46	47	7	4.65	2.47	1.12	5.47
PULMONARY ARTERIAL HYPERTENSION	30	3	4.44	3.67	1.12	12.04	30	3	4.46	3.68	1.12	12.06
RENAL ATROPHY	30	3	4.44	3.67	1.12	12.04	30	3	4.46	3.68	1.12	12.06
INJECTION SITE MUSCLE WEAKNESS	71	13	4.99	2.01	1.11	3.62	71	13	5.01	2.01	1.11	3.63
BLOOD GLUCOSE FLUCTUATION	63	11	4.83	2.10	1.11	3.99	63	11	4.86	2.11	1.11	4.00
ENDOCARDITIS	59	10	4.77	2.17	1.11	4.24	58	10	4.54	2.13	1.09	4.18
VENA CAVA FILTER INSERTION	59	10	4.77	2.17	1.11	4.24	58	10	4.54	2.13	1.09	4.18
OESOPHAGEAL SPASM	55	9	4.71	2.25	1.11	4.54	55	9	4.73	2.25	1.11	4.55
WALKING DISABILITY	51	8	4.66	2.34	1.11	4.94	51	8	4.69	2.35	1.11	4.94
ACNE CYSTIC	34	4	4.37	3.12	1.11	8.80	34	4	4.38	3.13	1.11	8.82
BLADDER SPASM	34	4	4.37	3.12	1.11	8.80	34	4	4.38	3.13	1.11	8.82
HIP SURGERY	34	4	4.37	3.12	1.11	8.80	35	4	4.68	3.22	1.14	9.06
VENTRICULAR ARRHYTHMIA	38	5	4.34	2.79	1.10	7.09	37	5	4.07	2.72	1.07	6.93
EFFUSION	66	12	4.67	2.02	1.09	3.74	66	12	4.69	2.02	1.09	3.74
CARDIAC OPERATION	58	10	4.52	2.13	1.09	4.17	60	10	5.04	2.21	1.13	4.31
ANTINUCLEAR ANTIBODY POSITIVE	42	6	4.34	2.57	1.09	6.05	41	6	4.08	2.51	1.07	5.92
METASTASIS	42	6	4.34	2.57	1.09	6.05	42	6	4.36	2.58	1.10	6.06
QRS AXIS ABNORMAL	42	6	4.34	2.57	1.09	6.05	43	6	4.63	2.64	1.12	6.20
COMPLICATION ASSOCIATED WITH DEVICE	53	9	4.21	2.16	1.07	4.39	53	9	4.23	2.17	1.07	4.39
REDUCED FACIAL EXPRESSION	37	5	4.06	2.72	1.07	6.92	37	5	4.07	2.72	1.07	6.93
ANAL HAEMORRHAGE	33	4	4.07	3.03	1.07	8.56	33	4	4.09	3.04	1.08	8.57
EYE COLOUR CHANGE	33	4	4.07	3.03	1.07	8.56	33	4	4.09	3.04	1.08	8.57
INCORRECT PRODUCT ADMINISTRATION DURATION	33	4	4.07	3.03	1.07	8.56	33	4	4.09	3.04	1.08	8.57
RALES	775	142	59.97	2.01	1.68	2.40	765	142	57.83	1.98	1.66	2.37
PULMONARY HYPERTENSION	267	49	20.20	2.00	1.48	2.72	263	49	19.34	1.98	1.46	2.68
HEART SOUNDS ABNORMAL	164	30	12.27	2.01	1.36	2.96	161	30	11.62	1.98	1.34	2.92
CARDIOPULMONARY FAILURE	42	6	4.34	2.57	1.09	6.05	40	6	3.82	2.45	1.04	5.79
DISEASE RECURRENCE	240	2	82.24	44.09	10.96	177.32	238	2	81.65	43.80	10.89	176.14
CEREBRAL THROMBOSIS	200	1	69.83	73.49	10.30	524.25	199	1	69.58	73.24	10.27	522.51
COVID-19 IMMUNISATION	196	2	66.09	36.01	8.94	145.00	196	2	66.21	36.07	8.96	145.24
INTENTIONAL PRODUCT USE ISSUE	144	1	49.26	52.91	7.40	378.18	144	1	49.35	53.00	7.42	378.81
RED BLOOD CELL TRANSFUSION	128	1	43.39	47.03	6.57	336.44	125	1	42.37	46.01	6.43	329.16
HYPERPYREXIA	110	1	36.79	40.42	5.64	289.49	110	1	36.86	40.49	5.65	289.97
SARS-COV-2 TEST NEGATIVE	109	1	36.42	40.05	5.59	286.88	109	1	36.49	40.12	5.60	287.36
RIGHT VENTRICULAR DYSFUNCTION	100	1	33.13	36.74	5.13	263.41	97	1	32.08	35.70	4.98	256.01
INTENTIONAL DOSE OMISSION	94	1	30.93	34.54	4.82	247.76	94	1	30.98	34.60	4.82	248.17
CEREBRAL ARTERY OCCLUSION	105	2	32.78	19.29	4.76	78.15	104	2	32.48	19.14	4.72	77.55
LYMPHOPENIA	104	2	32.42	19.11	4.72	77.42	103	2	32.11	18.95	4.68	76.81
INTRACARDIAC THROMBUS	96	2	29.50	17.64	4.35	71.54	96	2	29.56	17.67	4.36	71.66
CEREBELLAR STROKE	84	1	27.27	30.86	4.30	221.67	84	1	27.32	30.92	4.30	222.04
CEREBRAL MASS EFFECT	84	1	27.27	30.86	4.30	221.67	82	1	26.58	30.18	4.20	216.82
ABNORMAL UTERINE BLEEDING	83	1	26.90	30.50	4.25	219.06	81	1	26.22	29.81	4.15	214.20
RIGHT VENTRICULAR DILATATION	77	1	24.71	28.29	3.94	203.41	75	1	24.02	27.60	3.84	198.53
HAEMOFILTRATION	73	1	23.24	26.82	3.73	192.98	73	1	23.29	26.87	3.73	193.30
PERIPHERAL ARTERY THROMBOSIS	80	2	23.68	14.70	3.61	59.79	79	2	23.37	14.54	3.57	59.15
PORTAL VEIN THROMBOSIS	79	2	23.32	14.51	3.57	59.05	79	2	23.37	14.54	3.57	59.15
CRITICAL ILLNESS	78	2	22.96	14.33	3.52	58.32	77	2	22.64	14.17	3.48	57.68
VACCINATION SITE PARAESTHESIA	78	2	22.96	14.33	3.52	58.32	77	2	22.64	14.17	3.48	57.68
IMPLANTABLE CARDIAC MONITOR INSERTION	69	1	21.78	25.35	3.52	182.55	69	1	21.82	25.40	3.53	182.85

SARS-COV-2 TEST	67	1	21.05	24.62	3.42	177.33	65	1	20.36	23.92	3.32	172.40
TRANSVERSE SINUS THROMBOSIS	66	1	20.69	24.25	3.37	174.72	64	1	20.00	23.56	3.27	169.79
NIH STROKE SCALE	65	1	20.32	23.88	3.31	172.11	64	1	20.00	23.56	3.27	169.79
MYOCARDIAL STRAIN	64	1	19.96	23.52	3.26	169.51	64	1	20.00	23.56	3.27	169.79
INTERNAL HAEMORRHAGE	71	2	20.42	13.04	3.20	53.18	71	2	20.46	13.07	3.20	53.26
CHILLBLAINS	69	2	19.70	12.68	3.11	51.71	69	2	19.74	12.70	3.11	51.79
NIH STROKE SCALE ABNORMAL	59	1	18.14	21.68	3.00	156.47	59	1	18.17	21.71	3.01	156.73
PRE-EXISTING CONDITION IMPROVED	66	2	18.62	12.13	2.97	49.50	66	2	18.66	12.15	2.97	49.59
BODY HEIGHT DECREASED	57	1	17.41	20.94	2.90	151.25	57	1	17.44	20.98	2.90	151.50
CORONARY ARTERY DISSECTION	57	1	17.41	20.94	2.90	151.25	57	1	17.44	20.98	2.90	151.50
MESENTERIC VEIN THROMBOSIS	57	1	17.41	20.94	2.90	151.25	57	1	17.44	20.98	2.90	151.50
JUGULAR VEIN THROMBOSIS	55	1	16.68	20.21	2.80	146.03	54	1	16.35	19.87	2.75	143.66
LEFT VENTRICULAR DILATATION	54	1	16.32	19.84	2.74	143.42	53	1	15.98	19.51	2.70	141.05
NEUROLOGIC NEGLECT SYNDROME	54	1	16.32	19.84	2.74	143.42	54	1	16.35	19.87	2.75	143.66
HEPATIC MASS	50	1	14.86	18.37	2.54	132.99	49	1	14.53	18.03	2.49	130.60
THROMBOEMBOLECTOMY	49	1	14.50	18.00	2.49	130.38	49	1	14.53	18.03	2.49	130.60
AORTIC DISSECTION	54	2	14.31	9.92	2.42	40.69	52	2	13.62	9.57	2.33	39.29
COR PULMONALE ACUTE	47	1	13.77	17.27	2.38	125.17	47	1	13.80	17.30	2.39	125.37
COOLING THERAPY	53	2	13.95	9.74	2.37	39.95	53	2	13.98	9.75	2.38	40.02
INJECTION	53	2	13.95	9.74	2.37	39.95	52	2	13.62	9.57	2.33	39.29
MYOCARDIAL FIBROSIS	53	2	13.95	9.74	2.37	39.95	52	2	13.62	9.57	2.33	39.29
PREMENSTRUAL PAIN	45	1	13.05	16.53	2.28	119.95	45	1	13.08	16.56	2.28	120.15
TOTAL LUNG CAPACITY DECREASED	45	1	13.05	16.53	2.28	119.95	45	1	13.08	16.56	2.28	120.15
PERIPHERAL ARTERY OCCLUSION	44	1	12.69	16.17	2.23	117.34	44	1	12.71	16.19	2.23	117.54
VASCULAR DEMENTIA	44	1	12.69	16.17	2.23	117.34	40	1	11.27	14.72	2.02	107.09
ARTERIAL CATHETERISATION	49	2	12.53	9.00	2.19	37.02	49	2	12.55	9.02	2.19	37.08
PLATELET COUNT INCREASED	48	2	12.17	8.82	2.14	36.28	48	2	12.20	8.83	2.15	36.34
QUARANTINE	48	2	12.17	8.82	2.14	36.28	45	2	11.13	8.28	2.01	34.14
SENSATION OF BLOOD FLOW	48	2	12.17	8.82	2.14	36.28	48	2	12.20	8.83	2.15	36.34
VESTIBULAR MIGRAINE	48	2	12.17	8.82	2.14	36.28	48	2	12.20	8.83	2.15	36.34
BRAIN OPERATION	47	2	11.82	8.63	2.10	35.55	47	2	11.84	8.65	2.10	35.61
COLON CANCER	47	2	11.82	8.63	2.10	35.55	46	2	11.49	8.47	2.05	34.87
ACUTE CARDIAC EVENT	41	1	11.60	15.06	2.07	109.52	41	1	11.63	15.09	2.08	109.70
AORTIC VALVE REPLACEMENT	46	2	11.46	8.45	2.05	34.81	45	2	11.13	8.28	2.01	34.14
WRONG PATIENT	46	2	11.46	8.45	2.05	34.81	46	2	11.49	8.47	2.05	34.87
CARDIOVASCULAR SYMPTOM	40	1	11.24	14.70	2.02	106.91	40	1	11.27	14.72	2.02	107.09
LUNG ASSIST DEVICE THERAPY	45	2	11.11	8.27	2.01	34.08	45	2	11.13	8.28	2.01	34.14
FREEZING PHENOMENON	39	1	10.88	14.33	1.97	104.30	39	1	10.90	14.35	1.97	104.47
MITRAL VALVE CALCIFICATION	39	1	10.88	14.33	1.97	104.30	39	1	10.90	14.35	1.97	104.47
DEPERSONALISATION/DEREALISATION DISORDER	44	2	10.76	8.08	1.96	33.34	44	2	10.78	8.10	1.96	33.40
SUBDURAL HAEMORRHAGE	44	2	10.76	8.08	1.96	33.34	44	2	10.78	8.10	1.96	33.40
LACK OF SPONTANEOUS SPEECH	38	1	10.52	13.96	1.92	101.69	38	1	10.54	13.99	1.92	101.86
SENSITISATION	38	1	10.52	13.96	1.92	101.69	38	1	10.54	13.99	1.92	101.86
GLYCOSYLATED HAEMOGLOBIN INCREASED	43	2	10.40	7.90	1.91	32.61	43	2	10.43	7.91	1.92	32.66
NIH STROKE SCALE SCORE INCREASED	43	2	10.40	7.90	1.91	32.61	43	2	10.43	7.91	1.92	32.66
PRODUCT RECONSTITUTION QUALITY ISSUE	43	2	10.40	7.90	1.91	32.61	43	1	12.35	15.83	2.18	114.92
ENDOMETRIAL THICKENING	42	2	10.05	7.72	1.87	31.88	41	2	9.73	7.54	1.83	31.19
RESPIRATORY SYNCYTIAL VIRUS INFECTION	42	2	10.05	7.72	1.87	31.88	42	2	10.08	7.73	1.87	31.93
FEELING OF RELAXATION	36	1	9.80	13.23	1.81	96.48	36	1	9.82	13.25	1.82	96.64
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	36	1	9.80	13.23	1.81	96.48	35	1	9.46	12.88	1.76	94.03
HEMIPARAESTHESIA	36	1	9.80	13.23	1.81	96.48	36	1	9.82	13.25	1.82	96.64
RIGHT ATRIAL ENLARGEMENT	36	1	9.80	13.23	1.81	96.48	35	1	9.46	12.88	1.76	94.03
DIURETIC THERAPY	35	1	9.44	12.86	1.76	93.87	35	1	9.46	12.88	1.76	94.03
PRODUCT ADMINISTRATION INTERRUPTED	35	1	9.44	12.86	1.76	93.87	35	1	9.46	12.88	1.76	94.03
PLEURAL THICKENING	38	2	8.66	6.98	1.68	28.94	38	2	8.68	6.99	1.69	28.99
BRIEF RESOLVED UNEXPLAINED EVENT	33	1	8.73	12.13	1.66	88.65	33	1	8.75	12.15	1.66	88.80
INTRA-ABDOMINAL FLUID COLLECTION	33	1	8.73	12.13	1.66	88.65	33	1	8.75	12.15	1.66	88.80
LACUNAR STROKE	33	1	8.73	12.13	1.66	88.65	32	1	8.39	11.78	1.61	86.19
VITAL FUNCTIONS ABNORMAL	33	1	8.73	12.13	1.66	88.65	33	1	8.75	12.15	1.66	88.80
BEHAVIOUR DISORDER	37	2	8.31	6.80	1.64	28.20	37	2	8.33	6.81	1.64	28.25
IDIOPATHIC INTRACRANIAL HYPERTENSION	37	2	8.31	6.80	1.64	28.20	37	2	8.33	6.81	1.64	28.25

SUBCLAVIAN VEIN THROMBOSIS	37	2	8.31	6.80	1.64	28.20	37	2	8.33	6.81	1.64	28.25
ARTERIAL THROMBOSIS	32	1	8.37	11.76	1.61	86.05	32	1	8.39	11.78	1.61	86.19
METASTASES TO BONE	32	1	8.37	11.76	1.61	86.05	32	1	8.39	11.78	1.61	86.19
CEREBRAL ARTERY STENOSIS	36	2	7.96	6.61	1.59	27.47	36	2	7.98	6.62	1.60	27.51
MULTIMORBIDITY	36	2	7.96	6.61	1.59	27.47	36	2	7.98	6.62	1.60	27.51
RETINAL MIGRAINE	35	2	7.62	6.43	1.55	26.73	35	2	7.64	6.44	1.55	26.78
CHILD MALTREATMENT SYNDROME	31	1	8.01	11.39	1.55	83.44	31	1	8.03	11.41	1.56	83.58
EAR INFLAMMATION	31	1	8.01	11.39	1.55	83.44	31	1	8.03	11.41	1.56	83.58
FEMORAL NECK FRACTURE	31	1	8.01	11.39	1.55	83.44	31	1	8.03	11.41	1.56	83.58
URINARY TRACT DISCOMFORT	31	1	8.01	11.39	1.55	83.44	31	1	8.03	11.41	1.56	83.58
HAND DERMATITIS	34	2	7.27	6.25	1.50	26.00	34	2	7.29	6.26	1.50	26.04
OVERSENSING	34	2	7.27	6.25	1.50	26.00	34	2	7.29	6.26	1.50	26.04
VACCINATION SITE SCAR	34	2	7.27	6.25	1.50	26.00	34	2	7.29	6.26	1.50	26.04
EYELID SENSORY DISORDER	30	1	7.66	11.02	1.50	80.83	30	1	7.67	11.04	1.51	80.96
CYTOKINE STORM	29	1	7.30	10.66	1.45	78.22	29	1	7.32	10.67	1.45	78.35
ANTIINFLAMMATORY THERAPY	32	2	6.59	5.88	1.41	24.53	32	2	6.61	5.89	1.41	24.57
PATHOGEN RESISTANCE	32	2	6.59	5.88	1.41	24.53	32	2	6.61	5.89	1.41	24.57
CEREBRAL ARTERY EMBOLISM	28	1	6.95	10.29	1.40	75.61	28	1	6.96	10.31	1.40	75.74
HAEMORRHAGIC TRANSFORMATION STROKE	28	1	6.95	10.29	1.40	75.61	28	1	6.96	10.31	1.40	75.74
INFERIOR VENA CAVA DILATATION	28	1	6.95	10.29	1.40	75.61	28	1	6.96	10.31	1.40	75.74
PARAESTHESIA EAR	28	1	6.95	10.29	1.40	75.61	28	1	6.96	10.31	1.40	75.74
DAYDREAMING	27	1	6.60	9.92	1.35	73.01	27	1	6.61	9.94	1.35	73.13
OVULATION DISORDER	27	1	6.60	9.92	1.35	73.01	27	1	6.61	9.94	1.35	73.13
THERAPEUTIC PRODUCT EFFECT DECREASED	27	1	6.60	9.92	1.35	73.01	27	1	6.61	9.94	1.35	73.13
AORTIC THROMBOSIS	30	2	5.91	5.51	1.32	23.06	30	2	5.93	5.52	1.32	23.10
HYPERVIGILANCE	30	2	5.91	5.51	1.32	23.06	30	2	5.93	5.52	1.32	23.10
INJECTION RELATED REACTION	30	2	5.91	5.51	1.32	23.06	30	2	5.93	5.52	1.32	23.10
THROMBOSIS PROPHYLAXIS	30	2	5.91	5.51	1.32	23.06	30	2	5.93	5.52	1.32	23.10
THYROID PAIN	30	2	5.91	5.51	1.32	23.06	30	2	5.93	5.52	1.32	23.10
VASOGENIC CEREBRAL OEDEMA	30	2	5.91	5.51	1.32	23.06	30	2	5.93	5.52	1.32	23.10
VENTRICULAR DRAINAGE	30	2	5.91	5.51	1.32	23.06	30	2	5.93	5.52	1.32	23.10
VERTEBRAL ARTERY OCCLUSION	30	2	5.91	5.51	1.32	23.06	29	2	5.59	5.34	1.27	22.36
PRODUCT DOSE OMISSION IN ERROR	26	1	6.24	9.55	1.30	70.40	26	1	6.26	9.57	1.30	70.52
PULMONARY ARTERY DILATATION	26	1	6.24	9.55	1.30	70.40	26	1	6.26	9.57	1.30	70.52
SEDATIVE THERAPY	26	1	6.24	9.55	1.30	70.40	26	1	6.26	9.57	1.30	70.52
FOOD CRAVING	29	2	5.58	5.33	1.27	22.33	28	2	5.26	5.15	1.23	21.63
METASTASES TO CENTRAL NERVOUS SYSTEM	29	2	5.58	5.33	1.27	22.33	28	2	5.26	5.15	1.23	21.63
OBSTRUCTIVE SLEEP APNOEA SYNDROME	29	2	5.58	5.33	1.27	22.33	26	2	4.60	4.78	1.14	20.16
PANCREATIC CYST	29	2	5.58	5.33	1.27	22.33	29	2	5.59	5.34	1.27	22.36
BASAL GANGLIA HAEMORRHAGE	25	1	5.89	9.19	1.24	67.79	23	1	5.21	8.47	1.14	62.68
LARGE INTESTINE PERFORATION	25	1	5.89	9.19	1.24	67.79	25	1	5.91	9.20	1.25	67.90
LEFT VENTRICULAR ENLARGEMENT	25	1	5.89	9.19	1.24	67.79	24	1	5.55	8.83	1.19	65.29
OXYGEN CONSUMPTION INCREASED	25	1	5.89	9.19	1.24	67.79	25	1	5.91	9.20	1.25	67.90
COLD-STIMULUS HEADACHE	28	2	5.25	5.14	1.23	21.59	28	2	5.26	5.15	1.23	21.63
ORGANISING PNEUMONIA	28	2	5.25	5.14	1.23	21.59	28	2	5.26	5.15	1.23	21.63
BREAST DISORDER FEMALE	24	1	5.54	8.82	1.19	65.18	24	1	5.55	8.83	1.19	65.29
CEREBRAL HAEMATOMA	24	1	5.54	8.82	1.19	65.18	24	1	5.55	8.83	1.19	65.29
MENSTRUATION NORMAL	24	1	5.54	8.82	1.19	65.18	24	1	5.55	8.83	1.19	65.29
TOE AMPUTATION	24	1	5.54	8.82	1.19	65.18	23	1	5.21	8.47	1.14	62.68
VEIN RUPTURE	24	1	5.54	8.82	1.19	65.18	24	1	5.55	8.83	1.19	65.29
VENTRICULAR ASSIST DEVICE INSERTION	24	1	5.54	8.82	1.19	65.18	24	1	5.55	8.83	1.19	65.29
PNEUMOPERITONEUM	27	2	4.92	4.96	1.18	20.86	27	2	4.93	4.97	1.18	20.89
THORACIC CAVITY DRAINAGE	27	2	4.92	4.96	1.18	20.86	27	2	4.93	4.97	1.18	20.89
ARTERIAL STENT INSERTION	23	1	5.19	8.45	1.14	62.58	23	1	5.21	8.47	1.14	62.68
LITHOTRIPSY	23	1	5.19	8.45	1.14	62.58	23	1	5.21	8.47	1.14	62.68
PRODUCT DISPENSING ISSUE	23	1	5.19	8.45	1.14	62.58	22	1	4.86	8.10	1.09	60.07
PULMONARY CALCIFICATION	26	2	4.59	4.78	1.13	20.12	25	2	4.27	4.60	1.09	19.42
VERTEBRAL ARTERY STENOSIS	26	2	4.59	4.78	1.13	20.12	25	2	4.27	4.60	1.09	19.42
BLOOD LACTIC ACID INCREASED	25	2	4.26	4.59	1.09	19.39	25	2	4.27	4.60	1.09	19.42
CEREBRAL ARTERY THROMBOSIS	25	2	4.26	4.59	1.09	19.39	25	2	4.27	4.60	1.09	19.42
CORNEAL LIGHT REFLEX TEST ABNORMAL	25	2	4.26	4.59	1.09	19.39	25	2	4.27	4.60	1.09	19.42
THUNDERCLAP HEADACHE	25	2	4.26	4.59	1.09	19.39	25	2	4.27	4.60	1.09	19.42

BLUE TOE SYNDROME	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
DENTAL PARAESTHESIA	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
DISEASE COMPLICATION	22	1	4.85	8.08	1.09	59.97	20	1	4.17	7.36	0.99	54.85
METASTASES TO LYMPH NODES	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
ORBITAL SWELLING	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
OXYGEN CONSUMPTION DECREASED	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
PLATELET DISORDER	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
SPLENIC VEIN THROMBOSIS	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
SUPERFICIAL VEIN PROMINENCE	22	1	4.85	8.08	1.09	59.97	22	1	4.86	8.10	1.09	60.07
UTERINE POLYP	22	1	4.85	8.08	1.09	59.97	21	1	4.51	7.73	1.04	57.46
ABDOMINAL WALL HAEMATOMA	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
ACCIDENTAL DEATH	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
BREAST CANCER METASTATIC	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
CARDIAC ANEURYSM	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
CHEYNE-STOKES RESPIRATION	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
LUNG ADENOCARCINOMA	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
NEUTROPHIL COUNT INCREASED	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
POSITIVE END-EXPIRATORY PRESSURE	21	1	4.50	7.72	1.04	57.36	21	1	4.51	7.73	1.04	57.46
EPSTEIN-BARR VIRUS INFECTION REACTIVATION	20	1	4.16	7.35	0.99	54.76	20	1	4.17	7.36	0.99	54.85
FOLLICULAR LYMPHOMA	20	1	4.16	7.35	0.99	54.76	20	1	4.17	7.36	0.99	54.85
HAEMOPERITONEUM	20	1	4.16	7.35	0.99	54.76	20	1	4.17	7.36	0.99	54.85
MONOCLONAL ANTIBODY UNCONJUGATED THERAPY	20	1	4.16	7.35	0.99	54.76	20	1	4.17	7.36	0.99	54.85
VASCULAR PSEUDOANEURYSM	20	1	4.16	7.35	0.99	54.76	20	1	4.17	7.36	0.99	54.85
CAPILLARY DISORDER	20	1	4.16	7.35	0.99	54.76	19	1	3.83	6.99	0.94	52.24
VACCINATION SITE SWELLING	5254	967	408.38	2.00	1.86	2.14	5251	966	410.61	2.00	1.87	2.14
SEIZURE	3817	703	295.53	2.00	1.84	2.16	3809	698	299.61	2.01	1.85	2.18
ORAL DISCOMFORT	799	147	61.30	2.00	1.68	2.38	796	146	61.78	2.01	1.68	2.39
LIP DISORDER	125	23	9.10	2.00	1.28	3.12	125	23	9.15	2.00	1.28	3.12

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines \(SERIOUS AGES 5 YEARS-11 YEARS\)](#)
Compared to [ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines \(SERIOUS AGES 5 YEARS-11 YEARS\)](#)
SERIOUS AGES 5 YEARS-11 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022
Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (SERIOUS 5 Yrs-11 Yrs)	12/14/2020-07/22/2022 COVID19 mRNA N=316	01/01/2009-07/22/2022 NON-COVID19 N=1110	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020-07/15/2022 COVID19 mRNA N=312	01/01/2009-07/15/2022 NON-COVID19 N=1110	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
APPENDICITIS	14	3	32.69	16.39	4.74	56.68	14	3	33.18	16.60	4.80	57.41
MYOCARDITIS	14	4	29.51	12.29	4.08	37.09	14	4	29.97	12.45	4.13	37.56
CONJUNCTIVITIS	19	10	29.75	6.67	3.14	14.21	19	10	30.28	6.76	3.18	14.39
KAWASAKIS DISEASE	8	3	13.61	9.37	2.50	35.10	8	3	13.84	9.49	2.53	35.55
SHOCK	10	6	12.99	5.85	2.14	15.98	10	6	13.24	5.93	2.17	16.19
HYPOTENSION	25	27	19.48	3.25	1.92	5.52	25	27	19.97	3.29	1.94	5.59
APPENDICECTOMY	9	8	7.73	3.95	1.54	10.16	9	8	7.91	4.00	1.56	10.29
CONJUNCTIVAL HYPERAEMIA	9	8	7.73	3.95	1.54	10.16	9	8	7.91	4.00	1.56	10.29
CHEST PAIN	31	48	13.12	2.27	1.47	3.50	30	48	12.15	2.22	1.43	3.45
BLOOD PRESSURE INCREASED	9	9	6.64	3.51	1.41	8.77	9	9	6.80	3.56	1.42	8.89
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	5	3	5.42	5.85	1.41	24.36	5	3	5.53	5.93	1.42	24.67
HEART RATE INCREASED	15	20	7.72	2.63	1.36	5.09	15	20	7.96	2.67	1.38	5.15
BLOOD PRESSURE DECREASED	8	8	5.73	3.51	1.33	9.28	8	8	5.87	3.56	1.35	9.40
RESPIRATORY RATE INCREASED	8	9	4.81	3.12	1.21	8.03	8	9	4.94	3.16	1.23	8.13
ACUTE RESPIRATORY FAILURE	7	7	4.83	3.51	1.24	9.94	6	7	3.18	3.05	1.03	9.01
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN COVID-19	69	1	244.54	242.37	33.80	1738.25	69	1	247.75	245.48	34.23	1760.47
LEFT VENTRICULAR DYSFUNCTION	55	1	190.90	193.20	26.84	1390.55	54	1	189.57	192.12	26.68	1383.17
MITRAL VALVE INCOMPETENCE	11	1	29.95	38.64	5.01	298.14	11	1	30.37	39.13	5.07	301.95
ILLNESS	9	1	23.05	31.61	4.02	248.59	9	1	23.38	32.02	4.07	251.77
PLEURAL EFFUSION	9	2	19.52	15.81	3.43	72.79	9	2	19.82	16.01	3.48	73.72
PERICARDIAL EFFUSION	7	2	13.16	12.29	2.57	58.89	7	2	13.37	12.45	2.60	59.64
TRICUSPID VALVE INCOMPETENCE	6	1	12.98	21.08	2.55	174.42	6	1	13.17	21.35	2.58	176.65
PERICARDITIS	6	1	12.98	21.08	2.55	174.42	6	1	13.17	21.35	2.58	176.65
HEPATOMEGALY	5	1	9.75	17.56	2.06	149.79	5	1	9.90	17.79	2.09	151.70
SINUS TACHYCARDIA	5	2	7.24	8.78	1.71	45.05	5	2	7.36	8.89	1.73	45.62
PERIORBITAL SWELLING	5	2	7.24	8.78	1.71	45.05	5	2	7.36	8.89	1.73	45.62
VENTRICULAR EXTRASYSTOLES	4	1	6.66	14.05	1.58	125.26	4	1	6.77	14.23	1.60	126.86
	4	2	4.57	7.03	1.29	38.18	4	2	4.66	7.12	1.31	38.67

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)

For Current Week and Past Week Comparison

Following ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines (SERIOUS AGES 12 YEARS-17 YEARS)

Compared to ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines (SERIOUS AGES 12 YEARS-17 YEARS)

SERIOUS AGES 12 YEARS-17 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022

Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)

N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00

MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (SERIOUS 12 Yrs-17 Yrs)	12/14/2020-07/22/2022 COVID19 mRNA N=1889	01/01/2009-07/22/2022 NON-COVID19 N=1597	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020-07/15/2022 COVID19 mRNA N=1884	01/01/2009-07/15/2022 NON-COVID19 N=1595	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
MYOCARDITIS	668	11	661.16	51.34	28.40	92.81	667	11	661.16	51.33	28.40	92.80
RESPIRATORY RATE INCREASED	160	6	123.24	22.54	10.01	50.79	160	6	123.45	22.58	10.02	50.86
PERICARDITIS	148	8	107.18	15.64	7.70	31.76	147	8	106.45	15.56	7.66	31.59
BLOOD PRESSURE INCREASED	141	14	86.85	8.51	4.94	14.69	140	14	86.14	8.47	4.91	14.61
ANTICOAGULANT THERAPY	59	4	38.65	12.47	4.54	34.25	59	4	38.71	12.49	4.55	34.30
PAINFUL RESPIRATION	91	9	54.68	8.55	4.32	16.90	90	9	53.93	8.47	4.28	16.74
CHEST PAIN	905	172	557.33	4.45	3.83	5.16	902	172	555.15	4.44	3.83	5.15
RESPIRATORY RATE DECREASED	43	3	27.41	12.12	3.77	38.98	43	3	27.45	12.13	3.77	39.04
PERICARDIAL EFFUSION	63	7	35.45	7.61	3.49	16.57	63	7	35.51	7.62	3.50	16.59
HEART RATE DECREASED	62	7	34.62	7.49	3.44	16.31	61	7	33.86	7.38	3.38	16.08
PLEURITIC PAIN	37	3	22.39	10.43	3.22	33.75	37	3	22.43	10.44	3.23	33.80
CHEST DISCOMFORT	266	62	104.42	3.63	2.77	4.74	263	62	102.29	3.59	2.75	4.70
SINUS ARRHYTHMIA	27	3	14.21	7.61	2.31	25.03	27	3	14.24	7.62	2.32	25.07
HEART RATE INCREASED	195	59	55.31	2.79	2.10	3.71	195	59	55.48	2.80	2.11	3.72
BLOOD PRESSURE DECREASED	86	22	28.01	3.30	2.08	5.25	86	22	28.09	3.31	2.08	5.26
APPENDICITIS	50	12	16.73	3.52	1.88	6.59	50	12	16.77	3.53	1.89	6.60
BODY TEMPERATURE INCREASED	82	24	22.69	2.89	1.84	4.53	82	24	22.76	2.89	1.84	4.54
ACUTE KIDNEY INJURY	37	8	13.31	3.91	1.83	8.37	37	8	13.34	3.92	1.83	8.38
PULMONARY EMBOLISM	27	5	10.66	4.57	1.76	11.83	26	5	9.95	4.40	1.69	11.44
TACHYPNOEA	67	20	17.79	2.83	1.73	4.65	66	20	17.20	2.79	1.70	4.59
OXYGEN SATURATION DECREASED	55	19	11.53	2.45	1.46	4.11	54	19	11.00	2.41	1.43	4.04
SINUS TACHYCARDIA	44	14	10.29	2.66	1.46	4.83	44	14	10.32	2.66	1.46	4.84
ELECTROCARDIOGRAM AMBULATORY	17	3	6.50	4.79	1.41	16.32	17	3	6.51	4.80	1.41	16.34
MUSCULOSKELETAL CHEST PAIN	41	14	8.51	2.48	1.35	4.53	41	14	8.54	2.48	1.36	4.53
LYMPHOPENIA	15	3	5.07	4.23	1.23	14.58	15	3	5.08	4.23	1.23	14.60
PLEURAL EFFUSION	34	13	5.60	2.21	1.17	4.18	34	13	5.63	2.21	1.17	4.18
BREATH SOUNDS ABNORMAL	35	14	5.27	2.11	1.14	3.91	35	14	5.29	2.12	1.14	3.92
SINUS BRADYCARDIA	20	6	4.57	2.82	1.13	7.00	20	6	4.59	2.82	1.14	7.01
TROPONIN INCREASED	134	1	113.04	113.29	15.86	809.21	133	1	112.30	112.60	15.76	804.33
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	114	1	94.90	96.38	13.48	689.31	114	1	95.04	96.51	13.49	690.27
COVID-19	127	2	103.87	53.68	13.30	216.65	127	2	104.03	53.76	13.32	216.96
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	60	1	47.01	50.73	7.04	365.60	60	1	47.08	50.80	7.05	366.11
VENTRICULAR TACHYCARDIA	42	2	28.91	17.75	4.30	73.23	42	2	28.96	17.78	4.31	73.33
MITRAL VALVE INCOMPETENCE	36	1	26.27	30.44	4.18	221.73	36	1	26.31	30.48	4.18	222.04
TROPONIN I INCREASED	35	1	25.41	29.59	4.06	215.74	35	1	25.45	29.63	4.06	216.04
VENTRICULAR EXTRASYSTOLES	34	1	24.56	28.74	3.94	209.75	34	1	24.60	28.78	3.94	210.04
TRICUSPID VALVE INCOMPETENCE	25	1	16.92	21.14	2.87	155.81	25	1	16.95	21.17	2.87	156.03
EPINEPHRINE	24	1	16.08	20.29	2.75	149.82	24	1	16.10	20.32	2.75	150.02
BLOOD PRESSURE DIASTOLIC INCREASED	20	1	12.73	16.91	2.27	125.85	20	1	12.75	16.93	2.27	126.02
ILLNESS	20	1	12.73	16.91	2.27	125.85	20	1	12.75	16.93	2.27	126.02
HEART SOUNDS ABNORMAL	18	2	8.99	7.61	1.77	32.74	17	2	8.22	7.20	1.67	31.10
ELECTROCARDIOGRAM T WAVE INVERSION	14	2	5.90	5.92	1.35	26.00	14	2	5.91	5.93	1.35	26.04
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	14	2	5.90	5.92	1.35	26.00	14	2	5.91	5.93	1.35	26.04
EXPOSURE TO SARS-COV-2	12	1	6.17	10.15	1.32	77.94	12	1	6.19	10.16	1.32	78.05
SEDATION	11	1	5.38	9.30	1.20	71.95	11	1	5.39	9.31	1.20	72.05
C-REACTIVE PROTEIN INCREASED	10	1	4.60	8.45	1.08	65.97	10	1	4.61	8.47	1.08	66.06
PULMONARY VALVE INCOMPETENCE	10	1	4.60	8.45	1.08	65.97	10	1	4.61	8.47	1.08	66.06

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)

For Current Week and Past Week Comparison

Following ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines (SERIOUS AGES 18+ YEARS)

Compared to ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines (SERIOUS AGES 18+ YEARS)

SERIOUS AGES 18+ YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022

Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)

N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00

MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (SERIOUS 18+)	12/14/2020- 07/22/2022 COVID19 mRNA N=72822	01/01/2009- 07/22/2022 NON-COVID19 N=13279	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020- 07/15/2022 COVID19 mRNA N=72313	01/01/2009- 07/15/2022 NON-COVID19 N=13267	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
COVID-19	21252	42	5026.11	92.27	68.21	124.82	20976	42	4978.96	91.63	67.73	123.95
COVID-19 PNEUMONIA	4892	9	923.96	99.12	51.55	190.56	4844	9	920.20	98.75	51.36	189.85
LUNG OPACITY	1796	10	311.49	32.75	17.60	60.96	1786	10	311.66	32.77	17.60	60.99
POSITIVE AIRWAY PRESSURE THERAPY	945	7	158.06	24.62	11.71	51.77	931	7	156.51	24.40	11.60	51.31
PULMONARY THROMBOSIS	574	3	97.76	34.89	11.22	108.48	573	3	98.22	35.04	11.27	108.96
ANTICOAGULANT THERAPY	3743	66	571.50	10.34	8.11	13.18	3715	66	570.42	10.33	8.10	13.16
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	1254	22	185.26	10.39	6.82	15.84	1217	22	179.78	10.15	6.66	15.47
THROMBECTOMY	367	5	55.69	13.38	5.54	32.34	364	5	55.55	13.36	5.53	32.28
ILLNESS	534	13	70.83	7.49	4.32	12.98	530	13	70.68	7.48	4.32	12.96
BLOOD PRESSURE DIASTOLIC INCREASED	229	4	32.60	10.44	3.89	28.05	226	4	32.31	10.37	3.86	27.85
APPENDICITIS	544	16	67.26	6.20	3.77	10.19	543	16	67.66	6.23	3.79	10.23
PULMONARY EMBOLISM	2783	120	292.62	4.23	3.53	5.07	2774	119	295.59	4.28	3.56	5.13
EPINEPHRINE	327	9	41.02	6.63	3.42	12.84	327	9	41.37	6.67	3.44	12.92
THROMBOSIS	1444	60	152.51	4.39	3.39	5.68	1438	60	152.96	4.40	3.40	5.69
UNEVALUABLE EVENT	2290	107	226.14	3.90	3.22	4.73	2271	107	225.19	3.89	3.21	4.72
HYPERTHYROAEMIA	276	8	33.75	6.29	3.12	12.70	269	8	32.80	6.17	3.05	12.46
LEFT VENTRICULAR FAILURE	250	7	30.90	6.51	3.07	13.80	244	7	30.10	6.40	3.02	13.55
RESPIRATORY RATE INCREASED	1421	67	137.57	3.87	3.03	4.94	1405	67	136.27	3.85	3.01	4.91
BLOOD LOSS ANAEMIA	193	5	24.33	7.04	2.90	17.10	191	5	24.17	7.01	2.88	17.03
CARDIAC FAILURE ACUTE	348	13	37.93	4.88	2.81	8.49	340	13	36.90	4.80	2.76	8.35
DEATH	10097	616	876.74	2.99	2.76	3.24	10003	615	871.73	2.98	2.76	3.23
ANOSMIA	410	17	42.19	4.40	2.71	7.14	409	17	42.43	4.41	2.72	7.17
GENERAL PHYSICAL CONDITION ABNORMAL	312	12	33.34	4.74	2.66	8.44	308	12	32.97	4.71	2.65	8.38
RESPIRATORY RATE DECREASED	311	12	33.17	4.73	2.66	8.41	310	12	33.32	4.74	2.66	8.43
STENT PLACEMENT	290	11	31.17	4.81	2.63	8.78	290	11	31.47	4.84	2.65	8.83
BLOOD PRESSURE SYSTOLIC INCREASED	533	27	47.75	3.60	2.45	5.30	528	27	47.44	3.59	2.44	5.28
END STAGE RENAL DISEASE	200	7	22.15	5.21	2.45	11.07	196	7	21.66	5.14	2.42	10.92
SUPERINFECTION	126	3	16.00	7.66	2.44	24.06	123	3	15.60	7.52	2.39	23.64
BELL'S PALSY	465	23	42.33	3.69	2.43	5.60	466	22	44.45	3.89	2.54	5.96
ACUTE LEFT VENTRICULAR FAILURE	158	5	18.17	5.76	2.37	14.03	158	5	18.34	5.80	2.38	14.12
ACUTE RESPIRATORY FAILURE	4074	294	265.80	2.53	2.25	2.84	4030	294	262.64	2.51	2.24	2.83
HEART RATE DECREASED	789	48	60.07	3.00	2.24	4.01	782	48	59.69	2.99	2.23	4.00
GENERAL PHYSICAL HEALTH DETERIORATION	1132	74	80.15	2.79	2.21	3.53	1121	74	79.47	2.78	2.20	3.51
OXYGEN SATURATION DECREASED	2713	197	172.19	2.51	2.18	2.90	2694	197	171.73	2.51	2.17	2.90
APPENDICECTOMY	430	24	35.17	3.27	2.17	4.93	430	24	35.59	3.29	2.18	4.96
HOSPICE CARE	307	16	26.44	3.50	2.12	5.78	305	15	27.86	3.73	2.22	6.26
PULMONARY INFARCTION	122	4	13.59	5.56	2.05	15.05	122	3	15.42	7.46	2.37	23.45
TROPONIN INCREASED	401	24	30.54	3.05	2.02	4.60	400	24	30.76	3.06	2.03	4.61
ACUTE MYOCARDIAL INFARCTION	1450	111	83.55	2.38	1.97	2.89	1444	111	83.94	2.39	1.97	2.89
CHRONIC KIDNEY DISEASE	646	44	42.94	2.68	1.97	3.63	630	44	41.08	2.63	1.94	3.56
CHRONIC LEFT VENTRICULAR FAILURE	161	7	15.50	4.19	1.97	8.94	157	7	14.98	4.11	1.93	8.77
DYSPNOEA AT REST	100	3	11.43	6.08	1.93	19.16	99	3	11.36	6.05	1.92	19.09
IMMUNE THROMBOCYTOPENIA	278	16	21.77	3.17	1.91	5.24	278	16	22.03	3.19	1.93	5.27
DRUG INEFFECTIVE	154	7	14.33	4.01	1.88	8.55	154	7	14.48	4.04	1.89	8.61
PNEUMONIA BACTERIAL	385	25	26.75	2.81	1.87	4.21	378	25	26.02	2.77	1.85	4.16
HYPONATREMIA	4093	363	190.15	2.06	1.85	2.29	4054	362	189.10	2.05	1.85	2.28
ISCHAEMIC STROKE	465	32	30.24	2.65	1.85	3.79	463	32	30.36	2.65	1.86	3.80
BLOOD PRESSURE DIASTOLIC DECREASED	149	7	13.50	3.88	1.82	8.28	149	7	13.65	3.91	1.83	8.33
CORONARY ARTERIAL STENT INSERTION	273	17	19.66	2.93	1.79	4.78	271	17	19.60	2.92	1.79	4.77
DEEP VEIN THROMBOSIS	1433	122	69.11	2.14	1.78	2.57	1428	122	69.59	2.15	1.79	2.58
VENTRICULAR HYPOKINESIA	159	8	13.70	3.62	1.78	7.37	156	8	13.36	3.58	1.76	7.28
CARDIAC FAILURE	644	50	35.59	2.35	1.76	3.13	635	49	35.96	2.38	1.78	3.18
DEMENTIA	428	31	25.92	2.52	1.75	3.62	424	31	25.70	2.51	1.74	3.61
PULSELESS ELECTRICAL ACTIVITY	394	28	24.43	2.57	1.75	3.76	390	28	24.18	2.56	1.74	3.75
MULTIPLE ORGAN DYSFUNCTION SYNDROME	314	21	20.91	2.73	1.75	4.24	311	21	20.73	2.72	1.75	4.23
PNEUMONIA VIRAL	192	11	14.85	3.18	1.73	5.84	189	11	14.56	3.15	1.72	5.79

IMMUNISATION	141	7	12.19	3.67	1.72	7.84	141	7	12.32	3.70	1.73	7.89
LUNG INFILTRATION	1191	104	54.50	2.09	1.71	2.55	1180	104	53.96	2.08	1.70	2.54
BLOOD PRESSURE SYSTOLIC DECREASED	101	4	10.00	4.60	1.70	12.50	100	4	9.93	4.59	1.69	12.46
GENERAL SYMPTOM	112	5	10.33	4.08	1.67	10.00	110	5	10.10	4.04	1.65	9.89
CORONARY ARTERY OCCLUSION	193	12	13.70	2.93	1.64	5.25	194	12	14.03	2.97	1.66	5.31
INFUSION	121	6	10.35	3.68	1.62	8.35	121	6	10.47	3.70	1.63	8.40
CARDIO-RESPIRATORY ARREST	752	67	32.69	2.05	1.60	2.63	745	66	33.33	2.07	1.61	2.66
AUTOPSY	358	28	19.21	2.33	1.59	3.42	355	28	19.09	2.33	1.58	3.42
PULSE ABSENT	715	64	30.75	2.04	1.58	2.63	710	64	30.65	2.04	1.58	2.63
LUNG CONSOLIDATION	349	28	17.95	2.27	1.55	3.34	347	28	17.96	2.27	1.55	3.34
EXTRA DOSE ADMINISTERED	232	17	13.49	2.49	1.52	4.07	232	17	13.69	2.50	1.53	4.10
PHARYNGEAL SWELLING	413	36	18.41	2.09	1.49	2.94	412	36	18.60	2.10	1.49	2.95
DEMENTIA ALZHEIMER'S TYPE	144	9	9.97	2.92	1.49	5.72	142	9	9.80	2.89	1.48	5.68
CEREBRAL INFARCTION	421	37	18.48	2.07	1.48	2.90	419	37	18.54	2.08	1.49	2.91
ATYPICAL PNEUMONIA	107	6	8.11	3.25	1.43	7.40	105	6	7.90	3.21	1.41	7.31
RESPIRATORY SYMPTOM	236	19	11.85	2.26	1.42	3.61	233	19	11.63	2.25	1.41	3.59
HOSPITALISATION	117	7	8.37	3.05	1.42	6.53	117	7	8.47	3.07	1.43	6.57
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	235	19	11.72	2.26	1.41	3.60	234	19	11.77	2.26	1.42	3.61
PALLIATIVE CARE	116	7	8.21	3.02	1.41	6.48	116	7	8.32	3.04	1.42	6.52
CARDIOGENIC SHOCK	272	24	11.63	2.07	1.36	3.14	270	24	11.58	2.06	1.36	3.13
EMBOLIC STROKE	92	5	7.08	3.36	1.36	8.25	92	5	7.17	3.38	1.37	8.30
EJECTION FRACTION DECREASED	224	19	10.22	2.15	1.35	3.43	220	19	9.87	2.12	1.33	3.39
APPENDICITIS PERFORATED	110	7	7.30	2.87	1.34	6.15	110	7	7.39	2.88	1.34	6.19
HYPERTENSIVE EMERGENCY	80	4	6.53	3.65	1.34	9.95	79	4	6.45	3.62	1.33	9.89
PULMONARY PAIN	70	3	6.33	4.25	1.34	13.51	69	3	6.23	4.22	1.33	13.40
TASTE DISORDER	191	16	8.83	2.18	1.31	3.62	188	16	8.58	2.16	1.29	3.59
IMPAIRED SELF-CARE	96	6	6.41	2.92	1.28	6.65	96	6	6.50	2.94	1.29	6.70
DRAINAGE	65	3	5.51	3.95	1.24	12.57	64	3	5.41	3.91	1.23	12.46
JUGULAR VEIN DISTENSION	74	4	5.58	3.37	1.23	9.22	71	4	5.17	3.26	1.19	8.91
CORONARY ARTERY THROMBOSIS	64	3	5.35	3.89	1.22	12.38	65	3	5.57	3.98	1.25	12.65
ELECTRIC SHOCK SENSATION	126	10	6.19	2.30	1.21	4.37	126	10	6.30	2.31	1.21	4.40
ATRIOVENTRICULAR BLOCK COMPLETE	90	6	5.52	2.74	1.20	6.25	90	6	5.59	2.75	1.20	6.29
OROPHARYNGEAL DISCOMFORT	123	10	5.79	2.24	1.18	4.27	121	10	5.61	2.22	1.17	4.23
AORTIC ANEURYSM	114	9	5.60	2.31	1.17	4.55	113	9	5.55	2.30	1.17	4.54
HEPATIC CIRRHOSIS	146	13	5.87	2.05	1.16	3.61	143	13	5.60	2.02	1.14	3.56
GASTROINTESTINAL WALL THICKENING	61	3	4.86	3.71	1.16	11.81	61	3	4.92	3.73	1.17	11.89
RETINAL ARTERY OCCLUSION	86	6	4.93	2.61	1.14	5.98	86	6	5.01	2.63	1.15	6.01
THROMBOLYSIS	68	4	4.65	3.10	1.13	8.50	68	4	4.71	3.12	1.14	8.55
THALAMIC INFARCTION	66	4	4.34	3.01	1.10	8.25	66	4	4.40	3.03	1.10	8.30
CHOLECYSTITIS ACUTE	58	3	4.39	3.53	1.10	11.25	56	3	4.13	3.42	1.07	10.94
ANGINA UNSTABLE	57	3	4.23	3.46	1.09	11.06	56	3	4.13	3.42	1.07	10.94
ACQUIRED DIAPHRAGMATIC EVENTRATION	56	3	4.08	3.40	1.07	10.87	54	3	3.82	3.30	1.03	10.56
VACCINE BREAKTHROUGH INFECTION	3400	2	639.73	309.99	77.51	1239.84	3374	2	638.67	309.51	77.38	1237.90
EXPOSURE TO SARS-COV-2	788	1	141.65	143.69	20.22	1021.25	783	1	141.61	143.65	20.21	1021.00
ASYMPTOMATIC COVID-19	651	2	114.10	59.35	14.81	237.80	640	2	112.79	58.71	14.65	235.22
SUSPECTED COVID-19	137	1	21.78	24.98	3.49	178.60	137	1	21.93	25.13	3.52	179.70
RED BLOOD CELL TRANSFUSION	128	1	20.14	23.34	3.26	166.95	125	1	19.73	22.93	3.21	164.07
OFF LABEL USE	102	1	15.42	18.60	2.60	133.30	101	1	15.35	18.53	2.59	132.81
RIGHT VENTRICULAR DYSFUNCTION	94	1	13.97	17.14	2.39	122.94	91	1	13.53	16.70	2.33	119.79
CEREBRAL ARTERY OCCLUSION	103	2	13.71	9.39	2.32	38.05	102	2	13.64	9.36	2.31	37.92
LYMPHOPENIA	88	1	12.89	16.05	2.24	115.18	87	1	12.80	15.96	2.22	114.58
CEREBRAL MASS EFFECT	84	1	12.17	15.32	2.13	110.00	82	1	11.90	15.04	2.09	108.07
CEREBELLAR STROKE	82	1	11.81	14.95	2.08	107.41	82	1	11.90	15.04	2.09	108.07
INTRACARDIAC THROMBUS	91	2	11.57	8.30	2.04	33.68	91	2	11.67	8.35	2.06	33.88
PERCUTANEOUS CORONARY INTERVENTION	90	2	11.40	8.21	2.02	33.31	90	2	11.49	8.26	2.03	33.52
RIGHT VENTRICULAR DILATATION	76	1	10.73	13.86	1.93	99.65	74	1	10.45	13.58	1.89	97.65
CARDIAC ASSISTANCE DEVICE USER	83	2	10.16	7.57	1.86	30.76	83	2	10.25	7.61	1.87	30.95
HAEMOFILTRATION	73	1	10.19	13.31	1.85	95.76	73	1	10.27	13.39	1.86	96.35
CRITICAL ILLNESS	77	2	9.11	7.02	1.72	28.57	76	2	9.01	6.97	1.71	28.38
PORTAL VEIN THROMBOSIS	75	2	8.76	6.84	1.68	27.84	75	2	8.84	6.88	1.69	28.02
NIH STROKE SCALE	64	1	8.58	11.67	1.62	84.11	63	1	8.47	11.56	1.60	83.33
PERIPHERAL ARTERY THROMBOSIS	71	2	8.06	6.47	1.59	26.39	70	2	7.96	6.42	1.57	26.18
IMPLANTABLE CARDIAC MONITOR INSERTION	61	1	8.04	11.12	1.54	80.23	61	1	8.11	11.19	1.55	80.72
NORMAL LABOUR	61	1	8.04	11.12	1.54	80.23	61	1	8.11	11.19	1.55	80.72
MYOCARDIAL STRAIN	59	1	7.69	10.76	1.49	77.64	59	1	7.75	10.82	1.50	78.12
NIH STROKE SCALE ABNORMAL	57	1	7.33	10.39	1.44	75.05	57	1	7.39	10.46	1.45	75.51
MESENTERIC VEIN THROMBOSIS	55	1	6.98	10.03	1.39	72.47	54	1	6.86	9.91	1.37	71.61

NEUROLOGIC NEGLECT SYNDROME	54	1	6.80	9.85	1.36	71.17	54	1	6.86	9.91	1.37	71.61
CORONARY ARTERY DISSECTION	51	1	6.27	9.30	1.29	67.29	51	1	6.32	9.36	1.29	67.70
JUGULAR VEIN THROMBOSIS	49	1	5.92	8.94	1.23	64.70	47	1	5.62	8.62	1.19	62.49
LEFT VENTRICULAR DILATATION	49	1	5.92	8.94	1.23	64.70	48	1	5.79	8.81	1.22	63.79
THROMBOEMBOLECTOMY	49	1	5.92	8.94	1.23	64.70	49	1	5.97	8.99	1.24	65.10
INTERNAL HAEMORRHAGE	54	2	5.16	4.92	1.20	20.19	54	2	5.21	4.95	1.21	20.31
COR PULMONALE ACUTE	46	1	5.39	8.39	1.16	60.82	46	1	5.44	8.44	1.16	61.19
AORTIC DISSECTION	52	2	4.83	4.74	1.15	19.46	50	2	4.54	4.59	1.12	18.85
MYOCARDIAL FIBROSIS	51	2	4.66	4.65	1.13	19.10	50	2	4.54	4.59	1.12	18.85
POST-ACUTE COVID-19 SYNDROME	50	2	4.49	4.56	1.11	18.73	50	2	4.54	4.59	1.12	18.85
CORONARY ANGIOPLASTY	44	1	5.04	8.02	1.11	58.23	44	1	5.09	8.07	1.11	58.59
ARTERIAL CATHETERISATION	49	2	4.33	4.47	1.09	18.37	49	2	4.38	4.49	1.09	18.48
NIH STROKE SCALE SCORE INCREASED	43	1	4.87	7.84	1.08	56.93	43	1	4.92	7.89	1.09	57.28
VASCULAR DEMENTIA	42	1	4.70	7.66	1.05	55.64	38	1	4.05	6.97	0.96	50.77
HEPATIC MASS	40	1	4.35	7.29	1.00	53.05	39	1	4.22	7.16	0.98	52.07
PERIPHERAL ARTERY OCCLUSION	40	1	4.35	7.29	1.00	53.05	40	1	4.39	7.34	1.01	53.38
CEREBROVASCULAR ACCIDENT	2726	249	116.95	2.00	1.76	2.27	2715	249	117.65	2.00	1.76	2.27
NEOPLASM MALIGNANT	79	6	3.94	2.40	1.05	5.50	79	6	4.01	2.42	1.05	5.54

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines \(NON-SERIOUS AGES 5 YEARS-11 YEARS\)](#)
Compared to [ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines \(NON-SERIOUS AGES 5 YEARS-11 YEARS\)](#)
NON-SERIOUS AGES 5 YEARS-11 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022
Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PT's sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (NON-SERIOUS 5 Yrs-11 Yrs)	12/14/2020- 07/22/2022 COVID19 mRNA N=11869	01/01/2009- 07/22/2022 NON-COVID19 N=27937	12/14-07/22 Chi-Square	12/14/07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020- 07/15/2022 COVID19 mRNA N=11752	01/01/2009- 07/15/2022 NON-COVID19 N=27912	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
PRODUCT PREPARATION ISSUE	1913	45	4531.45	100.06	74.51	134.37	1880	43	4496.37	103.84	76.81	140.38
COVID-19	170	3	385.74	133.38	42.60	417.60	164	3	374.94	129.84	41.45	406.66
INCORRECT DOSE ADMINISTERED	1955	262	3818.81	17.56	15.47	19.94	1925	261	3785.42	17.52	15.42	19.90
PRODUCT ADMINISTRATION ERROR	98	12	182.36	19.22	10.56	34.99	95	12	177.24	18.80	10.32	34.26
UNDERDOSE	414	83	685.34	11.74	9.28	14.85	412	83	688.17	11.79	9.32	14.91
IMMUNISATION	71	13	117.78	12.86	7.12	23.21	71	13	119.04	12.97	7.18	23.42
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	1569	497	2213.25	7.43	6.73	8.20	1559	494	2224.49	7.50	6.79	8.27
PRODUCT PREPARATION ERROR	269	83	366.34	7.63	5.97	9.75	259	83	349.43	7.41	5.79	9.48
INCORRECT PRODUCT FORMULATION ADMINISTERED	173	60	218.97	6.79	5.06	9.10	172	60	219.59	6.81	5.08	9.13
PRODUCT USE ISSUE	44	11	63.90	9.42	4.86	18.22	44	11	64.62	9.50	4.91	18.39
INJURY ASSOCIATED WITH DEVICE	19	3	30.98	14.91	4.41	50.37	19	3	31.31	15.04	4.45	50.82
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	255	109	282.29	5.51	4.40	6.88	253	107	285.94	5.62	4.48	7.03
VACCINATION FAILURE	30	10	36.93	7.06	3.45	14.44	27	10	31.32	6.41	3.11	13.24
OVERDOSE	37	17	36.87	5.12	2.89	9.09	37	17	37.38	5.17	2.91	9.18
PRODUCT STORAGE ERROR	1147	866	746.16	3.12	2.86	3.40	1162	863	786.95	3.20	2.94	3.48
POOR QUALITY PRODUCT ADMINISTERED	18	6	21.32	7.06	2.80	17.78	18	6	21.58	7.13	2.83	17.95
OROPHARYNGEAL DISCOMFORT	12	3	15.74	9.42	2.66	33.36	12	3	15.92	9.50	2.68	33.66
PHARYNGEAL SWELLING	13	4	15.53	7.65	2.49	23.46	13	4	15.72	7.72	2.52	23.67
NEEDLE ISSUE	16	6	17.37	6.28	2.46	16.04	16	6	17.60	6.33	2.48	16.18
EXPIRED PRODUCT ADMINISTERED	639	551	333.11	2.73	2.44	3.05	624	549	320.85	2.70	2.41	3.02
ANGINA PECTORIS	11	3	13.66	8.63	2.41	30.93	11	3	13.83	8.71	2.43	31.21
CHEST PAIN	165	140	85.43	2.77	2.22	3.47	164	140	85.72	2.78	2.22	3.48
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS	52	36	34.73	3.40	2.22	5.20	52	36	35.31	3.43	2.24	5.24
MENSTRUATION IRREGULAR	10	3	11.63	7.85	2.16	28.50	10	3	11.77	7.92	2.18	28.76
PERIORBITAL SWELLING	15	7	13.70	5.04	2.06	12.37	15	7	13.90	5.09	2.08	12.48
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR	49	38	28.01	3.04	1.99	4.63	49	38	28.53	3.06	2.01	4.68
SLEEP DISORDER	33	23	21.34	3.38	1.98	5.75	32	23	20.19	3.30	1.93	5.64
NO ADVERSE EVENT	2522	2956	797.85	2.01	1.91	2.11	2494	2949	792.34	2.01	1.91	2.11
SYRINGE ISSUE	41	34	21.00	2.84	1.80	4.47	40	34	20.06	2.79	1.77	4.41
PAINFUL RESPIRATION	10	6	6.68	3.92	1.43	10.79	10	6	6.79	3.96	1.44	10.89
VACCINE BREAKTHROUGH INFECTION	9	5	6.39	4.24	1.42	12.64	9	5	6.49	4.28	1.43	12.75
PITYRIASIS ROSEA	7	3	5.92	5.49	1.42	21.24	7	3	6.00	5.54	1.43	21.43
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES	43	48	12.43	2.11	1.40	3.18	42	48	11.75	2.08	1.37	3.14
HAEMATURIA	10	7	5.52	3.36	1.28	8.83	10	7	5.62	3.39	1.29	8.91
SWELLING OF EYELID	16	16	5.31	2.35	1.18	4.71	15	16	4.37	2.23	1.10	4.50
PALPITATIONS	34	40	8.46	2.00	1.27	3.16	33	40	7.78	1.96	1.24	3.11
INTERCHANGE OF VACCINE PRODUCTS	20	20	6.86	2.35	1.27	4.37	16	20	3.12	1.90	0.98	3.67
DRUG INEFFECTIVE	25	1	51.58	58.84	7.97	434.22	24	1	49.71	57.00	7.71	421.30
ILLNESS	24	2	45.61	28.25	6.68	119.49	24	2	46.06	28.50	6.74	120.58
BELL'S PALSY	14	1	25.97	32.95	4.33	250.57	13	1	23.91	30.88	4.04	236.00
COSTOCHONDRITIS	7	2	7.74	8.24	1.71	39.65	6	2	5.87	7.13	1.44	35.30
APHONIA	6	1	7.95	14.12	1.70	117.29	6	1	8.04	14.25	1.72	118.35
APHTHOUS ULCER	5	1	5.85	11.77	1.38	100.72	5	1	5.92	11.88	1.39	101.64
VITILIGO	5	1	5.85	11.77	1.38	100.72	5	1	5.92	11.88	1.39	101.64
VACCINATION ERROR	17	20	3.86	2.00	1.05	3.82	16	18	4.16	2.11	1.08	4.14
PAROSMIA	5	2	3.97	5.88	1.14	30.33	5	2	4.03	5.94	1.15	30.60

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines \(NON-SERIOUS AGES 12 YEARS-17 YEARS\)](#)
Compared to [ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines \(NON-SERIOUS AGES 12 YEARS-17 YEARS\)](#)
NON-SERIOUS AGES 12 YEARS-17 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022
Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (NON-SERIOUS 12 Yrs-17 Yrs)	12/14/2020- 07/22/2022 COVID19 mRNA N=29485	01/01/2009- 07/22/2022 NON-COVID19 N=28443	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020- 07/15/2022 COVID19 mRNA N=29389	01/01/2009- 07/15/2022 NON-COVID19 N=28399	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
UNDERDOSE	1055	58	872.88	17.55	13.48	22.84	1053	58	872.62	17.54	13.48	22.84
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	8613	578	8009.60	14.37	13.23	15.61	8599	576	8016.48	14.43	13.28	15.67
BELLS PALSY	74	3	61.24	23.79	7.50	75.46	74	3	61.36	23.84	7.52	75.59
PERICARDITIS	70	4	54.87	16.88	6.16	46.23	70	4	54.98	16.91	6.17	46.31
PRODUCT ADMINISTRATION ERROR	91	7	67.48	12.54	5.81	27.05	91	4	75.08	21.98	8.08	59.83
ILLNESS	61	4	46.32	14.71	5.35	40.45	61	4	46.41	14.74	5.36	40.52
PRODUCT PREPARATION ISSUE	511	75	310.69	6.57	5.16	8.37	511	74	313.45	6.67	5.23	8.51
AGEUSIA	67	6	47.25	10.77	4.67	24.83	67	6	47.35	10.79	4.68	24.87
ANGINA PECTORIS	41	3	29.83	13.18	4.08	42.57	41	3	29.89	13.21	4.09	42.64
IMMUNISATION	87	14	48.87	5.99	3.41	10.54	87	14	48.99	6.00	3.42	10.56
PRODUCT STORAGE ERROR	2668	873	900.85	2.95	2.74	3.18	2641	869	888.11	2.94	2.72	3.17
PHARYNGEAL SWELLING	68	14	32.43	4.69	2.64	8.33	68	13	34.23	5.05	2.79	9.15
CHEST PAIN	919	298	300.35	2.97	2.61	3.39	920	298	302.15	2.98	2.62	3.40
FEAR OF INJECTION	34	5	19.13	6.56	2.57	16.77	34	5	19.17	6.57	2.57	16.80
MENSTRUAL DISORDER	76	19	31.09	3.86	2.33	6.38	76	19	31.18	3.87	2.34	6.39
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	596	212	170.46	2.71	2.32	3.17	596	210	173.42	2.74	2.35	3.21
OFF LABEL USE	89	27	29.99	3.18	2.07	4.89	89	27	30.09	3.19	2.07	4.90
DYSMENORRHOEA	67	19	24.07	3.40	2.04	5.66	67	19	24.14	3.41	2.05	5.67
PRODUCT TEMPERATURE EXCURSION ISSUE	36	8	15.63	4.34	2.02	9.34	36	8	15.67	4.35	2.02	9.35
FLUSHING	378	157	83.52	2.32	1.93	2.80	378	157	83.89	2.33	1.93	2.80
CARDIAC FLUTTER	26	5	12.20	5.02	1.93	13.06	26	5	12.24	5.02	1.93	13.08
PAROSMIA	23	4	11.37	5.55	1.92	16.04	23	4	11.40	5.56	1.92	16.06
INCORRECT DOSE ADMINISTERED	862	386	167.77	2.15	1.91	2.43	853	383	165.85	2.15	1.91	2.43
VAGINAL ULCERATION	25	5	11.37	4.82	1.85	12.60	25	5	11.40	4.83	1.85	12.62
INTERCHANGE OF VACCINE PRODUCTS	230	99	47.08	2.24	1.77	2.83	229	99	46.69	2.24	1.77	2.83
MOUTH SWELLING	24	5	10.54	4.63	1.77	12.13	24	5	10.57	4.64	1.77	12.15
PAINFUL RESPIRATION	50	17	14.18	2.84	1.64	4.92	50	17	14.23	2.84	1.64	4.93
MENSTRUATION IRREGULAR	99	41	21.26	2.33	1.62	3.35	99	41	21.35	2.33	1.62	3.36
PERIORBITAL SWELLING	21	5	8.13	4.05	1.53	10.74	21	5	8.15	4.06	1.53	10.76
HYPERTENSION	46	17	11.47	2.61	1.50	4.55	44	17	10.22	2.50	1.43	4.38
VACCINATION ERROR	42	15	10.96	2.70	1.50	4.87	42	15	11.00	2.71	1.50	4.88
POLYMENORRHOEA	18	4	7.23	4.34	1.47	12.82	18	4	7.25	4.35	1.47	12.85
AXILLARY PAIN	108	51	17.81	2.04	1.46	2.85	108	51	17.91	2.05	1.47	2.85
OROPHARYNGEAL DISCOMFORT	28	9	8.13	3.00	1.42	6.36	28	8	9.40	3.38	1.54	7.42
SINUS TACHYCARDIA	23	8	5.83	2.77	1.24	6.20	23	8	5.86	2.78	1.24	6.21
DYSPNOEA EXERTIONAL	19	6	5.34	3.05	1.22	7.65	19	6	5.36	3.06	1.22	7.66
NEEDLE ISSUE	19	6	5.34	3.05	1.22	7.65	19	6	5.36	3.06	1.22	7.66
OVERDOSE	36	16	6.28	2.17	1.20	3.91	36	16	6.31	2.17	1.21	3.92
OLIGOMENORRHOEA	15	4	4.91	3.62	1.20	10.90	15	4	4.93	3.62	1.20	10.92
THROMBOCYTOPENIA	15	4	4.91	3.62	1.20	10.90	15	4	4.93	3.62	1.20	10.92
POOR QUALITY PRODUCT ADMINISTERED	71	4	55.82	17.12	6.25	46.87	71	1	63.88	68.61	9.53	493.77
COVID-19	438	1	420.80	422.52	59.39	3006.02	430	1	413.69	415.51	58.40	2956.30
HEAVY MENSTRUAL BLEEDING	119	1	110.17	114.79	16.04	821.60	118	1	109.39	114.03	15.93	816.15
DRUG INEFFECTIVE	55	1	48.33	53.06	7.34	383.37	54	1	47.46	52.18	7.22	377.16
ANOSMIA	59	2	49.48	28.46	6.95	116.46	59	2	49.58	28.51	6.97	116.66
VACCINE BREAKTHROUGH INFECTION	31	1	25.27	29.90	4.08	219.04	29	1	23.40	28.02	3.82	205.70
EXPOSURE TO SARS-COV-2	27	1	21.45	26.05	3.54	191.66	27	1	21.49	26.09	3.55	191.99
PRODUCT DOSE OMISSION ISSUE	26	2	18.09	12.54	2.98	52.83	26	2	18.13	12.56	2.98	52.92
TASTE DISORDER	22	1	16.69	21.22	2.86	157.43	22	1	16.72	21.26	2.87	157.70
VULVAL ULCERATION	20	1	14.80	19.29	2.59	143.75	20	1	14.83	19.33	2.59	143.99
APHTHOUS ULCER	17	1	11.97	16.40	2.18	123.22	17	1	12.00	16.43	2.19	123.43
PLEURITIC PAIN	19	2	11.63	9.16	2.13	39.34	19	2	11.66	9.18	2.14	39.41
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	16	1	11.04	15.43	2.05	116.38	16	1	11.06	15.46	2.05	116.58
THROMBOSIS	18	2	10.72	8.68	2.01	37.41	18	2	10.75	8.70	2.02	37.48
VULVOVAGINAL PAIN	15	1	10.11	14.47	1.91	109.54	15	1	10.13	14.49	1.91	109.72
CARDIAC DISORDER	17	2	9.82	8.20	1.89	35.49	17	2	9.85	8.21	1.90	35.55
BLOOD GLUCOSE DECREASED	14	2	7.18	6.75	1.53	29.71	14	2	7.19	6.76	1.54	29.76
SENSITIVE SKIN	13	2	6.32	6.27	1.42	27.78	13	2	6.33	6.28	1.42	27.83
PLATELET COUNT DECREASED	11	1	6.43	10.61	1.37	82.18	11	1	6.45	10.63	1.37	82.33
RESPIRATORY SYMPTOM	11	2	4.64	5.31	1.18	23.93	11	1	6.45	10.63	1.37	82.33

MENSTRUATION DELAYED	29	14	4.07	2.00	1.06	3.78	29	14	4.10	2.00	1.06	3.79
----------------------	----	----	------	------	------	------	----	----	------	------	------	------

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/22/2022 COVID19 mRNA Vaccines \(NON-SERIOUS AGES 18+ YEARS\)](#)
Compared to [ALL 01/01/2009-07/22/2022 NON-COVID19 Vaccines \(NON-SERIOUS AGES 18+ YEARS\)](#)
NON-SERIOUS AGES 18+ YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/22/2022
Vaccination, Received, and Completed Date: 12/14 - 07/22 (Current Week) and 12/14 - 07/15 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PT's sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/22/2022

MedDRA Codes ALL Reports (NON-SERIOUS 18+)	12/14/2020- 07/22/2022 COVID19 mRNA N=585478	01/01/2009- 07/22/2022 NON-COVID19 N=228605	12/14-07/22 Chi-Square	12/14/07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL	12/14/2020- 07/15/2022 COVID19 mRNA N=583999	01/01/2009- 07/15/2022 NON-COVID19 N=228287	12/14-07/15 Chi-Square	12/14-07/15 PRR	12/14-07/15 LCL	12/14-07/15 UCL
PRODUCT TEMPERATURE EXCURSION ISSUE	3019	7	1165.09	168.40	80.21	353.53	3017	7	1165.66	168.48	80.25	353.70
POOR QUALITY PRODUCT ADMINISTERED	3205	8	1235.90	156.43	78.16	313.06	3203	7	1238.92	178.87	85.20	375.49
COVID-19	25290	112	9917.50	88.17	73.24	106.14	24631	113	9653.41	85.21	70.83	102.50
EXPOSURE TO SARS-COV-2	1600	3	617.43	208.24	67.09	646.36	1553	3	599.70	202.36	65.19	628.10
HEAVY MENSTRUAL BLEEDING	4120	29	1546.90	55.47	38.50	79.92	4108	29	1544.01	55.37	38.43	79.78
INTERMENSTRUAL BLEEDING	1308	7	493.61	72.96	34.71	153.34	1308	7	494.19	73.04	34.75	153.52
VACCINATION SITE PRURITUS	3966	33	1476.93	46.93	33.31	66.10	3966	33	1478.70	46.98	33.35	66.17
SARS-COV-2 TEST POSITIVE	781	3	296.75	101.65	32.71	315.85	780	3	296.70	101.63	32.71	315.81
DYSMENORRHOEA	1775	14	660.24	49.50	29.26	83.76	1773	14	660.24	49.51	29.26	83.76
DRUG INEFFECTIVE	3269	33	1202.70	38.68	27.45	54.50	3118	33	1144.75	36.93	26.21	52.04
INTERCHANGE OF VACCINE PRODUCTS	8378	100	3068.68	32.71	26.86	39.84	8374	100	3070.88	32.73	26.88	39.87
PRODUCT DOSE OMISSION ISSUE	1559	16	571.05	38.05	23.25	62.26	1558	16	571.34	38.06	23.26	62.29
VACCINE BREAKTHROUGH INFECTION	1349	15	491.18	35.12	21.11	58.41	1317	15	479.24	34.32	20.63	57.09
SUSPECTED COVID-19	720	6	265.92	46.86	20.98	104.64	685	6	252.55	44.63	19.98	99.68
MENSTRUATION IRREGULAR	3198	47	1142.94	26.57	19.92	35.43	3189	47	1140.82	26.52	19.89	35.37
MENSTRUAL DISORDER	2392	36	851.79	25.94	18.67	36.05	2391	36	852.45	25.96	18.68	36.08
ANOSMIA	3339	55	1180.29	23.70	18.16	30.94	3315	55	1172.34	23.56	18.05	30.75
POLYMENORRHOEA	664	7	241.76	37.04	17.59	77.99	663	7	241.66	37.02	17.58	77.96
POSTMENOPAUSAL HAEMORRHAGE	523	5	191.27	40.84	16.93	98.53	522	5	191.11	40.81	16.92	98.46
OLIGOMENORRHOEA	559	6	203.04	36.38	16.27	81.32	558	6	202.90	36.35	16.26	81.27
ILLNESS	3910	82	1344.32	18.62	14.96	23.17	3904	82	1343.69	18.61	14.96	23.16
TASTE DISORDER	1981	44	673.45	17.58	13.04	23.70	1974	44	671.58	17.54	13.01	23.64
MECHANICAL URTICARIA	842	19	284.44	17.30	10.98	27.26	842	19	284.81	17.32	10.99	27.30
MATERNAL EXPOSURE DURING BREAST FEEDING	287	4	101.49	28.02	10.44	75.15	287	4	101.62	28.05	10.46	75.24
AGEUSIA	4082	135	1298.03	11.81	9.95	14.01	4062	134	1294.10	11.85	9.98	14.07
VACCINATION SITE ERYTHEMA	6164	211	1951.03	11.41	9.94	13.08	6164	211	1953.72	11.42	9.96	13.10
DEEP VEIN THROMBOSIS	785	21	258.02	14.60	9.46	22.51	788	21	259.52	14.67	9.51	22.62
IMMUNISATION	2620	92	820.04	11.12	9.03	13.69	2619	92	820.78	11.13	9.04	13.70
VACCINATION SITE URTICARIA	320	7	107.72	17.85	8.44	37.74	320	7	107.86	17.87	8.45	37.79
THROMBOSIS	1802	66	557.45	10.66	8.34	13.63	1793	66	554.74	10.62	8.31	13.58
MENSTRUATION DELAYED	1065	36	334.84	11.55	8.29	16.10	1064	36	334.90	11.55	8.29	16.10
BELL'S PALSYP	2670	104	814.80	10.02	8.24	12.19	2671	104	816.32	10.04	8.25	12.21
VACCINATION SITE MASS	1174	41	366.57	11.18	8.19	15.26	1174	41	367.07	11.19	8.20	15.28
VACCINATION SITE MOVEMENT IMPAIRMENT	354	9	116.60	15.36	7.93	29.76	354	9	116.75	15.38	7.93	29.79
THROAT CLEARING	381	11	122.81	13.52	7.43	24.63	380	11	122.59	13.50	7.42	24.59
PAROSMIA	1248	50	376.71	9.75	7.35	12.93	1244	50	375.70	9.73	7.33	12.90
PRODUCT USE ISSUE	533	19	164.83	10.95	6.93	17.31	532	19	164.67	10.95	6.93	17.30
CARDIAC FLUTTER	1168	52	342.06	8.77	6.64	11.58	1163	52	340.64	8.74	6.62	11.54
ELECTRIC SHOCK SENSATION	730	30	218.20	9.50	6.60	13.69	728	28	221.76	10.16	6.97	14.82
VITAL SIGNS MEASUREMENT	143	3	47.70	18.61	5.93	58.39	143	3	47.76	18.63	5.94	58.46
OROPHARYNGEAL DISCOMFORT	1435	75	399.07	7.47	5.92	9.42	1428	74	398.92	7.54	5.97	9.53
BLOOD PRESSURE MEASUREMENT	184	5	59.31	14.37	5.91	34.93	184	5	59.39	14.39	5.92	34.97
FACIAL DISCOMFORT	299	11	91.21	10.61	5.81	19.37	299	11	91.34	10.63	5.82	19.39
OFF LABEL USE	1165	63	319.64	7.22	5.60	9.30	1166	63	320.50	7.23	5.61	9.32
SYMPTOM RECURRENCE	151	4	48.66	14.74	5.46	39.78	150	4	48.34	14.66	5.43	39.57
SUPPRESSED LACTATION	131	3	43.05	17.05	5.43	53.55	131	3	43.10	17.07	5.43	53.61
CHRONIC SPONTANEOUS URTICARIA	150	4	48.28	14.64	5.42	39.52	151	4	48.73	14.76	5.47	39.83
THERAPEUTIC RESPONSE UNEXPECTED	532	26	150.52	7.99	5.39	11.84	531	26	150.36	7.98	5.39	11.83
PULMONARY EMBOLISM	359	16	104.18	8.76	5.31	14.46	358	16	103.95	8.75	5.30	14.43
IMMUNODEFICIENCY	484	25	134.24	7.56	5.06	11.30	484	25	134.44	7.57	5.06	11.31
PHARYNGEAL PARAESTHESIA	893	53	235.85	6.58	4.99	8.68	891	53	235.47	6.57	4.98	8.67
CARDIAC DISCOMFORT	322	15	92.05	8.38	4.99	14.07	320	15	91.42	8.34	4.97	14.00

VACCINATION SITE PAIN	14250	1059	3459.28	5.25	4.94	5.59	14242	1057	3465.70	5.27	4.95	5.61
DEVICE CONNECTION ISSUE	341	17	95.40	7.83	4.81	12.75	341	17	95.54	7.84	4.82	12.76
ACCIDENTAL OVERDOSE	320	16	89.36	7.81	4.73	12.90	318	15	90.66	8.29	4.94	13.91
VACCINATION SITE RASH	2512	180	611.11	5.45	4.68	6.34	2511	180	611.75	5.45	4.69	6.34
PHARYNGEAL SWELLING	3888	289	929.99	5.25	4.66	5.92	3885	287	933.93	5.29	4.69	5.96
AMENORRHOEA	647	40	167.58	6.32	4.59	8.69	643	40	166.35	6.28	4.57	8.65
OPHTHALMIC MIGRAINE	107	3	33.77	13.93	4.42	43.86	106	3	33.43	13.81	4.38	43.51
TONGUE DISCOMFORT	573	37	145.42	6.05	4.34	8.43	572	37	145.28	6.04	4.33	8.43
HYPOMENORRHOEA	165	7	47.93	9.20	4.32	19.61	164	7	47.62	9.16	4.30	19.51
PRODUCT STORAGE ERROR	19855	1731	4418.16	4.48	4.27	4.70	19784	1727	4406.43	4.48	4.26	4.70
TINNITUS	11832	1015	2631.19	4.55	4.27	4.85	11813	1013	2632.28	4.56	4.28	4.86
APPENDICITIS	100	3	31.08	13.02	4.13	41.04	99	3	30.73	12.90	4.09	40.68
BREAST MASS	382	24	97.76	6.21	4.11	9.39	381	24	97.55	6.21	4.11	9.37
EXTRASYSTOLES	504	35	123.39	5.62	3.99	7.92	501	35	122.49	5.60	3.97	7.88
HEART RATE	124	5	36.24	9.68	3.96	23.67	124	5	36.29	9.69	3.97	23.70
PERICARDIAL EFFUSION	202	11	54.28	7.17	3.91	13.15	201	11	53.98	7.14	3.89	13.11
HAEMORRHAGE URINARY TRACT	106	4	31.35	10.35	3.81	28.08	106	4	31.40	10.36	3.82	28.11
VENTRICULAR EXTRASYSTOLES	749	59	171.89	4.96	3.80	6.46	744	59	170.37	4.93	3.78	6.43
PARANASAL SINUS DISCOMFORT	880	72	197.67	4.77	3.75	6.07	870	72	194.39	4.72	3.71	6.01
EPINEPHRINE	104	4	30.59	10.15	3.74	27.56	104	4	30.63	10.16	3.74	27.59
ADNEXA UTERI PAIN	130	6	36.57	8.46	3.73	19.18	130	6	36.62	8.47	3.74	19.20
ANGINA PECTORIS	873	73	193.48	4.67	3.68	5.93	871	72	194.75	4.73	3.72	6.01
BREAST FEEDING	102	4	29.82	9.96	3.67	27.04	102	4	29.87	9.97	3.67	27.07
TONGUE PRURITUS	462	35	107.96	5.15	3.66	7.27	462	35	108.14	5.16	3.66	7.28
ENERGY INCREASED	164	9	43.72	7.12	3.64	13.92	164	9	43.79	7.12	3.64	13.93
HEART RATE ABNORMAL	379	28	89.59	5.29	3.60	7.76	379	28	89.74	5.29	3.60	7.77
CARDIAC DISORDER	554	45	124.56	4.81	3.55	6.51	551	45	123.69	4.79	3.53	6.49
VACCINATION SITE DISCOMFORT	285	20	68.93	5.56	3.54	8.76	285	20	69.04	5.57	3.54	8.77
BODY TEMPERATURE ABNORMAL	159	9	41.85	6.90	3.52	13.50	159	9	41.91	6.91	3.53	13.52
BRADYKINESIA	135	7	36.56	7.53	3.52	16.10	135	7	36.61	7.54	3.53	16.12
EXPIRED PRODUCT ADMINISTERED	21168	2275	4035.41	3.63	3.48	3.79	20977	2255	4005.39	3.64	3.48	3.80
BLOOD GLUCOSE DECREASED	274	20	64.89	5.35	3.40	8.42	274	20	65.00	5.36	3.40	8.43
PRODUCT PREPARATION ISSUE	2304	232	450.59	3.88	3.39	4.44	2297	228	455.14	3.94	3.44	4.51
ANTICOAGULANT THERAPY	397	32	89.37	4.84	3.38	6.94	392	30	91.07	5.11	3.52	7.40
CLUSTER HEADACHE	117	6	31.66	7.61	3.35	17.29	118	6	32.08	7.69	3.39	17.46
CARDIOMEGALY	128	7	33.92	7.14	3.34	15.28	129	7	34.35	7.20	3.37	15.41
HYPERAESTHESIA TEETH SITTING DISABILITY	150	9	38.48	6.51	3.32	12.75	150	9	38.54	6.52	3.33	12.77
	127	7	33.55	7.08	3.31	15.16	127	7	33.60	7.09	3.31	15.18
DYSPNOEA EXERTIONAL	764	71	157.67	4.20	3.29	5.36	759	70	157.77	4.24	3.32	5.41
OXYGEN SATURATION	80	3	23.41	10.41	3.29	32.97	80	3	23.44	10.42	3.29	33.01
HEAD DISCOMFORT	2756	292	517.63	3.69	3.27	4.16	2746	291	516.68	3.69	3.27	4.16
COSTOCHONDRITIS	208	15	49.32	5.41	3.21	9.14	207	15	49.03	5.39	3.19	9.11
EAR DISCOMFORT	2378	258	437.32	3.60	3.17	4.09	2369	257	436.57	3.60	3.17	4.10
ARRHYTHMIA	722	72	141.32	3.92	3.07	4.99	720	72	140.90	3.91	3.07	4.98
VACCINATION SITE HAEMORRHAGE	236	19	52.74	4.85	3.04	7.74	235	19	52.47	4.83	3.03	7.72
MENOPAUSE	126	8	31.36	6.15	3.01	12.57	126	7	33.23	7.04	3.29	15.06
SUPRAVENTRICULAR EXTRASYSTOLES	202	16	45.43	4.93	2.96	8.20	198	16	44.06	4.84	2.91	8.05
EUPHORIC MOOD	248	21	53.77	4.61	2.95	7.20	248	21	53.87	4.62	2.96	7.21
BREAST DISCOMFORT	113	7	28.32	6.30	2.94	13.52	113	7	28.37	6.31	2.94	13.54
OCULAR DISCOMFORT	838	90	154.55	3.64	2.93	4.52	838	90	154.86	3.64	2.93	4.52
PERIORBITAL SWELLING	671	70	126.60	3.74	2.93	4.79	669	70	126.16	3.74	2.92	4.78
COAGULOPATHY	82	4	22.23	8.00	2.93	21.84	82	4	22.27	8.01	2.94	21.86
BREAST SWELLING	737	78	137.50	3.69	2.92	4.66	735	78	137.08	3.68	2.92	4.65
ATRIAL FIBRILLATION	1203	135	213.92	3.48	2.91	4.16	1197	134	213.75	3.49	2.92	4.17
SARS-COV-2 ANTIBODY TEST NEGATIVE	71	3	19.98	9.24	2.91	29.34	70	3	19.63	9.12	2.87	28.97
HEART RATE IRREGULAR	1555	180	269.05	3.37	2.89	3.94	1549	180	267.58	3.36	2.88	3.93
PULMONARY PAIN	434	43	84.97	3.94	2.88	5.39	434	43	85.14	3.95	2.88	5.40
DRAINAGE	166	13	37.40	4.99	2.84	8.77	162	13	36.02	4.87	2.77	8.57
PANIC ATTACK	1117	129	193.32	3.38	2.82	4.06	1115	129	193.05	3.38	2.82	4.05
BLOOD URINE PRESENT	528	56	98.04	3.68	2.80	4.85	527	55	99.38	3.75	2.84	4.94
PALPITATIONS	12821	1705	1955.35	2.94	2.79	3.09	12807	1704	1956.64	2.94	2.79	3.09
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	8942	1178	1370.72	2.96	2.79	3.15	8919	1168	1379.55	2.98	2.81	3.17
HYPERTENSION	5071	662	780.72	2.99	2.76	3.24	5066	659	784.84	3.01	2.77	3.26
ATRIAL FLUTTER	115	8	27.30	5.61	2.74	11.49	114	8	26.98	5.57	2.72	11.41
HORMONE LEVEL ABNORMAL	86	5	21.89	6.72	2.73	16.55	86	5	21.92	6.72	2.73	16.56
BLOOD GLUCOSE ABNORMAL	76	4	19.98	7.42	2.71	20.28	76	4	20.01	7.43	2.72	20.30
BREAST TENDERNESS	518	57	93.15	3.55	2.70	4.66	517	57	93.00	3.55	2.70	4.66
LYMPHADENOPATHY	21206	2982	3062.28	2.78	2.67	2.88	21181	2979	3065.51	2.78	2.68	2.89
VAGINAL HAEMORRHAGE	1385	173	221.94	3.13	2.67	3.66	1382	173	221.44	3.12	2.67	3.66
BLOOD PRESSURE ABNORMAL	370	39	68.78	3.70	2.66	5.15	370	39	68.91	3.71	2.67	5.16
SENSITIVE SKIN	1271	159	203.25	3.12	2.65	3.68	1268	158	204.06	3.14	2.66	3.70
SINUS PAIN	467	52	83.00	3.51	2.63	4.67	461	52	81.13	3.47	2.60	4.62
EPISTAXIS	1718	223	264.41	3.01	2.62	3.46	1716	223	264.36	3.01	2.62	3.46
SUPRAVENTRICULAR TACHYCARDIA	293	30	55.58	3.81	2.62	5.55	293	30	55.69	3.82	2.62	5.56

PSICOVID 00005258

NEW DAILY PERSISTENT HEADACHE	56	4	12.59	5.47	1.98	15.07	56	4	12.61	5.47	1.98	15.09
VITREOUS FLOATERS	459	71	55.91	2.52	1.97	3.24	456	71	55.15	2.51	1.96	3.22
TESTICULAR PAIN	179	23	27.06	3.04	1.97	4.69	179	23	27.13	3.04	1.97	4.70
GINGIVAL BLEEDING	196	26	28.66	2.94	1.96	4.43	196	26	28.73	2.95	1.96	4.44
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME	135	16	22.01	3.29	1.96	5.53	134	16	21.72	3.27	1.95	5.50
GOITRE	128	15	21.05	3.33	1.95	5.69	128	15	21.10	3.34	1.95	5.69
SEDATION	96	10	17.34	3.75	1.95	7.19	96	10	17.38	3.75	1.96	7.20
IMPAIRED QUALITY OF LIFE	69	6	14.00	4.49	1.95	10.34	69	6	14.03	4.50	1.95	10.35
MYOCARDIAL INFARCTION	260	37	35.14	2.74	1.94	3.87	261	37	35.54	2.76	1.95	3.89
HYPERACUSIS	562	91	64.05	2.41	1.93	3.01	562	91	64.23	2.41	1.93	3.01
MOOD SWINGS	176	23	26.10	2.99	1.93	4.61	177	23	26.48	3.01	1.95	4.64
SEIZURE	2669	492	245.54	2.12	1.92	2.33	2662	489	247.34	2.13	1.93	2.34
MOVEMENT DISORDER	1470	264	141.58	2.17	1.91	2.48	1464	264	140.36	2.17	1.90	2.47
COLITIS MICROSCOPIC	61	5	12.75	4.76	1.91	11.85	61	5	12.77	4.77	1.92	11.87
DISTURBANCE IN ATTENTION	2003	368	185.13	2.13	1.90	2.37	2001	368	185.18	2.13	1.90	2.38
TENSION HEADACHE	339	52	41.60	2.55	1.90	3.41	339	52	41.71	2.55	1.90	3.41
HYPERTHYROIDISM	149	19	22.58	3.06	1.90	4.94	149	18	23.96	3.24	1.98	5.28
GAIT INABILITY	1414	256	134.11	2.16	1.89	2.46	1412	256	133.98	2.16	1.89	2.46
PREGNANCY	236	34	31.32	2.71	1.89	3.88	236	34	31.40	2.71	1.89	3.89
MENTAL FATIGUE	67	6	13.29	4.36	1.89	10.05	67	6	13.32	4.37	1.89	10.06
FEEDING DISORDER	1158	208	111.31	2.17	1.88	2.52	1152	208	110.00	2.17	1.87	2.51
TRANSIENT ISCHAEMIC ATTACK	235	34	31.01	2.70	1.88	3.87	235	34	31.09	2.70	1.89	3.87
VASCULAR PAIN	99	11	16.93	3.51	1.88	6.55	98	11	16.62	3.48	1.87	6.49
EAR DISORDER	141	18	21.30	3.06	1.87	5.00	141	18	21.35	3.06	1.87	5.00
RENAL PAIN	569	96	60.68	2.31	1.86	2.87	568	96	60.57	2.31	1.86	2.87
HAEMATOCHIEZIA	396	64	45.05	2.42	1.86	3.15	396	63	46.28	2.46	1.88	3.21
MUSCLE DISCOMFORT	181	25	25.16	2.83	1.86	4.29	181	24	26.48	2.95	1.93	4.51
CONJUNCTIVAL HAEMORRHAGE	110	13	17.82	3.30	1.86	5.87	110	13	17.86	3.31	1.86	5.88
THYROIDITIS SUBACUTE	46	3	10.64	5.99	1.86	19.25	46	3	10.66	5.99	1.86	19.27
ABNORMAL DREAMS	491	82	53.16	2.34	1.85	2.95	493	82	53.89	2.35	1.86	2.97
DEPRESSED MOOD	421	69	46.89	2.38	1.85	3.07	419	69	46.44	2.37	1.84	3.06
HYPOAESTHESIA EYE	151	20	21.93	2.95	1.85	4.70	150	20	21.67	2.93	1.84	4.67
HYPOSIMIA	91	10	15.64	3.55	1.85	6.83	90	10	15.34	3.52	1.83	6.76
IRREGULAR BREATHING	59	5	12.04	4.61	1.85	11.48	59	5	12.06	4.61	1.85	11.49
LIP PRURITUS	360	58	41.09	2.42	1.84	3.20	359	58	40.91	2.42	1.83	3.19
JAW DISORDER	103	12	16.87	3.35	1.84	6.09	103	12	16.91	3.36	1.85	6.10
INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION	52	4	11.14	5.08	1.84	14.03	51	4	10.80	4.98	1.80	13.79
UNRESPONSIVE TO STIMULI	2421	469	201.17	2.02	1.83	2.22	2418	468	201.99	2.02	1.83	2.23
INCORRECT PRODUCT FORMULATION ADMINISTERED	699	124	68.45	2.20	1.82	2.66	696	124	67.83	2.19	1.81	2.66
SKIN SWELLING	689	122	67.69	2.21	1.82	2.67	689	122	67.89	2.21	1.82	2.68
EAR INFECTION	399	66	43.75	2.36	1.82	3.06	390	66	41.28	2.31	1.78	3.00
GENERAL PHYSICAL CONDITION	71	7	13.17	3.96	1.82	8.61	71	7	13.20	3.96	1.82	8.62
ABNORMAL AMNESIA	988	182	90.40	2.12	1.81	2.48	985	182	89.88	2.12	1.81	2.48
OVARIAN CYST	113	14	17.47	3.15	1.81	5.49	111	14	16.85	3.10	1.78	5.40
FACIAL SPASM	83	9	14.36	3.60	1.81	7.16	83	9	14.39	3.60	1.81	7.17
DRY THROAT	841	155	76.77	2.12	1.79	2.51	836	155	75.66	2.11	1.78	2.50
ORAL DISCOMFORT	747	136	69.74	2.14	1.79	2.57	744	135	70.12	2.15	1.79	2.59
PSORIASIS	475	82	48.60	2.26	1.79	2.86	475	81	49.78	2.29	1.81	2.90
HYPERVENTILATION	595	106	57.71	2.19	1.78	2.69	595	106	57.89	2.19	1.78	2.70
BRADYCARDIA	368	62	39.09	2.32	1.77	3.03	367	62	38.92	2.31	1.77	3.03
BLOOD PRESSURE SYSTOLIC	105	13	16.18	3.15	1.77	5.61	105	13	16.22	3.16	1.77	5.62
INCREASED DISCHARGE	99	12	15.55	3.22	1.77	5.86	96	11	15.95	3.41	1.83	6.37
BASEDOW'S DISEASE	93	11	14.93	3.30	1.77	6.17	93	11	14.96	3.30	1.77	6.17
COMMUNICATION DISORDER	69	7	12.48	3.85	1.77	8.37	68	7	12.17	3.80	1.74	8.27
VESTIBULAR DISORDER	63	6	11.90	4.10	1.77	9.47	63	6	11.92	4.10	1.78	9.48
MOUTH ULCERATION	329	55	35.33	2.34	1.76	3.11	329	55	35.43	2.34	1.76	3.11
BLOOD PRESSURE DIASTOLIC	50	4	10.43	4.88	1.76	13.51	51	4	10.80	4.98	1.80	13.79
INCREASED RETINAL VEIN OCCLUSION	50	4	10.43	4.88	1.76	13.51	50	4	10.45	4.89	1.76	13.53
VACCINATION SITE BRUISING	511	91	49.50	2.19	1.75	2.74	512	91	49.93	2.20	1.76	2.75
RAYNAUD'S PHENOMENON	165	24	21.39	2.68	1.75	4.12	165	24	21.45	2.69	1.75	4.12
HORDEOLUM	149	21	20.06	2.77	1.75	4.37	148	21	19.79	2.75	1.74	4.35
REFUSAL OF TREATMENT BY PATIENT	109	14	16.17	3.04	1.74	5.30	108	14	15.89	3.02	1.73	5.26
BLEPHAROSPASM	518	94	48.45	2.15	1.73	2.68	518	94	48.61	2.15	1.73	2.68
EAR SWELLING	484	87	46.05	2.17	1.73	2.73	481	87	45.37	2.16	1.72	2.72
VASODILATATION	125	17	17.46	2.87	1.73	4.77	125	17	17.50	2.87	1.73	4.77
VACCINATION SITE DISCHARGE	49	4	10.07	4.78	1.73	13.25	49	4	10.09	4.79	1.73	13.27
LYMPHOEDEMA	262	43	28.85	2.38	1.72	3.28	262	42	30.02	2.44	1.76	3.38
ATELECTASIS	85	10	13.64	3.32	1.72	6.39	85	10	13.67	3.32	1.73	6.40
APHTHOUS ULCER	300	51	31.26	2.30	1.71	3.09	301	51	31.64	2.31	1.71	3.10
PELVIC PAIN	381	68	36.59	2.19	1.69	2.83	381	68	36.70	2.19	1.69	2.83
EATING DISORDER	342	60	33.82	2.23	1.69	2.93	343	60	34.20	2.23	1.70	2.94
DENTAL DISCOMFORT	54	5	10.28	4.22	1.69	10.54	54	5	10.30	4.22	1.69	10.55
ANKYLOSING SPONDYLITIS	42	3	9.19	5.47	1.69	17.64	41	3	8.84	5.34	1.65	17.25
SLEEP TERROR	42	3	9.19	5.47	1.69	17.64	42	3	9.20	5.47	1.70	17.66
BODY TEMPERATURE FLUCTUATION	231	38	25.26	2.37	1.68	3.35	230	38	25.04	2.37	1.68	3.33
RECTAL HAEMORRHAGE	169	26	20.28	2.54	1.68	3.84	167	26	19.74	2.51	1.66	3.80
BLADDER PAIN	77	9	12.36	3.34	1.67	6.66	77	9	12.39	3.34	1.68	6.67

WHITE BLOOD CELL COUNT DECREASED	71	8	11.74	3.47	1.67	7.20	71	8	11.76	3.47	1.67	7.21
MOTION SICKNESS	172	27	20.05	2.49	1.66	3.73	171	27	19.81	2.48	1.65	3.72
APPENDICECTOMY	59	6	10.52	3.84	1.66	8.89	59	6	10.54	3.84	1.66	8.90
HYPERTENSIVE CRISIS	47	4	9.37	4.59	1.65	12.73	47	4	9.38	4.59	1.65	12.75
GOUT	362	67	32.40	2.11	1.63	2.74	361	66	33.20	2.14	1.64	2.78
HUNGER	184	30	20.27	2.39	1.63	3.52	183	30	20.04	2.38	1.62	3.51
GENERALISED TONIC-CLONIC SEIZURE	222	38	22.69	2.28	1.62	3.22	222	38	22.76	2.28	1.62	3.22
THROMBOPHLEBITIS	40	3	8.47	5.21	1.61	16.83	40	3	8.48	5.21	1.61	16.85
VERTIGO POSITIONAL	262	47	24.72	2.18	1.60	2.97	261	47	24.53	2.17	1.59	2.96
NEPHROLITHIASIS	210	36	21.37	2.28	1.60	3.24	210	36	21.44	2.28	1.60	3.25
HEPATIC ENZYME INCREASED	95	13	12.98	2.85	1.60	5.09	95	13	13.02	2.86	1.60	5.10
UTERINE LEIOMYOMA	90	12	12.65	2.93	1.60	5.35	90	12	12.68	2.93	1.61	5.35
HAEMATURIA	244	44	22.76	2.17	1.57	2.98	243	43	23.54	2.21	1.60	3.06
ANAL INCONTINENCE	182	31	18.64	2.29	1.57	3.35	181	31	18.41	2.28	1.56	3.34
GASTRITIS	163	27	17.42	2.36	1.57	3.54	162	27	17.19	2.35	1.56	3.52
NONINFECTIVE GINGIVITIS	83	11	11.69	2.95	1.57	5.53	83	11	11.72	2.95	1.57	5.53
VITILIGO	67	8	10.42	3.27	1.57	6.81	65	8	9.79	3.18	1.52	6.62
MENTAL DISORDER	167	28	17.51	2.33	1.56	3.47	167	28	17.56	2.33	1.56	3.48
TRIGGER FINGER	118	18	14.12	2.56	1.56	4.20	117	18	13.86	2.54	1.55	4.17
WHITE BLOOD CELL COUNT INCREASED	98	14	12.71	2.73	1.56	4.78	98	14	12.74	2.74	1.56	4.79
TYPE IV HYPERSENSITIVITY REACTION	127	20	14.55	2.48	1.55	3.97	127	20	14.59	2.48	1.55	3.98
POOR PERIPHERAL CIRCULATION	87	12	11.71	2.83	1.55	5.18	86	12	11.43	2.80	1.53	5.12
YAWNING	66	8	10.09	3.22	1.55	6.71	66	8	10.11	3.22	1.55	6.72
FEELING DRUNK	308	59	25.61	2.04	1.54	2.69	307	59	25.44	2.03	1.54	2.69
DISSOCIATION	121	19	13.89	2.49	1.53	4.03	121	19	13.93	2.49	1.53	4.04
THERMAL BURN	91	13	11.74	2.73	1.53	4.89	91	13	11.77	2.74	1.53	4.89
VACCINATION SITE VESICLES	91	13	11.74	2.73	1.53	4.89	91	13	11.77	2.74	1.53	4.89
VACCINATION SITE JOINT PAIN	38	3	7.76	4.95	1.53	16.02	38	3	7.77	4.95	1.53	16.04
SUICIDAL IDEATION	204	37	18.71	2.15	1.52	3.06	204	37	18.77	2.16	1.52	3.06
IRRITABLE BOWEL SYNDROME	171	30	16.58	2.23	1.51	3.28	171	30	16.64	2.23	1.51	3.28
RESPIRATORY SYMPTOM	166	29	16.20	2.24	1.51	3.32	160	29	14.61	2.16	1.45	3.20
CARDIAC MURMUR	108	17	12.27	2.48	1.49	4.14	108	17	12.31	2.48	1.49	4.14
BREAST INFLAMMATION	48	5	8.23	3.75	1.49	9.42	48	5	8.24	3.75	1.49	9.43
PULMONARY OEDEMA	93	14	11.19	2.59	1.48	4.55	93	14	11.22	2.60	1.48	4.55
HIDRADENITIS	37	3	7.40	4.82	1.48	15.62	37	3	7.42	4.82	1.49	15.64
VITAMIN D DECREASED	37	3	7.40	4.82	1.48	15.62	37	3	7.42	4.82	1.49	15.64
LIP ERYTHEMA	139	24	13.75	2.26	1.47	3.49	139	24	13.79	2.26	1.47	3.49
SKIN ODOUR ABNORMAL	78	11	10.13	2.77	1.47	5.20	79	11	10.46	2.81	1.49	5.28
LOWER RESPIRATORY TRACT CONGESTION	73	10	9.79	2.85	1.47	5.52	71	10	9.19	2.78	1.43	5.38
MAST CELL ACTIVATION SYNDROME	47	5	7.89	3.67	1.46	9.23	46	5	7.57	3.60	1.43	9.05
GLOSSITIS	133	23	13.09	2.26	1.45	3.51	133	23	13.13	2.26	1.45	3.52
COLITIS ULCERATIVE	128	22	12.71	2.27	1.45	3.57	128	22	12.75	2.27	1.45	3.58
MIDDLE EAR EFFUSION	189	36	15.67	2.05	1.44	2.93	187	36	15.21	2.03	1.42	2.90
SEASONAL ALLERGY	150	27	13.79	2.17	1.44	3.27	147	27	13.03	2.13	1.41	3.21
VULVOVAGINAL PAIN	109	18	11.49	2.36	1.44	3.89	108	18	11.24	2.35	1.42	3.86
RED BLOOD CELL SEDIMENTATION RATE INCREASED	36	3	7.05	4.69	1.44	15.21	36	3	7.06	4.69	1.44	15.23
FOOD AVERSION	41	4	7.29	4.00	1.43	11.17	40	4	6.96	3.91	1.40	10.93
ORTHOSTATIC HYPOTENSION	129	23	11.99	2.19	1.41	3.41	129	23	12.03	2.19	1.41	3.42
MASTITIS	98	16	10.45	2.39	1.41	4.06	98	16	10.48	2.39	1.41	4.06
ALOPECIA AREATA	102	17	10.54	2.34	1.40	3.91	101	17	10.29	2.32	1.39	3.88
VARICOSE VEIN	93	15	10.08	2.42	1.40	4.18	93	15	10.11	2.42	1.40	4.18
PARANOIA	88	14	9.71	2.45	1.40	4.31	87	14	9.45	2.43	1.38	4.27
ATRIAL TACHYCARDIA	35	3	6.70	4.56	1.40	14.81	35	3	6.71	4.56	1.40	14.83
PLEURISY	171	33	13.74	2.02	1.39	2.94	171	33	13.78	2.03	1.40	2.94
RENAL DISORDER	110	19	10.74	2.26	1.39	3.68	109	19	10.49	2.24	1.38	3.65
PSYCHOMOTOR HYPERACTIVITY	97	16	10.17	2.37	1.39	4.02	97	16	10.20	2.37	1.40	4.02
AUTOIMMUNE THYROIDITIS	92	15	9.79	2.39	1.39	4.13	91	15	9.54	2.37	1.37	4.09
EYE CONTUSION	109	19	10.46	2.24	1.38	3.65	109	19	10.49	2.24	1.38	3.65
STRIDOR	109	19	10.46	2.24	1.38	3.65	109	19	10.49	2.24	1.38	3.65
LICHEN PLANUS	100	17	9.98	2.30	1.37	3.84	100	17	10.01	2.30	1.38	3.85
KIDNEY INFECTION	91	15	9.51	2.37	1.37	4.09	91	15	9.54	2.37	1.37	4.09
LIVER DISORDER	54	7	7.53	3.01	1.37	6.62	54	7	7.55	3.02	1.37	6.63
CIRCUMORAL SWELLING	39	4	6.61	3.81	1.36	10.65	39	4	6.62	3.81	1.36	10.67
ANGIOPATHY	34	3	6.35	4.43	1.36	14.41	33	3	6.02	4.30	1.32	14.02
BLADDER DISCOMFORT	34	3	6.35	4.43	1.36	14.41	34	3	6.37	4.43	1.36	14.42
UTERINE HAEMORRHAGE	76	12	8.39	2.47	1.35	4.55	76	12	8.42	2.48	1.35	4.55
LIP DISORDER	115	21	10.14	2.14	1.34	3.40	115	21	10.18	2.14	1.34	3.41
SMALL FIBRE NEUROPATHY	80	13	8.47	2.40	1.34	4.32	81	13	8.79	2.44	1.36	4.37
BUNDLE BRANCH BLOCK RIGHT	71	11	8.02	2.52	1.34	4.76	70	11	7.75	2.49	1.32	4.70
CONTRACEPTION	43	5	6.57	3.36	1.33	8.48	43	5	6.58	3.36	1.33	8.49
HANGOVER	92	16	8.77	2.25	1.32	3.82	92	16	8.79	2.25	1.32	3.82
GALLBLADDER DISORDER	52	7	6.90	2.90	1.32	6.39	51	7	6.61	2.85	1.29	6.28
HOSPITALISATION	38	4	6.27	3.71	1.32	10.39	38	4	6.29	3.71	1.33	10.40
CUTANEOUS VASCULITIS	33	3	6.01	4.30	1.32	14.00	33	3	6.02	4.30	1.32	14.02
ORAL LICHEN PLANUS	33	3	6.01	4.30	1.32	14.00	33	3	6.02	4.30	1.32	14.02
THIRST DECREASED	33	3	6.01	4.30	1.32	14.00	33	3	6.02	4.30	1.32	14.02
PULMONARY FIBROSIS	42	5	6.24	3.28	1.30	8.29	41	5	5.94	3.21	1.27	8.11
FAECES SOFT	90	16	8.22	2.20	1.29	3.74	90	16	8.25	2.20	1.29	3.74

WRONG TECHNIQUE IN DEVICE USAGE PROCESS	37	4	5.94	3.61	1.29	10.13	37	4	5.95	3.62	1.29	10.14
DYSPHEMIA	114	22	8.97	2.02	1.28	3.19	114	22	9.00	2.03	1.28	3.20
NASAL PRURITUS	85	15	7.84	2.21	1.28	3.83	85	15	7.86	2.22	1.28	3.84
FEELING OF DESPAIR	55	8	6.64	2.68	1.28	5.64	55	8	6.66	2.69	1.28	5.64
ACNE CYSTIC	32	3	5.67	4.16	1.28	13.60	32	3	5.68	4.17	1.28	13.62
LIBIDO DECREASED	32	3	5.67	4.16	1.28	13.60	31	3	5.34	4.04	1.23	13.21
PARANASAL SINUS INFLAMMATION	32	3	5.67	4.16	1.28	13.60	32	3	5.68	4.17	1.28	13.62
SLEEP PARALYSIS	32	3	5.67	4.16	1.28	13.60	32	3	5.68	4.17	1.28	13.62
SPINAL STENOSIS	32	3	5.67	4.16	1.28	13.60	32	3	5.68	4.17	1.28	13.62
PALATAL SWELLING	76	13	7.35	2.28	1.27	4.11	75	13	7.10	2.26	1.25	4.06
GENITAL PAIN	41	5	5.92	3.20	1.27	8.10	41	5	5.94	3.21	1.27	8.11
APPETITE DISORDER	88	16	7.69	2.15	1.26	3.66	88	16	7.71	2.15	1.26	3.66
HYPOTHERMIA	50	7	6.29	2.79	1.26	6.15	50	7	6.30	2.79	1.27	6.16
APATHY	91	17	7.55	2.09	1.25	3.51	90	17	7.31	2.07	1.23	3.47
NAIL DISCOLOURATION	83	15	7.30	2.16	1.25	3.74	83	15	7.32	2.16	1.25	3.75
OESOPHAGITIS	54	8	6.34	2.64	1.25	5.54	54	8	6.36	2.64	1.26	5.54
INNER EAR DISORDER	45	6	5.94	2.93	1.25	6.86	45	6	5.95	2.93	1.25	6.87
SKIN TEXTURE ABNORMAL	62	10	6.50	2.42	1.24	4.72	62	10	6.51	2.42	1.24	4.73
SPLENOMEGALY	62	10	6.50	2.42	1.24	4.72	62	10	6.51	2.42	1.24	4.73
ATRIOVENTRICULAR BLOCK	40	5	5.60	3.12	1.23	7.91	40	5	5.62	3.13	1.23	7.92
ATYPICAL PNEUMONIA	31	3	5.33	4.03	1.23	13.20	31	3	5.34	4.04	1.23	13.21
RENAL IMPAIRMENT	89	17	7.03	2.04	1.22	3.43	89	17	7.05	2.05	1.22	3.44
GENITAL ULCERATION	35	4	5.29	3.42	1.21	9.61	35	4	5.30	3.42	1.22	9.62
LAZINESS	35	4	5.29	3.42	1.21	9.61	34	4	4.97	3.32	1.18	9.36
CEREBRAL DISORDER	64	11	6.04	2.27	1.20	4.31	64	11	6.05	2.27	1.20	4.31
INJECTION SITE MUSCLE WEAKNESS	64	11	6.04	2.27	1.20	4.31	64	11	6.05	2.27	1.20	4.31
SINUS ARRHYTHMIA	60	10	5.93	2.34	1.20	4.58	60	10	5.95	2.35	1.20	4.58
CARDITIS	39	5	5.29	3.05	1.20	7.73	39	5	5.30	3.05	1.20	7.74
CYSTITIS INTERSTITIAL	30	3	4.99	3.90	1.19	12.79	30	3	5.00	3.91	1.19	12.81
PHANTOM LIMB SYNDROME	30	3	4.99	3.90	1.19	12.79	30	3	5.00	3.91	1.19	12.81
ERYTHEMA NODOSUM	71	13	6.00	2.13	1.18	3.85	71	13	6.02	2.13	1.18	3.86
TONGUE ERUPTION	71	13	6.00	2.13	1.18	3.85	71	13	6.02	2.13	1.18	3.86
MUSCLE STRENGTH ABNORMAL	34	4	4.96	3.32	1.18	9.35	35	4	5.30	3.42	1.22	9.62
MOUTH HAEMORRHAGE	66	12	5.61	2.15	1.16	3.97	66	12	5.63	2.15	1.16	3.98
MYASTHENIA GRAVIS	77	15	5.75	2.00	1.15	3.48	77	15	5.77	2.01	1.15	3.49
PANCREATITIS	69	13	5.48	2.07	1.15	3.75	69	13	5.50	2.07	1.15	3.75
SKIN EROSION	69	13	5.48	2.07	1.15	3.75	69	13	5.50	2.07	1.15	3.75
WALKING DISABILITY	29	3	4.66	3.77	1.15	12.39	29	3	4.67	3.78	1.15	12.40
VEIN DISCOLOURATION	37	5	4.67	2.89	1.14	7.35	37	5	4.68	2.89	1.14	7.36
INCORRECT PRODUCT ADMINISTRATION DURATION	33	4	4.64	3.22	1.14	9.09	33	4	4.65	3.22	1.14	9.10
LIVER FUNCTION TEST INCREASED	33	4	4.64	3.22	1.14	9.09	33	4	4.65	3.22	1.14	9.10
GASTROINTESTINAL HAEMORRHAGE	49	8	4.89	2.39	1.13	5.05	49	8	4.91	2.39	1.13	5.06
EXOPHTHALMOS	41	6	4.73	2.67	1.13	6.28	41	6	4.74	2.67	1.13	6.29
IMPAIRED GASTRIC EMPTYING	41	6	4.73	2.67	1.13	6.28	40	6	4.45	2.61	1.10	6.15
GASTROINTESTINAL INFLAMMATION	56	10	4.84	2.19	1.12	4.29	56	10	4.86	2.19	1.12	4.29
PLANTAR FASCITIS	56	10	4.84	2.19	1.12	4.29	55	10	4.59	2.15	1.10	4.22
VACCINATION SITE IRRITATION	63	12	4.84	2.05	1.11	3.80	63	12	4.86	2.05	1.11	3.80
TOOTH ABSCESS	48	8	4.62	2.34	1.11	4.95	48	7	5.70	2.68	1.21	5.92
RED BLOOD CELL ABNORMALITY	36	5	4.37	2.81	1.10	7.16	36	5	4.38	2.81	1.10	7.17
EUSTACHIAN TUBE DISORDER	32	4	4.33	3.12	1.10	8.83	31	4	4.03	3.03	1.07	8.58
SKIN WRINKLING	46	8	4.07	2.25	1.06	4.76	46	8	4.09	2.25	1.06	4.76
ANTINUCLEAR ANTIBODY POSITIVE	27	3	4.00	3.51	1.07	11.58	26	3	3.69	3.39	1.03	11.19
BREAST INDURATION	27	3	4.00	3.51	1.07	11.58	26	3	3.69	3.39	1.03	11.19
ASYMPTOMATIC COVID-19	520	1	199.41	203.04	28.55	1444.09	515	1	197.68	201.32	28.30	1431.86
POST-ACUTE COVID-19 SYNDROME	293	1	110.70	114.40	16.06	814.88	292	1	110.44	114.14	16.02	813.03
DISEASE RECURRENCE	197	2	70.92	38.46	9.55	154.86	197	2	71.01	38.50	9.56	155.04
COVID-19 PNEUMONIA	159	2	56.11	31.04	7.70	125.20	158	2	55.79	30.88	7.66	124.56
PREMENSTRUAL SYNDROME	151	2	53.00	29.48	7.31	118.95	150	2	52.68	29.32	7.27	118.31
SARS-COV-2 TEST NEGATIVE	88	1	30.71	34.36	4.79	246.65	88	1	30.75	34.40	4.79	246.93
LUNG OPACITY	87	1	30.32	33.97	4.73	243.88	87	1	30.36	34.01	4.74	244.15
INTENTIONAL DOSE OMISSION	81	1	27.98	31.63	4.40	227.25	81	1	28.02	31.66	4.41	227.51
COVID-19 IMMUNISATION	89	2	28.92	17.38	4.28	70.56	89	2	28.96	17.40	4.28	70.64
NEAR DEATH EXPERIENCE	83	2	26.60	16.20	3.99	65.87	83	2	26.64	16.22	3.99	65.95
BREAST CYST	72	1	24.49	28.11	3.91	202.30	72	1	24.52	28.15	3.91	202.53
VACCINATION SITE PARAESTHESIA	75	2	23.52	14.64	3.60	59.63	74	2	23.16	14.46	3.55	58.92
PRE-EXISTING CONDITION IMPROVED	62	1	20.61	24.21	3.36	174.58	62	1	20.63	24.24	3.36	174.78
PULMONARY THROMBOSIS	68	2	20.82	13.28	3.25	54.17	68	2	20.85	13.29	3.26	54.23
CHILLBLAINS	60	1	19.83	23.43	3.25	169.04	60	1	19.86	23.45	3.25	169.23
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	60	1	19.83	23.43	3.25	169.04	60	1	19.86	23.45	3.25	169.23
ABNORMAL UTERINE BLEEDING	58	1	19.06	22.65	3.14	163.50	57	1	18.69	22.28	3.09	160.91
SARS-COV-2 TEST	53	1	17.12	20.69	2.86	149.64	52	1	16.76	20.33	2.81	147.03
C-REACTIVE PROTEIN INCREASED	57	2	16.61	11.13	2.72	45.58	57	2	16.63	11.14	2.72	45.63
BODY HEIGHT DECREASED	50	1	15.96	19.52	2.70	141.32	50	1	15.98	19.55	2.70	141.48
MANIA	55	2	15.85	10.74	2.62	44.02	55	2	15.87	10.75	2.62	44.07

UTERINE PAIN	53	2	15.09	10.35	2.52	42.46	53	2	15.11	10.36	2.52	42.51
INJECTION	46	1	14.42	17.96	2.48	130.24	45	1	14.05	17.59	2.42	127.61
BLOOD IRON DECREASED	44	1	13.65	17.18	2.37	124.69	44	1	13.67	17.20	2.37	124.84
PREMENSTRUAL PAIN	44	1	13.65	17.18	2.37	124.69	44	1	13.67	17.20	2.37	124.84
BLOOD DISORDER	43	1	13.26	16.79	2.31	121.92	43	1	13.28	16.81	2.31	122.06
GIANT CELL ARTERITIS	43	1	13.26	16.79	2.31	121.92	43	1	13.28	16.81	2.31	122.06
COOLING THERAPY	47	2	12.81	9.18	2.23	37.77	47	2	12.83	9.19	2.23	37.82
OXYGEN SATURATION												
ABNORMAL	41	1	12.49	16.01	2.20	116.38	39	1	11.74	15.25	2.09	110.96
WRONG PATIENT	46	2	12.44	8.98	2.18	36.99	46	2	12.45	8.99	2.18	37.04
DIZZINESS EXERTIONAL	39	1	11.73	15.23	2.09	110.84	39	1	11.74	15.25	2.09	110.96
PLATELET COUNT INCREASED	38	1	11.34	14.84	2.04	108.06	38	1	11.36	14.85	2.04	108.19
SENSITISATION	38	1	11.34	14.84	2.04	108.06	38	1	11.36	14.85	2.04	108.19
PRODUCT RECONSTITUTION												
QUALITY ISSUE	43	2	11.31	8.39	2.03	34.65	43	1	13.28	16.81	2.31	122.06
SENSATION OF BLOOD FLOW	43	2	11.31	8.39	2.03	34.65	43	2	11.32	8.40	2.04	34.69
FREEZING PHENOMENON	37	1	10.96	14.45	1.98	105.29	37	1	10.98	14.46	1.98	105.41
BLOOD THYROID STIMULATING												
HORMONE INCREASED	36	1	10.58	14.06	1.93	102.52	36	1	10.59	14.07	1.93	102.64
QUARANTINE	40	2	10.18	7.81	1.89	32.31	37	2	9.08	7.23	1.74	30.00
SINUS RHYTHM	40	2	10.18	7.81	1.89	32.31	40	2	10.20	7.82	1.89	32.35
FEELING OF RELAXATION	35	1	10.20	13.67	1.87	99.75	35	1	10.21	13.68	1.87	99.86
GLYCOSYLATED HAEMOGLOBIN												
INCREASED	35	1	10.20	13.67	1.87	99.75	35	1	10.21	13.68	1.87	99.86
DYSCHROMATOPSIA	39	2	9.81	7.61	1.84	31.53	39	2	9.83	7.62	1.84	31.57
MENOMETRORRHAGIA	39	2	9.81	7.61	1.84	31.53	39	2	9.83	7.62	1.84	31.57
PRODUCT ADMINISTRATION												
INTERRUPTED	34	1	9.81	13.28	1.82	96.98	34	1	9.83	13.29	1.82	97.09
CHILD MALTREATMENT												
SYNDROME	31	1	8.67	12.10	1.65	88.67	31	1	8.68	12.12	1.65	88.77
OVERSENSING	31	1	8.67	12.10	1.65	88.67	31	1	8.68	12.12	1.65	88.77
RED BLOOD CELL COUNT												
DECREASED	31	1	8.67	12.10	1.65	88.67	31	1	8.68	12.12	1.65	88.77
BILIARY COLIC	35	2	8.33	6.83	1.64	28.41	35	2	8.35	6.84	1.65	28.44
DEPERSONALISATION/DEREALIS												
ATION DISORDER	35	2	8.33	6.83	1.64	28.41	35	2	8.35	6.84	1.65	28.44
LEFT ATRIAL ENLARGEMENT	35	2	8.33	6.83	1.64	28.41	35	2	8.35	6.84	1.65	28.44
ENDOMETRIAL THICKENING	30	1	8.29	11.71	1.60	85.89	29	1	7.93	11.34	1.54	83.22
ENDOMETRIOSIS	34	2	7.96	6.64	1.59	27.63	34	2	7.98	6.65	1.60	27.66
SUFFOCATION FEELING	33	2	7.60	6.44	1.55	26.85	33	2	7.61	6.45	1.55	26.88
VACCINATION SITE SCAR	33	2	7.60	6.44	1.55	26.85	33	2	7.61	6.45	1.55	26.88
EYELID SENSORY DISORDER	29	1	7.91	11.32	1.54	83.12	29	1	7.93	11.34	1.54	83.22
PULMONARY HYPERTENSION	29	1	7.91	11.32	1.54	83.12	29	1	7.93	11.34	1.54	83.22
THYROID PAIN	29	1	7.91	11.32	1.54	83.12	29	1	7.93	11.34	1.54	83.22
HAND DERMATITIS	28	1	7.54	10.93	1.49	80.35	28	1	7.55	10.95	1.49	80.44
PARAESTHESIA EAR	28	1	7.54	10.93	1.49	80.35	28	1	7.55	10.95	1.49	80.44
VESTIBULAR MIGRAINE	28	1	7.54	10.93	1.49	80.35	28	1	7.55	10.95	1.49	80.44
RETINAL MIGRAINE	31	2	6.87	6.05	1.45	25.29	31	2	6.88	6.06	1.45	25.32
BLOOD URINE	30	2	6.51	5.86	1.40	24.51	30	2	6.52	5.86	1.40	24.54
BODY HEIGHT	30	2	6.51	5.86	1.40	24.51	30	2	6.52	5.86	1.40	24.54
CHOLECYSTITIS	26	1	6.78	10.15	1.38	74.81	26	1	6.79	10.16	1.38	74.90
EAR INFLAMMATION	26	1	6.78	10.15	1.38	74.81	26	1	6.79	10.16	1.38	74.90
IMMUNE-MEDIATED ADVERSE												
REACTION	26	1	6.78	10.15	1.38	74.81	26	1	6.79	10.16	1.38	74.90
APRAXIA	25	1	6.41	9.76	1.32	72.04	25	1	6.42	9.77	1.32	72.12
OVARIAN CYST RUPTURED	25	1	6.41	9.76	1.32	72.04	25	1	6.42	9.77	1.32	72.12
OVULATION DISORDER	25	1	6.41	9.76	1.32	72.04	25	1	6.42	9.77	1.32	72.12
REDUCED FACIAL EXPRESSION	25	1	6.41	9.76	1.32	72.04	25	1	6.42	9.77	1.32	72.12
TOTAL LUNG CAPACITY												
DECREASED	25	1	6.41	9.76	1.32	72.04	25	1	6.42	9.77	1.32	72.12
HYPERVIGILANCE	28	2	5.79	5.47	1.30	22.95	28	2	5.80	5.47	1.30	22.97
INJECTION RELATED REACTION	24	1	6.04	9.37	1.27	69.27	24	1	6.05	9.38	1.27	69.35
MENSTRUATION NORMAL	24	1	6.04	9.37	1.27	69.27	24	1	6.05	9.38	1.27	69.35
CHEST INJURY	27	2	5.44	5.27	1.25	22.17	27	2	5.45	5.28	1.25	22.19
COLD-STIMULUS HEADACHE	27	2	5.44	5.27	1.25	22.17	27	2	5.45	5.28	1.25	22.19
BLADDER SPASM	23	1	5.66	8.98	1.21	66.50	23	1	5.67	8.99	1.21	66.57
PRODUCT DISPENSING ISSUE	23	1	5.66	8.98	1.21	66.50	22	1	5.30	8.60	1.16	63.80
HEPATIC ENZYME ABNORMAL	26	2	5.09	5.08	1.20	21.39	26	2	5.10	5.08	1.21	21.41
PRODUCT AVAILABILITY ISSUE	26	2	5.09	5.08	1.20	21.39	26	2	5.10	5.08	1.21	21.41
FOOD CRAVING	25	2	4.74	4.88	1.16	20.61	24	2	4.40	4.69	1.11	19.85
DAYDREAMING	22	1	5.29	8.59	1.16	63.73	22	1	5.30	8.60	1.16	63.80
LIVER INJURY	22	1	5.29	8.59	1.16	63.73	22	1	5.30	8.60	1.16	63.80
THERAPEUTIC PRODUCT EFFECT												
DECREASED	22	1	5.29	8.59	1.16	63.73	22	1	5.30	8.60	1.16	63.80
THERAPY CHANGE	24	2	4.39	4.69	1.11	19.83	24	2	4.40	4.69	1.11	19.85
BREAST DISORDER FEMALE	21	1	4.93	8.20	1.10	60.96	21	1	4.93	8.21	1.10	61.03
DYSHIDROTIC ECZEMA	21	1	4.93	8.20	1.10	60.96	21	1	4.93	8.21	1.10	61.03
SUPERFICIAL VEIN												
PROMINENCE	21	1	4.93	8.20	1.10	60.96	21	1	4.93	8.21	1.10	61.03
APTALISM	23	2	4.05	4.49	1.06	19.05	23	2	4.06	4.50	1.06	19.07
VEIN RUPTURE	20	1	4.56	7.81	1.05	58.19	20	1	4.57	7.82	1.05	58.25
ECZEMA NUMMULAR	19	1	4.19	7.42	0.99	55.42	19	1	4.20	7.43	0.99	55.48

NEPHROTIC SYNDROME	19	1	4.19	7.42	0.99	55.42	19	1	4.20	7.43	0.99	55.48
SUBSTANCE USE	19	1	4.19	7.42	0.99	55.42	19	1	4.20	7.43	0.99	55.48
POLYP	23	2	4.05	4.49	1.06	19.05	22	2	3.72	4.30	1.01	18.29
BLOOD CREATINE												
PHOSPHOKINASE INCREASED	19	1	4.19	7.42	0.99	55.42	18	1	3.84	7.04	0.94	52.71
HYDRONEPHROSIS	19	1	4.19	7.42	0.99	55.42	18	1	3.84	7.04	0.94	52.71
HEPATIC LESION	11	1	1.44	4.30	0.55	33.27	11	0	.	.	.	.

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines \(AGES 5 YEARS-11 YEARS\)](#)
Compared to [ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines \(AGES 5 YEARS-11 YEARS\)](#)
AGES 5 YEARS-11 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022
Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (5 Yrs-11 Yrs)	12/14/2020- 07/29/2022 COVID19 mRNA N=12329	01/01/2009- 07/29/2022 NON-COVID19 N=29071	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020- 07/22/2022 COVID19 mRNA N=12185	01/01/2009- 07/22/2022 NON-COVID19 N=29047	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
PRODUCT PREPARATION ISSUE	1930	45	4574.60	101.13	75.31	135.80	1913	45	4582.30	101.34	75.46	136.09
COVID-19	231	4	527.30	136.17	50.69	365.81	225	4	518.75	134.09	49.90	360.30
INCORRECT DOSE ADMINISTERED	1982	265	3875.58	17.64	15.54	20.01	1956	264	3861.33	17.66	15.56	20.05
PRODUCT ADMINISTRATION ERROR	99	12	185.01	19.45	10.69	35.40	98	12	184.94	19.47	10.69	35.44
UNDERDOSE	416	82	693.90	11.96	9.45	15.14	414	83	695.43	11.89	9.40	15.04
IMMUNISATION	71	13	118.02	12.88	7.13	23.25	71	13	119.54	13.02	7.21	23.51
ILLNESS	34	4	61.99	20.04	7.11	56.47	33	4	60.43	19.67	6.97	55.50
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	1587	503	2239.77	7.44	6.74	8.21	1570	498	2245.92	7.52	6.81	8.29
PRODUCT PREPARATION ERROR	278	83	386.17	7.90	6.19	10.08	269	83	372.33	7.73	6.05	9.87
INCORRECT PRODUCT FORMULATION ADMINISTERED	173	60	219.45	6.80	5.07	9.11	173	60	222.70	6.87	5.13	9.21
PRODUCT USE ISSUE	44	11	64.04	9.43	4.87	18.26	44	11	64.92	9.54	4.93	18.46
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	267	114	296.69	5.52	4.44	6.87	260	112	291.47	5.53	4.44	6.90
INJURY ASSOCIATED WITH DEVICE	19	3	31.05	14.93	4.42	50.45	19	3	31.45	15.10	4.47	51.01
MYOCARDITIS	20	4	30.42	11.79	4.03	34.49	20	4	30.83	11.92	4.07	34.86
APPENDICITIS	18	4	26.07	10.61	3.59	31.35	18	4	26.43	10.73	3.63	31.69
VACCINATION FAILURE	33	12	38.81	6.48	3.35	12.55	30	12	33.43	5.96	3.05	11.64
POOR QUALITY PRODUCT ADMINISTERED	19	6	23.39	7.47	2.98	18.69	18	6	21.69	7.15	2.84	18.01
PRODUCT STORAGE ERROR	1150	867	750.72	3.13	2.87	3.41	1147	866	763.32	3.16	2.90	3.44
NEEDLE ISSUE	18	6	21.37	7.07	2.81	17.82	16	6	17.69	6.36	2.49	16.24
OVERDOSE	37	18	35.25	4.85	2.76	8.51	37	17	37.58	5.19	2.92	9.21
ANGINA PECTORIS	12	3	15.77	9.43	2.66	33.42	12	3	16.00	9.54	2.69	33.78
OROPHARYNGEAL DISCOMFORT	12	3	15.77	9.43	2.66	33.42	12	3	16.00	9.54	2.69	33.78
EXPIRED PRODUCT ADMINISTERED	669	551	376.15	2.86	2.56	3.20	639	551	341.94	2.76	2.47	3.09
PHARYNGEAL SWELLING	13	4	15.57	7.66	2.50	23.50	13	4	15.80	7.75	2.53	23.76
PERIORBITAL SWELLING	19	8	19.39	5.60	2.45	12.79	19	8	19.70	5.66	2.48	12.93
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS	52	36	34.84	3.41	2.23	5.21	52	36	35.55	3.44	2.25	5.26
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR	52	38	32.48	3.23	2.12	4.90	49	38	28.73	3.07	2.01	4.69
CHEST PAIN	196	189	81.95	2.45	2.00	2.98	196	188	84.94	2.49	2.04	3.03
VACCINE BREAKTHROUGH INFECTION	12	5	11.66	5.66	1.99	16.06	12	5	11.85	5.72	2.02	16.24
SYRINGE ISSUE	44	34	25.24	3.05	1.95	4.77	41	34	21.57	2.87	1.83	4.53
NO ADVERSE EVENT	2533	2962	805.72	2.02	1.92	2.12	2522	2958	822.51	2.03	1.94	2.13
CONJUNCTIVITIS	33	25	19.14	3.11	1.85	5.23	33	25	19.57	3.15	1.87	5.29
MENSTRUATION IRREGULAR	10	4	9.71	5.89	1.85	18.79	10	4	9.87	5.96	1.87	19.00
COSTOCHONDRITIS	8	3	7.76	6.29	1.67	23.70	8	3	7.89	6.36	1.69	23.96
KAWASAKI'S DISEASE	8	3	7.76	6.29	1.67	23.70	8	3	7.89	6.36	1.69	23.96
APPENDICECTOMY	13	8	8.89	3.83	1.59	9.24	13	8	9.07	3.87	1.61	9.34
INTERCHANGE OF VACCINE PRODUCTS	23	20	10.46	2.71	1.49	4.94	20	20	7.09	2.38	1.28	4.43
SHOCK	11	7	7.02	3.71	1.44	9.56	11	7	7.17	3.75	1.45	9.66
SLEEP DISORDER	40	45	11.35	2.10	1.37	3.21	39	45	10.72	2.07	1.35	3.17
PAINFUL RESPIRATION	13	10	6.64	3.07	1.34	6.99	13	10	6.80	3.10	1.36	7.07
PITYRIASIS ROSEA	7	4	4.52	4.13	1.21	14.09	7	4	4.61	4.17	1.22	14.25
SWELLING OF EYELID	17	17	5.72	2.36	1.20	4.62	17	17	5.89	2.38	1.22	4.67
AGEUSIA	6	3	4.23	4.72	1.18	18.85	6	3	4.31	4.77	1.19	19.06
VENTRICULAR EXTRASYSTOLES	6	3	4.23	4.72	1.18	18.85	6	3	4.31	4.77	1.19	19.06
VACCINATION ERROR	18	20	4.82	2.12	1.12	4.01	17	20	4.02	2.03	1.06	3.87
GENERAL PHYSICAL CONDITION ABNORMAL	8	5	4.84	3.77	1.23	11.53	7	5	3.49	3.34	1.06	10.51
INJECTION SITE EXTRAVASATION	9	7	4.17	3.03	1.13	8.14	8	7	3.01	2.72	0.99	7.51
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	70	1	157.76	165.06	22.93	1188.07	70	1	159.53	166.87	23.18	1201.11
DRUG INEFFECTIVE	26	2	50.33	30.65	7.28	129.13	26	2	50.93	30.99	7.36	130.55
BELL'S PALSY	17	1	32.98	40.08	5.34	301.17	17	1	33.37	40.53	5.39	304.48
LEFT VENTRICULAR DYSFUNCTION	12	1	21.41	28.30	3.68	217.58	12	1	21.68	28.61	3.72	219.97
MITRAL VALVE INCOMPETENCE	9	1	14.59	21.22	2.69	167.48	9	1	14.77	21.45	2.72	169.32

PERICARDITIS	8	1	12.35	18.86	2.36	150.80	8	1	12.51	19.07	2.39	152.46
SINUS TACHYCARDIA	9	2	11.87	10.61	2.29	49.10	9	2	12.04	10.73	2.32	49.64
PERICARDIAL EFFUSION	7	1	10.14	16.51	2.03	134.14	7	1	10.27	16.69	2.05	135.61
MENSTRUAL DISORDER	8	2	9.78	9.43	2.00	44.41	8	2	9.92	9.54	2.03	44.90
TASTE DISORDER	8	2	9.78	9.43	2.00	44.41	8	2	9.92	9.54	2.03	44.90
APHONIA	7	2	7.75	8.25	1.71	39.72	7	2	7.87	8.34	1.73	40.16
PLEURAL EFFUSION	7	2	7.75	8.25	1.71	39.72	7	2	7.87	8.34	1.73	40.16
BEHAVIOUR DISORDER	6	1	7.97	14.15	1.70	117.50	6	1	8.08	14.30	1.72	118.79
BLOOD PRESSURE DIASTOLIC DECREASED	6	1	7.97	14.15	1.70	117.50	6	1	8.08	14.30	1.72	118.79
TRICUSPID VALVE INCOMPETENCE	6	1	7.97	14.15	1.70	117.50	6	1	8.08	14.30	1.72	118.79
HEPATOMEGALY	6	2	5.81	7.07	1.43	35.04	6	2	5.91	7.15	1.44	35.43
VITILIGO	5	1	5.87	11.79	1.38	100.90	5	1	5.95	11.92	1.39	102.01
OFF LABEL USE	22	26	5.18	2.00	1.13	3.52	22	26	5.36	2.02	1.14	3.56
APHTHOUS ULCER	5	2	3.99	5.89	1.14	30.38	5	2	4.06	5.96	1.16	30.71
PAROSMIA	5	2	3.99	5.89	1.14	30.38	5	2	4.06	5.96	1.16	30.71

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines \(AGES 12 YEARS-17 YEARS\)](#)
Compared to [ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines \(AGES 12 YEARS-17 YEARS\)](#)
AGES 12 YEARS-17 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022
Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (12 Yrs-17 Yrs)	12/14/2020- 07/29/2022 COVID19 mRNA N=31447	01/01/2009- 07/29/2022 NON-COVID19 N=30084	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020- 07/22/2022 COVID19 mRNA N=31374	01/01/2009- 07/22/2022 NON-COVID19 N=30040	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
COVID-19	568	3	537.63	181.13	58.25	563.21	565	3	535.18	180.33	57.99	560.73
MYOCARDITIS	739	11	681.50	64.27	35.44	116.54	738	11	681.14	64.24	35.43	116.48
UNDERDOSE	1057	58	865.71	17.43	13.39	22.70	1055	58	864.63	17.42	13.38	22.68
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	8636	584	7858.95	14.15	13.03	15.36	8622	578	7868.28	14.28	13.15	15.51
PERICARDITIS	219	12	175.44	17.46	9.77	31.21	218	12	174.66	17.39	9.73	31.10
HEAVY MENSTRUAL BLEEDING	133	6	109.00	21.21	9.36	48.04	133	6	109.11	21.22	9.37	48.09
BELL'S PALSY	76	3	62.58	24.24	7.65	76.82	76	3	62.64	24.26	7.65	76.88
ILLNESS	81	5	62.24	15.50	6.28	38.23	81	5	62.31	15.51	6.29	38.27
POOR QUALITY PRODUCT ADMINISTERED	71	4	55.29	16.98	6.20	46.49	71	4	55.34	17.00	6.21	46.53
PRODUCT ADMINISTRATION ERROR	91	7	66.81	12.44	5.77	26.82	91	7	66.87	12.45	5.77	26.85
ANTICOAGULANT THERAPY	61	4	45.87	14.59	5.31	40.11	61	4	45.91	14.60	5.31	40.15
PRODUCT PREPARATION ISSUE	512	75	307.90	6.53	5.13	8.32	511	75	307.36	6.52	5.12	8.31
PERICARDIAL EFFUSION	72	7	49.14	9.84	4.53	21.38	72	7	49.19	9.85	4.53	21.39
PLEURITIC PAIN	57	5	39.78	10.91	4.37	27.20	56	5	38.90	10.72	4.30	26.77
AGEUSIA	74	8	48.77	8.85	4.27	18.35	74	8	48.83	8.86	4.27	18.37
ANGINA PECTORIS	50	5	33.32	9.57	3.82	23.99	50	5	33.36	9.57	3.82	24.01
IMMUNISATION	96	14	56.24	6.56	3.75	11.49	96	14	56.31	6.57	3.75	11.50
PAINFUL RESPIRATION	140	26	72.23	5.15	3.39	7.83	141	26	73.18	5.19	3.42	7.89
CHEST PAIN	1825	470	769.02	3.71	3.36	4.11	1824	470	769.39	3.72	3.36	4.11
PHARYNGEAL SWELLING	76	15	37.02	4.85	2.79	8.43	76	15	37.07	4.85	2.79	8.44
PRODUCT STORAGE ERROR	2669	874	881.84	2.92	2.71	3.15	2668	873	884.00	2.93	2.72	3.15
VENTRICULAR EXTRASYSTOLES	40	6	22.26	6.38	2.70	15.04	40	6	22.29	6.38	2.71	15.05
RESPIRATORY RATE INCREASED	200	53	78.27	3.61	2.67	4.88	198	53	76.83	3.58	2.64	4.84
TASTE DISORDER	27	3	16.65	8.61	2.61	28.38	27	3	16.66	8.62	2.61	28.40
TRICUSPID VALVE INCOMPETENCE	29	4	16.42	6.94	2.44	19.73	29	4	16.44	6.94	2.44	19.74
FEAR OF INJECTION	35	6	17.92	5.58	2.35	13.27	35	6	17.95	5.59	2.35	13.28
SINUS ARRHYTHMIA	35	6	17.92	5.58	2.35	13.27	35	6	17.95	5.59	2.35	13.28
RESPIRATORY RATE DECREASED	48	10	22.02	4.59	2.32	9.07	48	10	22.05	4.60	2.33	9.08
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	612	217	172.62	2.70	2.31	3.15	610	214	175.01	2.73	2.34	3.19
PULMONARY EMBOLISM	31	5	16.29	5.93	2.31	15.25	31	5	16.31	5.94	2.31	15.26
ACUTE KIDNEY INJURY	40	8	18.69	4.78	2.24	10.22	40	8	18.72	4.79	2.24	10.23
BLOOD PRESSURE INCREASED	195	63	61.12	2.96	2.23	3.93	195	63	61.23	2.96	2.23	3.94
OFF LABEL USE	92	27	31.72	3.26	2.12	5.00	92	27	31.77	3.26	2.13	5.01
CHEST DISCOMFORT	647	255	154.96	2.43	2.10	2.80	646	254	155.66	2.44	2.11	2.81
PRODUCT TEMPERATURE EXCURSION ISSUE	36	8	15.41	4.30	2.00	9.26	36	8	15.43	4.31	2.00	9.27
HEART SOUNDS ABNORMAL	20	3	10.44	6.38	1.90	21.46	20	3	10.46	6.38	1.90	21.48
INCORRECT DOSE ADMINISTERED	867	390	163.19	2.13	1.89	2.39	862	386	164.15	2.14	1.90	2.41
APPENDICITIS	57	17	18.89	3.21	1.87	5.51	57	17	18.93	3.21	1.87	5.52
INTENSIVE CARE	376	161	76.77	2.23	1.86	2.69	374	161	75.75	2.22	1.85	2.67
THROMBOSIS	33	8	13.02	3.95	1.82	8.54	33	8	13.04	3.95	1.82	8.55
SINUS TACHYCARDIA	67	22	19.89	2.91	1.80	4.71	67	22	19.92	2.92	1.80	4.72
CARDIAC DISORDER	30	7	12.14	4.10	1.80	9.33	29	7	11.37	3.97	1.74	9.05
HEART RATE INCREASED	479	220	85.15	2.08	1.78	2.44	476	220	83.66	2.07	1.77	2.43
INTERCHANGE OF VACCINE PRODUCTS	231	100	45.73	2.21	1.75	2.79	230	100	45.24	2.20	1.74	2.78
VULVOVAGINAL PAIN	18	3	8.73	5.74	1.69	19.48	18	3	8.74	5.74	1.69	19.50
CARDIAC FLUTTER	28	7	10.57	3.83	1.67	8.76	28	7	10.59	3.83	1.67	8.77
VAGINAL ULCERATION	25	6	9.68	3.99	1.64	9.72	25	6	9.69	3.99	1.64	9.72
TACHYPNOEA	76	29	18.21	2.51	1.63	3.84	74	29	16.97	2.44	1.59	3.75
PERIORBITAL SWELLING	22	5	8.79	4.21	1.59	11.11	22	5	8.81	4.21	1.60	11.12
OROPHARYNGEAL DISCOMFORT	38	12	11.43	3.03	1.58	5.80	38	12	11.45	3.03	1.58	5.80
APHTHOUS ULCER	19	4	7.92	4.54	1.55	13.36	19	4	7.93	4.55	1.55	13.37
MENSTRUAL DISORDER	79	34	15.27	2.22	1.49	3.32	79	34	15.31	2.22	1.49	3.32
AXILLARY PAIN	113	53	18.50	2.04	1.47	2.83	113	53	18.54	2.04	1.47	2.83
IMMUNE THROMBOCYTOPENIA	20	5	7.24	3.83	1.44	10.19	20	5	7.25	3.83	1.44	10.20
VACCINATION ERROR	43	17	9.35	2.42	1.38	4.24	42	16	9.73	2.51	1.41	4.47
ELECTROCARDIOGRAM T WAVE INVERSION	15	3	6.25	4.78	1.38	16.52	15	3	6.26	4.79	1.39	16.53
PLEURAL EFFUSION	36	14	7.92	2.46	1.33	4.56	36	14	7.94	2.46	1.33	4.56
PAROSMIA	26	9	6.63	2.76	1.30	5.90	26	9	6.64	2.77	1.30	5.90
OVERDOSE	40	17	7.56	2.25	1.28	3.97	40	16	8.49	2.39	1.34	4.27
SENSITIVE SKIN	14	3	5.45	4.46	1.28	15.53	14	3	5.46	4.47	1.28	15.55

SINUS BRADYCARDIA	32	13	6.43	2.35	1.24	4.49	32	13	6.45	2.36	1.24	4.49
STEROID THERAPY	21	7	5.48	2.87	1.22	6.75	21	7	5.49	2.87	1.22	6.76
NEEDLE ISSUE	19	6	5.25	3.03	1.21	7.58	19	6	5.26	3.03	1.21	7.59
ELECTROCARDIOGRAM AMBULATORY	17	5	5.03	3.25	1.20	8.82	17	5	5.04	3.26	1.20	8.82
MOUTH SWELLING	24	9	5.34	2.55	1.19	5.49	24	9	5.35	2.55	1.19	5.49
LYMPHOPENIA	15	4	4.83	3.59	1.19	10.81	15	3	6.26	4.79	1.39	16.53
SWELLING OF EYELID	36	17	5.35	2.03	1.14	3.61	36	17	5.36	2.03	1.14	3.61
RESPIRATORY SYMPTOM	19	7	4.18	2.60	1.09	6.18	19	7	4.19	2.60	1.09	6.18
ACUTE RESPIRATORY FAILURE	22	9	4.13	2.34	1.08	5.08	22	9	4.14	2.34	1.08	5.08
DYSPNOEA EXERTIONAL	53	25	8.20	2.03	1.26	3.26	52	25	7.70	1.99	1.24	3.21
TROPONIN I INCREASED	145	1	134.18	138.72	19.41	991.35	146	1	135.26	139.79	19.56	999.00
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	130	2	116.94	62.18	15.39	251.27	130	2	117.04	62.24	15.40	251.48
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	61	1	53.64	58.36	8.09	420.93	61	1	53.69	58.41	8.10	421.29
DRUG INEFFECTIVE	57	1	49.82	54.53	7.55	393.77	57	1	49.86	54.58	7.56	394.11
ANOSMIA	63	2	52.84	30.13	7.37	123.14	63	2	52.89	30.16	7.38	123.25
BLOOD PRESSURE SYSTOLIC INCREASED	50	1	43.13	47.83	6.61	346.23	49	1	42.22	46.92	6.48	339.74
VACCINE BREAKTHROUGH INFECTION	43	1	36.45	41.14	5.67	298.70	43	1	36.49	41.17	5.67	298.96
MITRAL VALVE INCOMPETENCE	39	1	32.64	37.31	5.13	271.54	39	1	32.67	37.34	5.13	271.78
TROPONIN I INCREASED	38	1	31.69	36.35	4.99	264.75	38	1	31.72	36.38	5.00	264.98
VENTRICULAR TACHYCARDIA	43	2	33.85	20.57	4.98	84.90	43	2	33.88	20.59	4.99	84.97
EXPOSURE TO SARS-COV-2	40	2	31.01	19.13	4.62	79.16	39	2	30.10	18.67	4.51	77.31
EPINEPHRINE	30	1	24.09	28.70	3.91	210.44	30	1	24.11	28.72	3.92	210.62
COVID-19 IMMUNISATION	26	1	20.30	24.87	3.38	183.28	26	1	20.32	24.89	3.38	183.44
PRODUCT DOSE OMISSION ISSUE	26	2	17.90	12.44	2.95	52.39	26	2	17.92	12.45	2.95	52.44
BLOOD PRESSURE DIASTOLIC INCREASED	21	1	15.59	20.09	2.70	149.34	21	1	15.61	20.11	2.70	149.47
GENITAL ULCERATION	19	1	13.72	18.18	2.43	135.77	19	1	13.73	18.19	2.44	135.88
VULVAL ULCERATION	20	2	12.40	9.57	2.24	40.92	20	2	12.42	9.57	2.24	40.96
BLOOD PRESSURE DIASTOLIC DECREASED	17	1	11.85	16.26	2.16	122.20	17	1	11.87	16.28	2.17	122.30
C-REACTIVE PROTEIN INCREASED	15	2	7.95	7.17	1.64	31.37	15	2	7.96	7.18	1.64	31.40
ELECTROCARDIOGRAM ABNORMAL	15	2	7.95	7.17	1.64	31.37	15	2	7.96	7.18	1.64	31.40
GENERAL PHYSICAL CONDITION ABNORMAL	14	2	7.09	6.70	1.52	29.46	14	2	7.10	6.70	1.52	29.49
PULMONARY VALVE INCOMPETENCE	11	1	6.36	10.52	1.36	81.50	11	1	6.37	10.53	1.36	81.57
SEDATION	11	1	6.36	10.52	1.36	81.50	11	1	6.37	10.53	1.36	81.57
BUNDLE BRANCH BLOCK RIGHT	12	2	5.40	5.74	1.28	25.64	12	2	5.41	5.74	1.29	25.67
APPENDICITIS PERFORATED	9	1	4.60	8.61	1.09	67.95	9	1	4.60	8.62	1.09	68.01
GENITAL PAIN	9	1	4.60	8.61	1.09	67.95	9	1	4.60	8.62	1.09	68.01

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)

For Current Week and Past Week Comparison

Following ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines (AGES 18+ YEARS)

Compared to ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines (AGES 18+ YEARS)

AGES 18+ YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022

Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)

N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00

MedDRA PT's sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (18+)	12/14/2020- 07/29/2022 COVID19 mRNA N=669643	01/01/2009- 07/29/2022 NON-COVID19 N=242091	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020- 07/22/2022 COVID19 mRNA N=658300	01/01/2009- 07/22/2022 NON-COVID19 N=241884	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
COVID-19	47637	157	18041.38	111.19	95.07	130.04	46542	154	17653.68	111.05	94.81	130.07
COVID-19 PNEUMONIA	5084	11	1846.17	169.37	93.74	306.01	5051	11	1838.99	168.72	93.38	304.85
EXPOSURE TO SARS-COV-2	2430	4	882.06	222.62	83.49	593.61	2388	4	868.96	219.36	82.26	584.94
PRODUCT TEMPERATURE EXCURSION ISSUE	3066	7	1109.47	160.50	76.45	336.95	3021	7	1095.87	158.58	75.53	332.91
POOR QUALITY PRODUCT ADMINISTERED	3247	8	1173.90	148.73	74.32	297.65	3207	8	1162.33	147.30	73.60	294.79
VACCINE BREAKTHROUGH INFECTION	4852	17	1746.15	104.59	64.97	168.38	4749	17	1712.74	102.64	63.76	165.25
ASYMPTOMATIC COVID-19	1179	3	424.18	144.01	46.38	447.16	1171	3	422.40	143.42	46.19	445.33
HEAVY MENSTRUAL BLEEDING	4312	29	1518.45	54.49	37.82	78.50	4300	29	1518.28	54.48	37.82	78.49
SARS-COV-2 TEST POSITIVE	945	3	338.25	115.43	37.16	358.54	943	3	338.45	115.50	37.18	358.75
LUNG OPACITY	1890	11	666.95	62.96	34.81	113.88	1883	11	666.23	62.90	34.77	113.77
INTERMENSTRUAL BLEEDING	1339	7	473.66	70.10	33.35	147.32	1337	7	474.25	70.18	33.39	147.49
VACCINATION SITE PRURITUS	3991	35	1386.08	41.79	29.96	58.28	3989	35	1389.28	41.88	30.03	58.41
INTERCHANGE OF VACCINE PRODUCTS	8544	100	2926.90	31.31	25.71	38.13	8533	100	2931.30	31.35	25.74	38.18
DRUG INEFFECTIVE	3716	41	1270.95	33.21	24.41	45.18	3423	40	1168.58	31.44	23.02	42.94
PRODUCT DOSE OMISSION ISSUE	1713	16	590.43	39.23	23.98	64.18	1711	16	591.38	39.29	24.02	64.28
SUSPECTED COVID-19	878	7	304.43	45.96	21.85	96.70	857	7	297.57	44.98	21.38	94.64
PULMONARY THROMBOSIS	648	5	224.66	47.49	19.70	114.48	642	5	223.09	47.18	19.57	113.73
POSITIVE AIRWAY PRESSURE THERAPY	983	10	336.12	36.02	19.32	67.16	964	9	332.37	39.36	20.42	75.87
DYSMENORRHOEA	1848	25	619.72	27.09	18.26	40.19	1843	25	619.69	27.09	18.26	40.19
POLYMENORRHOEA	692	7	236.24	36.23	17.21	76.27	692	7	236.92	36.32	17.25	76.48
MENSTRUATION IRREGULAR	3298	59	1076.94	20.48	15.84	26.50	3295	59	1079.05	20.52	15.86	26.54
MENSTRUAL DISORDER	2474	43	809.56	21.08	15.60	28.50	2469	43	810.13	21.10	15.61	28.52
ANOSMIA	3776	72	1224.13	19.22	15.22	24.26	3749	72	1217.87	19.13	15.15	24.16
POSTMENOPAUSAL HAEMORRHAGE	542	6	183.55	33.10	14.81	74.01	541	6	183.72	33.13	14.82	74.07
OLIGOMENORRHOEA	573	7	192.66	30.00	14.24	63.20	572	7	192.85	30.02	14.25	63.26
ILLNESS	4466	95	1427.78	17.23	14.06	21.11	4444	95	1424.02	17.19	14.03	21.06
POST-ACUTE COVID-19 SYNDROME	345	3	118.18	42.14	13.53	131.30	343	3	117.79	42.01	13.48	130.90
ANTICOAGULANT THERAPY	4169	98	1312.23	15.59	12.76	19.05	4140	98	1305.61	15.52	12.71	18.96
THROMBECTOMY	375	5	124.68	27.48	11.37	66.41	375	5	125.04	27.56	11.40	66.59
TASTE DISORDER	2178	61	662.65	13.08	10.15	16.87	2172	60	664.65	13.30	10.29	17.19
MECHANICAL URTICARIA	872	23	267.16	13.89	9.18	21.02	870	23	267.26	13.90	9.19	21.03
MATERNAL EXPOSURE DURING BREAST FEEDING	296	5	95.81	21.69	8.96	52.50	296	5	96.10	21.75	8.99	52.65
IMMUNISATION	2762	99	796.64	10.22	8.37	12.49	2761	99	798.91	10.25	8.39	12.52
AGEUSIA	4628	182	1306.10	9.32	8.04	10.81	4602	183	1299.05	9.24	7.97	10.71
THROMBOSIS	3258	126	921.90	9.48	7.93	11.32	3246	126	920.64	9.47	7.92	11.31
APPENDICITIS	644	19	192.73	12.42	7.87	19.60	644	19	193.34	12.45	7.89	19.65
MENSTRUATION DELAYED	1092	37	317.98	10.82	7.79	15.01	1092	37	319.02	10.84	7.82	15.05
VACCINATION SITE ERYTHEMA	6225	264	1722.34	8.64	7.64	9.77	6219	264	1726.07	8.66	7.65	9.79
BELL'S PALSY	3143	129	874.39	8.93	7.49	10.65	3135	127	878.43	9.07	7.60	10.83
VACCINATION SITE MASS	1185	43	339.43	10.10	7.45	13.69	1183	43	339.83	10.11	7.46	13.70
VACCINATION SITE URTICARIA	327	8	100.67	14.98	7.43	30.20	325	8	100.25	14.93	7.40	30.10
PULMONARY EMBOLISM	3154	136	864.58	8.50	7.16	10.09	3142	136	863.22	8.49	7.15	10.08
EPINEPHRINE	433	13	128.69	12.21	7.03	21.19	431	13	128.37	12.18	7.02	21.15
SYMPTOM RECURRENCE	195	4	61.16	17.86	6.64	48.08	192	4	60.25	17.64	6.55	47.47
HYPERVOLEMIA	286	8	85.79	13.10	6.49	26.45	282	8	84.61	12.95	6.41	26.15
THROAT CLEARING	421	14	122.30	11.02	6.47	18.77	418	14	121.61	10.97	6.44	18.69
PRODUCT USE ISSUE	570	21	161.90	9.95	6.43	15.37	569	21	162.08	9.96	6.44	15.39
BLOOD PRESSURE DIASTOLIC INCREASED	282	8	84.34	12.92	6.40	26.08	279	8	83.52	12.81	6.35	25.88
LEFT VENTRICULAR FAILURE	255	7	76.63	13.35	6.30	28.29	253	7	76.15	13.28	6.27	28.14
PAROSMIA	1363	63	364.00	7.93	6.16	10.21	1360	63	364.19	7.93	6.16	10.21
BLOOD LOSS ANAEMIA	200	5	60.86	14.66	6.04	35.60	196	5	59.59	14.40	5.93	34.99
CARDIAC FLUTTER	1318	66	342.23	7.32	5.72	9.37	1317	66	343.10	7.33	5.73	9.39
ELECTRIC SHOCK SENSATION	856	40	227.21	7.84	5.71	10.77	856	40	228.00	7.86	5.73	10.80
VITAL SIGNS MEASUREMENT	146	3	45.46	17.83	5.69	55.94	146	3	45.60	17.88	5.70	56.09
OFF LABEL USE	1268	64	328.24	7.26	5.65	9.33	1267	64	329.05	7.27	5.66	9.35
DEATH	10189	627	2463.62	5.95	5.49	6.45	10117	625	2450.95	5.95	5.49	6.45

OROPHARYNGEAL DISCOMFORT	1565	85	394.27	6.75	5.42	8.39	1558	85	393.23	6.73	5.41	8.38
CARDIAC FAILURE ACUTE	352	14	97.46	9.21	5.40	15.72	351	14	97.43	9.21	5.40	15.72
INFUSION	197	6	57.70	12.03	5.34	27.11	196	6	57.52	12.00	5.33	27.04
VACCINATION SITE MOVEMENT IMPAIRMENT	364	15	99.80	8.89	5.31	14.90	363	15	99.78	8.89	5.31	14.90
FACIAL DISCOMFORT	327	13	90.46	9.22	5.30	16.04	327	13	90.77	9.24	5.31	16.09
BLOOD PRESSURE MEASUREMENT	194	6	56.61	11.85	5.26	26.70	194	6	56.80	11.88	5.27	26.77
THERAPEUTIC RESPONSE UNEXPECTED	538	27	138.80	7.30	4.96	10.75	536	27	138.58	7.29	4.96	10.74
CHRONIC SPONTANEOUS URTICARIA	164	5	47.82	12.02	4.94	29.26	162	5	47.25	11.90	4.89	28.99
SUPERINFECTION	127	3	38.56	15.51	4.94	48.74	127	3	38.68	15.55	4.95	48.87
OPHTHALMIC MIGRAINE	126	3	38.20	15.39	4.90	48.36	124	3	37.59	15.19	4.83	47.73
ACUTE LEFT VENTRICULAR FAILURE	161	5	46.74	11.80	4.85	28.73	159	5	46.16	11.68	4.80	28.46
DEEP VEIN THROMBOSIS	2231	143	523.35	5.72	4.83	6.77	2218	143	520.82	5.70	4.81	6.75
GENERAL PHYSICAL CONDITION ABNORMAL	387	19	100.30	7.46	4.71	11.83	383	19	99.24	7.41	4.67	11.74
END STAGE RENAL DISEASE	204	8	56.21	9.34	4.61	18.94	201	8	55.32	9.23	4.55	18.71
PREMENSTRUAL SYNDROME	153	5	43.85	11.21	4.60	27.33	153	5	44.00	11.24	4.61	27.40
ACCIDENTAL OVERDOSE	343	17	88.47	7.39	4.54	12.03	339	17	87.36	7.33	4.50	11.93
DEVICE CONNECTION ISSUE	343	17	88.47	7.39	4.54	12.03	343	17	88.78	7.41	4.56	12.06
ACUTE RESPIRATORY FAILURE	4146	298	919.41	5.10	4.53	5.73	4100	298	907.16	5.06	4.49	5.69
STENT PLACEMENT	327	16	84.68	7.49	4.53	12.37	324	16	83.91	7.44	4.50	12.29
SUPPRESSED LACTATION	133	4	38.66	12.18	4.51	32.94	133	4	38.79	12.22	4.52	33.03
PHARYNGEAL PARAESTHESIA	931	59	218.64	5.78	4.44	7.52	930	59	219.13	5.79	4.45	7.53
VACCINATION SITE PAIN	14528	1149	3086.40	4.63	4.36	4.92	14514	1147	3097.94	4.65	4.38	4.94
CARDIAC DISCOMFORT	358	19	90.04	6.90	4.35	10.95	357	19	90.01	6.90	4.35	10.95
BLOOD PRESSURE SYSTOLIC INCREASED	650	40	154.40	5.95	4.33	8.19	638	40	150.79	5.86	4.26	8.07
PHARYNGEAL SWELLING	4303	326	926.09	4.84	4.32	5.41	4301	325	930.90	4.86	4.34	5.44
VACCINATION SITE RASH	2535	191	545.78	4.86	4.20	5.63	2533	190	549.02	4.90	4.23	5.68
HOSPICE CARE	317	17	79.27	6.83	4.19	11.13	312	17	77.79	6.74	4.14	10.99
APPENDICECTOMY	491	30	116.73	6.00	4.15	8.67	489	30	116.47	5.99	4.14	8.66
HYPOMENORRHOEA	169	7	45.64	8.85	4.15	18.84	169	7	45.79	8.87	4.17	18.89
BLOOD PRESSURE DIASTOLIC DECREASED	167	7	44.92	8.74	4.10	18.62	164	7	44.00	8.61	4.04	18.34
PRODUCT STORAGE ERROR	19966	1735	4013.01	4.22	4.02	4.43	19859	1735	3993.69	4.21	4.01	4.42
BREAST FEEDING	118	4	33.26	10.81	3.99	29.28	118	4	33.37	10.84	4.00	29.36
IMMUNE THROMBOCYTOPENIA	352	21	84.28	6.14	3.95	9.54	350	21	83.89	6.12	3.94	9.51
TROPONIN INCREASED	432	28	99.73	5.65	3.86	8.29	429	28	99.07	5.63	3.84	8.25
GENERAL PHYSICAL HEALTH DETERIORATION	1247	97	262.48	4.71	3.83	5.79	1226	97	256.41	4.64	3.78	5.71
OXYGEN SATURATION DECREASED	3418	295	675.66	4.25	3.77	4.78	3386	294	669.42	4.23	3.76	4.77
TONGUE DISCOMFORT	601	43	132.18	5.12	3.76	6.98	601	43	132.71	5.14	3.77	7.00
CHRONIC LEFT VENTRICULAR FAILURE	166	8	42.66	7.60	3.74	15.46	164	8	42.10	7.53	3.70	15.32
HYPOXIA	4265	378	828.50	4.13	3.72	4.59	4239	378	823.44	4.12	3.71	4.58
BODY TEMPERATURE ABNORMAL	175	9	43.97	7.13	3.65	13.92	174	9	43.78	7.10	3.64	13.88
PERCUTANEOUS CORONARY INTERVENTION	94	3	26.63	11.48	3.64	36.24	93	3	26.35	11.39	3.61	35.96
PULMONARY INFARCTION	134	6	35.08	8.18	3.61	18.54	134	6	35.21	8.21	3.62	18.59
DYSPNOEA AT REST	120	5	32.01	8.79	3.60	21.51	120	5	32.12	8.82	3.60	21.57
PNEUMONIA VIRAL	210	12	50.79	6.41	3.58	11.47	209	12	50.63	6.40	3.58	11.45
TINNITUS	13517	1312	2479.78	3.78	3.57	3.99	13478	1310	2481.39	3.78	3.57	4.00
PULSELESS ELECTRICAL ACTIVITY	399	28	88.32	5.22	3.56	7.66	395	28	87.30	5.18	3.53	7.60
CORONARY ARTERIAL STENT INSERTION	291	19	66.58	5.61	3.53	8.93	290	19	66.49	5.61	3.53	8.92
ACUTE MYOCARDIAL INFARCTION	1491	130	291.42	4.20	3.51	5.03	1482	130	289.69	4.19	3.50	5.01
ISCHAEMIC STROKE	488	37	103.61	4.83	3.46	6.75	488	37	104.04	4.85	3.47	6.77
VENTRICULAR HYPOKINESIA	166	9	40.80	6.76	3.46	13.22	165	9	40.60	6.74	3.44	13.18
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	296	20	66.57	5.42	3.45	8.53	295	20	66.49	5.42	3.45	8.52
RESPIRATORY RATE DECREASED	395	29	85.25	4.99	3.42	7.28	389	29	83.54	4.93	3.38	7.19
BLOOD PRESSURE SYSTOLIC DECREASED	127	6	32.60	7.76	3.42	17.59	122	6	30.94	7.47	3.29	16.96
CEREBROVASCULAR ACCIDENT	3169	305	577.25	3.81	3.39	4.28	3153	305	574.65	3.80	3.38	4.27
HEART RATE	126	6	32.24	7.70	3.39	17.45	126	6	32.36	7.72	3.40	17.50
PNEUMONIA BACTERIAL	420	32	88.77	4.81	3.36	6.89	415	32	87.43	4.77	3.33	6.83
CORONARY ARTERY OCCLUSION	208	13	48.30	5.86	3.35	10.27	205	13	47.45	5.79	3.31	10.15
ENERGY INCREASED	173	10	41.44	6.34	3.35	11.99	173	10	41.60	6.36	3.36	12.02
TONGUE PRURITUS	492	39	101.67	4.62	3.34	6.40	492	39	102.10	4.64	3.35	6.42

MULTIPLE ORGAN DYSFUNCTION SYNDROME	317	23	68.67	5.05	3.31	7.71	314	23	67.92	5.02	3.28	7.66
AMENORRHOEA	714	61	140.91	4.29	3.30	5.57	713	61	141.19	4.29	3.31	5.58
EXPIRED PRODUCT ADMINISTERED	21498	2292	3675.11	3.44	3.29	3.59	21179	2276	3610.81	3.42	3.28	3.57
LUNG INFILTRATION	1239	114	232.61	3.98	3.29	4.82	1232	114	231.34	3.97	3.28	4.81
CARDIAC FAILURE	699	60	137.48	4.27	3.28	5.56	696	60	137.08	4.26	3.27	5.55
AUTOPSY	366	28	77.03	4.79	3.26	7.03	363	28	76.33	4.76	3.24	7.00
IMMUNODEFICIENCY	620	53	122.17	4.29	3.24	5.67	616	53	121.36	4.27	3.23	5.65
BREAST MASS	444	36	90.33	4.52	3.22	6.35	441	36	89.71	4.50	3.20	6.32
DRAINAGE	233	16	51.74	5.34	3.22	8.86	231	16	51.25	5.30	3.20	8.80
CARDIO-RESPIRATORY ARREST	782	70	149.41	4.09	3.21	5.23	773	70	147.08	4.06	3.18	5.18
HYPERAESTHESIA TEETH	153	9	36.25	6.23	3.18	12.20	153	9	36.39	6.25	3.19	12.23
EXTRASYSTOLES	617	54	119.59	4.19	3.17	5.53	613	54	118.78	4.17	3.16	5.51
SITTING DISABILITY	174	11	40.02	5.80	3.15	10.66	174	11	40.17	5.81	3.16	10.69
PRODUCT PREPARATION ISSUE	2310	236	399.71	3.59	3.14	4.10	2307	234	403.60	3.62	3.17	4.14
CARDIAC ARREST	1795	180	315.19	3.65	3.14	4.26	1776	180	310.50	3.63	3.11	4.23
VACCINATION SITE DISCOMFORT	301	23	63.21	4.80	3.14	7.33	298	23	62.46	4.76	3.12	7.28
GIANT CELL ARTERITIS	80	3	21.60	9.77	3.09	30.94	78	3	20.96	9.55	3.02	30.27
CARDIAC ASSISTANCE DEVICE USER	91	4	23.60	8.34	3.06	22.69	89	4	22.98	8.18	3.00	22.26
ACUTE KIDNEY INJURY	2953	316	490.87	3.42	3.05	3.85	2927	316	484.95	3.40	3.03	3.82
LUNG CONSOLIDATION	362	30	72.42	4.42	3.05	6.42	358	30	71.38	4.38	3.02	6.36
CARDIAC ABLATION	178	12	39.66	5.44	3.03	9.75	177	12	39.48	5.42	3.02	9.72
DEMENTIA	491	44	93.35	4.09	3.00	5.57	485	44	91.78	4.05	2.97	5.51
PULMONARY PAIN	508	46	95.88	4.05	2.99	5.47	504	46	94.98	4.03	2.98	5.44
HEART RATE ABNORMAL	498	45	94.12	4.06	2.99	5.50	495	45	93.55	4.04	2.98	5.48
CHRONIC KIDNEY DISEASE	692	66	125.86	3.84	2.98	4.95	684	65	125.33	3.87	3.00	4.99
HAEMORRHAGE URINARY TRACT	133	8	31.06	6.09	2.98	12.43	133	8	31.17	6.11	2.99	12.47
CEREBRAL INFARCTION	439	39	83.89	4.12	2.97	5.72	438	39	83.93	4.13	2.97	5.73
SARS-COV-2 ANTIBODY TEST NEGATIVE	77	3	20.53	9.41	2.97	29.81	77	3	20.60	9.43	2.98	29.89
PERICARDIAL EFFUSION	839	83	148.35	3.70	2.96	4.64	835	84	146.27	3.65	2.92	4.57
NEAR DEATH EXPERIENCE	153	10	34.49	5.61	2.96	10.63	151	10	33.93	5.55	2.93	10.52
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	10256	1208	1567.28	3.11	2.93	3.30	10196	1200	1567.52	3.12	2.94	3.31
PARANASAL SINUS DISCOMFORT	968	99	166.55	3.58	2.91	4.41	958	99	164.12	3.56	2.89	4.37
ATYPICAL PNEUMONIA	139	9	31.38	5.66	2.88	11.11	138	9	31.16	5.63	2.87	11.06
APPENDICITIS PERFORATED	118	7	27.61	6.18	2.88	13.24	118	7	27.71	6.19	2.89	13.28
EMBOLIC STROKE	96	5	23.51	7.04	2.86	17.29	93	5	22.54	6.83	2.78	16.81
OXYGEN SATURATION	96	5	23.51	7.04	2.86	17.29	96	5	23.60	7.05	2.87	17.34
HEAD DISCOMFORT	3039	350	470.48	3.18	2.85	3.55	3021	350	467.27	3.17	2.84	3.54
MYOCARDIAL INFARCTION	1615	179	258.88	3.31	2.83	3.86	1609	179	258.29	3.30	2.83	3.85
IMPAIRED SELF-CARE	116	7	26.91	6.07	2.83	13.02	114	7	26.32	5.98	2.79	12.84
RESPIRATORY RATE INCREASED	1825	205	288.93	3.26	2.82	3.77	1805	205	284.09	3.24	2.80	3.74
VACCINATION SITE HAEMORRHAGE	242	20	48.17	4.43	2.81	7.00	241	19	49.66	4.66	2.92	7.43
HOSPITALISATION	155	11	33.47	5.16	2.80	9.52	155	11	33.60	5.18	2.81	9.54
CARDIOGENIC SHOCK	276	24	53.19	4.21	2.78	6.40	275	24	53.09	4.21	2.77	6.39
BRADYKINESIA	183	14	38.01	4.79	2.78	8.25	182	14	37.83	4.78	2.77	8.23
CLUSTER HEADACHE	133	9	29.32	5.42	2.76	10.64	133	9	29.43	5.43	2.76	10.67
ANGINA PECTORIS	1099	122	175.51	3.30	2.74	3.98	1095	121	176.54	3.33	2.76	4.01
FIBRIN D DIMER INCREASED	161	12	33.84	4.92	2.73	8.84	161	12	33.98	4.93	2.74	8.86
PALLIATIVE CARE	122	8	27.24	5.59	2.73	11.43	117	8	25.63	5.37	2.63	11.00
EJECTION FRACTION DECREASED	243	21	46.92	4.24	2.72	6.62	240	21	46.13	4.20	2.69	6.56
MYOCARDITIS	2030	241	303.83	3.09	2.70	3.53	2022	241	302.95	3.08	2.70	3.52
BLOOD GLUCOSE DECREASED	313	29	57.69	3.96	2.70	5.79	312	29	57.63	3.95	2.70	5.78
DEMENTIA ALZHEIMER'S TYPE	159	12	33.16	4.86	2.70	8.73	159	12	33.30	4.87	2.71	8.75
JUGULAR VEIN DISTENSION	80	4	19.71	7.33	2.68	20.01	78	4	19.08	7.17	2.62	19.57
HAEMOGLOBIN DECREASED	109	7	24.49	5.71	2.66	12.25	109	7	24.58	5.72	2.66	12.29
PULSE ABSENT	760	84	121.57	3.32	2.65	4.15	749	84	118.71	3.28	2.61	4.10
VENTRICULAR EXTRASYSTOLES	1066	124	162.41	3.15	2.62	3.79	1062	124	162.01	3.15	2.61	3.79
ADNEXA UTERI PAIN	136	10	28.66	4.98	2.62	9.47	136	10	28.78	5.00	2.63	9.50
PERIORBITAL SWELLING	709	79	112.46	3.29	2.61	4.15	708	78	114.12	3.34	2.64	4.21
BLOOD DISORDER	77	4	18.66	7.05	2.58	19.27	77	4	18.73	7.07	2.59	19.33
ATRIAL FIBRILLATION	3972	517	537.36	2.82	2.57	3.09	3946	515	535.11	2.82	2.57	3.09
GASTROINTESTINAL WALL THICKENING	67	3	16.98	8.18	2.57	26.02	66	3	16.69	8.08	2.54	25.71
CEREBRAL HAEMORRHAGE	443	47	73.25	3.45	2.56	4.67	440	47	72.65	3.44	2.55	4.65
RESUSCITATION	1236	150	180.14	3.02	2.55	3.58	1218	150	175.58	2.98	2.52	3.53
MENOPAUSE	141	11	28.71	4.70	2.54	8.68	139	11	28.16	4.64	2.51	8.58
CARDIAC DISORDER	1000	120	147.35	3.05	2.53	3.69	994	120	146.29	3.04	2.52	3.68
CORONARY ARTERY THROMBOSIS	66	3	16.63	8.06	2.53	25.64	65	3	16.33	7.96	2.50	25.33
SINUS RHYTHM	66	3	16.63	8.06	2.53	25.64	66	3	16.69	8.08	2.54	25.71
ATRIOVENTRICULAR BLOCK COMPLETE	94	6	21.04	5.74	2.52	13.10	93	6	20.77	5.70	2.49	13.00
BREAST SWELLING	759	89	114.39	3.13	2.51	3.89	759	89	114.99	3.13	2.52	3.90
DYSPNOEA EXERTIONAL	2460	322	329.61	2.80	2.49	3.14	2443	321	327.65	2.80	2.49	3.14
LUNG DISORDER	686	80	103.89	3.14	2.49	3.96	679	80	102.26	3.12	2.47	3.93
EUPHORIC MOOD	262	26	45.55	3.69	2.47	5.53	261	26	45.45	3.69	2.46	5.52
GENERAL SYMPTOM	162	14	30.96	4.24	2.46	7.32	159	14	30.10	4.17	2.42	7.21

PERICARDITIS	1701	221	229.53	2.82	2.45	3.24	1695	221	229.03	2.82	2.45	3.24
BREAST TENDERNESS	537	62	81.98	3.17	2.44	4.13	537	62	82.41	3.18	2.45	4.14
CARDIOMEGALY	963	120	136.03	2.94	2.43	3.55	961	120	136.17	2.94	2.43	3.56
HYPERTENSIVE EMERGENCY	91	6	20.00	5.56	2.43	12.70	91	6	20.08	5.57	2.44	12.73
EAR DISCOMFORT	2705	367	346.58	2.70	2.42	3.01	2687	366	344.52	2.70	2.42	3.01
LYMPHADENOPATHY	22000	3247	2577.15	2.48	2.39	2.58	21974	3245	2588.41	2.49	2.40	2.58
SENSITIVE SKIN	1306	171	174.30	2.80	2.39	3.28	1306	169	177.82	2.84	2.42	3.33
NORMAL LABOUR	62	3	15.22	7.57	2.38	24.13	62	3	15.27	7.59	2.38	24.19
CARDIOVERSION	579	70	84.24	3.03	2.37	3.88	569	70	81.62	2.99	2.33	3.83
BLOOD PRESSURE ABNORMAL	572	69	83.41	3.04	2.37	3.90	567	68	83.65	3.06	2.38	3.94
VACCINATION SITE DISCOLOURATION	334	37	52.80	3.31	2.36	4.65	334	37	53.07	3.32	2.36	4.66
PALPITATIONS	14811	2217	1682.84	2.45	2.34	2.56	14784	2216	1687.13	2.45	2.34	2.56
OCULAR DISCOMFORT	920	119	124.33	2.83	2.34	3.43	919	119	124.74	2.84	2.34	3.43
THALAMIC INFARCTION	70	4	16.21	6.41	2.34	17.56	70	4	16.28	6.43	2.35	17.61
THROMBOLYSIS	70	4	16.21	6.41	2.34	17.56	69	4	15.93	6.34	2.31	17.37
PULMONARY MASS	557	68	80.14	3.00	2.33	3.86	552	68	79.04	2.98	2.32	3.84
RETINAL VEIN OCCLUSION	96	7	20.03	5.03	2.33	10.82	96	7	20.12	5.04	2.34	10.85
ARRHYTHMIA	1219	165	155.95	2.71	2.30	3.19	1211	165	154.51	2.70	2.29	3.17
RESPIRATORY SYMPTOM	405	48	59.94	3.09	2.29	4.17	402	48	59.34	3.08	2.28	4.15
EYE HAEMORRHAGE	308	35	47.41	3.22	2.27	4.57	308	35	47.66	3.23	2.28	4.59
LYMPHADENOPATHY MEDIASTINAL	126	11	23.70	4.20	2.27	7.77	126	11	23.80	4.21	2.27	7.79
HEART RATE DECREASED	1583	223	192.32	2.60	2.26	2.99	1571	223	190.01	2.59	2.25	2.98
DISCOLOURED VOMIT	59	3	14.16	7.21	2.26	22.99	58	3	13.86	7.10	2.23	22.67
HEART RATE IRREGULAR	2164	313	253.80	2.53	2.25	2.85	2151	313	251.66	2.53	2.24	2.84
PULMONARY OEDEMA	871	117	112.26	2.73	2.25	3.31	869	117	112.33	2.73	2.25	3.31
NEOPLASM	101	8	20.09	4.63	2.25	9.50	101	8	20.18	4.64	2.26	9.53
URTICARIA CHRONIC	186	19	31.29	3.59	2.24	5.75	186	19	31.44	3.60	2.24	5.77
VENTRICULAR FIBRILLATION	266	30	41.14	3.25	2.23	4.74	264	30	40.73	3.23	2.22	4.72
RETINAL ARTERY OCCLUSION	108	9	20.84	4.40	2.23	8.68	107	9	20.60	4.37	2.21	8.62
BREAST CYST	75	5	16.21	5.50	2.22	13.59	74	5	15.94	5.44	2.20	13.45
CARDIAC FAILURE CHRONIC	58	3	13.81	7.08	2.22	22.61	58	3	13.86	7.10	2.23	22.67
PLATELET COUNT DECREASED	293	34	44.11	3.16	2.21	4.50	293	34	44.34	3.17	2.22	4.52
LYMPH NODE PAIN	5315	828	560.04	2.35	2.19	2.53	5305	828	561.04	2.35	2.19	2.53
TONGUE ERYTHEMA	137	13	24.27	3.86	2.19	6.82	137	13	24.38	3.87	2.19	6.84
HYPERTENSIVE URGENCY	122	11	22.38	4.06	2.19	7.53	122	11	22.48	4.08	2.20	7.55
IMPAIRED QUALITY OF LIFE	129	12	23.16	3.94	2.18	7.12	127	12	22.61	3.89	2.15	7.03
ACUTE CORONARY SYNDROME	98	8	19.09	4.49	2.18	9.23	97	8	18.84	4.46	2.17	9.16
SLEEP DEFICIT	98	8	19.09	4.49	2.18	9.23	98	8	19.17	4.50	2.19	9.25
UTERINE PAIN	57	3	13.46	6.96	2.18	22.23	57	3	13.51	6.98	2.19	22.29
EPISTAXIS	2033	304	226.97	2.45	2.17	2.76	2027	304	226.74	2.45	2.17	2.76
SWELLING OF EYELID	1125	162	132.26	2.54	2.16	3.00	1122	162	132.22	2.54	2.16	3.00
MIGRAINE	8318	1348	824.18	2.26	2.14	2.39	8296	1346	826.09	2.26	2.14	2.40
VAGINAL HAEMORRHAGE	1588	237	177.55	2.46	2.14	2.81	1587	237	178.41	2.46	2.15	2.82
DIVERTICULITIS	325	40	45.99	2.98	2.14	4.13	322	40	45.33	2.96	2.13	4.11
BONE SWELLING	64	4	14.14	5.86	2.14	16.10	64	4	14.20	5.88	2.14	16.14
BREAST ENLARGEMENT	72	5	15.19	5.28	2.13	13.06	72	5	15.25	5.29	2.14	13.10
BREAST DISCOMFORT	118	11	21.07	3.93	2.12	7.29	118	11	21.17	3.94	2.12	7.31
BREAST DISCHARGE	63	4	13.79	5.77	2.10	15.86	63	4	13.85	5.79	2.11	15.90
BLOOD IRON DECREASED	55	3	12.77	6.72	2.10	21.47	55	3	12.81	6.74	2.11	21.53
VENTRICULAR TACHYCARDIA	436	58	56.48	2.75	2.09	3.62	434	58	56.22	2.75	2.09	3.62
HYPERTENSIVE HEART DISEASE	250	30	36.19	3.05	2.09	4.46	247	30	35.47	3.03	2.07	4.42
BLOOD URINE PRESENT	624	88	75.16	2.60	2.08	3.25	621	88	74.75	2.59	2.07	3.24
DISORGANISED SPEECH	138	14	23.12	3.61	2.08	6.26	138	14	23.24	3.62	2.09	6.28
CARDIAC FAILURE CONGESTIVE	1308	200	140.72	2.40	2.07	2.78	1296	200	138.32	2.38	2.05	2.76
PLEURAL EFFUSION	1385	213	147.71	2.38	2.06	2.75	1377	214	145.39	2.36	2.05	2.73
PRODUCT ADMINISTRATION ERROR	790	116	90.04	2.50	2.05	3.03	787	116	89.76	2.49	2.05	3.03
CHEST PAIN	21763	3785	1929.24	2.11	2.04	2.18	21704	3783	1930.38	2.11	2.04	2.18
CONDITION AGGRAVATED	18536	3213	1646.69	2.11	2.04	2.19	18471	3207	1648.04	2.12	2.04	2.20
VACCINATION FAILURE	2591	420	254.26	2.26	2.04	2.51	2370	418	200.18	2.08	1.88	2.31
PANIC ATTACK	1251	194	131.58	2.36	2.03	2.75	1249	193	133.00	2.38	2.04	2.77
DIABETIC KETOACIDOSIS	223	27	31.88	3.03	2.03	4.51	223	27	32.05	3.03	2.04	4.52
SUPRAVENTRICULAR EXTRASYSTOLES	299	39	39.45	2.81	2.01	3.92	296	39	38.78	2.79	2.00	3.89
FEAR OF INJECTION	227	28	31.80	2.97	2.01	4.40	227	28	31.97	2.98	2.01	4.41
CROHN'S DISEASE	193	23	27.96	3.07	2.00	4.74	193	23	28.11	3.08	2.00	4.75
VACCINATION SITE INDURATION	1199	189	122.76	2.32	1.99	2.71	1197	189	123.05	2.33	2.00	2.71
SUPRAVENTRICULAR TACHYCARDIA	562	82	64.43	2.51	1.99	3.17	558	82	63.70	2.50	1.98	3.15
ACUTE RESPIRATORY DISTRESS SYNDROME	463	66	54.74	2.57	1.99	3.33	455	66	52.79	2.53	1.96	3.28
PULMONARY FIBROSIS	232	29	32.02	2.93	1.99	4.31	228	29	30.99	2.89	1.96	4.25
HEPATIC CIRRHOSIS	159	18	24.16	3.24	1.99	5.27	155	18	23.04	3.16	1.94	5.15
INJECTION SITE	125	13	20.41	3.52	1.99	6.24	125	13	20.51	3.53	2.00	6.25
LYMPHADENOPATHY	67	5	13.50	4.91	1.98	12.18	65	5	12.88	4.78	1.92	11.86
LUNG HYPERINFLATION												
VENTRICULAR HYPERTROPHY	67	5	13.50	4.91	1.98	12.18	67	5	13.55	4.92	1.98	12.22
FEAR	918	143	95.64	2.35	1.97	2.81	912	142	95.72	2.36	1.98	2.82
LEFT ATRIAL ENLARGEMENT	96	9	16.90	3.91	1.97	7.74	96	9	16.98	3.92	1.98	7.76
HEART VALVE INCOMPETENCE	74	6	14.24	4.52	1.97	10.38	74	6	14.31	4.53	1.97	10.41

SUDDEN CARDIAC DEATH	74	6	14.24	4.52	1.97	10.38	74	6	14.31	4.53	1.97	10.41
HOT FLUSH	3471	594	309.31	2.14	1.96	2.34	3463	593	310.53	2.15	1.97	2.34
PHARYNGEAL HYPOAESTHESIA	464	67	53.87	2.54	1.96	3.28	464	67	54.20	2.54	1.97	3.29
VEIN DISORDER	137	15	21.40	3.35	1.96	5.70	137	14	22.92	3.60	2.07	6.23
PERIPHERAL ISCHAEMIA	59	4	12.43	5.41	1.96	14.88	59	4	12.48	5.42	1.97	14.92
BLOOD GLUCOSE INCREASED	843	132	87.02	2.34	1.95	2.81	843	132	87.61	2.35	1.95	2.82
INTERSTITIAL LUNG DISEASE	253	33	33.26	2.81	1.95	4.04	250	33	32.56	2.78	1.94	4.00
HORMONE LEVEL ABNORMAL	102	10	17.36	3.74	1.95	7.16	101	10	17.13	3.71	1.94	7.11
IMPLANTABLE DEFIBRILLATOR INSERTION	88	8	15.79	4.03	1.95	8.31	88	8	15.86	4.04	1.96	8.33
HEPATIC LESION	66	5	13.16	4.84	1.95	12.01	64	5	12.54	4.70	1.89	11.69
INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION	66	5	13.16	4.84	1.95	12.01	65	5	12.88	4.78	1.92	11.86
TACHYPNOEA	1561	258	147.59	2.22	1.94	2.53	1544	258	144.16	2.20	1.93	2.51
SINUS PAIN	513	76	57.44	2.47	1.94	3.15	508	76	56.40	2.46	1.93	3.13
NIPPLE PAIN	122	13	19.46	3.44	1.94	6.09	122	13	19.56	3.45	1.95	6.11
DIZZINESS EXERTIONAL	51	3	11.38	6.23	1.94	19.96	51	3	11.42	6.25	1.95	20.01
CORONARY ARTERY DISEASE	752	118	77.28	2.34	1.92	2.84	748	118	76.71	2.33	1.92	2.83
ASCITES	205	26	27.72	2.89	1.92	4.34	205	26	27.88	2.90	1.93	4.36
SKIN SENSITISATION	173	21	24.48	3.02	1.92	4.75	174	21	24.92	3.04	1.94	4.79
TOXIC ENCEPHALOPATHY	121	13	19.14	3.41	1.92	6.04	117	13	17.98	3.31	1.86	5.87
FEEDING DISORDER	1487	249	137.27	2.19	1.91	2.50	1476	248	136.39	2.19	1.91	2.50
VACCINATION SITE REACTION	1286	214	119.96	2.20	1.91	2.54	1279	214	118.98	2.20	1.90	2.54
ARTERIOSCLEROSIS CORONARY ARTERY	272	37	33.95	2.69	1.91	3.80	272	37	34.15	2.70	1.92	3.81
SUDDEN DEATH	166	20	23.65	3.04	1.91	4.84	164	20	23.17	3.01	1.89	4.79
THROMBOPHLEBITIS SUPERFICIAL	140	16	20.97	3.21	1.91	5.38	140	16	21.08	3.22	1.92	5.39
PERICARDIAL DRAINAGE	100	10	16.72	3.66	1.91	7.02	100	10	16.80	3.67	1.92	7.04
CARDIAC TAMPONADE	86	8	15.13	3.94	1.91	8.13	85	9	13.45	3.47	1.75	6.90
PARAESTHESIA ORAL	6346	1147	509.44	2.03	1.90	2.16	6340	1146	512.94	2.03	1.91	2.16
VACCINATION SITE WARMTH	3311	585	277.11	2.07	1.90	2.26	3309	584	279.71	2.08	1.91	2.27
BREAST PAIN	1975	340	173.41	2.13	1.90	2.39	1967	340	172.65	2.13	1.89	2.38
POLYURIA	330	47	38.85	2.57	1.90	3.49	330	47	39.09	2.58	1.90	3.50
SINUS OPERATION	258	35	32.28	2.70	1.90	3.84	251	35	30.43	2.64	1.85	3.75
TRANSIENT ISCHAEMIC ATTACK	788	127	77.46	2.27	1.89	2.74	783	126	77.71	2.28	1.89	2.76
DIALYSIS	287	40	34.72	2.63	1.89	3.66	285	39	35.54	2.69	1.92	3.75
SMALL INTESTINAL OBSTRUCTION	164	20	23.04	3.00	1.89	4.78	164	20	23.17	3.01	1.89	4.79
HILAR LYMPHADENOPATHY	64	5	12.49	4.69	1.89	11.65	64	5	12.54	4.70	1.89	11.69
SHOCK HAEMORRHAGIC	57	4	11.75	5.22	1.89	14.39	53	4	10.45	4.87	1.76	13.45
RENAL IMPAIRMENT	432	65	47.13	2.44	1.88	3.16	431	65	47.16	2.44	1.88	3.16
MENTAL FATIGUE	78	7	14.02	4.08	1.88	8.85	77	7	13.76	4.04	1.86	8.76
UNRESPONSIVE TO STIMULI	4507	819	356.69	2.02	1.87	2.17	4478	818	353.29	2.01	1.87	2.17
GASTROINTESTINAL HAEMORRHAGE	472	72	50.48	2.40	1.87	3.08	467	72	49.43	2.38	1.86	3.05
SEPTIC SHOCK	638	102	63.44	2.29	1.86	2.82	636	102	63.34	2.29	1.86	2.82
UTERINE SPASM	130	15	19.22	3.18	1.86	5.42	130	15	19.32	3.18	1.87	5.43
AUTOSCOPY	84	8	14.49	3.85	1.86	7.95	85	8	14.88	3.90	1.89	8.06
HAEMORRHAGIC STROKE	123	14	18.40	3.22	1.85	5.60	124	14	18.81	3.25	1.87	5.66
HYPERKALAEMIA	417	64	44.08	2.39	1.84	3.11	416	64	44.10	2.39	1.84	3.11
COMA SCALE ABNORMAL	135	16	19.43	3.09	1.84	5.19	128	16	17.41	2.94	1.75	4.94
NASAL DRYNESS	122	14	18.09	3.19	1.84	5.55	122	14	18.19	3.20	1.84	5.57
MOUTH SWELLING	936	158	84.84	2.17	1.83	2.57	935	158	85.20	2.17	1.84	2.57
PNEUMONITIS	273	39	31.87	2.57	1.83	3.59	272	39	31.79	2.56	1.83	3.58
SYSTOLIC DYSFUNCTION	62	5	11.82	4.54	1.83	11.30	61	5	11.54	4.48	1.80	11.16
RENAL INFARCT	55	4	11.07	5.04	1.83	13.90	55	4	11.12	5.05	1.83	13.94
ALOPECIA	1437	255	118.58	2.07	1.81	2.36	1432	254	119.20	2.07	1.81	2.37
BLOOD PRESSURE FLUCTUATION	489	78	48.65	2.30	1.81	2.92	486	78	48.18	2.29	1.80	2.91
NEW DAILY PERSISTENT HEADACHE	68	6	12.26	4.15	1.80	9.57	68	6	12.32	4.16	1.81	9.59
ATRIAL FLUTTER	373	58	38.54	2.36	1.79	3.11	371	58	38.25	2.35	1.78	3.10
SUBDURAL HAEMATOMA	162	21	21.18	2.83	1.79	4.45	160	21	20.71	2.80	1.78	4.41
INSULIN THERAPY	47	3	10.01	5.74	1.79	18.44	47	3	10.05	5.76	1.79	18.49
HYPOGEUSIA	155	20	20.34	2.84	1.78	4.52	155	20	20.46	2.85	1.79	4.54
CARDITIS	87	9	14.01	3.54	1.78	7.04	87	9	14.08	3.55	1.79	7.06
OXYGEN SATURATION ABNORMAL	87	9	14.01	3.54	1.78	7.04	87	9	14.08	3.55	1.79	7.06
BRAIN INJURY	195	27	23.56	2.65	1.77	3.96	192	27	22.84	2.61	1.75	3.91
ARTERIOSCLEROSIS	578	97	52.69	2.18	1.76	2.71	574	97	52.04	2.17	1.75	2.70
USE OF ACCESSORY RESPIRATORY MUSCLES	200	28	23.82	2.62	1.76	3.89	196	28	22.82	2.57	1.73	3.82
CHEST TUBE INSERTION	165	22	20.83	2.75	1.76	4.29	164	22	20.66	2.74	1.76	4.27
SEDATION	242	36	26.55	2.46	1.74	3.50	242	36	26.72	2.47	1.74	3.51
PSORIATIC ARTHROPATHY	116	14	16.25	3.04	1.74	5.29	116	14	16.34	3.04	1.75	5.30
BREAST CANCER	59	5	10.83	4.32	1.74	10.77	59	5	10.88	4.34	1.74	10.80
DENTAL DISCOMFORT	59	5	10.83	4.32	1.74	10.77	59	5	10.88	4.34	1.74	10.80
THYROID MASS	156	21	19.41	2.72	1.73	4.29	154	21	18.95	2.69	1.71	4.25
DISCHARGE	115	14	15.95	3.01	1.73	5.24	113	14	15.44	2.97	1.70	5.17
ARTERIAL OCCLUSIVE DISEASE	78	8	12.57	3.57	1.73	7.40	78	8	12.63	3.58	1.73	7.42
MUSCLE DISCOMFORT	195	28	22.40	2.55	1.72	3.79	194	27	23.41	2.64	1.77	3.95
AORTIC ANEURYSM	132	17	17.25	2.85	1.72	4.71	132	17	17.35	2.85	1.72	4.73

INCREASED APPETITE	90	10	13.57	3.30	1.72	6.34	90	10	13.64	3.31	1.72	6.36
ATRIAL ENLARGEMENT	52	4	10.07	4.76	1.72	13.17	52	4	10.11	4.78	1.73	13.21
INCORRECT PRODUCT FORMULATION ADMINISTERED	701	124	57.86	2.07	1.71	2.51	701	124	58.31	2.08	1.72	2.51
CHRONIC RESPIRATORY FAILURE	96	11	14.08	3.20	1.71	5.97	94	11	13.54	3.14	1.68	5.86
RALES	787	142	62.43	2.03	1.70	2.43	775	142	59.97	2.01	1.68	2.40
SKIN SWELLING	722	129	58.40	2.05	1.70	2.47	720	127	60.25	2.08	1.73	2.52
HYPERCAPNIA	237	36	25.16	2.41	1.70	3.43	235	36	24.78	2.40	1.69	3.41
VASCULAR PAIN	107	13	14.82	3.02	1.70	5.36	107	13	14.90	3.02	1.70	5.38
RENAL PAIN	619	110	50.54	2.06	1.68	2.53	619	110	50.94	2.07	1.69	2.53
COLITIS	336	55	31.76	2.24	1.68	2.98	335	55	31.72	2.24	1.68	2.98
LEFT VENTRICULAR DYSFUNCTION	223	34	23.50	2.40	1.68	3.45	223	34	23.65	2.41	1.68	3.46
HAEMORRHAGE INTRACRANIAL	152	21	18.26	2.65	1.68	4.19	149	21	17.51	2.61	1.65	4.12
ISCHAEMIC CARDIOMYOPATHY	94	11	13.47	3.13	1.68	5.85	93	11	13.24	3.11	1.66	5.80
CORONARY ARTERY STENOSIS	82	9	12.44	3.34	1.68	6.64	81	9	12.19	3.31	1.66	6.58
THYROIDITIS	82	9	12.44	3.34	1.68	6.64	81	9	12.19	3.31	1.66	6.58
ACUTE PULMONARY OEDEMA	70	7	11.44	3.66	1.68	7.97	69	7	11.18	3.62	1.66	7.88
LIP PRURITUS	374	63	33.63	2.18	1.67	2.84	374	62	34.88	2.22	1.69	2.90
ASTHENOPIA	370	62	33.59	2.19	1.67	2.86	370	62	33.84	2.19	1.68	2.87
MUSCLE STRENGTH ABNORMAL	117	15	15.29	2.86	1.67	4.89	116	15	15.08	2.84	1.66	4.87
ACQUIRED DIAPHRAGMATIC EVENTRATION	63	6	10.64	3.85	1.67	8.89	63	6	10.69	3.86	1.67	8.91
NEPHROSCLEROSIS	57	5	10.18	4.18	1.67	10.42	57	5	10.22	4.19	1.68	10.45
CORONARY ANGIOPLASTY	44	3	8.99	5.37	1.67	17.31	44	3	9.02	5.39	1.67	17.36
IMMUNE-MEDIATED ADVERSE REACTION	44	3	8.99	5.37	1.67	17.31	44	3	9.02	5.39	1.67	17.36
METABOLIC ENCEPHALOPATHY	449	78	38.19	2.11	1.66	2.68	443	78	36.96	2.09	1.64	2.65
PHYSICAL DECONDITIONING	161	23	18.50	2.57	1.66	3.97	161	23	18.62	2.57	1.66	3.98
ABNORMAL DREAMS	518	92	42.24	2.06	1.65	2.58	515	92	41.82	2.06	1.65	2.57
CHEST INJURY	50	4	9.40	4.58	1.65	12.68	50	4	9.44	4.59	1.66	12.72
HUNGER	203	31	21.27	2.40	1.64	3.50	202	31	21.14	2.39	1.64	3.49
SUBARACHNOID HAEMORRHAGE	197	30	20.72	2.41	1.64	3.53	194	30	20.03	2.38	1.62	3.49
POOR PERIPHERAL CIRCULATION	126	17	15.49	2.72	1.64	4.51	125	17	15.29	2.70	1.63	4.48
LACUNAR INFARCTION	109	14	14.16	2.85	1.64	4.98	109	14	14.24	2.86	1.64	4.99
ANGINA UNSTABLE	62	6	10.32	3.79	1.64	8.75	61	6	10.05	3.74	1.62	8.64
VACCINATION SITE BRUISING	521	94	41.12	2.03	1.63	2.53	521	94	41.45	2.04	1.64	2.54
LYMPHOEDEMA	321	54	28.85	2.18	1.63	2.91	321	54	29.06	2.18	1.64	2.91
AORTIC DILATATION	74	8	11.31	3.39	1.63	7.03	74	8	11.37	3.40	1.64	7.05
THYROIDITIS SUBACUTE	49	4	9.07	4.49	1.62	12.44	49	4	9.11	4.50	1.62	12.47
COSTOCHONDRITIS	245	40	23.09	2.24	1.61	3.14	245	40	23.25	2.25	1.61	3.14
BASSEDOW'S DISEASE	146	21	16.55	2.55	1.61	4.03	145	21	16.37	2.54	1.61	4.01
METAMORPHOPSIA	146	21	16.55	2.55	1.61	4.03	144	20	17.24	2.65	1.66	4.22
AUTOIMMUNE HEPATITIS	61	6	10.00	3.73	1.61	8.62	60	6	9.73	3.67	1.59	8.50
CHOLECYSTITIS ACUTE	61	6	10.00	3.73	1.61	8.62	60	6	9.73	3.67	1.59	8.50
HYPOTHERMIA	177	27	18.49	2.40	1.60	3.60	177	27	18.62	2.41	1.61	3.61
HYPOSIMIA	107	14	13.57	2.80	1.60	4.89	107	14	13.65	2.81	1.61	4.90
BUNDLE BRANCH BLOCK RIGHT	282	48	24.71	2.15	1.59	2.92	280	48	24.38	2.14	1.58	2.91
VASODILATATION	149	22	16.26	2.48	1.59	3.88	149	22	16.37	2.49	1.59	3.89
AORTIC STENOSIS	133	19	15.16	2.57	1.59	4.15	132	19	14.97	2.55	1.58	4.13
ANGIOPLASTY	72	8	10.69	3.30	1.59	6.85	72	8	10.75	3.31	1.59	6.87
PATIENT UNCOOPERATIVE	48	4	8.74	4.40	1.59	12.19	47	4	8.45	4.32	1.56	11.98
AORTIC VALVE STENOSIS	42	3	8.31	5.13	1.59	16.55	42	3	8.35	5.14	1.59	16.60
CEREBRAL VENOUS THROMBOSIS	42	3	8.31	5.13	1.59	16.55	42	3	8.35	5.14	1.59	16.60
HYPOSMOLAR STATE	42	3	8.31	5.13	1.59	16.55	42	3	8.35	5.14	1.59	16.60
PARANASAL SINUS INFLAMMATION	42	3	8.31	5.13	1.59	16.55	42	3	8.35	5.14	1.59	16.60
RED BLOOD CELL COUNT DECREASED	42	3	8.31	5.13	1.59	16.55	42	3	8.35	5.14	1.59	16.60
FAILURE TO THRIVE	190	30	18.81	2.32	1.58	3.41	189	30	18.68	2.31	1.57	3.40
EAR DISORDER	169	26	17.39	2.38	1.58	3.60	166	26	16.69	2.35	1.55	3.55
HIP FRACTURE	138	20	15.43	2.53	1.58	4.04	138	20	15.53	2.54	1.59	4.05
INTRACRANIAL ANEURYSM	83	10	11.43	3.04	1.58	5.86	82	10	11.19	3.01	1.56	5.81
INFLAMMATORY MARKER INCREASED	54	5	9.20	3.96	1.58	9.89	53	5	8.92	3.89	1.56	9.74
SPLenic INFARCTION	54	5	9.20	3.96	1.58	9.89	54	5	9.25	3.97	1.59	9.92
PUPIL FIXED	352	63	28.06	2.05	1.57	2.68	347	63	27.05	2.02	1.55	2.65
HYPOAESTHESIA EYE	163	25	16.83	2.39	1.57	3.64	163	25	16.94	2.40	1.57	3.65
C-REACTIVE PROTEIN INCREASED	93	12	11.90	2.84	1.56	5.18	92	12	11.67	2.82	1.54	5.14
PUPILLARY LIGHT REFLEX TESTS ABNORMAL	65	7	9.87	3.40	1.56	7.42	63	7	9.30	3.31	1.51	7.22
MYOCARDIAL ISCHAEMIA	166	26	16.58	2.34	1.55	3.54	165	26	16.42	2.33	1.54	3.53
INTRAVENTRICULAR HAEMORRHAGE	53	5	8.88	3.88	1.55	9.72	52	5	8.60	3.82	1.53	9.57
NONINFECTIVE GINGIVITIS	92	12	11.61	2.81	1.54	5.13	90	12	11.09	2.76	1.51	5.03
IRREGULAR BREATHING	81	10	10.83	2.97	1.54	5.73	81	10	10.89	2.98	1.54	5.74
BOWEL MOVEMENT IRREGULARITY	234	40	20.23	2.14	1.53	3.00	234	40	20.39	2.15	1.54	3.01
MAST CELL ACTIVATION SYNDROME	75	9	10.29	3.05	1.53	6.10	74	9	10.05	3.02	1.51	6.03

ATRIOVENTRICULAR BLOCK	163	26	15.77	2.30	1.52	3.48	163	26	15.88	2.30	1.52	3.48
CORONAVIRUS INFECTION	52	5	8.56	3.81	1.52	9.54	52	5	8.60	3.82	1.53	9.57
BLOOD THYROID STIMULATING HORMONE INCREASED	46	4	8.09	4.21	1.52	11.71	46	4	8.13	4.23	1.52	11.74
ISCHAEMIC CEREBRAL INFARCTION	46	4	8.09	4.21	1.52	11.71	45	4	7.80	4.13	1.49	11.49
MUCOSAL DISORDER	46	4	8.09	4.21	1.52	11.71	45	4	7.80	4.13	1.49	11.49
GINGIVAL BLEEDING	274	49	21.74	2.05	1.51	2.78	273	49	21.67	2.05	1.51	2.77
HYPERTHYROIDISM	206	35	17.95	2.16	1.51	3.09	206	35	18.08	2.16	1.51	3.09
HEPATIC PAIN	101	14	11.83	2.64	1.51	4.62	100	14	11.62	2.62	1.50	4.59
COLITIS MICROSCOPIC	74	9	9.99	3.01	1.51	6.02	74	9	10.05	3.02	1.51	6.03
EPIDIDYMITIS	40	3	7.64	4.89	1.51	15.79	40	3	7.68	4.90	1.52	15.84
HAEMODIALYSIS	191	32	17.04	2.19	1.50	3.18	190	32	16.90	2.18	1.50	3.17
APPETITE DISORDER	126	19	13.21	2.43	1.50	3.94	125	19	13.02	2.42	1.49	3.92
BLADDER PAIN	90	12	11.02	2.75	1.50	5.02	89	12	10.80	2.73	1.49	4.98
MEDICAL DIET	57	6	8.74	3.48	1.50	8.07	57	6	8.79	3.49	1.51	8.10
MELAENA	179	30	15.92	2.19	1.49	3.22	176	30	15.26	2.16	1.46	3.17
EMBOLISM	73	9	9.70	2.97	1.49	5.94	73	9	9.75	2.98	1.49	5.96
HYPERCOAGULATION	73	9	9.70	2.97	1.49	5.94	73	9	9.75	2.98	1.49	5.96
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	62	7	8.94	3.25	1.49	7.09	59	7	8.08	3.10	1.41	6.78
EMBOLISM VENOUS	51	5	8.24	3.74	1.49	9.36	51	5	8.28	3.75	1.50	9.39
RED BLOOD CELL SEDIMENTATION RATE INCREASED	51	5	8.24	3.74	1.49	9.36	51	5	8.28	3.75	1.50	9.39
PULMONARY HYPERTENSION	268	49	20.28	2.00	1.48	2.72	267	49	20.20	2.00	1.48	2.72
NORMOCYTIC ANAEMIA	129	20	12.95	2.36	1.48	3.79	127	20	12.50	2.33	1.46	3.74
CARDIOVASCULAR DISORDER	124	19	12.66	2.39	1.48	3.88	122	19	12.20	2.36	1.46	3.83
BLOOD GLUCOSE ABNORMAL	94	13	11.00	2.65	1.48	4.73	94	13	11.06	2.66	1.49	4.75
BREATH SOUNDS ABSENT	45	4	7.76	4.12	1.48	11.46	45	4	7.80	4.13	1.49	11.49
HYPORESPONSIVE TO STIMULI	244	44	18.96	2.03	1.47	2.80	242	44	18.63	2.02	1.47	2.79
COAGULOPATHY	206	36	16.98	2.10	1.47	2.99	205	36	16.87	2.09	1.47	2.98
BILIARY COLIC	56	6	8.43	3.42	1.47	7.94	56	6	8.47	3.43	1.48	7.96
ORAL LICHEN PLANUS	39	3	7.31	4.76	1.47	15.42	38	3	7.01	4.65	1.44	15.08
COLITIS ULCERATIVE	200	35	16.43	2.09	1.46	3.00	200	35	16.56	2.10	1.47	3.01
CORONARY ARTERY BYPASS	108	16	11.54	2.47	1.46	4.18	107	16	11.33	2.46	1.45	4.16
THERMAL BURN	108	16	11.54	2.47	1.46	4.18	107	16	11.33	2.46	1.45	4.16
FEMUR FRACTURE	82	11	9.90	2.73	1.46	5.13	82	11	9.96	2.74	1.46	5.14
EMPHYSEMA	217	39	16.92	2.04	1.45	2.87	213	39	16.08	2.01	1.43	2.82
PARKINSON'S DISEASE	137	22	13.00	2.28	1.45	3.58	135	22	12.56	2.25	1.44	3.54
CARDIAC VALVE DISEASE	55	6	8.12	3.36	1.45	7.80	55	6	8.16	3.37	1.45	7.82
RENAL TRANSPLANT	44	4	7.44	4.03	1.45	11.22	40	4	6.20	3.67	1.31	10.27
TESTICULAR PAIN	206	37	16.05	2.04	1.44	2.90	206	37	16.18	2.05	1.44	2.90
LUNG NEOPLASM MALIGNANT	106	16	10.99	2.43	1.44	4.11	105	15	11.89	2.57	1.50	4.42
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	60	7	8.33	3.14	1.44	6.87	59	7	8.08	3.10	1.41	6.78
PNEUMOMEDIASTINUM	60	7	8.33	3.14	1.44	6.87	58	7	7.78	3.04	1.39	6.67
EYE CONTUSION	130	21	12.18	2.27	1.43	3.60	130	21	12.26	2.27	1.43	3.61
FEEDING TUBE USER	49	5	7.61	3.59	1.43	9.01	49	5	7.65	3.60	1.43	9.04
VACCINATION SITE DISCHARGE	49	5	7.61	3.59	1.43	9.01	49	5	7.65	3.60	1.43	9.04
LANGUAGE DISORDER	38	3	6.98	4.64	1.43	15.04	38	3	7.01	4.65	1.44	15.08
GASTROINTESTINAL INFLAMMATION	90	13	9.87	2.54	1.42	4.54	90	13	9.93	2.54	1.42	4.55
VITILIGO	85	12	9.59	2.60	1.42	4.75	82	12	8.81	2.51	1.37	4.60
WHITE BLOOD CELL COUNT DECREASED	85	12	9.59	2.60	1.42	4.75	85	12	9.65	2.60	1.42	4.76
DISSOCIATION	138	23	12.25	2.20	1.41	3.42	138	23	12.35	2.20	1.42	3.43
ACIDOSIS	114	18	11.03	2.32	1.41	3.82	113	18	10.84	2.31	1.40	3.79
ISCHAEMIA	99	15	10.15	2.42	1.41	4.16	99	15	10.22	2.43	1.41	4.17
INTESTINAL ISCHAEMIA	64	8	8.27	2.93	1.41	6.11	64	8	8.32	2.94	1.41	6.13
ENTERAL NUTRITION	43	4	7.12	3.94	1.41	10.97	43	4	7.16	3.95	1.42	11.00
LEG AMPUTATION	43	4	7.12	3.94	1.41	10.97	43	4	7.16	3.95	1.42	11.00
MENOMETRORRHAGIA	43	4	7.12	3.94	1.41	10.97	43	4	7.16	3.95	1.42	11.00
MYOCARDIAL OEDEMA	43	4	7.12	3.94	1.41	10.97	42	4	6.84	3.86	1.38	10.76
PERICARDIAL EXCISION	43	4	7.12	3.94	1.41	10.97	43	4	7.16	3.95	1.42	11.00
HORDEOLUM	155	27	12.71	2.10	1.40	3.17	155	27	12.81	2.11	1.40	3.17
STRESS CARDIOMYOPATHY	89	13	9.59	2.51	1.40	4.49	88	13	9.37	2.49	1.39	4.45
CHRONIC LYMPHOCYTIC LEUKAEMIA	74	10	8.77	2.71	1.40	5.25	73	10	8.54	2.68	1.39	5.19
COLECTOMY	69	9	8.52	2.81	1.40	5.63	69	9	8.57	2.82	1.41	5.64
FOOD AVERSION	48	5	7.30	3.52	1.40	8.84	48	5	7.34	3.53	1.40	8.86
COMMUNICATION DISORDER	177	32	13.52	2.03	1.39	2.95	177	32	13.63	2.03	1.39	2.96
PERITONITIS	53	6	7.51	3.24	1.39	7.53	53	6	7.55	3.25	1.40	7.55
ESCHERICHIA BACTERAEMIA	37	3	6.65	4.52	1.39	14.66	37	3	6.68	4.53	1.40	14.70
PANCREATITIS ACUTE	162	29	12.59	2.05	1.38	3.04	159	29	11.96	2.01	1.36	2.99
RESPIRATORY ACIDOSIS	83	12	9.03	2.53	1.38	4.64	82	12	8.81	2.51	1.37	4.60
STAPHYLOCOCCAL BACTERAEMIA	83	12	9.03	2.53	1.38	4.64	83	12	9.09	2.54	1.39	4.66
HEART SOUNDS ABNORMAL	166	30	12.66	2.03	1.37	2.99	164	30	12.27	2.01	1.36	2.96
SUFFOCATION FEELING	47	5	6.99	3.44	1.37	8.66	47	5	7.03	3.45	1.37	8.68
BUNDLE BRANCH BLOCK LEFT	160	29	12.10	2.02	1.36	3.00	158	29	11.72	2.00	1.35	2.97
FAECES SOFT	105	17	9.67	2.26	1.36	3.78	104	17	9.48	2.25	1.35	3.75
SICK RELATIVE	72	10	8.20	2.64	1.36	5.11	70	10	7.69	2.57	1.33	4.99
ADULT FAILURE TO THRIVE	62	8	7.68	2.84	1.36	5.93	62	8	7.73	2.85	1.36	5.95
BRONCHIAL WALL THICKENING	57	7	7.43	2.98	1.36	6.54	56	7	7.18	2.94	1.34	6.45
BREAST INFLAMMATION	52	6	7.20	3.18	1.36	7.39	52	6	7.24	3.18	1.37	7.41

GLOSSITIS	141	25	11.10	2.07	1.35	3.16	141	25	11.19	2.07	1.35	3.17
CRANIOTOMY	76	11	8.20	2.53	1.35	4.76	76	11	8.25	2.54	1.35	4.78
LAPAROSCOPIC SURGERY	131	23	10.48	2.09	1.34	3.25	131	23	10.57	2.09	1.34	3.26
ELECTROCARDIOGRAM T WAVE INVERSION	90	14	8.79	2.36	1.34	4.14	88	14	8.31	2.31	1.31	4.06
BRAIN HERNIATION	51	6	6.90	3.11	1.34	7.26	51	6	6.94	3.12	1.34	7.28
RIGHT VENTRICULAR FAILURE	46	5	6.68	3.37	1.34	8.48	45	5	6.41	3.31	1.31	8.33
ALOPECIA AREATA	121	21	9.87	2.11	1.33	3.36	120	21	9.69	2.10	1.32	3.34
HYDRONEPHROSIS	108	18	9.46	2.20	1.33	3.62	107	18	9.27	2.18	1.33	3.60
VACCINATION SITE VESICLES	94	15	8.81	2.30	1.33	3.96	92	15	8.35	2.25	1.31	3.89
LICHEN PLANUS	120	21	9.62	2.09	1.32	3.33	115	21	8.47	2.01	1.26	3.20
JAW DISORDER	116	20	9.56	2.13	1.32	3.42	116	20	9.63	2.13	1.33	3.43
PLASMA CELL MYELOMA	70	10	7.64	2.57	1.32	4.98	69	10	7.41	2.54	1.31	4.92
SKIN TEXTURE ABNORMAL	70	10	7.64	2.57	1.32	4.98	70	10	7.69	2.57	1.33	4.99
CAROTID ARTERY OCCLUSION	65	9	7.37	2.65	1.32	5.31	65	9	7.42	2.65	1.32	5.33
ANGIOPATHY	74	11	7.65	2.47	1.31	4.64	74	11	7.70	2.47	1.31	4.66
FEBRILE NEUTROPENIA	60	8	7.10	2.75	1.31	5.75	60	8	7.15	2.76	1.32	5.76
BLOOD URINE	45	5	6.37	3.30	1.31	8.31	45	5	6.41	3.31	1.31	8.33
CIRCUMORAL SWELLING	40	4	6.17	3.66	1.31	10.24	40	4	6.20	3.67	1.31	10.27
MUCOSAL HYPERTROPHY	40	4	6.17	3.66	1.31	10.24	40	4	6.20	3.67	1.31	10.27
DECREASED NASOLABIAL FOLD	35	3	6.00	4.28	1.31	13.90	35	3	6.03	4.29	1.32	13.94
PANCREATIC CARCINOMA	35	3	6.00	4.28	1.31	13.90	35	3	6.03	4.29	1.32	13.94
TYPE IV HYPERSENSITIVITY REACTION	132	24	9.82	2.02	1.30	3.11	131	24	9.66	2.01	1.30	3.10
CACHEXIA	123	22	9.44	2.05	1.30	3.22	123	22	9.51	2.05	1.31	3.23
LOWER RESPIRATORY TRACT CONGESTION	87	14	7.99	2.28	1.30	4.00	83	14	7.02	2.18	1.24	3.84
SKIN ODOUR ABNORMAL	87	14	7.99	2.28	1.30	4.00	86	14	7.79	2.26	1.28	3.97
UPPER GASTROINTESTINAL HAEMORRHAGE	83	13	7.96	2.34	1.30	4.20	81	13	7.49	2.29	1.27	4.11
PALATAL SWELLING	82	13	7.69	2.31	1.29	4.15	82	13	7.75	2.32	1.29	4.16
SPINAL STENOSIS	99	17	8.14	2.13	1.28	3.57	99	17	8.20	2.14	1.28	3.58
HANGOVER	95	16	8.08	2.18	1.28	3.70	95	16	8.14	2.18	1.28	3.71
CONTRACEPTION	49	6	6.31	2.99	1.28	6.99	49	6	6.34	3.00	1.29	7.00
GANGRENE	44	5	6.07	3.22	1.28	8.13	44	5	6.10	3.23	1.28	8.15
INTRACRANIAL MASS	44	5	6.07	3.22	1.28	8.13	44	5	6.10	3.23	1.28	8.15
ATTENTION DEFICIT HYPERACTIVITY DISORDER	39	4	5.86	3.57	1.28	10.00	39	4	5.89	3.58	1.28	10.02
BASAL GANGLIA INFARCTION	39	4	5.86	3.57	1.28	10.00	39	4	5.89	3.58	1.28	10.02
ANTIPHOSPHOLIPID SYNDROME	34	3	5.68	4.15	1.28	13.52	34	3	5.71	4.16	1.28	13.56
COR PULMONALE	34	3	5.68	4.15	1.28	13.52	34	3	5.71	4.16	1.28	13.56
METASTASES TO LIVER	34	3	5.68	4.15	1.28	13.52	31	3	4.75	3.80	1.16	12.42
PHANTOM LIMB SYNDROME	34	3	5.68	4.15	1.28	13.52	34	3	5.71	4.16	1.28	13.56
IMMUNOSUPPRESSION	106	19	8.02	2.04	1.25	3.33	105	18	8.76	2.14	1.30	3.53
MASTITIS	106	19	8.02	2.04	1.25	3.33	106	19	8.08	2.05	1.26	3.34
DYSпноEA PAROXYSMAL NOCTURNAL	57	8	6.25	2.61	1.25	5.47	57	8	6.29	2.62	1.25	5.49
PULMONARY HAEMORRHAGE	43	5	5.77	3.15	1.25	7.96	43	5	5.80	3.16	1.25	7.98
VENOUS THROMBOSIS LIMB FIBROSIS	43	5	5.77	3.15	1.25	7.96	43	5	5.80	3.16	1.25	7.98
STENOSIS	38	4	5.55	3.48	1.24	9.75	38	4	5.58	3.49	1.25	9.78
THIRST DECREASED	38	4	5.55	3.48	1.24	9.75	37	4	5.27	3.40	1.21	9.54
VACCINATION SITE JOINT PAIN	38	4	5.55	3.48	1.24	9.75	38	4	5.58	3.49	1.25	9.78
INNER EAR INFLAMMATION	33	3	5.36	4.03	1.24	13.14	33	3	5.39	4.04	1.24	13.18
CONGESTIVE CARDIOMYOPATHY	91	16	7.08	2.08	1.23	3.55	91	16	7.14	2.09	1.23	3.56
CUTANEOUS VASCULITIS	47	6	5.72	2.87	1.23	6.71	47	6	5.75	2.88	1.23	6.73
ANTIBIOTIC THERAPY	65	10	6.28	2.38	1.22	4.64	65	10	6.32	2.39	1.23	4.65
HIDRADENITIS	42	5	5.47	3.08	1.22	7.78	42	5	5.50	3.09	1.22	7.80
URETERAL STENT INSERTION	42	5	5.47	3.08	1.22	7.78	42	5	5.50	3.09	1.22	7.80
LIVER FUNCTION TEST INCREASED	86	15	6.77	2.10	1.21	3.64	84	15	6.34	2.06	1.19	3.56
MENIERE'S DISEASE	86	15	6.77	2.10	1.21	3.64	85	15	6.58	2.08	1.20	3.60
PATIENT ISOLATION	51	7	5.70	2.67	1.21	5.88	51	7	5.74	2.68	1.21	5.90
NEUTROPHILIA	37	4	5.24	3.39	1.21	9.51	37	4	5.27	3.40	1.21	9.54
RIGHT ATRIAL DILATATION	37	4	5.24	3.39	1.21	9.51	37	4	5.27	3.40	1.21	9.54
WRONG TECHNIQUE IN DEVICE USAGE PROCESS	37	4	5.24	3.39	1.21	9.51	37	4	5.27	3.40	1.21	9.54
LIVER INJURY	68	11	6.05	2.27	1.20	4.28	68	11	6.10	2.27	1.20	4.29
SLEEP TERROR	46	6	5.43	2.81	1.20	6.58	46	6	5.47	2.82	1.20	6.60
BODY HEIGHT	32	3	5.04	3.91	1.20	12.76	32	3	5.07	3.92	1.20	12.80
LOWER GASTROINTESTINAL HAEMORRHAGE	32	3	5.04	3.91	1.20	12.76	31	3	4.75	3.80	1.16	12.42
OVARIAN CYST RUPTURED	32	3	5.04	3.91	1.20	12.76	32	3	5.07	3.92	1.20	12.80
ATRIAL SEPTAL DEFECT	76	13	6.15	2.14	1.19	3.86	76	13	6.20	2.15	1.19	3.87
DYSCHROMATOPSIA	59	9	5.72	2.40	1.19	4.84	59	9	5.76	2.41	1.19	4.86
GALLBLADDER ENLARGEMENT	41	5	5.18	3.00	1.19	7.60	41	5	5.21	3.01	1.19	7.62

INTESTINAL PERFORATION	41	5	5.18	3.00	1.19	7.60	41	5	5.21	3.01	1.19	7.62
CAPILLARY NAIL REFILL TEST ABNORMAL	63	10	5.75	2.31	1.18	4.50	63	10	5.79	2.31	1.19	4.51
ISCHAEMIC HEPATITIS	63	10	5.75	2.31	1.18	4.50	63	10	5.79	2.31	1.19	4.51
ORAL BLOOD BLISTER	45	6	5.15	2.75	1.17	6.44	45	6	5.18	2.76	1.18	6.46
B-CELL LYMPHOMA	36	4	4.94	3.30	1.17	9.27	36	4	4.97	3.31	1.18	9.29
HEMIPLEGIC MIGRAINE	36	4	4.94	3.30	1.17	9.27	37	4	5.27	3.40	1.21	9.54
LAZINESS	36	4	4.94	3.30	1.17	9.27	36	4	4.97	3.31	1.18	9.29
CLOSTRIDIUM DIFFICILE INFECTION	78	14	5.73	2.04	1.16	3.61	78	14	5.78	2.05	1.16	3.62
COLITIS ISCHAEMIC	70	12	5.60	2.14	1.16	3.94	70	12	5.64	2.14	1.16	3.95
INFARCTION	49	7	5.14	2.57	1.16	5.66	49	7	5.18	2.57	1.17	5.68
BLADDER DISCOMFORT	40	5	4.88	2.93	1.16	7.43	40	5	4.91	2.94	1.16	7.45
PRODUCT AVAILABILITY ISSUE	31	3	4.73	3.79	1.16	12.39	31	3	4.75	3.80	1.16	12.42
PULMONARY VASCULAR DISORDER	31	3	4.73	3.79	1.16	12.39	31	3	4.75	3.80	1.16	12.42
AZOTAEMIA	73	13	5.42	2.06	1.14	3.71	73	13	5.46	2.06	1.14	3.72
THROMBOTIC THROMBOCYTOPENIC PURPURA	65	11	5.29	2.17	1.14	4.10	64	11	5.08	2.14	1.13	4.05
BRAIN DEATH	60	10	4.98	2.20	1.13	4.29	60	10	5.02	2.20	1.13	4.31
RED BLOOD CELL ABNORMALITY	39	5	4.60	2.86	1.13	7.25	39	5	4.62	2.87	1.13	7.27
VEIN DISCOLOURATION	39	5	4.60	2.86	1.13	7.25	39	5	4.62	2.87	1.13	7.27
METASTASIS	43	6	4.59	2.63	1.12	6.17	42	6	4.34	2.57	1.09	6.05
PULMONARY ARTERIAL HYPERTENSION	30	3	4.42	3.66	1.12	12.01	30	3	4.44	3.67	1.12	12.04
RENAL ATROPHY	30	3	4.42	3.66	1.12	12.01	30	3	4.44	3.67	1.12	12.04
INJECTION SITE MUSCLE WEAKNESS	71	13	4.94	2.00	1.11	3.61	71	13	4.99	2.01	1.11	3.62
BLOOD GLUCOSE FLUCTUATION	63	11	4.80	2.10	1.11	3.98	63	11	4.83	2.10	1.11	3.99
ENDOCARDITIS	59	10	4.73	2.16	1.11	4.23	59	10	4.77	2.17	1.11	4.24
VENA CAVA FILTER INSERTION	59	10	4.73	2.16	1.11	4.23	59	10	4.77	2.17	1.11	4.24
OESOPHAGEAL SPASM	55	9	4.68	2.24	1.11	4.53	55	9	4.71	2.25	1.11	4.54
WALKING DISABILITY	51	8	4.63	2.34	1.11	4.92	51	8	4.66	2.34	1.11	4.94
ANTIALLERGIC THERAPY	47	7	4.60	2.46	1.11	5.44	47	7	4.63	2.47	1.12	5.46
ELECTROCARDIOGRAM AMBULATORY	47	7	4.60	2.46	1.11	5.44	47	7	4.63	2.47	1.12	5.46
OESOPHAGEAL DISORDER	47	7	4.60	2.46	1.11	5.44	47	7	4.63	2.47	1.12	5.46
ACNE CYSTIC	34	4	4.34	3.11	1.11	8.78	34	4	4.37	3.12	1.11	8.80
BLADDER SPASM	34	4	4.34	3.11	1.11	8.78	34	4	4.37	3.12	1.11	8.80
HIP SURGERY	34	4	4.34	3.11	1.11	8.78	34	4	4.37	3.12	1.11	8.80
VENTRICULAR ARRHYTHMIA	38	5	4.31	2.79	1.10	7.08	38	5	4.34	2.79	1.10	7.09
EFFUSION	66	12	4.63	2.02	1.09	3.73	66	12	4.67	2.02	1.09	3.74
CARDIAC OPERATION	58	10	4.48	2.13	1.09	4.16	58	10	4.52	2.13	1.09	4.17
ANTINUCLEAR ANTIBODY POSITIVE	42	6	4.31	2.57	1.09	6.03	42	6	4.34	2.57	1.09	6.05
CARDIOPULMONARY FAILURE	42	6	4.31	2.57	1.09	6.03	42	6	4.34	2.57	1.09	6.05
QRS AXIS ABNORMAL	42	6	4.31	2.57	1.09	6.03	42	6	4.34	2.57	1.09	6.05
REDUCED FACIAL EXPRESSION	37	5	4.03	2.71	1.07	6.90	37	5	4.06	2.72	1.07	6.92
ANAL HAEMORRHAGE	33	4	4.05	3.02	1.07	8.53	33	4	4.07	3.03	1.07	8.56
EYE COLOUR CHANGE	33	4	4.05	3.02	1.07	8.53	33	4	4.07	3.03	1.07	8.56
INCORRECT PRODUCT ADMINISTRATION DURATION	33	4	4.05	3.02	1.07	8.53	33	4	4.07	3.03	1.07	8.56
COMPLICATION ASSOCIATED WITH DEVICE	53	9	4.17	2.16	1.06	4.37	53	9	4.21	2.16	1.07	4.39
ORAL DISCOMFORT	801	146	62.20	2.01	1.69	2.40	799	147	61.30	2.00	1.68	2.38
LACTIC ACIDOSIS	389	71	29.81	2.01	1.56	2.59	386	71	29.32	2.00	1.55	2.57
AORTIC ARTERIOSCLEROSIS	187	34	14.15	2.02	1.40	2.90	184	34	13.54	1.99	1.38	2.87
LIVER DISORDER	121	22	8.95	2.02	1.28	3.17	118	22	8.31	1.97	1.25	3.11
ADRENAL MASS	42	6	4.31	2.57	1.09	6.03	40	6	3.80	2.45	1.04	5.78
APTALISM	33	4	4.05	3.02	1.07	8.53	32	4	3.78	2.94	1.04	8.31
DISEASE RECURRENCE	245	2	83.83	44.89	11.16	180.50	240	2	82.24	44.09	10.96	177.32
CEREBRAL THROMBOSIS	201	1	70.00	73.66	10.33	525.44	200	1	69.83	73.49	10.30	524.25
COVID-19 IMMUNISATION	196	2	65.90	35.91	8.92	144.61	196	2	66.09	36.01	8.94	145.00
INTENTIONAL PRODUCT USE ISSUE	144	1	49.12	52.77	7.38	377.16	144	1	49.26	52.91	7.40	378.18
RED BLOOD CELL TRANSFUSION	134	1	45.46	49.10	6.87	351.14	128	1	43.39	47.03	6.57	336.44
HYPERPYREXIA	110	1	36.68	40.31	5.63	288.71	110	1	36.79	40.42	5.64	289.49
SARS-COV-2 TEST NEGATIVE	109	1	36.32	39.94	5.58	286.11	109	1	36.42	40.05	5.59	286.88
RIGHT VENTRICULAR DYSFUNCTION	100	1	33.03	36.64	5.11	262.70	100	1	33.13	36.74	5.13	263.41
INTENTIONAL DOSE OMISSION	95	1	31.20	34.81	4.85	249.69	94	1	30.93	34.54	4.82	247.76
CEREBRAL ARTERY OCCLUSION	107	2	33.41	19.60	4.84	79.41	105	2	32.78	19.29	4.76	78.15
LYMPHOPENIA	105	2	32.68	19.24	4.75	77.94	104	2	32.42	19.11	4.72	77.42
INTRACARDIAC THROMBUS	96	2	29.41	17.59	4.34	71.35	96	2	29.50	17.64	4.35	71.54
CEREBRAL MASS EFFECT	85	1	27.55	31.15	4.34	223.68	84	1	27.27	30.86	4.30	221.67
CEREBELLAR STROKE	84	1	27.19	30.78	4.29	221.08	84	1	27.27	30.86	4.30	221.67
ABNORMAL UTERINE BLEEDING	83	1	26.82	30.42	4.23	218.47	83	1	26.90	30.50	4.25	219.06
RIGHT VENTRICULAR DILATATION	77	1	24.63	28.22	3.92	202.87	77	1	24.71	28.29	3.94	203.41
HAEMOFILTRATION	76	1	24.27	27.85	3.87	200.27	73	1	23.24	26.82	3.73	192.98
CRITICAL ILLNESS	81	2	23.97	14.84	3.65	60.36	78	2	22.96	14.33	3.52	58.32
PERIPHERAL ARTERY THROMBOSIS	81	2	23.97	14.84	3.65	60.36	80	2	23.68	14.70	3.61	59.79

PORTAL VEIN THROMBOSIS	79	2	23.25	14.47	3.56	58.89	79	2	23.32	14.51	3.57	59.05
VACCINATION SITE PARAESTHESIA	78	2	22.88	14.29	3.51	58.16	78	2	22.96	14.33	3.52	58.32
IMPLANTABLE CARDIAC MONITOR INSERTION	69	1	21.72	25.28	3.51	182.06	69	1	21.78	25.35	3.52	182.55
SARS-COV-2 TEST	68	1	21.35	24.92	3.46	179.46	67	1	21.05	24.62	3.42	177.33
NIH STROKE SCALE	66	1	20.63	24.19	3.36	174.25	65	1	20.32	23.88	3.31	172.11
TRANSVERSE SINUS THROMBOSIS	66	1	20.63	24.19	3.36	174.25	66	1	20.69	24.25	3.37	174.72
INTERNAL HAEMORRHAGE	74	2	21.44	13.56	3.33	55.23	71	2	20.42	13.04	3.20	53.18
MYOCARDIAL STRAIN	64	1	19.90	23.45	3.25	169.05	64	1	19.96	23.52	3.26	169.51
CHILLBLAINS	69	2	19.64	12.64	3.10	51.57	69	2	19.70	12.68	3.11	51.71
BODY HEIGHT DECREASED	60	1	18.44	21.99	3.05	158.64	57	1	17.41	20.94	2.90	151.25
NIH STROKE SCALE ABNORMAL	59	1	18.08	21.62	3.00	156.04	59	1	18.14	21.68	3.00	156.47
PRE-EXISTING CONDITION IMPROVED	66	2	18.56	12.09	2.96	49.37	66	2	18.62	12.13	2.97	49.50
CORONARY ARTERY DISSECTION	57	1	17.35	20.89	2.89	150.84	57	1	17.41	20.94	2.90	151.25
MESENTERIC VEIN THROMBOSIS	57	1	17.35	20.89	2.89	150.84	57	1	17.41	20.94	2.90	151.25
JUGULAR VEIN THROMBOSIS	55	1	16.63	20.15	2.79	145.64	55	1	16.68	20.21	2.80	146.03
LEFT VENTRICULAR DILATATION	54	1	16.26	19.79	2.74	143.04	54	1	16.32	19.84	2.74	143.42
NEUROLOGIC NEGLECT SYNDROME	54	1	16.26	19.79	2.74	143.04	54	1	16.32	19.84	2.74	143.42
HEPATIC MASS	50	1	14.82	18.32	2.53	132.63	50	1	14.86	18.37	2.54	132.99
THROMBOEMBOLECTOMY	49	1	14.45	17.96	2.48	130.03	49	1	14.50	18.00	2.49	130.38
AORTIC DISSECTION	55	2	14.61	10.08	2.46	41.31	54	2	14.31	9.92	2.42	40.69
INJECTION	54	2	14.26	9.89	2.41	40.58	53	2	13.95	9.74	2.37	39.95
MYOCARDIAL FIBROSIS	54	2	14.26	9.89	2.41	40.58	53	2	13.95	9.74	2.37	39.95
COR PULMONALE ACUTE	47	1	13.73	17.22	2.38	124.83	47	1	13.77	17.27	2.38	125.17
COOLING THERAPY	53	2	13.90	9.71	2.37	39.85	53	2	13.95	9.74	2.37	39.95
PERIPHERAL ARTERY OCCLUSION	45	1	13.01	16.49	2.27	119.63	44	1	12.69	16.17	2.23	117.34
PREMENSTRUAL PAIN	45	1	13.01	16.49	2.27	119.63	45	1	13.05	16.53	2.28	119.95
TOTAL LUNG CAPACITY DECREASED	45	1	13.01	16.49	2.27	119.63	45	1	13.05	16.53	2.28	119.95
QUARANTINE	50	2	12.84	9.16	2.23	37.65	48	2	12.17	8.82	2.14	36.28
VASCULAR DEMENTIA	44	1	12.65	16.12	2.22	117.03	44	1	12.69	16.17	2.23	117.34
ARTERIAL CATHETERISATION	49	2	12.48	8.98	2.18	36.92	49	2	12.53	9.00	2.19	37.02
PLATELET COUNT INCREASED	48	2	12.13	8.79	2.14	36.18	48	2	12.17	8.82	2.14	36.28
SENSATION OF BLOOD FLOW	48	2	12.13	8.79	2.14	36.18	48	2	12.17	8.82	2.14	36.28
VESTIBULAR MIGRAINE	48	2	12.13	8.79	2.14	36.18	48	2	12.17	8.82	2.14	36.28
AORTIC VALVE REPLACEMENT	47	2	11.77	8.61	2.09	35.45	46	2	11.46	8.45	2.05	34.81
BRAIN OPERATION	47	2	11.77	8.61	2.09	35.45	47	2	11.82	8.63	2.10	35.55
COLON CANCER	47	2	11.77	8.61	2.09	35.45	47	2	11.82	8.63	2.10	35.55
ACUTE CARDIAC EVENT	41	1	11.56	15.02	2.07	109.22	41	1	11.60	15.06	2.07	109.52
CARDIOVASCULAR SYMPTOM	41	1	11.56	15.02	2.07	109.22	40	1	11.24	14.70	2.02	106.91
LUNG ASSIST DEVICE THERAPY	46	2	11.42	8.43	2.05	34.72	45	2	11.11	8.27	2.01	34.08
WRONG PATIENT	46	2	11.42	8.43	2.05	34.72	46	2	11.46	8.45	2.05	34.81
FREEZING PHENOMENON	39	1	10.85	14.29	1.96	104.02	39	1	10.88	14.33	1.97	104.30
MITRAL VALVE CALCIFICATION	39	1	10.85	14.29	1.96	104.02	39	1	10.88	14.33	1.97	104.30
DEPERSONALISATION/DEREALIS ATION DISORDER	44	2	10.72	8.06	1.95	33.25	44	2	10.76	8.08	1.96	33.34
SUBDURAL HAEMORRHAGE	44	2	10.72	8.06	1.95	33.25	44	2	10.76	8.08	1.96	33.34
GLYCOSYLATED HAEMOGLOBIN INCREASED	43	2	10.37	7.88	1.91	32.52	43	2	10.40	7.90	1.91	32.61
NIH STROKE SCALE SCORE INCREASED	43	2	10.37	7.88	1.91	32.52	43	2	10.40	7.90	1.91	32.61
PRODUCT RECONSTITUTION QUALITY ISSUE	43	2	10.37	7.88	1.91	32.52	43	2	10.40	7.90	1.91	32.61
LACK OF SPONTANEOUS SPEECH	38	1	10.49	13.93	1.91	101.42	38	1	10.52	13.96	1.92	101.69
SENSITISATION	38	1	10.49	13.93	1.91	101.42	38	1	10.52	13.96	1.92	101.69
ENDOMETRIAL THICKENING	42	2	10.02	7.70	1.86	31.79	42	2	10.05	7.72	1.87	31.88
RESPIRATORY SYNCYTIAL VIRUS INFECTION	42	2	10.02	7.70	1.86	31.79	42	2	10.05	7.72	1.87	31.88
FEELING OF RELAXATION	36	1	9.77	13.19	1.81	96.22	36	1	9.80	13.23	1.81	96.48
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS	36	1	9.77	13.19	1.81	96.22	36	1	9.80	13.23	1.81	96.48
HEMIPARAESTHESIA	36	1	9.77	13.19	1.81	96.22	36	1	9.80	13.23	1.81	96.48
PRODUCT ADMINISTRATION INTERRUPTED	36	1	9.77	13.19	1.81	96.22	35	1	9.44	12.86	1.76	93.87
RIGHT ATRIAL ENLARGEMENT	36	1	9.77	13.19	1.81	96.22	36	1	9.80	13.23	1.81	96.48
DIURETIC THERAPY	35	1	9.41	12.83	1.76	93.62	35	1	9.44	12.86	1.76	93.87
BRIEF RESOLVED UNEXPLAINED EVENT	34	1	9.05	12.46	1.71	91.02	33	1	8.73	12.13	1.66	88.65
PLEURAL THICKENING	38	2	8.62	6.96	1.68	28.86	38	2	8.66	6.98	1.68	28.94
INTRA-ABDOMINAL FLUID COLLECTION	33	1	8.70	12.09	1.65	88.41	33	1	8.73	12.13	1.66	88.65
LACUNAR STROKE	33	1	8.70	12.09	1.65	88.41	33	1	8.73	12.13	1.66	88.65

VITAL FUNCTIONS ABNORMAL	33	1	8.70	12.09	1.65	88.41	33	1	8.73	12.13	1.66	88.65
BEHAVIOUR DISORDER	37	2	8.28	6.78	1.63	28.13	37	2	8.31	6.80	1.64	28.20
CEREBRAL ARTERY STENOSIS	37	2	8.28	6.78	1.63	28.13	36	2	7.96	6.61	1.59	27.47
IDIOPATHIC INTRACRANIAL HYPERTENSION	37	2	8.28	6.78	1.63	28.13	37	2	8.31	6.80	1.64	28.20
SUBCLAVIAN VEIN THROMBOSIS	37	2	8.28	6.78	1.63	28.13	37	2	8.31	6.80	1.64	28.20
ARTERIAL THROMBOSIS	32	1	8.34	11.73	1.60	85.81	32	1	8.37	11.76	1.61	86.05
METASTASES TO BONE	32	1	8.34	11.73	1.60	85.81	32	1	8.37	11.76	1.61	86.05
MULTIMORBIDITY	36	2	7.93	6.60	1.59	27.39	36	2	7.96	6.61	1.59	27.47
RETINAL MIGRAINE	36	2	7.93	6.60	1.59	27.39	35	2	7.62	6.43	1.55	26.73
CHILD MALTREATMENT SYNDROME	31	1	7.99	11.36	1.55	83.21	31	1	8.01	11.39	1.55	83.44
EAR INFLAMMATION	31	1	7.99	11.36	1.55	83.21	31	1	8.01	11.39	1.55	83.44
FEMORAL NECK FRACTURE	31	1	7.99	11.36	1.55	83.21	31	1	8.01	11.39	1.55	83.44
URINARY TRACT DISCOMFORT	31	1	7.99	11.36	1.55	83.21	31	1	8.01	11.39	1.55	83.44
HAND DERMATITIS	34	2	7.24	6.23	1.50	25.93	34	2	7.27	6.25	1.50	26.00
OVERSENSING	34	2	7.24	6.23	1.50	25.93	34	2	7.27	6.25	1.50	26.00
VACCINATION SITE SCAR	34	2	7.24	6.23	1.50	25.93	34	2	7.27	6.25	1.50	26.00
EYELID SENSORY DISORDER	30	1	7.63	10.99	1.50	80.61	30	1	7.66	11.02	1.50	80.83
CYTOKINE STORM	29	1	7.28	10.63	1.45	78.01	29	1	7.30	10.66	1.45	78.22
ANTINFLAMMATORY THERAPY	32	2	6.56	5.86	1.41	24.46	32	2	6.59	5.88	1.41	24.53
PATHOGEN RESISTANCE	32	2	6.56	5.86	1.41	24.46	32	2	6.59	5.88	1.41	24.53
CEREBRAL ARTERY EMBOLISM	28	1	6.92	10.26	1.40	75.41	28	1	6.95	10.29	1.40	75.61
HAEMORRHAGIC TRANSFORMATION STROKE	28	1	6.92	10.26	1.40	75.41	28	1	6.95	10.29	1.40	75.61
INFERIOR VENA CAVA DILATATION	28	1	6.92	10.26	1.40	75.41	28	1	6.95	10.29	1.40	75.61
PARAESTHESIA EAR	28	1	6.92	10.26	1.40	75.41	28	1	6.95	10.29	1.40	75.61
THORACIC CAVITY DRAINAGE	28	1	6.92	10.26	1.40	75.41	27	2	4.92	4.96	1.18	20.86
OBSTRUCTIVE SLEEP APNOEA SYNDROME	31	2	6.23	5.68	1.36	23.73	29	2	5.58	5.33	1.27	22.33
THROMBOSIS PROPHYLAXIS	31	2	6.23	5.68	1.36	23.73	30	2	5.91	5.51	1.32	23.06
VENTRICULAR DRAINAGE	31	2	6.23	5.68	1.36	23.73	30	2	5.91	5.51	1.32	23.06
DAYDREAMING	27	1	6.57	9.89	1.34	72.81	27	1	6.60	9.92	1.35	73.01
OVULATION DISORDER	27	1	6.57	9.89	1.34	72.81	27	1	6.60	9.92	1.35	73.01
THERAPEUTIC PRODUCT EFFECT DECREASED	27	1	6.57	9.89	1.34	72.81	27	1	6.60	9.92	1.35	73.01
AORTIC THROMBOSIS	30	2	5.89	5.50	1.31	23.00	30	2	5.91	5.51	1.32	23.06
HYPERVIGILANCE	30	2	5.89	5.50	1.31	23.00	30	2	5.91	5.51	1.32	23.06
INJECTION RELATED REACTION	30	2	5.89	5.50	1.31	23.00	30	2	5.91	5.51	1.32	23.06
THYROID PAIN	30	2	5.89	5.50	1.31	23.00	30	2	5.91	5.51	1.32	23.06
VASOGENIC CEREBRAL OEDEMA	30	2	5.89	5.50	1.31	23.00	30	2	5.91	5.51	1.32	23.06
VERTEBRAL ARTERY OCCLUSION	30	2	5.89	5.50	1.31	23.00	30	2	5.91	5.51	1.32	23.06
OXYGEN CONSUMPTION INCREASED	26	1	6.22	9.53	1.29	70.21	25	1	5.89	9.19	1.24	67.79
PRODUCT DOSE OMISSION IN ERROR	26	1	6.22	9.53	1.29	70.21	26	1	6.24	9.55	1.30	70.40
PULMONARY ARTERY DILATATION	26	1	6.22	9.53	1.29	70.21	26	1	6.24	9.55	1.30	70.40
SEDATIVE THERAPY	26	1	6.22	9.53	1.29	70.21	26	1	6.24	9.55	1.30	70.40
FOOD CRAVING	29	2	5.56	5.31	1.27	22.27	29	2	5.58	5.33	1.27	22.33
METASTASES TO CENTRAL NERVOUS SYSTEM	29	2	5.56	5.31	1.27	22.27	29	2	5.58	5.33	1.27	22.33
ORGANISING PNEUMONIA	29	2	5.56	5.31	1.27	22.27	28	2	5.25	5.14	1.23	21.59
PANCREATIC CYST	29	2	5.56	5.31	1.27	22.27	29	2	5.58	5.33	1.27	22.33
BASAL GANGLIA HAEMORRHAGE	25	1	5.87	9.16	1.24	67.61	25	1	5.89	9.19	1.24	67.79
LARGE INTESTINE PERFORATION	25	1	5.87	9.16	1.24	67.61	25	1	5.89	9.19	1.24	67.79
LEFT VENTRICULAR ENLARGEMENT	25	1	5.87	9.16	1.24	67.61	25	1	5.89	9.19	1.24	67.79
COLD-STIMULUS HEADACHE	28	2	5.22	5.13	1.22	21.54	28	2	5.25	5.14	1.23	21.59
BREAST DISORDER FEMALE	24	1	5.52	8.79	1.19	65.01	24	1	5.54	8.82	1.19	65.18
CEREBRAL HAEMATOMA	24	1	5.52	8.79	1.19	65.01	24	1	5.54	8.82	1.19	65.18
MENSTRUATION NORMAL	24	1	5.52	8.79	1.19	65.01	24	1	5.54	8.82	1.19	65.18
TOE AMPUTATION	24	1	5.52	8.79	1.19	65.01	24	1	5.54	8.82	1.19	65.18
VEIN RUPTURE	24	1	5.52	8.79	1.19	65.01	24	1	5.54	8.82	1.19	65.18
VENTRICULAR ASSIST DEVICE INSERTION	24	1	5.52	8.79	1.19	65.01	24	1	5.54	8.82	1.19	65.18
PNEUMOPERITONEUM	27	2	4.89	4.95	1.18	20.80	27	2	4.92	4.96	1.18	20.86
ARTERIAL STENT INSERTION	23	1	5.17	8.43	1.14	62.41	23	1	5.19	8.45	1.14	62.58
DISEASE COMPLICATION	23	1	5.17	8.43	1.14	62.41	22	1	4.85	8.08	1.09	59.97
LITHOTRIPSY	23	1	5.17	8.43	1.14	62.41	23	1	5.19	8.45	1.14	62.58
PRODUCT DISPENSING ISSUE	23	1	5.17	8.43	1.14	62.41	23	1	5.19	8.45	1.14	62.58
PULMONARY CALCIFICATION	26	2	4.57	4.76	1.13	20.07	26	2	4.59	4.78	1.13	20.12
VERTEBRAL ARTERY STENOSIS	26	2	4.57	4.76	1.13	20.07	26	2	4.59	4.78	1.13	20.12
BLUE TOE SYNDROME	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97

BREAST CANCER METASTATIC	22	1	4.83	8.06	1.09	59.81	21	1	4.50	7.72	1.04	57.36
DENTAL PARAESTHESIA	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
METASTASES TO LYMPH NODES	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
ORBITAL SWELLING	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
OXYGEN CONSUMPTION DECREASED	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
PLATELET DISORDER	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
SPLENIC VEIN THROMBOSIS	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
SUPERFICIAL VEIN PROMINENCE	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
UTERINE POLYP	22	1	4.83	8.06	1.09	59.81	22	1	4.85	8.08	1.09	59.97
BLOOD LACTIC ACID INCREASED	25	2	4.24	4.58	1.08	19.34	25	2	4.26	4.59	1.09	19.39
CEREBRAL ARTERY THROMBOSIS	25	2	4.24	4.58	1.08	19.34	25	2	4.26	4.59	1.09	19.39
CORNEAL LIGHT REFLEX TEST ABNORMAL	25	2	4.24	4.58	1.08	19.34	25	2	4.26	4.59	1.09	19.39
THUNDERCLAP HEADACHE	25	2	4.24	4.58	1.08	19.34	25	2	4.26	4.59	1.09	19.39
ABDOMINAL WALL HAEMATOMA	21	1	4.48	7.70	1.04	57.21	21	1	4.50	7.72	1.04	57.36
ACCIDENTAL DEATH	21	1	4.48	7.70	1.04	57.21	21	1	4.50	7.72	1.04	57.36
CARDIAC ANEURYSM	21	1	4.48	7.70	1.04	57.21	21	1	4.50	7.72	1.04	57.36
CHEYNE-STOKES RESPIRATION	21	1	4.48	7.70	1.04	57.21	21	1	4.50	7.72	1.04	57.36
LUNG ADENOCARCINOMA	21	1	4.48	7.70	1.04	57.21	21	1	4.50	7.72	1.04	57.36
MONOCLONAL ANTIBODY UNCONJUGATED THERAPY	21	1	4.48	7.70	1.04	57.21	20	1	4.16	7.33	0.99	54.76
NEUTROPHIL COUNT INCREASED	21	1	4.48	7.70	1.04	57.21	21	1	4.50	7.72	1.04	57.36
POSITIVE END-EXPIRATORY PRESSURE	21	1	4.48	7.70	1.04	57.21	21	1	4.50	7.72	1.04	57.36
CAPILLARY DISORDER	20	1	4.14	7.33	0.98	54.61	20	1	4.16	7.33	0.99	54.76
EPSTEIN-BARR VIRUS INFECTION REACTIVATION	20	1	4.14	7.33	0.98	54.61	20	1	4.16	7.33	0.99	54.76
FOLLICULAR LYMPHOMA	20	1	4.14	7.33	0.98	54.61	20	1	4.16	7.33	0.99	54.76
HAEMOPERITONEUM	20	1	4.14	7.33	0.98	54.61	20	1	4.16	7.33	0.99	54.76
VASCULAR PSEUDOANEURYSM	20	1	4.14	7.33	0.98	54.61	20	1	4.16	7.33	0.99	54.76
AORTIC DISORDER	25	2	4.24	4.58	1.08	19.34	24	2	3.94	4.41	1.04	18.66
DYSHIDROTIC ECZEMA	25	2	4.24	4.58	1.08	19.34	24	2	3.94	4.41	1.04	18.66
ENDOTRACHEAL INTUBATION COMPLICATION	25	2	4.24	4.58	1.08	19.34	23	2	3.62	4.23	1.00	17.92
THYROID CANCER	13	1	1.85	4.76	0.62	36.42	13	0	.	.	.	.
AMYLOIDOSIS	12	1	1.55	4.40	0.57	33.82	12	0	.	.	.	.

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)

For Current Week and Past Week Comparison

Following ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines (SERIOUS AGES 5 YEARS-11 YEARS)

Compared to ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines (SERIOUS AGES 5 YEARS-11 YEARS)

SERIOUS AGES 5 YEARS-11 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022

Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)

N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00

MedDRA PT's sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (SERIOUS 5 Yrs-11 Yrs)	12/14/2020-07/29/2022 COVID19 mRNA N=319	01/01/2009-07/29/2022 NON-COVID19 N=1111	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020-07/22/2022 COVID19 mRNA N=316	01/01/2009-07/22/2022 NON-COVID19 N=1110	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
APPENDICITIS	14	3	32.37	16.25	4.70	56.20	14	3	32.69	16.39	4.74	56.68
MYOCARDITIS	14	4	29.20	12.19	4.04	36.77	14	4	29.51	12.29	4.08	37.09
CONJUNCTIVITIS	19	10	29.39	6.62	3.11	14.09	19	10	29.75	6.67	3.14	14.21
KAWASAKIS DISEASE	8	3	13.46	9.29	2.48	34.80	8	3	13.61	9.37	2.50	35.10
SHOCK	10	6	12.83	5.80	2.13	15.85	10	6	12.99	5.85	2.14	15.98
HYPOTENSION	26	27	21.15	3.35	1.99	5.66	25	27	19.48	3.25	1.92	5.52
APPENDICECTOMY	9	8	7.61	3.92	1.52	10.07	9	8	7.73	3.95	1.54	10.16
CONJUNCTIVAL HYPERAEMIA	9	8	7.61	3.92	1.52	10.07	9	8	7.73	3.95	1.54	10.16
CHEST PAIN	31	48	12.82	2.25	1.46	3.47	31	48	13.12	2.27	1.47	3.50
ACUTE RESPIRATORY FAILURE	8	7	6.71	3.98	1.45	10.89	7	7	4.83	3.51	1.24	9.94
BLOOD PRESSURE INCREASED	9	9	6.53	3.48	1.39	8.70	9	9	6.64	3.51	1.41	8.77
RESPIRATORY RATE INCREASED	9	9	6.53	3.48	1.39	8.70	8	9	4.81	3.12	1.21	8.03
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	5	3	5.35	5.80	1.39	24.16	5	3	5.42	5.85	1.41	24.36
HEART RATE INCREASED	15	20	7.57	2.61	1.35	5.04	15	20	7.72	2.63	1.36	5.09
BLOOD PRESSURE DECREASED	8	8	5.63	3.48	1.32	9.21	8	8	5.73	3.51	1.33	9.28
GENERAL PHYSICAL CONDITION ABNORMAL	5	3	5.35	5.80	1.39	24.16	4	3	3.16	4.68	1.05	20.82
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	69	1	242.40	240.31	33.51	1723.51	69	1	244.54	242.37	33.80	1738.25
COVID-19	56	1	192.99	195.03	27.10	1403.38	55	1	190.90	193.20	26.84	1390.55
LEFT VENTRICULAR DYSFUNCTION	11	1	29.68	38.31	4.96	295.61	11	1	29.95	38.64	5.01	298.14
MITRAL VALVE INCOMPETENCE	9	1	22.84	31.34	3.99	246.48	9	1	23.05	31.61	4.02	248.59
ILLNESS	9	2	19.32	15.67	3.40	72.17	9	2	19.52	15.81	3.43	72.79
PLEURAL EFFUSION	7	2	13.02	12.19	2.54	58.39	7	2	13.16	12.29	2.57	58.89
PERICARDIAL EFFUSION	6	1	12.85	20.90	2.53	172.94	6	1	12.98	21.08	2.55	174.42
TRICUSPID VALVE INCOMPETENCE	6	1	12.85	20.90	2.53	172.94	6	1	12.98	21.08	2.55	174.42
PERICARDITIS	5	1	9.65	17.41	2.04	148.51	5	1	9.75	17.56	2.06	149.79
HEPATOMEGALY	5	2	7.15	8.71	1.70	44.67	5	2	7.24	8.78	1.71	45.05
SINUS TACHYCARDIA	5	2	7.15	8.71	1.70	44.67	5	2	7.24	8.78	1.71	45.05
PERIORBITAL SWELLING	4	1	6.58	13.93	1.56	124.20	4	1	6.66	14.05	1.58	125.26
VENTRICULAR EXTRASYSTOLES	4	2	4.51	6.97	1.28	37.86	4	2	4.57	7.03	1.29	38.18

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines \(SERIOUS AGES 12 YEARS-17 YEARS\)](#)
Compared to [ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines \(SERIOUS AGES 12 YEARS-17 YEARS\)](#)
SERIOUS AGES 12 YEARS-17 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022
Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (SERIOUS 12 Yrs-17 Yrs)	12/14/2020-07/29/2022 COVID19 mRNA N=1893	01/01/2009-07/29/2022 NON-COVID19 N=1598	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020-07/22/2022 COVID19 mRNA N=1889	01/01/2009-07/22/2022 NON-COVID19 N=1597	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
MYOCARDITIS	670	11	662.47	51.42	28.44	92.95	668	11	661.16	51.34	28.40	92.81
RESPIRATORY RATE INCREASED	161	6	123.95	22.65	10.05	51.03	160	6	123.24	22.54	10.01	50.79
PERICARDITIS	149	8	107.89	15.72	7.74	31.92	148	8	107.18	15.64	7.70	31.76
BLOOD PRESSURE INCREASED	141	14	86.68	8.50	4.93	14.66	141	14	86.85	8.51	4.94	14.69
ANTICOAGULANT THERAPY	59	4	38.58	12.45	4.53	34.20	59	4	38.65	12.47	4.54	34.25
PAINFUL RESPIRATION	90	9	53.73	8.44	4.27	16.70	91	9	54.68	8.55	4.32	16.90
CHEST PAIN	907	172	558.27	4.45	3.84	5.17	905	172	557.33	4.45	3.83	5.16
RESPIRATORY RATE DECREASED	43	3	27.36	12.10	3.76	38.93	43	3	27.41	12.12	3.77	38.98
PERICARDIAL EFFUSION	63	7	35.38	7.60	3.49	16.54	63	7	35.45	7.61	3.49	16.57
HEART RATE DECREASED	62	7	34.55	7.48	3.43	16.29	62	7	34.62	7.49	3.44	16.31
PLEURITIC PAIN	38	3	23.18	10.69	3.31	34.57	37	3	22.39	10.43	3.22	33.75
CHEST DISCOMFORT	266	62	104.13	3.62	2.77	4.74	266	62	104.42	3.63	2.77	4.74
SINUS ARRHYTHMIA	27	3	14.18	7.60	2.31	25.00	27	3	14.21	7.61	2.31	25.03
HEART RATE INCREASED	197	59	56.51	2.82	2.12	3.74	195	59	55.31	2.79	2.10	3.71
BLOOD PRESSURE DECREASED	86	22	27.93	3.30	2.08	5.25	86	22	28.01	3.30	2.08	5.25
APPENDICITIS	50	12	16.68	3.52	1.88	6.58	50	12	16.73	3.52	1.88	6.59
BODY TEMPERATURE INCREASED	83	24	23.28	2.92	1.86	4.58	82	24	22.69	2.89	1.84	4.53
ACUTE KIDNEY INJURY	37	8	13.28	3.90	1.82	8.36	37	8	13.31	3.91	1.83	8.37
TACHYPNOEA	69	20	19.03	2.91	1.78	4.77	67	20	17.79	2.83	1.73	4.65
PULMONARY EMBOLISM	27	5	10.63	4.56	1.76	11.81	27	5	10.66	4.57	1.76	11.83
OXYGEN SATURATION DECREASED	55	19	11.49	2.44	1.46	4.10	55	19	11.53	2.45	1.46	4.11
SINUS TACHYCARDIA	44	14	10.26	2.65	1.46	4.82	44	14	10.29	2.66	1.46	4.83
ELECTROCARDIOGRAM AMBULATORY	17	3	6.48	4.78	1.40	16.29	17	3	6.50	4.79	1.41	16.32
MUSCULOSKELETAL CHEST PAIN	41	14	8.48	2.47	1.35	4.52	41	14	8.51	2.48	1.35	4.53
BREATH SOUNDS ABNORMAL	37	14	6.27	2.23	1.21	4.11	35	14	5.27	2.11	1.14	3.91
PLEURAL EFFUSION	34	13	5.58	2.21	1.17	4.17	34	13	5.60	2.21	1.17	4.18
SINUS BRADYCARDIA	20	6	4.55	2.81	1.13	6.99	20	6	4.57	2.82	1.13	7.00
INTENSIVE CARE	373	157	64.91	2.01	1.68	2.39	371	157	64.03	2.00	1.68	2.38
TROPONIN INCREASED	133	1	111.95	112.27	15.72	802.02	134	1	113.04	113.29	15.86	809.21
COVID-19	129	2	105.52	54.45	13.49	219.70	127	2	103.87	53.68	13.30	216.65
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	114	1	94.75	96.23	13.46	688.29	114	1	94.90	96.38	13.48	689.31
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN	60	1	46.93	50.65	7.03	365.05	60	1	47.01	50.73	7.04	365.60
VENTRICULAR TACHYCARDIA	42	2	28.86	17.73	4.30	73.12	42	2	28.91	17.75	4.30	73.23
MITRAL VALVE INCOMPETENCE	36	1	26.22	30.39	4.17	221.40	36	1	26.27	30.44	4.18	221.73
TROPONIN I INCREASED	35	1	25.37	29.55	4.05	215.42	35	1	25.41	29.59	4.06	215.74
VENTRICULAR EXTRASYSTOLES	34	1	24.52	28.70	3.93	209.44	34	1	24.56	28.74	3.94	209.75
TRICUSPID VALVE INCOMPETENCE	25	1	16.89	21.10	2.86	155.58	25	1	16.92	21.14	2.87	155.81
EPINEPHRINE	24	1	16.05	20.26	2.74	149.59	24	1	16.08	20.29	2.75	149.82
BLOOD PRESSURE DIASTOLIC INCREASED	20	1	12.70	16.88	2.27	125.66	20	1	12.73	16.91	2.27	125.85
ILLNESS	20	1	12.70	16.88	2.27	125.66	20	1	12.73	16.91	2.27	125.85
HEART SOUNDS ABNORMAL	18	2	8.97	7.60	1.77	32.69	18	2	8.99	7.61	1.77	32.74
ELECTROCARDIOGRAM T WAVE INVERSION	14	2	5.89	5.91	1.35	25.96	14	2	5.90	5.92	1.35	26.00
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	14	2	5.89	5.91	1.35	25.96	14	2	5.90	5.92	1.35	26.00
EXPOSURE TO SARS-COV-2	12	1	6.16	10.13	1.32	77.82	12	1	6.17	10.15	1.32	77.94
SEDATION	11	1	5.37	9.29	1.20	71.85	11	1	5.38	9.30	1.20	71.95
C-REACTIVE PROTEIN INCREASED	10	1	4.59	8.44	1.08	65.87	10	1	4.60	8.45	1.08	65.97
PULMONARY VALVE INCOMPETENCE	10	1	4.59	8.44	1.08	65.87	10	1	4.60	8.45	1.08	65.97
LYMPHOPENIA	15	4	3.76	3.17	1.05	9.52	15	3	5.07	4.23	1.23	14.58

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)

For Current Week and Past Week Comparison

Following ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines (SERIOUS AGES 18+ YEARS)

Compared to ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines (SERIOUS AGES 18+ YEARS)

SERIOUS AGES 18+ YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022

Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)

N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00

MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (SERIOUS 18+)	12/14/2020- 07/29/2022 COVID19 mRNA N=73178	01/01/2009- 07/29/2022 NON-COVID19 N=13287	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020- 07/22/2022 COVID19 mRNA N=72822	01/01/2009- 07/22/2022 NON-COVID19 N=13279	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
COVID-19	21473	42	5067.70	92.83	68.62	125.58	21252	42	5026.11	92.27	68.21	124.82
COVID-19 PNEUMONIA	4924	9	926.22	99.34	51.67	190.99	4892	9	923.96	99.12	51.55	190.56
LUNG OPACITY	1802	10	311.18	32.72	17.58	60.90	1796	10	311.49	32.75	17.60	60.96
POSITIVE AIRWAY PRESSURE THERAPY	962	7	160.46	24.95	11.87	52.47	945	7	158.06	24.62	11.71	51.77
PULMONARY THROMBOSIS	579	3	98.23	35.04	11.27	108.96	574	3	97.76	34.89	11.22	108.48
ANTICOAGULANT THERAPY	3770	66	573.67	10.37	8.14	13.22	3743	66	571.50	10.34	8.11	13.18
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	1278	22	188.70	10.55	6.92	16.07	1254	22	185.26	10.39	6.82	15.84
THROMBECTOMY	367	5	55.41	13.33	5.52	32.20	367	5	55.69	13.38	5.54	32.34
ILLNESS	539	13	71.32	7.53	4.34	13.05	534	13	70.83	7.49	4.32	12.98
BLOOD PRESSURE DIASTOLIC INCREASED	232	4	32.97	10.53	3.92	28.29	229	4	32.60	10.44	3.89	28.05
APPENDICITIS	544	16	66.86	6.17	3.76	10.15	544	16	67.26	6.20	3.77	10.19
PULMONARY EMBOLISM	2794	120	292.51	4.23	3.52	5.07	2783	120	292.62	4.23	3.53	5.07
EPINEPHRINE	329	9	41.14	6.64	3.42	12.87	327	9	41.02	6.63	3.42	12.84
THROMBOSIS	1449	60	152.33	4.38	3.39	5.67	1444	60	152.51	4.39	3.39	5.68
UNEVALUABLE EVENT	2293	107	225.00	3.89	3.21	4.72	2290	107	226.14	3.90	3.22	4.73
HYPERVOLAEMIA	280	8	34.25	6.35	3.15	12.83	276	8	33.75	6.29	3.12	12.70
LEFT VENTRICULAR FAILURE	252	7	31.07	6.54	3.09	13.85	250	7	30.90	6.51	3.07	13.80
RESPIRATORY RATE INCREASED	1440	67	139.80	3.90	3.06	4.98	1421	67	137.57	3.87	3.03	4.94
BLOOD LOSS ANAEMIA	197	5	24.89	7.15	2.95	17.38	193	5	24.33	7.04	2.90	17.10
CARDIAC FAILURE ACUTE	349	13	37.86	4.87	2.80	8.48	348	13	37.93	4.88	2.81	8.49
DEATH	10169	618	879.39	2.99	2.76	3.23	10097	616	876.74	2.99	2.76	3.24
ANOSMIA	410	17	41.90	4.38	2.70	7.11	410	17	42.19	4.40	2.71	7.14
RESPIRATORY RATE DECREASED	317	12	33.98	4.80	2.70	8.53	311	12	33.17	4.73	2.66	8.41
GENERAL PHYSICAL CONDITION ABNORMAL	316	12	33.81	4.78	2.69	8.51	312	12	33.34	4.74	2.66	8.44
STENT PLACEMENT	292	11	31.31	4.82	2.64	8.80	290	11	31.17	4.81	2.63	8.78
BLOOD PRESSURE SYSTOLIC INCREASED	543	27	49.03	3.65	2.48	5.37	533	27	47.75	3.60	2.45	5.30
END STAGE RENAL DISEASE	203	7	22.52	5.27	2.48	11.18	200	7	22.15	5.21	2.45	11.07
BELL'S Palsy	468	23	42.51	3.69	2.43	5.61	465	23	42.33	3.69	2.43	5.60
SUPERINFECTION	126	3	15.91	7.63	2.43	23.96	126	3	16.00	7.66	2.44	24.06
ACUTE LEFT VENTRICULAR FAILURE	159	5	18.23	5.77	2.37	14.06	158	5	18.17	5.76	2.37	14.03
ACUTE RESPIRATORY FAILURE	4120	294	270.39	2.54	2.26	2.86	4074	294	265.80	2.53	2.25	2.84
HEART RATE DECREASED	799	48	61.13	3.02	2.26	4.04	789	48	60.07	3.00	2.24	4.01
GENERAL PHYSICAL HEALTH DETERIORATION	1151	74	82.38	2.82	2.23	3.57	1132	74	80.15	2.79	2.21	3.53
OXYGEN SATURATION DECREASED	2740	197	174.60	2.53	2.19	2.91	2713	197	172.19	2.51	2.18	2.90
APPENDICECTOMY	432	24	35.21	3.27	2.17	4.93	430	24	35.17	3.27	2.17	4.93
HOSPICE CARE	312	16	27.05	3.54	2.14	5.85	307	16	26.44	3.50	2.12	5.78
PULMONARY INFARCTION	122	4	13.50	5.54	2.05	14.99	122	4	13.59	5.56	2.05	15.05
TROPONIN INCREASED	404	24	30.75	3.06	2.03	4.61	401	24	30.54	3.05	2.02	4.60
CHRONIC LEFT VENTRICULAR FAILURE	163	7	15.72	4.23	1.98	9.01	161	7	15.50	4.19	1.97	8.94
ACUTE MYOCARDIAL INFARCTION	1458	111	83.84	2.38	1.97	2.89	1450	111	83.55	2.38	1.97	2.89
CHRONIC KIDNEY DISEASE	654	45	42.51	2.64	1.95	3.57	646	44	42.94	2.68	1.97	3.63
DRUG INEFFECTIVE	159	7	15.05	4.12	1.94	8.79	154	7	14.33	4.01	1.88	8.55
IMMUNE THROMBOCYTOPENIA	280	16	21.90	3.18	1.92	5.26	278	16	21.77	3.17	1.91	5.24
DYSPNOEA AT REST	100	3	11.36	6.05	1.92	19.08	100	3	11.43	6.08	1.93	19.16
PNEUMONIA BACTERIAL	390	25	27.27	2.83	1.89	4.24	385	25	26.75	2.81	1.87	4.21
HYPOXIA	4119	363	191.40	2.06	1.85	2.29	4093	363	190.15	2.06	1.85	2.29
BLOOD PRESSURE DIASTOLIC DECREASED	152	7	13.89	3.94	1.85	8.41	149	7	13.50	3.88	1.82	8.28
ISCHAEMIC STROKE	465	32	29.95	2.64	1.84	3.77	465	32	30.24	2.65	1.85	3.79
CORONARY ARTERIAL STENT INSERTION	273	17	19.49	2.92	1.79	4.76	273	17	19.66	2.93	1.79	4.78
VENTRICULAR HYPOKINESIA	160	8	13.75	3.63	1.79	7.38	159	8	13.70	3.62	1.78	7.37
DEEP VEIN THROMBOSIS	1441	122	69.39	2.14	1.78	2.58	1433	122	69.11	2.14	1.78	2.57
DEMENTIA	434	31	26.54	2.54	1.77	3.66	428	31	25.92	2.52	1.75	3.62
CARDIAC FAILURE	647	50	35.64	2.35	1.76	3.13	644	50	35.59	2.35	1.76	3.13
PULSELESS ELECTRICAL ACTIVITY	398	28	24.78	2.58	1.76	3.78	394	28	24.43	2.57	1.75	3.76
MULTIPLE ORGAN DYSFUNCTION SYNDROME	317	21	21.16	2.74	1.76	4.26	314	21	20.91	2.73	1.75	4.24

BLOOD PRESSURE SYSTOLIC DECREASED	105	4	10.60	4.77	1.76	12.93	101	4	10.00	4.60	1.70	12.50
PNEUMONIA VIRAL	193	11	14.88	3.19	1.74	5.85	192	11	14.85	3.18	1.73	5.84
LUNG INFILTRATION	1198	104	54.77	2.09	1.71	2.55	1191	104	54.50	2.09	1.71	2.55
IMMUNISATION	141	7	12.09	3.66	1.71	7.81	141	7	12.19	3.67	1.72	7.84
GENERAL SYMPTOM	114	5	10.58	4.14	1.69	10.14	112	5	10.33	4.08	1.67	10.00
CORONARY ARTERY OCCLUSION	194	12	13.73	2.94	1.64	5.26	193	12	13.70	2.93	1.64	5.25
INFUSION	122	6	10.43	3.69	1.63	8.38	121	6	10.35	3.68	1.62	8.35
CARDIO-RESPIRATORY ARREST	761	67	33.46	2.06	1.61	2.65	752	67	32.69	2.05	1.60	2.63
PULSE ABSENT	726	64	31.80	2.06	1.60	2.66	715	64	30.75	2.04	1.58	2.63
AUTOPSY	361	28	19.42	2.34	1.59	3.44	358	28	19.21	2.33	1.59	3.42
LUNG CONSOLIDATION	352	28	18.16	2.28	1.55	3.35	349	28	17.95	2.27	1.55	3.34
EXTRA DOSE ADMINISTERED	234	17	13.64	2.50	1.53	4.09	232	17	13.49	2.49	1.52	4.07
CEREBRAL INFARCTION	422	37	18.38	2.07	1.48	2.90	421	37	18.48	2.07	1.48	2.90
PHARYNGEAL SWELLING	412	36	18.05	2.08	1.48	2.92	413	36	18.41	2.09	1.49	2.94
DEMENTIA ALZHEIMER'S TYPE	144	9	9.88	2.91	1.48	5.70	144	9	9.97	2.92	1.49	5.72
PALLIATIVE CARE	121	7	8.91	3.14	1.47	6.72	116	7	8.21	3.02	1.41	6.48
ATYPICAL PNEUMONIA	108	6	8.20	3.27	1.44	7.43	107	6	8.11	3.25	1.43	7.40
HOSPITALISATION	117	7	8.29	3.03	1.42	6.50	117	7	8.37	3.05	1.42	6.53
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	236	19	11.72	2.26	1.41	3.60	235	19	11.72	2.26	1.41	3.60
RESPIRATORY SYMPTOM	236	19	11.72	2.26	1.41	3.60	236	19	11.85	2.26	1.42	3.61
EMBOLIC STROKE	94	5	7.34	3.41	1.39	8.39	92	5	7.08	3.36	1.36	8.25
CARDIOGENIC SHOCK	273	24	11.61	2.07	1.36	3.13	272	24	11.63	2.07	1.36	3.14
EJECTION FRACTION DECREASED	227	19	10.50	2.17	1.36	3.46	224	19	10.22	2.15	1.35	3.43
APPENDICITIS PERFORATED	110	7	7.23	2.85	1.33	6.12	110	7	7.30	2.87	1.34	6.15
HYPERTENSIVE EMERGENCY	80	4	6.48	3.63	1.33	9.91	80	4	6.53	3.65	1.34	9.95
PULMONARY PAIN	70	3	6.28	4.24	1.33	13.45	70	3	6.33	4.25	1.34	13.51
TASTE DISORDER	192	16	8.86	2.18	1.31	3.63	191	16	8.83	2.18	1.31	3.62
IMPAIRED SELF-CARE	97	6	6.50	2.94	1.29	6.69	96	6	6.41	2.92	1.28	6.65
JUGULAR VEIN DISTENSION	76	4	5.84	3.45	1.26	9.43	74	4	5.58	3.37	1.23	9.22
CORONARY ARTERY THROMBOSIS	65	3	5.47	3.93	1.24	12.51	64	3	5.35	3.89	1.22	12.38
DRAINAGE	65	3	5.47	3.93	1.24	12.51	65	3	5.51	3.95	1.24	12.57
ATRIOVENTRICULAR BLOCK COMPLETE	91	6	5.61	2.75	1.21	6.29	90	6	5.52	2.74	1.20	6.25
HEPATIC CIRRHOSIS	150	13	6.30	2.10	1.19	3.69	146	13	5.87	2.05	1.16	3.61
ELECTRIC SHOCK SENSATION	125	10	5.99	2.27	1.19	4.32	126	10	6.19	2.30	1.21	4.37
GASTROINTESTINAL WALL THICKENING	62	3	4.98	3.75	1.18	11.95	61	3	4.86	3.71	1.16	11.81
OROPHARYNGEAL DISCOMFORT	123	10	5.72	2.23	1.17	4.25	123	10	5.79	2.24	1.18	4.27
AORTIC ANEURYSM	114	9	5.53	2.30	1.17	4.53	114	9	5.60	2.31	1.17	4.55
RETINAL ARTERY OCCLUSION	87	6	5.02	2.63	1.15	6.02	86	6	4.93	2.61	1.14	5.98
THROMBOLYSIS	69	4	4.76	3.13	1.14	8.58	68	4	4.65	3.10	1.13	8.50
CHOLECYSTITIS ACUTE	59	3	4.51	3.57	1.12	11.39	58	3	4.39	3.53	1.10	11.25
ANGINA UNSTABLE	58	3	4.35	3.51	1.10	11.20	57	3	4.23	3.46	1.09	11.06
THALAMIC INFARCTION	66	4	4.30	3.00	1.09	8.22	66	4	4.34	3.01	1.10	8.25
ACQUIRED DIAPHRAGMATIC EVENTRATION	56	3	4.04	3.39	1.06	10.83	56	3	4.08	3.40	1.07	10.87
VACCINE BREAKTHROUGH INFECTION	3471	2	650.84	315.12	78.79	1260.32	3400	2	639.73	309.99	77.51	1239.84
EXPOSURE TO SARS-COV-2	794	1	142.13	144.17	20.28	1024.63	788	1	141.65	143.69	20.22	1021.25
ASYMPTOMATIC COVID-19	657	2	114.69	59.65	14.89	238.96	651	2	114.10	59.35	14.81	237.80
SUSPECTED COVID-19	137	1	21.67	24.88	3.48	177.84	137	1	21.78	24.98	3.49	178.60
RED BLOOD CELL TRANSFUSION	134	1	21.13	24.33	3.40	173.97	128	1	20.14	23.34	3.26	166.95
OFF LABEL USE	102	1	15.34	18.52	2.58	132.73	102	1	15.42	18.60	2.60	133.30
RIGHT VENTRICULAR DYSFUNCTION	94	1	13.90	17.07	2.38	122.42	94	1	13.97	17.14	2.39	122.94
CEREBRAL ARTERY OCCLUSION	105	2	13.99	9.53	2.35	38.61	103	2	13.71	9.39	2.32	38.05
LYMPHOPENIA	89	1	13.00	16.16	2.25	115.98	88	1	12.89	16.05	2.24	115.18
CEREBRAL MASS EFFECT	85	1	12.28	15.43	2.15	110.82	84	1	12.17	15.32	2.13	110.00
CEREBELLAR STROKE	82	1	11.75	14.89	2.07	106.95	82	1	11.81	14.95	2.08	107.41
INTRACARDIAC THROMBUS	91	2	11.51	8.26	2.04	33.53	91	2	11.57	8.30	2.04	33.68
PERCUTANEOUS CORONARY INTERVENTION	91	2	11.51	8.26	2.04	33.53	90	2	11.40	8.21	2.02	33.31
HAEMOFILTRATION	76	1	10.67	13.80	1.92	99.22	73	1	10.19	13.31	1.85	95.76
RIGHT VENTRICULAR DILATATION	76	1	10.67	13.80	1.92	99.22	76	1	10.73	13.86	1.93	99.65
CARDIAC ASSISTANCE DEVICE USER	85	2	10.45	7.72	1.90	31.36	83	2	10.16	7.57	1.86	30.76
CRITICAL ILLNESS	80	2	9.58	7.26	1.79	29.54	77	2	9.11	7.02	1.72	28.57
PORTAL VEIN THROMBOSIS	75	2	8.70	6.81	1.67	27.73	75	2	8.76	6.84	1.68	27.84
NIH STROKE SCALE	65	1	8.71	11.80	1.64	85.04	64	1	8.58	11.67	1.62	84.11
PERIPHERAL ARTERY THROMBOSIS	72	2	8.18	6.54	1.60	26.64	71	2	8.06	6.47	1.59	26.39
IMPLANTABLE CARDIAC MONITOR INSERTION	61	1	8.00	11.08	1.54	79.89	61	1	8.04	11.12	1.54	80.23
NORMAL LABOUR	61	1	8.00	11.08	1.54	79.89	61	1	8.04	11.12	1.54	80.23
MYOCARDIAL STRAIN	59	1	7.64	10.71	1.48	77.31	59	1	7.69	10.76	1.49	77.64
NIH STROKE SCALE ABNORMAL	57	1	7.29	10.35	1.43	74.73	57	1	7.33	10.39	1.44	75.05

MESENTERIC VEIN THROMBOSIS	55	1	6.94	9.99	1.38	72.16	55	1	6.98	10.03	1.39	72.47
NEUROLOGIC NEGLECT SYNDROME	54	1	6.76	9.80	1.36	70.87	54	1	6.80	9.85	1.36	71.17
CORONARY ARTERY DISSECTION	51	1	6.23	9.26	1.28	67.00	51	1	6.27	9.30	1.29	67.29
INTERNAL HAEMORRHAGE	56	2	5.46	5.08	1.24	20.83	54	2	5.16	4.92	1.20	20.19
JUGULAR VEIN THROMBOSIS	49	1	5.88	8.90	1.23	64.42	49	1	5.92	8.94	1.23	64.70
LEFT VENTRICULAR DILATATION	49	1	5.88	8.90	1.23	64.42	49	1	5.92	8.94	1.23	64.70
THROMBOEMBOLECTOMY	49	1	5.88	8.90	1.23	64.42	49	1	5.92	8.94	1.23	64.70
AORTIC DISSECTION	53	2	4.96	4.81	1.17	19.74	52	2	4.83	4.74	1.15	19.46
MYOCARDIAL FIBROSIS	52	2	4.79	4.72	1.15	19.38	51	2	4.66	4.65	1.13	19.10
COR PULMONALE ACUTE	46	1	5.36	8.35	1.15	60.56	46	1	5.39	8.39	1.16	60.82
POST-ACUTE COVID-19 SYNDROME	50	2	4.46	4.54	1.10	18.65	50	2	4.49	4.56	1.11	18.73
CORONARY ANGIOPLASTY	44	1	5.01	7.99	1.10	57.98	44	1	5.04	8.02	1.11	58.23
ARTERIAL CATHETERISATION	49	2	4.30	4.45	1.08	18.29	49	2	4.33	4.47	1.09	18.37
NIH STROKE SCALE SCORE INCREASED	43	1	4.84	7.81	1.08	56.69	43	1	4.87	7.84	1.08	56.93
VASCULAR DEMENTIA	42	1	4.67	7.63	1.05	55.40	42	1	4.70	7.66	1.05	55.64
HEPATIC MASS	40	1	4.32	7.26	1.00	52.83	40	1	4.35	7.29	1.00	53.05
PERIPHERAL ARTERY OCCLUSION	40	1	4.32	7.26	1.00	52.83	40	1	4.35	7.29	1.00	53.05
AMYLOIDOSIS	9	1	0.00	1.63	0.21	12.90	9	0	-	-	-	-

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines \(NON-SERIOUS AGES 5 YEARS-11 YEARS\)](#)
Compared to [ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines \(NON-SERIOUS AGES 5 YEARS-11 YEARS\)](#)
NON-SERIOUS AGES 5 YEARS-11 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022
Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (NON-SERIOUS 5 Yrs-11 Yrs)	12/14/2020- 07/29/2022 COVID19 mRNA N=12010	01/01/2009- 07/29/2022 NON-COVID19 N=27960	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020- 07/22/2022 COVID19 mRNA N=11869	01/01/2009- 07/22/2022 NON-COVID19 N=27937	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
PRODUCT PREPARATION ISSUE	1930	45	4523.57	99.85	74.36	134.08	1913	45	4531.45	100.06	74.51	134.37
COVID-19	175	3	393.18	135.80	43.39	425.07	170	3	385.74	133.38	42.60	417.60
INCORRECT DOSE ADMINISTERED	1981	263	3832.66	17.54	15.45	19.91	1955	262	3818.81	17.56	15.47	19.94
PRODUCT ADMINISTRATION ERROR	99	12	182.42	19.21	10.55	34.95	98	12	182.36	19.22	10.56	34.99
UNDERDOSE	416	82	683.79	11.81	9.33	14.95	414	83	685.34	11.74	9.28	14.85
IMMUNISATION	71	13	116.27	12.71	7.04	22.96	71	13	117.78	12.86	7.12	23.21
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	1586	502	2206.92	7.36	6.67	8.11	1569	497	2213.25	7.43	6.73	8.20
PRODUCT PREPARATION ERROR	278	83	379.96	7.80	6.11	9.95	269	83	366.34	7.63	5.97	9.75
INCORRECT PRODUCT FORMULATION ADMINISTERED	173	60	215.74	6.71	5.01	9.00	173	60	218.97	6.79	5.06	9.10
PRODUCT USE ISSUE	44	11	63.02	9.31	4.81	18.02	44	11	63.90	9.42	4.86	18.22
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	262	111	287.46	5.50	4.41	6.85	255	109	282.29	5.51	4.40	6.88
INJURY ASSOCIATED WITH DEVICE	19	3	30.59	14.74	4.36	49.82	19	3	30.98	14.91	4.41	50.37
VACCINATION FAILURE	33	10	42.46	7.68	3.79	15.58	30	10	36.93	7.06	3.45	14.44
POOR QUALITY PRODUCT ADMINISTERED	19	6	22.99	7.37	2.95	18.45	18	6	21.32	7.06	2.80	17.78
PRODUCT STORAGE ERROR	1150	867	733.63	3.09	2.83	3.36	1147	866	746.16	3.12	2.86	3.40
NEEDLE ISSUE	18	6	21.00	6.98	2.77	17.59	16	6	17.37	6.28	2.46	16.04
OVERDOSE	37	18	34.56	4.79	2.73	8.40	37	17	36.87	5.12	2.89	9.09
OROPHARYNGEAL DISCOMFORT	12	3	15.52	9.31	2.63	32.99	12	3	15.74	9.42	2.66	33.36
EXPIRED PRODUCT ADMINISTERED	669	551	366.67	2.83	2.53	3.16	639	551	333.11	2.73	2.44	3.05
PHARYNGEAL SWELLING	13	4	15.30	7.57	2.47	23.20	13	4	15.53	7.65	2.49	23.46
ANGINA PECTORIS	11	3	13.46	8.54	2.38	30.59	11	3	13.66	8.63	2.41	30.93
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS	52	36	34.02	3.36	2.20	5.14	52	36	34.73	3.40	2.22	5.20
CHEST PAIN	165	141	82.48	2.72	2.18	3.41	165	140	85.43	2.77	2.22	3.47
MENSTRUATION IRREGULAR	10	3	11.46	7.76	2.14	28.19	10	3	11.63	7.85	2.16	28.50
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR	52	38	31.69	3.19	2.10	4.84	49	38	28.01	3.04	1.99	4.63
SLEEP DISORDER	34	23	22.41	3.44	2.03	5.84	33	23	21.34	3.38	1.98	5.75
PERIORBITAL SWELLING	15	7	13.47	4.99	2.03	12.23	15	7	13.70	5.04	2.06	12.37
SYRINGE ISSUE	44	34	24.60	3.01	1.93	4.71	41	34	21.00	2.84	1.80	4.47
INTERCHANGE OF VACCINE PRODUCTS	23	20	10.16	2.68	1.47	4.87	20	20	6.86	2.35	1.27	4.37
PAINFUL RESPIRATION	10	6	6.55	3.88	1.41	10.67	10	6	6.68	3.92	1.43	10.79
VACCINE BREAKTHROUGH INFECTION	9	5	6.27	4.19	1.40	12.50	9	5	6.39	4.24	1.42	12.64
PITYRIASIS ROSEA	7	3	5.81	5.43	1.40	21.00	7	3	5.92	5.49	1.42	21.24
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES	43	48	12.04	2.09	1.38	3.15	43	48	12.43	2.11	1.40	3.18
HAEMATURIA	10	7	5.40	3.33	1.27	8.74	10	7	5.52	3.36	1.28	8.83
SWELLING OF EYELID	16	16	5.15	2.33	1.16	4.65	16	16	5.31	2.35	1.18	4.71
INJECTION SITE EXTRAVASATION	9	6	5.06	3.49	1.24	9.81	8	6	3.78	3.14	1.09	9.04
VACCINATION ERROR	18	20	4.64	2.10	1.11	3.96	17	20	3.86	2.00	1.05	3.82
DRUG INEFFECTIVE	25	1	50.99	58.20	7.89	429.48	25	1	51.58	58.84	7.97	434.22
ILLNESS	25	2	47.35	29.10	6.89	122.84	24	2	45.61	28.25	6.68	119.49
BELL'S PALSY	14	1	25.66	32.59	4.29	247.83	14	1	25.97	32.95	4.33	250.57
COSTOCHONDRITIS	7	2	7.62	8.15	1.69	39.22	7	2	7.74	8.24	1.71	39.65
APHONIA	6	1	7.84	13.97	1.68	116.01	6	1	7.95	14.12	1.70	117.29
APHTHOUS ULCER	5	1	5.77	11.64	1.36	99.62	5	1	5.85	11.77	1.38	100.72
VITILIGO	5	1	5.77	11.64	1.36	99.62	5	1	5.85	11.77	1.38	100.72
NO ADVERSE EVENT	2533	2960	781.10	1.99	1.90	2.09	2522	2956	797.85	2.01	1.91	2.11
PALPITATIONS	34	40	8.17	1.98	1.25	3.12	34	40	8.46	2.00	1.27	3.16

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines \(NON-SERIOUS AGES 12 YEARS-17 YEARS\)](#)
Compared to [ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines \(NON-SERIOUS AGES 12 YEARS-17 YEARS\)](#)
NON-SERIOUS AGES 12 YEARS-17 YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022
Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (NON-SERIOUS 12 Yrs-17 Yrs)	12/14/2020- 07/29/2022 COVID19 mRNA N=29554	01/01/2009- 07/29/2022 NON-COVID19 N=28486	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020- 07/22/2022 COVID19 mRNA N=29485	01/01/2009- 07/22/2022 NON-COVID19 N=28443	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
UNDERDOSE	1057	58	874.01	17.57	13.49	22.87	1055	58	872.88	17.55	13.48	22.84
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE	8627	584	8000.48	14.24	13.11	15.46	8613	578	8009.60	14.37	13.23	15.61
BELL'S PALS	74	3	61.19	23.78	7.50	75.40	74	3	61.24	23.79	7.50	75.46
POOR QUALITY PRODUCT ADMINISTERED	71	4	55.77	17.11	6.25	46.84	71	4	55.82	17.12	6.25	46.87
PERICARDITIS	70	4	54.82	16.87	6.16	46.19	70	4	54.87	16.88	6.16	46.23
PRODUCT ADMINISTRATION ERROR	91	7	67.41	12.53	5.81	27.02	91	7	67.48	12.54	5.81	27.05
ILLNESS	61	4	46.27	14.70	5.35	40.42	61	4	46.32	14.71	5.35	40.45
PRODUCT PREPARATION ISSUE	512	75	311.25	6.58	5.17	8.38	511	75	310.69	6.57	5.16	8.37
AGEUSIA	67	6	47.21	10.76	4.67	24.81	67	6	47.25	10.77	4.67	24.83
ANGINA PECTORIS	41	3	29.80	13.17	4.08	42.53	41	3	29.83	13.18	4.08	42.57
IMMUNISATION	87	14	48.81	5.99	3.41	10.53	87	14	48.87	5.99	3.41	10.54
PRODUCT STORAGE ERROR	2669	874	898.72	2.94	2.73	3.17	2668	873	900.85	2.95	2.74	3.18
PHARYNGEAL SWELLING	68	14	32.39	4.68	2.63	8.32	68	14	32.43	4.69	2.64	8.33
CHEST PAIN	918	298	299.10	2.97	2.61	3.38	919	298	300.35	2.97	2.61	3.39
FEAR OF INJECTION	34	5	19.10	6.55	2.56	16.76	34	5	19.13	6.56	2.57	16.77
MENSTRUAL DISORDER	76	19	31.04	3.86	2.33	6.37	76	19	31.09	3.86	2.33	6.38
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	598	215	168.12	2.68	2.30	3.13	596	212	170.46	2.71	2.32	3.17
OFF LABEL USE	89	27	29.94	3.18	2.07	4.89	89	27	29.99	3.18	2.07	4.89
DYSMENORRHOEA	67	19	24.03	3.40	2.04	5.66	67	19	24.07	3.40	2.04	5.66
PRODUCT TEMPERATURE EXCURSION ISSUE	36	8	15.61	4.34	2.02	9.33	36	8	15.63	4.34	2.02	9.34
FLUSHING	379	157	83.97	2.33	1.93	2.80	378	157	83.52	2.32	1.93	2.80
CARDIAC FLUTTER	26	5	12.19	5.01	1.92	13.05	26	5	12.20	5.02	1.93	13.06
PAROSMIA	23	4	11.36	5.54	1.92	16.02	23	4	11.37	5.55	1.92	16.04
INCORRECT DOSE ADMINISTERED	867	390	166.83	2.14	1.90	2.41	862	386	167.77	2.15	1.91	2.43
VAGINAL ULCERATION	25	5	11.35	4.82	1.85	12.59	25	5	11.37	4.82	1.85	12.60
INTERCHANGE OF VACCINE PRODUCTS	231	99	47.58	2.25	1.78	2.84	230	99	47.08	2.24	1.77	2.83
MOUTH SWELLING	24	5	10.53	4.63	1.77	12.12	24	5	10.54	4.63	1.77	12.13
PAINFUL RESPIRATION	50	17	14.15	2.83	1.64	4.91	50	17	14.18	2.84	1.64	4.92
MENSTRUATION IRREGULAR	99	41	21.22	2.33	1.62	3.35	99	41	21.26	2.33	1.62	3.35
PERIORBITAL SWELLING	21	5	8.12	4.05	1.53	10.73	21	5	8.13	4.05	1.53	10.74
POLYMERORRHOEA	18	4	7.22	4.34	1.47	12.81	18	4	7.23	4.34	1.47	12.82
AXILLARY PAIN	108	51	17.77	2.04	1.46	2.85	108	51	17.81	2.04	1.46	2.85
HYPERTENSION	45	17	10.80	2.55	1.46	4.46	46	17	11.47	2.61	1.50	4.55
VACCINATION ERROR	43	16	10.54	2.59	1.46	4.60	42	15	10.96	2.70	1.50	4.87
OROPHARYNGEAL DISCOMFORT	28	9	8.11	3.00	1.42	6.35	28	9	8.13	3.00	1.42	6.36
SINUS TACHYCARDIA	23	8	5.82	2.77	1.24	6.19	23	8	5.83	2.77	1.24	6.20
DYSPNOEA EXERTIONAL	19	6	5.33	3.05	1.22	7.64	19	6	5.34	3.05	1.22	7.65
NEEDLE ISSUE	19	6	5.33	3.05	1.22	7.64	19	6	5.34	3.05	1.22	7.65
OLIGOMENORRHOEA	15	4	4.90	3.61	1.20	10.89	15	4	4.91	3.62	1.20	10.90
THROMBOCYTOPENIA	15	4	4.90	3.61	1.20	10.89	15	4	4.91	3.62	1.20	10.90
OVERDOSE	36	17	5.48	2.04	1.15	3.63	36	16	6.28	2.17	1.20	3.91
COVID-19	439	1	421.42	423.14	59.48	3010.38	438	1	420.80	422.52	59.39	3006.02
HEAVY MENSTRUAL BLEEDING	119	1	110.07	114.70	16.03	820.92	119	1	110.17	114.79	16.04	821.60
DRUG INEFFECTIVE	55	1	48.29	53.01	7.34	383.05	55	1	48.33	53.06	7.34	383.37
ANOSMIA	59	2	49.44	28.43	6.95	116.36	59	2	49.48	28.46	6.95	116.46
VACCINE BREAKTHROUGH INFECTION	31	1	25.25	29.88	4.08	218.86	31	1	25.27	29.90	4.08	219.04
EXPOSURE TO SARS-COV-2	28	1	22.38	26.99	3.67	198.34	27	1	21.45	26.05	3.54	191.66
PRODUCT DOSE OMISSION ISSUE	26	2	18.07	12.53	2.97	52.79	26	2	18.09	12.54	2.98	52.83
TASTE DISORDER	22	1	16.68	21.20	2.86	157.30	22	1	16.69	21.22	2.86	157.43
VULVAL ULCERATION	20	1	14.78	19.28	2.59	143.63	20	1	14.80	19.29	2.59	143.75
APHTHOUS ULCER	17	1	11.96	16.39	2.18	123.12	17	1	11.97	16.40	2.18	123.22
PLEURITIC PAIN	19	2	11.62	9.16	2.13	39.31	19	2	11.63	9.16	2.13	39.34
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	16	1	11.03	15.42	2.05	116.28	16	1	11.04	15.43	2.05	116.38
CARDIAC DISORDER	18	2	10.71	8.67	2.01	37.38	17	2	9.82	8.20	1.89	35.49
THROMBOSIS	18	2	10.71	8.67	2.01	37.38	18	2	10.72	8.68	2.01	37.41
VULVOVAGINAL PAIN	15	1	10.10	14.46	1.91	109.44	15	1	10.11	14.47	1.91	109.54
BLOOD GLUCOSE DECREASED	14	2	7.17	6.75	1.53	29.68	14	2	7.18	6.75	1.53	29.71
SENSITIVE SKIN	13	2	6.31	6.27	1.41	27.76	13	2	6.32	6.27	1.42	27.78
PLATELET COUNT DECREASED	11	1	6.43	10.60	1.37	82.12	11	1	6.43	10.61	1.37	82.18
RESPIRATORY SYMPTOM	11	2	4.64	5.30	1.18	23.91	11	2	4.64	5.31	1.18	23.93

PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
For Current Week and Past Week Comparison
Following [ALL 12/14/2020-07/29/2022 COVID19 mRNA Vaccines \(NON-SERIOUS AGES 18+ YEARS\)](#)
Compared to [ALL 01/01/2009-07/29/2022 NON-COVID19 Vaccines \(NON-SERIOUS AGES 18+ YEARS\)](#)
NON-SERIOUS AGES 18+ YEARS Excludes missing ages, Initial domestic reports only, VAERS reports as of 07/29/2022
Vaccination, Received, and Completed Date: 12/14 - 07/29 (Current Week) and 12/14 - 07/22 (Past Week)
N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
MedDRA PT's sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-07/29/2022

MedDRA Codes ALL Reports (NON-SERIOUS 18+)	12/14/2020- 07/29/2022 COVID19 mRNA N=587465	01/01/2009- 07/29/2022 NON-COVID19 N=228804	12/14-07/29 Chi-Square	12/14-07/29 PRR	12/14-07/29 LCL	12/14-07/29 UCL	12/14/2020- 07/22/2022 COVID19 mRNA N=585478	01/01/2009- 07/22/2022 NON-COVID19 N=228605	12/14-07/22 Chi-Square	12/14-07/22 PRR	12/14-07/22 LCL	12/14-07/22 UCL
PRODUCT TEMPERATURE EXCURSION ISSUE	3064	7	1179.77	170.48	81.21	357.90	3019	7	1165.09	168.40	80.21	353.53
POOR QUALITY PRODUCT ADMINISTERED	3245	8	1248.43	157.98	78.94	316.17	3205	8	1235.90	156.43	78.16	313.06
COVID-19	26164	115	10246.48	88.61	73.78	106.42	25290	112	9917.50	88.17	73.24	106.14
EXPOSURE TO SARS-COV-2	1636	3	629.93	212.39	68.43	659.22	1600	3	617.43	208.24	67.09	646.36
HEAVY MENSTRUAL BLEEDING	4130	29	1546.77	55.47	38.50	79.92	4120	29	1546.90	55.47	38.50	79.92
INTERMENSTRUAL BLEEDING	1310	7	493.11	72.89	34.68	153.19	1308	7	493.61	72.96	34.71	153.34
VACCINATION SITE PRURITUS	3968	33	1473.82	46.83	33.25	65.97	3966	33	1476.93	46.93	33.31	66.10
SARS-COV-2 TEST POSITIVE	783	3	296.77	101.65	32.71	315.86	781	3	296.75	101.65	32.71	315.85
DYSMENORRHOEA	1780	14	660.46	49.52	29.27	83.78	1775	14	660.24	49.50	29.26	83.76
DRUG INEFFECTIVE	3557	34	1310.14	40.75	29.07	57.11	3269	33	1202.70	38.68	27.45	54.50
INTERCHANGE OF VACCINE PRODUCTS	8389	100	3064.75	32.67	26.83	39.79	8378	100	3068.68	32.71	26.86	39.84
PRODUCT DOSE OMISSION ISSUE	1560	16	569.92	37.97	23.21	62.14	1559	16	571.05	38.05	23.25	62.26
VACCINE BREAKTHROUGH INFECTION	1381	15	502.35	35.86	21.56	59.64	1349	15	491.18	35.12	21.11	58.41
SUSPECTED COVID-19	741	6	273.41	48.10	21.54	107.41	720	6	265.92	46.86	20.98	104.64
MENSTRUATION IRREGULAR	3201	47	1141.00	26.53	19.89	35.38	3198	47	1142.94	26.57	19.92	35.43
MENSTRUAL DISORDER	2397	36	851.42	25.93	18.66	36.04	2392	36	851.79	25.94	18.67	36.05
ANOSMIA	3366	55	1187.61	23.84	18.26	31.11	3339	55	1180.29	23.70	18.16	30.94
POLYMENORRHOEA	664	7	241.11	36.94	17.54	77.80	664	7	241.76	37.04	17.59	77.99
POSTMENOPAUSAL HAEMORRHAGE	524	5	191.16	40.82	16.92	98.47	523	5	191.27	40.84	16.93	98.53
OLIGOMENORRHOEA	560	6	202.89	36.35	16.26	81.26	559	6	203.04	36.38	16.27	81.32
ILLNESS	3927	82	1347.18	18.65	14.99	23.21	3910	82	1344.32	18.62	14.96	23.17
TASTE DISORDER	1986	45	671.31	17.19	12.79	23.10	1981	44	673.45	17.58	13.04	23.70
MECHANICAL URTICARIA	844	19	284.41	17.30	10.98	27.26	842	19	284.44	17.30	10.98	27.26
MATERNAL EXPOSURE DURING BREAST FEEDING	287	4	101.21	27.94	10.42	74.96	287	4	101.49	28.02	10.44	75.15
AGEUSIA	4108	134	1306.32	11.94	10.05	14.18	4082	135	1298.03	11.81	9.95	14.01
VACCINATION SITE ERYTHEMA	6170	211	1947.48	11.39	9.93	13.06	6164	211	1951.03	11.41	9.94	13.08
DEEP VEIN THROMBOSIS	790	21	259.20	14.65	9.50	22.60	785	21	258.02	14.60	9.46	22.51
IMMUNISATION	2621	92	817.95	11.10	9.01	13.66	2620	92	820.04	11.12	9.03	13.69
VACCINATION SITE URTICARIA	322	7	108.19	17.92	8.47	37.88	320	7	107.72	17.85	8.44	37.74
THROMBOSIS	1809	66	558.44	10.68	8.35	13.65	1802	66	557.45	10.66	8.34	13.63
MENSTRUATION DELAYED	1065	36	333.83	11.52	8.27	16.06	1065	36	334.84	11.55	8.29	16.10
VACCINATION SITE MASS	1176	41	366.23	11.17	8.18	15.25	1174	41	366.57	11.18	8.19	15.26
BELL'S PALSY	2675	106	810.15	9.83	8.10	11.93	2670	104	814.80	10.02	8.24	12.19
VACCINATION SITE MOVEMENT IMPAIRMENT	355	9	116.65	15.36	7.93	29.77	354	9	116.60	15.36	7.93	29.76
THROAT CLEARING	384	11	123.60	13.60	7.47	24.76	381	11	122.81	13.52	7.43	24.63
PAROSMIA	1250	50	376.31	9.74	7.34	12.92	1248	50	376.71	9.75	7.35	12.93
PRODUCT USE ISSUE	534	19	164.71	10.95	6.93	17.30	533	19	164.83	10.95	6.93	17.31
CARDIAC FLUTTER	1169	52	341.36	8.76	6.63	11.56	1168	52	342.06	8.77	6.64	11.58
ELECTRIC SHOCK SENSATION	731	30	217.90	9.49	6.59	13.67	730	30	218.20	9.50	6.60	13.69
OROPHARYNGEAL DISCOMFORT	1442	75	400.40	7.49	5.94	9.44	1435	75	399.07	7.47	5.92	9.42
VITAL SIGNS MEASUREMENT	143	3	47.56	18.57	5.92	58.25	143	3	47.70	18.61	5.93	58.39
BLOOD PRESSURE MEASUREMENT	184	5	59.13	14.33	5.90	34.84	184	5	59.31	14.37	5.91	34.93
FACIAL DISCOMFORT	299	11	90.93	10.59	5.80	19.32	299	11	91.21	10.61	5.81	19.37
OFF LABEL USE	1166	63	318.95	7.21	5.59	9.29	1165	63	319.64	7.22	5.60	9.30
SYMPTOM RECURRENCE	154	4	49.68	14.99	5.56	40.46	151	4	48.66	14.74	5.46	39.78
CHRONIC SPONTANEOUS URTICARIA	152	4	48.91	14.80	5.48	39.94	150	4	48.28	14.64	5.42	39.52
SUPPRESSED LACTATION	131	3	42.92	17.01	5.42	53.42	131	3	43.05	17.05	5.43	53.55
THERAPEUTIC RESPONSE UNEXPECTED	534	26	150.78	8.00	5.40	11.86	532	26	150.52	7.99	5.39	11.84
PULMONARY EMBOLISM	360	16	104.23	8.76	5.31	14.46	359	16	104.18	8.76	5.31	14.46
IMMUNODEFICIENCY	486	25	134.55	7.57	5.07	11.32	484	25	134.24	7.56	5.06	11.30
PHARYNGEAL PARAESTHESIA	894	53	235.42	6.57	4.98	8.67	893	53	235.85	6.58	4.99	8.68
CARDIAC DISCOMFORT	322	15	91.75	8.36	4.98	14.03	322	15	92.05	8.38	4.99	14.07

VACCINATION SITE PAIN	14264	1061	3448.08	5.24	4.92	5.57	14250	1059	3459.28	5.25	4.94	5.59
DEVICE CONNECTION ISSUE	341	17	95.08	7.81	4.80	12.71	341	17	95.40	7.83	4.81	12.75
ACCIDENTAL OVERDOSE	323	16	90.20	7.86	4.76	12.99	320	16	89.36	7.81	4.73	12.90
VACCINATION SITE RASH	2514	181	607.86	5.41	4.65	6.29	2512	180	611.11	5.45	4.68	6.34
PHARYNGEAL SWELLING	3891	290	925.91	5.23	4.64	5.89	3888	289	929.99	5.25	4.66	5.92
AMENORRHOEA	648	40	167.37	6.31	4.58	8.68	647	40	167.58	6.32	4.59	8.69
OPHTHALMIC MIGRAINE	108	3	34.06	14.02	4.45	44.16	107	3	33.77	13.93	4.42	43.86
TONGUE DISCOMFORT	573	37	144.91	6.03	4.33	8.41	573	37	145.42	6.05	4.34	8.43
HYPOMENORRHOEA	165	7	47.78	9.18	4.31	19.56	165	7	47.93	9.20	4.32	19.61
PRODUCT STORAGE ERROR	19962	1731	4440.25	4.49	4.28	4.72	19855	1731	4418.16	4.48	4.27	4.70
TINNITUS	11860	1017	2627.70	4.54	4.26	4.84	11832	1015	2631.19	4.55	4.27	4.85
BREAST MASS	384	24	98.16	6.23	4.13	9.41	382	24	97.76	6.21	4.11	9.39
APPENDICITIS	100	3	30.98	12.98	4.12	40.94	100	3	31.08	13.02	4.13	41.04
EXTRASYSTOLES	507	35	124.05	5.64	4.01	7.95	504	35	123.39	5.62	3.99	7.92
HEART RATE	124	5	36.13	9.66	3.95	23.62	124	5	36.24	9.68	3.96	23.67
PERICARDIAL EFFUSION	203	11	54.47	7.19	3.92	13.19	202	11	54.28	7.17	3.91	13.15
VENTRICULAR EXTRASYSTOLES	752	59	172.33	4.96	3.81	6.47	749	59	171.89	4.96	3.80	6.46
HAEMORRHAGE URINARY TRACT	106	4	31.25	10.32	3.80	28.01	106	4	31.35	10.35	3.81	28.08
PARANASAL SINUS DISCOMFORT	890	72	200.52	4.81	3.79	6.12	880	72	197.67	4.77	3.75	6.07
EPINEPHRINE	104	4	30.49	10.13	3.73	27.49	104	4	30.59	10.15	3.74	27.56
ADNEXA UTERI PAIN	130	6	36.45	8.44	3.72	19.13	130	6	36.57	8.46	3.73	19.18
BREAST FEEDING	102	4	29.73	9.93	3.66	26.97	102	4	29.82	9.96	3.67	27.04
TONGUE PRURITUS	462	35	107.55	5.14	3.65	7.25	462	35	107.96	5.15	3.66	7.27
ANGINA PECTORIS	876	74	192.16	4.61	3.64	5.84	873	73	193.48	4.67	3.68	5.93
ENERGY INCREASED	164	9	43.57	7.10	3.63	13.88	164	9	43.72	7.12	3.64	13.92
HEART RATE ABNORMAL	381	28	89.99	5.30	3.61	7.78	379	28	89.59	5.29	3.60	7.76
CARDIAC DISORDER	557	45	125.16	4.82	3.56	6.53	554	45	124.56	4.81	3.55	6.51
VACCINATION SITE DISCOMFORT	288	20	69.78	5.61	3.56	8.82	285	20	68.93	5.56	3.54	8.76
BRADYKINESIA	136	7	36.81	7.57	3.54	16.17	135	7	36.56	7.53	3.52	16.10
BODY TEMPERATURE ABNORMAL	159	9	41.70	6.88	3.52	13.47	159	9	41.85	6.90	3.52	13.50
EXPIRED PRODUCT ADMINISTERED	21487	2291	4107.33	3.65	3.50	3.81	21168	2275	4035.41	3.63	3.48	3.79
ANTICOAGULANT THERAPY	399	32	89.74	4.86	3.39	6.96	397	32	89.37	4.84	3.38	6.94
BLOOD GLUCOSE DECREASED	274	20	64.65	5.34	3.39	8.40	274	20	64.89	5.35	3.40	8.42
PRODUCT PREPARATION ISSUE	2307	234	446.66	3.84	3.36	4.39	2304	232	450.59	3.88	3.39	4.44
CLUSTER HEADACHE	117	6	31.55	7.59	3.34	17.25	117	6	31.66	7.61	3.35	17.29
CARDIOMEGALY	128	7	33.81	7.12	3.33	15.24	128	7	33.92	7.14	3.34	15.28
HYPERAESTHESIA TEETH	150	9	38.35	6.49	3.31	12.72	150	9	38.48	6.51	3.32	12.75
SITTING DISABILITY	127	7	33.43	7.07	3.30	15.12	127	7	33.55	7.08	3.31	15.16
HEAD DISCOMFORT	2773	292	521.23	3.70	3.28	4.17	2756	292	517.63	3.69	3.27	4.16
DYSPNOEA EXERTIONAL	772	72	158.28	4.18	3.28	5.32	764	71	157.67	4.20	3.29	5.36
OXYGEN SATURATION	80	3	23.33	10.39	3.28	32.89	80	3	23.41	10.41	3.29	32.97
COSTOCHONDRITIS	208	15	49.13	5.40	3.20	9.12	208	15	49.32	5.41	3.21	9.14
EAR DISCOMFORT	2393	259	439.05	3.60	3.17	4.09	2378	258	437.32	3.60	3.17	4.09
ARRHYTHMIA	725	72	141.77	3.92	3.08	5.00	722	72	141.32	3.92	3.07	4.99
MENOPAUSE	127	8	31.62	6.18	3.03	12.63	126	8	31.36	6.15	3.01	12.57
EUPHORIC MOOD	249	21	53.92	4.62	2.96	7.21	248	21	53.77	4.61	2.95	7.20
SUPRAVENTRICULAR EXTRASYSTOLES	202	16	45.26	4.92	2.96	8.18	202	16	45.43	4.93	2.96	8.20
COAGULOPATHY	83	4	22.54	8.08	2.96	22.04	82	4	22.23	8.00	2.93	21.84
BREAST DISCOMFORT	113	7	28.22	6.29	2.93	13.49	113	7	28.32	6.30	2.94	13.52
OCULAR DISCOMFORT	839	90	154.21	3.63	2.92	4.51	838	90	154.55	3.64	2.93	4.52
VACCINATION SITE HAEMORRHAGE	237	20	51.25	4.62	2.92	7.28	236	19	52.74	4.85	3.04	7.74
BREAST SWELLING	737	78	136.89	3.68	2.91	4.65	737	78	137.50	3.69	2.92	4.66
PULMONARY PAIN	438	43	86.01	3.97	2.90	5.43	434	43	84.97	3.94	2.88	5.39
SARS-COV-2 ANTIBODY TEST NEGATIVE	71	3	19.92	9.22	2.90	29.26	71	3	19.98	9.24	2.91	29.34
HEART RATE IRREGULAR	1560	180	269.48	3.38	2.89	3.94	1555	180	269.05	3.37	2.89	3.94
PERIORBITAL SWELLING	672	71	124.91	3.69	2.89	4.71	671	70	126.60	3.74	2.93	4.79
ATRIAL FIBRILLATION	1208	137	211.77	3.43	2.88	4.10	1203	135	213.92	3.48	2.91	4.16
DRAINAGE	168	13	37.98	5.03	2.86	8.85	166	13	37.40	4.99	2.84	8.77
PANIC ATTACK	1119	129	193.10	3.38	2.82	4.05	1117	129	193.32	3.38	2.82	4.06
BLOOD URINE PRESENT	530	56	98.30	3.69	2.80	4.85	528	56	98.04	3.68	2.80	4.85
PALPITATIONS	12837	1706	1949.22	2.93	2.79	3.08	12821	1705	1955.35	2.94	2.79	3.09
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION	8978	1186	1364.99	2.95	2.78	3.13	8942	1178	1370.72	2.96	2.79	3.15
ATRIAL FLUTTER	116	8	27.57	5.65	2.76	11.56	115	8	27.30	5.61	2.74	11.49
HYPERTENSION	5080	664	777.07	2.98	2.75	3.23	5071	662	780.72	2.99	2.76	3.24
HORMONE LEVEL ABNORMAL	87	5	22.18	6.78	2.75	16.69	86	5	21.89	6.72	2.73	16.55
BLOOD GLUCOSE ABNORMAL	76	4	19.91	7.40	2.71	20.22	76	4	19.98	7.42	2.71	20.28
BREAST TENDERNESS	518	57	92.73	3.54	2.69	4.65	518	57	93.15	3.55	2.70	4.66
LYMPHADENOPATHY	21228	2984	3050.32	2.77	2.67	2.88	21206	2982	3062.28	2.78	2.67	2.88
BLOOD PRESSURE ABNORMAL	372	39	69.16	3.72	2.67	5.17	370	39	68.78	3.70	2.66	5.15
VAGINAL HAEMORRHAGE	1385	173	220.85	3.12	2.66	3.65	1385	173	221.94	3.13	2.67	3.66
SINUS PAIN	470	52	83.64	3.52	2.64	4.69	467	52	83.00	3.51	2.63	4.67
THYROIDITIS	74	4	19.16	7.21	2.63	19.71	73	4	18.86	7.13	2.60	19.50
EPISTAXIS	1723	223	264.70	3.01	2.62	3.46	1718	223	264.41	3.01	2.62	3.46
SUPRAVENTRICULAR TACHYCARDIA	294	30	55.69	3.82	2.62	5.56	293	30	55.58	3.81	2.62	5.55
PULMONARY MASS	119	9	26.95	5.15	2.62	10.14	116	9	25.97	5.03	2.55	9.92
SENSITIVE SKIN	1271	161	199.57	3.07	2.61	3.62	1271	159	203.25	3.12	2.65	3.68

VACCINATION SITE DISCOLOURATION	331	35	60.99	3.68	2.60	5.22	331	35	61.26	3.69	2.61	5.23
URTICARIA CHRONIC	170	15	35.42	4.41	2.60	7.48	169	15	35.21	4.40	2.59	7.46
SLEEP DEFICIT	82	5	20.33	6.39	2.59	15.76	82	5	20.40	6.40	2.60	15.79
BLOOD GLUCOSE INCREASED	742	90	121.47	3.21	2.58	4.00	742	90	122.06	3.22	2.59	4.01
TACHYCARDIA	4795	670	677.52	2.79	2.57	3.02	4788	669	680.18	2.79	2.58	3.03
MIGRAINE	7698	1098	1064.67	2.73	2.56	2.91	7681	1096	1067.58	2.74	2.57	2.91
INCREASED APPETITE	81	5	19.96	6.31	2.56	15.57	81	5	20.03	6.33	2.56	15.61
CROHN'S DISEASE	141	12	29.92	4.58	2.54	8.25	141	12	30.04	4.59	2.54	8.27
FIBRIN D DIMER INCREASED	71	4	18.05	6.91	2.52	18.93	71	4	18.11	6.93	2.53	18.98
EYE HAEMORRHAGE	264	28	48.33	3.67	2.49	5.42	264	28	48.55	3.68	2.49	5.43
PHARYNGEAL HYPOAESTHESIA	441	52	73.88	3.30	2.48	4.40	441	52	74.23	3.31	2.48	4.41
DIVERTICULITIS	170	16	33.85	4.14	2.48	6.91	168	16	33.29	4.10	2.46	6.85
BREAST DISCHARGE	61	3	16.15	7.92	2.48	25.24	61	3	16.21	7.94	2.49	25.30
UTERINE SPASM	121	10	26.02	4.71	2.47	8.98	121	10	26.12	4.72	2.48	9.00
MYOCARDITIS	582	72	93.16	3.15	2.46	4.02	580	72	92.96	3.15	2.46	4.02
APHASIA	961	127	143.69	2.95	2.45	3.55	958	127	143.46	2.95	2.45	3.54
PNEUMONITIS	120	10	25.66	4.67	2.45	8.91	120	10	25.76	4.69	2.46	8.93
PERICARDITIS	769	100	116.91	3.00	2.43	3.69	766	100	116.53	2.99	2.43	3.68
SINUS TACHYCARDIA	337	39	57.27	3.37	2.42	4.69	337	39	57.54	3.37	2.42	4.70
BREAST ENLARGEMENT	68	4	16.93	6.62	2.42	18.15	68	4	16.99	6.64	2.42	18.20
LYMPH NODE PAIN	5228	783	675.04	2.60	2.41	2.80	5219	783	676.10	2.60	2.41	2.81
BLOOD POTASSIUM DECREASED	59	3	15.40	7.66	2.40	24.43	59	3	15.45	7.68	2.41	24.50
SKIN SENSITISATION	171	17	32.67	3.92	2.38	6.45	172	17	33.16	3.95	2.40	6.50
VACCINATION FAILURE	2494	367	328.18	2.65	2.37	2.95	2274	365	265.51	2.43	2.18	2.72
CHEST PAIN	15662	2486	1889.12	2.45	2.35	2.56	15633	2485	1892.82	2.46	2.36	2.56
TONGUE ERYTHEMA	123	11	25.13	4.36	2.35	8.07	123	11	25.23	4.37	2.36	8.09
NASAL DRYNESS	115	10	23.88	4.48	2.35	8.55	115	10	23.98	4.49	2.35	8.57
SWELLING OF EYELID	1070	150	149.18	2.78	2.34	3.30	1068	150	149.35	2.78	2.34	3.30
COLITIS	152	15	29.11	3.95	2.32	6.71	152	15	29.23	3.96	2.33	6.72
HOT FLUSH	3327	521	401.72	2.49	2.27	2.73	3321	520	403.44	2.49	2.27	2.73
CEREBROVASCULAR ACCIDENT	431	56	65.20	3.00	2.27	3.96	427	56	64.23	2.98	2.25	3.93
PLATELET COUNT DECREASED	185	20	33.04	3.60	2.27	5.71	185	20	33.19	3.61	2.28	5.73
AUTONOMIC NERVOUS SYSTEM IMBALANCE	88	7	19.10	4.90	2.27	10.57	88	7	19.17	4.91	2.27	10.60
CARDIOVERSION	88	7	19.10	4.90	2.27	10.57	87	7	18.81	4.85	2.25	10.48
IMMUNE THROMBOCYTOPENIA	72	5	16.65	5.61	2.27	13.88	72	5	16.72	5.62	2.27	13.92
VENTRICULAR TACHYCARDIA	72	5	16.65	5.61	2.27	13.88	72	5	16.72	5.62	2.27	13.92
CONDITION AGGRAVATED	12232	2025	1374.46	2.35	2.25	2.47	12200	2020	1379.11	2.36	2.25	2.47
PARAESTHESIA ORAL	6064	983	697.97	2.40	2.25	2.57	6057	982	701.29	2.41	2.25	2.58
FEAR	737	104	101.62	2.76	2.25	3.39	733	103	102.15	2.78	2.26	3.41
NIPPLE PAIN	118	11	23.37	4.18	2.25	7.75	118	11	23.47	4.19	2.26	7.77
BLOOD PRESSURE FLUCTUATION	333	42	51.85	3.09	2.24	4.26	333	42	52.11	3.10	2.25	4.27
BOWEL MOVEMENT IRREGULARITY	197	22	34.24	3.49	2.24	5.42	197	22	34.40	3.50	2.25	5.43
MEMORY IMPAIRMENT	1320	199	167.41	2.58	2.23	3.00	1314	198	167.71	2.59	2.23	3.01
HYPOXIA	146	15	27.03	3.79	2.23	6.45	146	15	27.15	3.80	2.23	6.47
PSYCHOTIC DISORDER	71	5	16.29	5.53	2.23	13.70	71	5	16.35	5.54	2.24	13.73
FRUSTRATION TOLERANCE DECREASED	109	10	21.76	4.25	2.22	8.11	109	10	21.86	4.26	2.23	8.13
VERTIGO	6842	1131	764.37	2.36	2.21	2.51	6831	1130	767.02	2.36	2.22	2.51
PRODUCT ADMINISTRATION ERROR	787	114	104.97	2.69	2.21	3.27	784	114	104.62	2.69	2.21	3.27
VACCINATION SITE INDURATION	1184	179	149.46	2.58	2.20	3.01	1182	179	149.71	2.58	2.20	3.02
VACCINATION SITE REACTION	1266	194	156.85	2.54	2.19	2.96	1260	194	155.95	2.54	2.18	2.95
NEOPLASM	54	3	13.54	7.01	2.19	22.42	54	3	13.59	7.03	2.20	22.48
OXYGEN SATURATION DECREASED	678	98	90.57	2.69	2.18	3.33	673	97	90.73	2.71	2.19	3.35
ALOPECIA	1266	195	155.70	2.53	2.17	2.94	1262	194	156.55	2.54	2.18	2.95
ANXIETY	6914	1174	738.98	2.29	2.16	2.44	6898	1169	744.44	2.30	2.17	2.45
BREAST PAIN	1883	301	219.67	2.44	2.16	2.75	1875	301	218.63	2.43	2.15	2.75
HYPOACUSIS	1127	173	139.18	2.54	2.16	2.98	1126	172	140.84	2.56	2.18	3.00
COGNITIVE DISORDER	566	81	76.46	2.72	2.16	3.43	564	81	76.25	2.72	2.15	3.43
BONE SWELLING	61	4	14.36	5.94	2.16	16.33	61	4	14.41	5.95	2.17	16.37
AUTOSCOPY	76	6	16.43	4.93	2.15	11.33	77	6	16.85	5.01	2.18	11.50
VACCINATION SITE WARMTH	3284	555	351.59	2.30	2.11	2.52	3282	554	354.34	2.31	2.11	2.53
EXERCISE TOLERANCE DECREASED	473	68	63.38	2.71	2.10	3.49	467	68	61.87	2.68	2.08	3.46
ASTHENOPIA	344	47	48.91	2.85	2.10	3.87	344	47	49.17	2.86	2.11	3.88
DISORGANISED SPEECH	67	5	14.84	5.22	2.10	12.95	67	5	14.90	5.23	2.11	12.98
DYSGEUSIA	4092	703	426.69	2.27	2.09	2.46	4085	703	427.47	2.27	2.09	2.46
SINUS OPERATION	229	29	35.24	3.08	2.09	4.53	222	29	33.15	2.99	2.03	4.40
HEPATIC PAIN	88	8	17.50	4.28	2.08	8.83	87	8	17.22	4.25	2.06	8.76
THYROID MASS	81	7	16.60	4.51	2.08	9.75	81	7	16.67	4.52	2.09	9.78
MOUTH SWELLING	860	135	102.58	2.48	2.07	2.97	859	135	102.89	2.48	2.07	2.98
FEAR OF INJECTION	221	28	33.96	3.07	2.07	4.55	221	28	34.13	3.08	2.08	4.57
VACCINATION SITE SWELLING	5199	918	517.50	2.21	2.06	2.37	5195	918	519.86	2.21	2.06	2.37
DEAFNESS	1046	168	120.68	2.42	2.06	2.85	1043	167	121.64	2.44	2.07	2.87
HYPOGEUSIA	128	14	22.35	3.56	2.05	6.18	128	14	22.46	3.57	2.06	6.20
INJECTION SITE LYMPHADENOPATHY	121	13	21.42	3.63	2.05	6.42	121	13	21.52	3.63	2.05	6.44
MENIERE'S DISEASE	65	5	14.12	5.06	2.04	12.57	65	5	14.18	5.08	2.04	12.61
HYPOAESTHESIA ORAL	4264	757	419.58	2.19	2.03	2.37	4262	757	421.86	2.20	2.04	2.37
PSORIATIC ARTHROPATHY	93	9	17.71	4.02	2.03	7.98	93	9	17.79	4.03	2.04	8.00
METAMORPHOPSIA	113	12	20.15	3.67	2.02	6.65	112	12	19.90	3.64	2.01	6.61
BLOOD GLUCOSE FLUCTUATION	50	3	12.06	6.49	2.02	20.81	50	3	12.11	6.51	2.03	20.86
LUNG DISORDER	256	35	36.17	2.85	2.00	4.06	255	35	36.04	2.84	2.00	4.05
IMPAIRED QUALITY OF LIFE	71	6	14.65	4.61	2.00	10.60	69	6	14.00	4.49	1.95	10.34
VEIN DISORDER	118	13	20.41	3.54	1.99	6.27	118	12	21.95	3.84	2.12	6.95

GOITRE	130	15	21.62	3.38	1.98	5.76	128	15	21.05	3.33	1.95	5.69
NEW DAILY PERSISTENT HEADACHE	56	4	12.54	5.45	1.98	15.04	56	4	12.59	5.47	1.98	15.07
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME	136	16	22.23	3.31	1.97	5.56	135	16	22.01	3.29	1.96	5.53
VITREOUS FLOATERS	459	71	55.58	2.52	1.96	3.23	459	71	55.91	2.52	1.97	3.24
TESTICULAR PAIN	179	23	26.93	3.03	1.96	4.68	179	23	27.06	3.04	1.97	4.69
MYOCARDIAL INFARCTION	262	37	35.57	2.76	1.95	3.89	260	37	35.14	2.74	1.94	3.87
GINGIVAL BLEEDING	196	26	28.51	2.94	1.95	4.42	196	26	28.66	2.94	1.96	4.43
SEDATION	96	10	17.26	3.74	1.95	7.17	96	10	17.34	3.75	1.95	7.19
HYPERACUSIS	564	91	64.25	2.41	1.93	3.01	562	91	64.05	2.41	1.93	3.01
MOOD SWINGS	176	23	25.96	2.98	1.93	4.60	176	23	26.10	2.99	1.93	4.61
MENTAL FATIGUE	68	6	13.59	4.41	1.92	10.17	67	6	13.29	4.36	1.89	10.05
SEIZURE	2671	494	242.42	2.11	1.91	2.32	2669	492	245.54	2.12	1.92	2.33
MOVEMENT DISORDER	1473	264	141.44	2.17	1.91	2.48	1470	264	141.58	2.17	1.91	2.48
EAR DISORDER	144	18	22.16	3.12	1.91	5.09	141	18	21.30	3.06	1.87	5.00
COLITIS MICROSCOPIC	61	5	12.69	4.75	1.91	11.82	61	5	12.75	4.76	1.91	11.85
DISTURBANCE IN ATTENTION	2008	368	185.19	2.13	1.90	2.37	2003	368	185.13	2.13	1.90	2.37
TENSION HEADACHE	339	52	41.35	2.54	1.90	3.40	339	52	41.60	2.55	1.90	3.41
PREGNANCY	237	34	31.46	2.71	1.90	3.89	236	34	31.32	2.71	1.89	3.88
HYPERTHYROIDISM	149	19	22.47	3.05	1.89	4.92	149	19	22.58	3.06	1.90	4.94
GAIT INABILITY	1419	257	133.57	2.15	1.88	2.46	1414	256	134.11	2.16	1.89	2.46
VASCULAR PAIN	99	11	16.85	3.51	1.88	6.54	99	11	16.93	3.51	1.88	6.55
FEEDING DISORDER	1163	209	110.93	2.17	1.87	2.51	1158	208	111.31	2.17	1.88	2.52
INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION	53	4	11.46	5.16	1.87	14.26	52	4	11.14	5.08	1.84	14.03
RENAL PAIN	569	96	60.30	2.31	1.86	2.87	569	96	60.68	2.31	1.86	2.87
ABNORMAL DREAMS	494	82	53.69	2.35	1.86	2.96	491	82	53.16	2.34	1.85	2.95
HAEMATOCHYZIA	398	64	45.36	2.42	1.86	3.15	396	64	45.05	2.42	1.86	3.15
THYROIDITIS SUBACUTE	46	3	10.60	5.97	1.86	19.20	46	3	10.64	5.99	1.86	19.25
DEPRESSED MOOD	423	69	47.18	2.39	1.85	3.08	421	69	46.89	2.38	1.85	3.07
CONJUNCTIVAL HAEMORRHAGE	110	13	17.74	3.30	1.85	5.86	110	13	17.82	3.30	1.86	5.87
HYPOAESTHESIA EYE	151	20	21.82	2.94	1.84	4.69	151	20	21.93	2.95	1.85	4.70
JAW DISORDER	103	12	16.79	3.34	1.84	6.08	103	12	16.87	3.35	1.84	6.09
HYPOSMIA	91	10	15.57	3.54	1.84	6.81	91	10	15.64	3.55	1.85	6.83
IRREGULAR BREATHING	59	5	11.99	4.60	1.84	11.45	59	5	12.04	4.61	1.85	11.48
TRANSIENT ISCHAEMIC ATTACK	235	35	29.65	2.62	1.83	3.73	235	34	31.01	2.70	1.88	3.87
UNRESPONSIVE TO STIMULI	2427	470	200.31	2.01	1.82	2.22	2421	469	201.17	2.02	1.83	2.22
EAR INFECTION	401	66	44.05	2.37	1.82	3.07	399	66	43.75	2.36	1.82	3.06
GENERAL PHYSICAL CONDITION ABNORMAL	71	7	13.11	3.95	1.82	8.59	71	7	13.17	3.96	1.82	8.61
AMNESIA	989	182	90.04	2.12	1.81	2.48	988	182	90.40	2.12	1.81	2.48
INCORRECT PRODUCT FORMULATION ADMINISTERED	699	124	67.99	2.20	1.81	2.66	699	124	68.45	2.20	1.82	2.66
MUSCLE DISCOMFORT	182	26	24.11	2.73	1.81	4.11	181	25	25.16	2.83	1.86	4.29
FACIAL SPASM	83	9	14.30	3.59	1.81	7.15	83	9	14.36	3.60	1.81	7.16
ORAL DISCOMFORT	748	135	70.51	2.16	1.80	2.59	747	136	69.74	2.14	1.79	2.57
PSORIASIS	478	82	49.12	2.27	1.80	2.87	475	82	48.60	2.26	1.79	2.86
LIP PRURITUS	360	59	39.75	2.38	1.80	3.13	360	58	41.09	2.42	1.84	3.20
OVARIAN CYST	113	14	17.38	3.14	1.80	5.48	113	14	17.47	3.15	1.81	5.49
BLOOD PRESSURE SYSTOLIC	107	13	16.75	3.21	1.80	5.70	105	13	16.18	3.15	1.77	5.61
INCREASED DISCHARGE	101	12	16.13	3.28	1.80	5.96	99	12	15.55	3.22	1.77	5.86
VESTIBULAR DISORDER	64	6	12.19	4.15	1.80	9.59	63	6	11.90	4.10	1.77	9.47
SKIN SWELLING	691	124	65.79	2.17	1.79	2.63	689	122	67.69	2.21	1.82	2.67
DRY THROAT	843	155	76.77	2.12	1.78	2.51	841	155	76.77	2.12	1.79	2.51
HYPERVENTILATION	595	106	57.32	2.19	1.78	2.69	595	106	57.71	2.19	1.78	2.69
BRADYCARDIA	370	62	39.41	2.32	1.78	3.04	368	62	39.09	2.32	1.77	3.03
RAYNAUD'S PHENOMENON	167	24	21.89	2.71	1.77	4.16	165	24	21.39	2.68	1.75	4.12
MOUTH ULCERATION	330	55	35.39	2.34	1.76	3.11	329	55	35.33	2.34	1.76	3.11
BASEDOW'S DISEASE	93	11	14.85	3.29	1.76	6.15	93	11	14.93	3.30	1.77	6.17
COMMUNICATION DISORDER	69	7	12.43	3.84	1.76	8.35	69	7	12.48	3.85	1.77	8.37
BLOOD PRESSURE DIASTOLIC	50	4	10.39	4.87	1.76	13.48	50	4	10.43	4.88	1.76	13.51
RETINAL VEIN OCCLUSION	50	4	10.39	4.87	1.76	13.48	50	4	10.43	4.88	1.76	13.51
VACCINATION SITE BRUISING	511	91	49.17	2.19	1.75	2.73	511	91	49.50	2.19	1.75	2.74
HORDEOLUM	149	21	19.95	2.76	1.75	4.36	149	21	20.06	2.77	1.75	4.37
REFUSAL OF TREATMENT BY PATIENT	109	14	16.09	3.03	1.74	5.29	109	14	16.17	3.04	1.74	5.30
BLEPHAROSPASM	519	94	48.39	2.15	1.73	2.68	518	94	48.45	2.15	1.73	2.68
EAR SWELLING	486	87	46.28	2.18	1.73	2.73	484	87	46.05	2.17	1.73	2.73
VASODILATATION	125	17	17.37	2.86	1.73	4.75	125	17	17.46	2.87	1.73	4.77
ANKYLOSING SPONDYLITIS	43	3	9.51	5.58	1.73	17.99	42	3	9.19	5.47	1.69	17.64
LYMPHOEDEMA	262	43	28.67	2.37	1.72	3.28	262	43	28.85	2.38	1.72	3.28
ATELECTASIS	85	10	13.58	3.31	1.72	6.37	85	10	13.64	3.32	1.72	6.39
VACCINATION SITE DISCHARGE	49	4	10.03	4.77	1.72	13.22	49	4	10.07	4.78	1.73	13.25
EATING DISORDER	345	60	34.43	2.24	1.70	2.95	342	60	33.82	2.23	1.69	2.93
APHTHOUS ULCER	300	51	31.06	2.29	1.70	3.08	300	51	31.26	2.30	1.71	3.09
PELVIC PAIN	382	68	36.61	2.19	1.69	2.83	381	68	36.59	2.19	1.69	2.83
BODY TEMPERATURE FLUCTUATION	232	38	25.39	2.38	1.69	3.35	231	38	25.26	2.37	1.68	3.35
BLADDER PAIN	78	9	12.63	3.38	1.69	6.73	77	9	12.36	3.34	1.67	6.66
SLEEP TERROR	42	3	9.15	5.45	1.69	17.59	42	3	9.19	5.47	1.69	17.64
RECTAL HAEMORRHAGE	169	26	20.16	2.53	1.68	3.83	169	26	20.28	2.54	1.68	3.84
DENTAL DISCOMFORT	54	5	10.24	4.21	1.68	10.51	54	5	10.28	4.22	1.69	10.54
WHITE BLOOD CELL COUNT DECREASED	71	8	11.68	3.46	1.66	7.18	71	8	11.74	3.47	1.67	7.20
MOTION SICKNESS	172	27	19.93	2.48	1.65	3.72	172	27	20.05	2.49	1.66	3.73

APPENDICECTOMY	59	6	10.48	3.83	1.65	8.87	59	6	10.52	3.84	1.66	8.89
HYPERTENSIVE CRISIS	47	4	9.33	4.58	1.65	12.70	47	4	9.37	4.59	1.65	12.73
VITILIGO	70	8	11.35	3.41	1.64	7.08	67	8	10.42	3.27	1.57	6.81
GOUT	364	67	32.70	2.12	1.63	2.75	362	67	32.40	2.11	1.63	2.74
HUNGER	185	30	20.43	2.40	1.63	3.53	184	30	20.27	2.39	1.63	3.52
GENERALISED TONIC-CLONIC SEIZURE	222	38	22.54	2.28	1.61	3.21	222	38	22.69	2.28	1.62	3.22
NONINFECTIVE GINGIVITIS	85	11	12.26	3.01	1.61	5.64	83	11	11.69	2.95	1.57	5.53
THROMBOPHLEBITIS	40	3	8.43	5.19	1.61	16.79	40	3	8.47	5.21	1.61	16.83
NEPHROLITHIASIS	210	36	21.23	2.27	1.60	3.24	210	36	21.37	2.28	1.60	3.24
UTERINE LEIOMYOMA	90	12	12.58	2.92	1.60	5.33	90	12	12.65	2.93	1.60	5.35
VERTIGO POSITIONAL	262	47	24.55	2.17	1.59	2.96	262	47	24.72	2.18	1.60	2.97
HEPATIC ENZYME INCREASED	95	13	12.91	2.85	1.59	5.08	95	13	12.98	2.85	1.60	5.09
HAEMATURIA	244	44	22.60	2.16	1.57	2.98	244	44	22.76	2.17	1.57	2.98
ANAL INCONTINENCE	183	31	18.80	2.30	1.57	3.36	182	31	18.64	2.29	1.57	3.35
MENTAL DISORDER	168	28	17.68	2.34	1.57	3.49	167	28	17.51	2.33	1.56	3.47
GASTRITIS	163	27	17.31	2.35	1.56	3.53	163	27	17.42	2.36	1.57	3.54
WHITE BLOOD CELL COUNT INCREASED	98	14	12.63	2.73	1.56	4.77	98	14	12.71	2.73	1.56	4.78
VACCINATION SITE VESICLES	93	13	12.29	2.79	1.56	4.98	91	13	11.74	2.73	1.53	4.89
TRIGGER FINGER	118	18	14.04	2.55	1.55	4.19	118	18	14.12	2.56	1.56	4.20
LOWER RESPIRATORY TRACT CONGESTION	77	10	10.99	3.00	1.55	5.80	73	10	9.79	2.85	1.47	5.52
FEELING DRUNK	308	59	25.42	2.03	1.54	2.69	308	59	25.61	2.04	1.54	2.69
TYPE IV HYPERSENSITIVITY REACTION	127	20	14.46	2.47	1.54	3.96	127	20	14.55	2.48	1.55	3.97
THERMAL BURN	92	13	11.98	2.76	1.54	4.93	91	13	11.74	2.73	1.53	4.89
POOR PERIPHERAL CIRCULATION	87	12	11.65	2.82	1.54	5.16	87	12	11.71	2.83	1.55	5.18
YAWNING	66	8	10.04	3.21	1.54	6.69	66	8	10.09	3.22	1.55	6.71
RESPIRATORY SYMPTOM	169	29	16.93	2.27	1.53	3.37	166	29	16.20	2.24	1.51	3.32
DISSOCIATION	121	19	13.80	2.48	1.53	4.02	121	19	13.89	2.49	1.53	4.03
IRRITABLE BOWEL SYNDROME	172	30	16.75	2.23	1.52	3.29	171	30	16.58	2.23	1.51	3.28
VACCINATION SITE JOINT PAIN	38	3	7.72	4.93	1.52	15.98	38	3	7.76	4.95	1.53	16.02
SUICIDAL IDEATION	204	37	18.58	2.15	1.51	3.05	204	37	18.71	2.15	1.52	3.06
SKIN ODOUR ABNORMAL	79	11	10.38	2.80	1.49	5.26	78	11	10.13	2.77	1.47	5.20
BREAST INFLAMMATION	48	5	8.19	3.74	1.49	9.39	48	5	8.23	3.75	1.49	9.42
MAST CELL ACTIVATION SYNDROME	48	5	8.19	3.74	1.49	9.39	47	5	7.89	3.67	1.46	9.23
CARDIAC MURMUR	108	17	12.20	2.47	1.48	4.13	108	17	12.27	2.48	1.49	4.14
PULMONARY OEDEMA	93	14	11.12	2.59	1.48	4.54	93	14	11.19	2.59	1.48	4.55
HIDRADENITIS	37	3	7.37	4.80	1.48	15.58	37	3	7.40	4.82	1.48	15.62
VITAMIN D DECREASED	37	3	7.37	4.80	1.48	15.58	37	3	7.40	4.82	1.48	15.62
LIP ERYTHEMA	139	24	13.66	2.26	1.46	3.48	139	24	13.75	2.26	1.47	3.49
GLOSSITIS	133	23	13.00	2.25	1.45	3.51	133	23	13.09	2.26	1.45	3.51
COLITIS ULCERATIVE	129	22	12.91	2.28	1.45	3.59	128	22	12.71	2.27	1.45	3.57
MIDDLE EAR EFFUSION	190	36	15.82	2.06	1.44	2.94	189	36	15.67	2.05	1.44	2.93
SEASONAL ALLERGY	150	27	13.70	2.16	1.44	3.26	150	27	13.79	2.17	1.44	3.27
LICHEN PLANUS	105	17	11.33	2.41	1.44	4.02	100	17	9.98	2.30	1.37	3.84
RED BLOOD CELL SEDIMENTATION RATE INCREASED	36	3	7.02	4.67	1.44	15.18	36	3	7.05	4.69	1.44	15.21
VULVOVAGINAL PAIN	109	18	11.41	2.36	1.43	3.88	109	18	11.49	2.36	1.44	3.89
FOOD AVERSION	41	4	7.25	3.99	1.43	11.14	41	4	7.29	4.00	1.43	11.17
VARICOSE VEIN	94	15	10.31	2.44	1.42	4.21	93	15	10.08	2.42	1.40	4.18
ALOPECIA AREATA	103	17	10.76	2.36	1.41	3.94	102	17	10.54	2.34	1.40	3.91
MASTITIS	98	16	10.39	2.39	1.41	4.05	98	16	10.45	2.39	1.41	4.06
ORTHOSTATIC HYPOTENSION	129	23	11.91	2.18	1.40	3.40	129	23	11.99	2.19	1.41	3.41
RENAL DISORDER	111	19	10.94	2.28	1.40	3.70	110	19	10.74	2.26	1.39	3.68
AUTOIMMUNE THYROIDITIS	93	15	10.02	2.41	1.40	4.17	92	15	9.79	2.39	1.39	4.13
ATRIAL TACHYCARDIA	35	3	6.67	4.54	1.40	14.77	35	3	6.70	4.56	1.40	14.81
PLEURISY	171	33	13.63	2.02	1.39	2.93	171	33	13.74	2.02	1.39	2.94
PSYCHOMOTOR HYPERACTIVITY	97	16	10.10	2.36	1.39	4.01	97	16	10.17	2.37	1.39	4.02
PARANOIA	88	14	9.65	2.45	1.39	4.30	88	14	9.71	2.45	1.40	4.31
EYE CONTUSION	109	19	10.39	2.23	1.37	3.64	109	19	10.46	2.24	1.38	3.65
STRIDOR	109	19	10.39	2.23	1.37	3.64	109	19	10.46	2.24	1.38	3.65
KIDNEY INFECTION	91	15	9.45	2.36	1.37	4.08	91	15	9.51	2.37	1.37	4.09
LIVER DISORDER	54	7	7.49	3.00	1.37	6.60	54	7	7.53	3.01	1.37	6.62
CIRCUMORAL SWELLING	39	4	6.58	3.80	1.36	10.63	39	4	6.61	3.81	1.36	10.65
ANGIOPATHY	34	3	6.33	4.41	1.36	14.37	34	3	6.35	4.43	1.36	14.41
BLADDER DISCOMFORT	34	3	6.33	4.41	1.36	14.37	34	3	6.35	4.43	1.36	14.41
ORAL LICHEN PLANUS	34	3	6.33	4.41	1.36	14.37	33	3	6.01	4.30	1.32	14.00
BUNDLE BRANCH BLOCK RIGHT	72	11	8.27	2.55	1.35	4.81	71	11	8.02	2.52	1.34	4.76
LIP DISORDER	115	21	10.07	2.13	1.34	3.40	115	21	10.14	2.14	1.34	3.40
UTERINE HAEMORRHAGE	76	12	8.34	2.47	1.34	4.53	76	12	8.39	2.47	1.35	4.55
SMALL FIBRE NEUROPATHY	80	13	8.42	2.40	1.33	4.31	80	13	8.47	2.40	1.34	4.32
CONTRACEPTION	43	5	6.53	3.35	1.33	8.46	43	5	6.57	3.36	1.33	8.48
HANGOVER	92	16	8.71	2.24	1.32	3.81	92	16	8.77	2.25	1.32	3.82
HOSPITALISATION	38	4	6.24	3.70	1.32	10.37	38	4	6.27	3.71	1.32	10.39
GALLBLADDER DISORDER	52	7	6.86	2.89	1.31	6.37	52	7	6.90	2.90	1.32	6.39
CUTANEOUS VASCULITIS	33	3	5.98	4.28	1.31	13.97	33	3	6.01	4.30	1.32	14.00
LIBIDO DECREASED	33	3	5.98	4.28	1.31	13.97	32	3	5.67	4.16	1.28	13.60
THIRST DECREASED	33	3	5.98	4.28	1.31	13.97	33	3	6.01	4.30	1.32	14.00
FAECES SOFT	91	16	8.44	2.22	1.30	3.77	90	16	8.22	2.20	1.29	3.74
DYSPHEMIA	115	22	9.15	2.04	1.29	3.21	114	22	8.97	2.02	1.28	3.19
PULMONARY FIBROSIS	42	5	6.21	3.27	1.29	8.27	42	5	6.24	3.28	1.30	8.29
FEELING OF DESPAIR	55	8	6.60	2.68	1.28	5.62	55	8	6.64	2.68	1.28	5.64

WRONG TECHNIQUE IN DEVICE USAGE PROCESS	37	4	5.91	3.60	1.28	10.11	37	4	5.94	3.61	1.29	10.13
APATHY	93	17	8.01	2.13	1.27	3.57	91	17	7.55	2.09	1.25	3.51
APPETITE DISORDER	89	16	7.90	2.17	1.27	3.69	88	16	7.69	2.15	1.26	3.66
NASAL PRURITUS	85	15	7.78	2.21	1.27	3.82	85	15	7.84	2.21	1.28	3.83
ACNE CYSTIC	32	3	5.64	4.15	1.27	13.57	32	3	5.67	4.16	1.28	13.60
CYSTITIS INTERSTITIAL	32	3	5.64	4.15	1.27	13.57	30	3	4.99	3.90	1.19	12.79
PARANASAL SINUS INFLAMMATION	32	3	5.64	4.15	1.27	13.57	32	3	5.67	4.16	1.28	13.60
SLEEP PARALYSIS	32	3	5.64	4.15	1.27	13.57	32	3	5.67	4.16	1.28	13.60
SPINAL STENOSIS	32	3	5.64	4.15	1.27	13.57	32	3	5.67	4.16	1.28	13.60
NAIL DISCOLOURATION	84	15	7.51	2.18	1.26	3.78	83	15	7.30	2.16	1.25	3.74
PALATAL SWELLING	76	13	7.30	2.28	1.26	4.10	76	13	7.35	2.28	1.27	4.11
HYPOTHERMIA	50	7	6.25	2.78	1.26	6.14	50	7	6.29	2.79	1.26	6.15
GENITAL PAIN	41	5	5.89	3.19	1.26	8.08	41	5	5.92	3.20	1.27	8.10
OESOPHAGITIS	54	8	6.30	2.63	1.25	5.52	54	8	6.34	2.64	1.25	5.54
INNER EAR DISORDER	45	6	5.91	2.92	1.25	6.85	45	6	5.94	2.93	1.25	6.86
SKIN TEXTURE ABNORMAL	62	10	6.45	2.41	1.24	4.71	62	10	6.50	2.42	1.24	4.72
SPLENOMEGALY	62	10	6.45	2.41	1.24	4.71	62	10	6.50	2.42	1.24	4.72
ATRIOVENTRICULAR BLOCK	40	5	5.57	3.12	1.23	7.89	40	5	5.60	3.12	1.23	7.91
ATYPICAL PNEUMONIA	31	3	5.30	4.02	1.23	13.16	31	3	5.33	4.03	1.23	13.20
RENAL IMPAIRMENT	89	17	6.98	2.04	1.21	3.43	89	17	7.03	2.04	1.22	3.43
GENITAL ULCERATION	35	4	5.26	3.41	1.21	9.59	35	4	5.29	3.42	1.21	9.61
LAZINESS	35	4	5.26	3.41	1.21	9.59	35	4	5.29	3.42	1.21	9.61
CEREBRAL DISORDER	64	11	5.99	2.27	1.20	4.30	64	11	6.04	2.27	1.20	4.31
INJECTION SITE MUSCLE WEAKNESS	64	11	5.99	2.27	1.20	4.30	64	11	6.04	2.27	1.20	4.31
SINUS ARRHYTHMIA	60	10	5.89	2.34	1.20	4.56	60	10	5.93	2.34	1.20	4.58
CARDITIS	39	5	5.26	3.04	1.20	7.71	39	5	5.29	3.05	1.20	7.73
PHANTOM LIMB SYNDROME	30	3	4.97	3.89	1.19	12.76	30	3	4.99	3.90	1.19	12.79
ERYTHEMA NODOSUM	71	13	5.96	2.13	1.18	3.84	71	13	6.00	2.13	1.18	3.85
TONGUE ERUPTION	71	13	5.96	2.13	1.18	3.84	71	13	6.00	2.13	1.18	3.85
LIVER FUNCTION TEST INCREASED	34	4	4.94	3.31	1.17	9.33	33	4	4.64	3.22	1.14	9.09
MUSCLE STRENGTH ABNORMAL	34	4	4.94	3.31	1.17	9.33	34	4	4.96	3.32	1.18	9.35
MOUTH HAEMORRHAGE	66	12	5.57	2.14	1.16	3.96	66	12	5.61	2.15	1.16	3.97
PLANTAR FASCIITIS	58	10	5.34	2.26	1.15	4.42	56	10	4.84	2.19	1.12	4.29
WALKING DISABILITY	29	3	4.63	3.76	1.15	12.36	29	3	4.66	3.77	1.15	12.39
PANCREATITIS	69	13	5.44	2.07	1.14	3.74	69	13	5.48	2.07	1.15	3.75
INCORRECT PRODUCT ADMINISTRATION DURATION	33	4	4.62	3.21	1.14	9.07	33	4	4.64	3.22	1.14	9.09
GASTROINTESTINAL HAEMORRHAGE	49	8	4.86	2.39	1.13	5.04	49	8	4.89	2.39	1.13	5.05
EXOPHTHALMOS	41	6	4.70	2.66	1.13	6.27	41	6	4.73	2.67	1.13	6.28
IMPAIRED GASTRIC EMPTYING	41	6	4.70	2.66	1.13	6.27	41	6	4.73	2.67	1.13	6.28
VEIN DISCOLOURATION	37	5	4.64	2.88	1.13	7.33	37	5	4.67	2.89	1.14	7.35
GASTROINTESTINAL INFLAMMATION	56	10	4.81	2.18	1.11	4.27	56	10	4.84	2.19	1.12	4.29
TOOTH ABSCESS	48	8	4.59	2.34	1.11	4.94	48	8	4.62	2.34	1.11	4.95
VACCINATION SITE IRRITATION	63	12	4.80	2.04	1.10	3.79	63	12	4.84	2.05	1.11	3.80
RED BLOOD CELL ABNORMALITY	36	5	4.34	2.80	1.10	7.15	36	5	4.37	2.81	1.10	7.16
EUSTACHIAN TUBE DISORDER	32	4	4.30	3.12	1.10	8.81	32	4	4.33	3.12	1.10	8.83
SKIN WRINKLING	46	8	4.04	2.24	1.06	4.74	46	8	4.07	2.25	1.06	4.76
STENT PLACEMENT	35	5	4.04	2.73	1.07	6.96	34	5	3.77	2.66	1.04	6.79
ASYMPTOMATIC COVID-19	522	1	199.68	203.31	28.59	1445.99	520	1	199.41	203.04	28.55	1444.09
POST-ACUTE COVID-19 SYNDROME	295	1	111.19	114.90	16.13	818.36	293	1	110.70	114.40	16.06	814.88
DISEASE RECURRENCE	202	2	72.68	39.34	9.77	158.37	197	2	70.92	38.46	9.55	154.86
COVID-19 PNEUMONIA	160	2	56.35	31.16	7.73	125.66	159	2	56.11	31.04	7.70	125.20
PREMENSTRUAL SYNDROME	151	2	52.85	29.41	7.29	118.66	151	2	53.00	29.48	7.31	118.95
LUNG OPACITY	88	1	30.62	34.27	4.77	246.03	87	1	30.32	33.97	4.73	243.88
SARS-COV-2 TEST NEGATIVE	88	1	30.62	34.27	4.77	246.03	88	1	30.71	34.36	4.79	246.65
INTENTIONAL DOSE OMISSION	81	1	27.91	31.55	4.39	226.68	81	1	27.98	31.63	4.40	227.25
COVID-19 IMMUNISATION	89	2	28.84	17.33	4.27	70.38	89	2	28.92	17.38	4.28	70.56
NEAR DEATH EXPERIENCE	85	2	27.30	16.55	4.07	67.27	83	2	26.60	16.20	3.99	65.87
BREAST CYST	73	1	24.81	28.43	3.95	204.56	72	1	24.49	28.11	3.91	202.30
VACCINATION SITE PARAESTHESIA	75	2	23.45	14.61	3.59	59.48	75	2	23.52	14.64	3.60	59.63
PRE-EXISTING CONDITION IMPROVED	62	1	20.55	24.15	3.35	174.14	62	1	20.61	24.21	3.36	174.58
PULMONARY THROMBOSIS	69	2	21.14	13.44	3.29	54.81	68	2	20.82	13.28	3.25	54.17
CHILLBLAINS	60	1	19.77	23.37	3.24	168.61	60	1	19.83	23.43	3.25	169.04
ELECTROCARDIOGRAM ST SEGMENT ELEVATION	60	1	19.77	23.37	3.24	168.61	60	1	19.83	23.43	3.25	169.04
ABNORMAL UTERINE BLEEDING	58	1	19.00	22.59	3.13	163.09	58	1	19.06	22.65	3.14	163.50
SARS-COV-2 TEST	54	1	17.46	21.03	2.91	152.03	53	1	17.12	20.69	2.86	149.64
BODY HEIGHT DECREASED	53	1	17.07	20.64	2.85	149.26	50	1	15.96	19.52	2.70	141.32
C-REACTIVE PROTEIN INCREASED	58	2	16.94	11.29	2.76	46.24	57	2	16.61	11.13	2.72	45.58
MANIA	55	2	15.80	10.71	2.61	43.91	55	2	15.85	10.74	2.62	44.02
INJECTION	47	1	14.76	18.31	2.53	132.67	46	1	14.42	17.96	2.48	130.24
UTERINE PAIN	53	2	15.04	10.32	2.52	42.35	53	2	15.09	10.35	2.52	42.46
BLOOD IRON DECREASED	44	1	13.61	17.14	2.36	124.38	44	1	13.65	17.18	2.37	124.69
GIANT CELL ARTERITIS	44	1	13.61	17.14	2.36	124.38	43	1	13.26	16.79	2.31	121.92
PREMENSTRUAL PAIN	44	1	13.61	17.14	2.36	124.38	44	1	13.65	17.18	2.37	124.69
BLOOD DISORDER	43	1	13.22	16.75	2.31	121.62	43	1	13.26	16.79	2.31	121.92

COOLING THERAPY	47	2	12.77	9.15	2.22	37.68	47	2	12.81	9.18	2.23	37.77
OXYGEN SATURATION ABNORMAL	41	1	12.46	15.97	2.20	116.09	41	1	12.49	16.01	2.20	116.38
WRONG PATIENT	46	2	12.39	8.96	2.17	36.90	46	2	12.44	8.98	2.18	36.99
DIZZINESS EXERTIONAL	39	1	11.69	15.19	2.09	110.56	39	1	11.73	15.23	2.09	110.84
PRODUCT RECONSTITUTION QUALITY ISSUE	43	2	11.27	8.37	2.03	34.57	43	2	11.31	8.39	2.03	34.65
SENSATION OF BLOOD FLOW	43	2	11.27	8.37	2.03	34.57	43	2	11.31	8.39	2.03	34.65
PLATELET COUNT INCREASED	38	1	11.31	14.80	2.03	107.79	38	1	11.34	14.84	2.04	108.06
SENSITISATION	38	1	11.31	14.80	2.03	107.79	38	1	11.34	14.84	2.04	108.06
QUARANTINE	42	2	10.89	8.18	1.98	33.79	40	2	10.18	7.81	1.89	32.31
FREEZING PHENOMENON	37	1	10.93	14.41	1.98	105.03	37	1	10.96	14.45	1.98	105.29
BLOOD THYROID STIMULATING HORMONE INCREASED	36	1	10.54	14.02	1.92	102.26	36	1	10.58	14.06	1.93	102.52
SINUS RHYTHM	40	2	10.15	7.79	1.88	32.23	40	2	10.18	7.81	1.89	32.31
FEELING OF RELAXATION	35	1	10.16	13.63	1.87	99.50	35	1	10.20	13.67	1.87	99.75
GLYCOSYLATED HAEMOGLOBIN INCREASED	35	1	10.16	13.63	1.87	99.50	35	1	10.20	13.67	1.87	99.75
PRODUCT ADMINISTRATION INTERRUPTED	35	1	10.16	13.63	1.87	99.50	34	1	9.81	13.28	1.82	96.98
DYSCHROMATOPSIA	39	2	9.78	7.59	1.83	31.45	39	2	9.81	7.61	1.84	31.53
MENOMETRORRHAGIA	39	2	9.78	7.59	1.83	31.45	39	2	9.81	7.61	1.84	31.53
CHILD MALTREATMENT SYNDROME	31	1	8.64	12.07	1.65	88.44	31	1	8.67	12.10	1.65	88.67
OVERSENSING	31	1	8.64	12.07	1.65	88.44	31	1	8.67	12.10	1.65	88.67
RED BLOOD CELL COUNT DECREASED	31	1	8.64	12.07	1.65	88.44	31	1	8.67	12.10	1.65	88.67
BILIARY COLIC	35	2	8.30	6.82	1.64	28.34	35	2	8.33	6.83	1.64	28.41
DEPERSONALISATION/DEREALISATION DISORDER	35	2	8.30	6.82	1.64	28.34	35	2	8.33	6.83	1.64	28.41
LEFT ATRIAL ENLARGEMENT	35	2	8.30	6.82	1.64	28.34	35	2	8.33	6.83	1.64	28.41
ENDOMETRIOSIS	34	2	7.93	6.62	1.59	27.56	34	2	7.96	6.64	1.59	27.63
ENDOMETRIAL THICKENING	30	1	8.27	11.68	1.59	85.68	30	1	8.29	11.71	1.60	85.89
SUFFOCATION FEELING	33	2	7.57	6.43	1.54	26.78	33	2	7.60	6.44	1.55	26.85
VACCINATION SITE SCAR	33	2	7.57	6.43	1.54	26.78	33	2	7.60	6.44	1.55	26.85
EYELID SENSORY DISORDER	29	1	7.89	11.29	1.54	82.91	29	1	7.91	11.32	1.54	83.12
PULMONARY HYPERTENSION	29	1	7.89	11.29	1.54	82.91	29	1	7.91	11.32	1.54	83.12
THYROID PAIN	29	1	7.89	11.29	1.54	82.91	29	1	7.91	11.32	1.54	83.12
HAND DERMATITIS	28	1	7.51	10.91	1.48	80.15	28	1	7.54	10.93	1.49	80.35
PARAESTHESIA EAR	28	1	7.51	10.91	1.48	80.15	28	1	7.54	10.93	1.49	80.35
VESTIBULAR MIGRAINE	28	1	7.51	10.91	1.48	80.15	28	1	7.54	10.93	1.49	80.35
RETINAL MIGRAINE	31	2	6.84	6.04	1.44	25.22	31	2	6.87	6.05	1.45	25.29
BLOOD URINE	30	2	6.48	5.84	1.40	24.45	30	2	6.51	5.86	1.40	24.51
BODY HEIGHT	30	2	6.48	5.84	1.40	24.45	30	2	6.51	5.86	1.40	24.51
CHOLECYSTITIS	26	1	6.76	10.13	1.37	74.62	26	1	6.78	10.15	1.38	74.81
EAR INFLAMMATION	26	1	6.76	10.13	1.37	74.62	26	1	6.78	10.15	1.38	74.81
IMMUNE-MEDIATED ADVERSE REACTION	26	1	6.76	10.13	1.37	74.62	26	1	6.78	10.15	1.38	74.81
APRAXIA	25	1	6.39	9.74	1.32	71.86	25	1	6.41	9.76	1.32	72.04
OVARIAN CYST RUPTURED	25	1	6.39	9.74	1.32	71.86	25	1	6.41	9.76	1.32	72.04
OVULATION DISORDER	25	1	6.39	9.74	1.32	71.86	25	1	6.41	9.76	1.32	72.04
REDUCED FACIAL EXPRESSION	25	1	6.39	9.74	1.32	71.86	25	1	6.41	9.76	1.32	72.04
TOTAL LUNG CAPACITY DECREASED	25	1	6.39	9.74	1.32	71.86	25	1	6.41	9.76	1.32	72.04
HYPERVIGILANCE	28	2	5.77	5.45	1.30	22.89	28	2	5.79	5.47	1.30	22.95
INJECTION RELATED REACTION	24	1	6.01	9.35	1.26	69.09	24	1	6.04	9.37	1.27	69.27
MENSTRUATION NORMAL	24	1	6.01	9.35	1.26	69.09	24	1	6.04	9.37	1.27	69.27
CHEST INJURY	27	2	5.42	5.26	1.25	22.11	27	2	5.44	5.27	1.25	22.17
COLD-STIMULUS HEADACHE	27	2	5.42	5.26	1.25	22.11	27	2	5.44	5.27	1.25	22.17
BLADDER SPASM	23	1	5.64	8.96	1.21	66.33	23	1	5.66	8.98	1.21	66.50
PRODUCT DISPENSING ISSUE	23	1	5.64	8.96	1.21	66.33	23	1	5.66	8.98	1.21	66.50
HEPATIC ENZYME ABNORMAL	26	2	5.06	5.06	1.20	21.33	26	2	5.09	5.08	1.20	21.39
PRODUCT AVAILABILITY ISSUE	26	2	5.06	5.06	1.20	21.33	26	2	5.09	5.08	1.20	21.39
FOOD CRAVING	25	2	4.72	4.87	1.15	20.55	25	2	4.74	4.88	1.16	20.61
DAYDREAMING	22	1	5.27	8.57	1.15	63.57	22	1	5.29	8.59	1.16	63.73
DYSHIDROTIC ECZEMA	22	1	5.27	8.57	1.15	63.57	21	1	4.93	8.20	1.10	60.96
LIVER INJURY	22	1	5.27	8.57	1.15	63.57	22	1	5.29	8.59	1.16	63.73
THERAPEUTIC PRODUCT EFFECT DECREASED	22	1	5.27	8.57	1.15	63.57	22	1	5.29	8.59	1.16	63.73
APTALISM	24	2	4.37	4.67	1.10	19.78	23	2	4.05	4.49	1.06	19.05
THERAPY CHANGE	24	2	4.37	4.67	1.10	19.78	24	2	4.39	4.69	1.11	19.83
BREAST DISORDER FEMALE	21	1	4.91	8.18	1.10	60.80	21	1	4.93	8.20	1.10	60.96
SUPERFICIAL VEIN PROMINENCE	21	1	4.91	8.18	1.10	60.80	21	1	4.93	8.20	1.10	60.96
POLYP	23	2	4.03	4.48	1.06	19.00	23	2	4.05	4.49	1.06	19.05
SUBSTANCE USE	20	1	4.54	7.79	1.05	58.04	19	1	4.19	7.42	0.99	55.42
VEIN RUPTURE	20	1	4.54	7.79	1.05	58.04	20	1	4.56	7.81	1.05	58.19
BLOOD CREATINE PHOSPHOKINASE INCREASED	19	1	4.18	7.40	0.99	55.28	19	1	4.19	7.42	0.99	55.42
ECZEMA NUMMULAR	19	1	4.18	7.40	0.99	55.28	19	1	4.19	7.42	0.99	55.42
HYDRONEPHROSIS	19	1	4.18	7.40	0.99	55.28	19	1	4.19	7.42	0.99	55.42
NEPHROTIC SYNDROME	19	1	4.18	7.40	0.99	55.28	19	1	4.19	7.42	0.99	55.42

IMPAIRED SELF-CARE	19	1	4.18	7.40	0.99	55.28	18	1	3.83	7.03	0.94	52.65
LOGORRHOEA	19	1	4.18	7.40	0.99	55.28	18	1	3.83	7.03	0.94	52.65
MYASTHENIA GRAVIS	77	15	5.70	2.00	1.15	3.48	77	15	5.75	2.00	1.15	3.48
SKIN EROSION	70	14	4.83	1.95	1.10	3.46	69	13	5.48	2.07	1.15	3.75
ANTINUCLEAR ANTIBODY POSITIVE	27	3	3.98	3.51	1.06	11.55	27	3	4.00	3.51	1.07	11.58
BREAST INDURATION	27	3	3.98	3.51	1.06	11.55	27	3	4.00	3.51	1.07	11.58
THYROID CANCER	8	1	0.58	3.12	0.39	24.91	8	0	.	.	.	.